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ABSTRACT 
 
Background: Coronary Heart Disease (CHD), a complication of uncontrolled 
hypertension, is a leading cause of death in women. The gap between women’s 
perceived global CHD risk (GCR) and their actual or calculated CHD risk may 
contribute to these alarming statistics. Understanding the factors influencing the 
inaccurate perception of GCR has significant implications for the implementation of 
effective CHD preventive interventions. Global CHD risk assessment is the most 
important approach to hypertension treatment. However, despite the availability of over 
100 different effective drugs for hypertension treatment, the reported rates of blood 
pressure control are disappointing. The issue of medication non-adherence (MNA) has 
received little attention in India. Therefore, this study examined hypertensive womens’ 
actual and perceived CHD risks, and adherence patterns to antihypertensive treatment 
recommendations. The study also explores the factors that influence CHD risk 
perceptions and medication adherence to hypertension treatment among women in a 
low-income community in Delhi, India. 
 
Methods: A mixed-methods design comprised a quantitative survey and semi-
structured interviews. The Health Belief Model (HBM) was used to design and construct 
the questionnaire. Between August and October 2015, 500 women from a low-income 
urban community in Delhi were recruited to take part in the study. An 81 item 
questionnaire was administered to each participant to collect socio-demographic 
information, comorbidities, knowledge of CHD risk factors, family history of heart 
disease, history of hypertension and its treatment, the perceived GCR, and 
hypertension perception. In the qualitative phase of the study, 30 hypertensive women 
and nine health care providers were interviewed to determine the reasons that may 
influence adherence to prescribed hypertensive medications. Participants’ actual GCR 
was calculated by the NHANES non-laboratory-based risk scoring chart, and perceived 
GCR was determined by participants’ answer to a survey question about personal CHD 
risk. Prevalence of MNA was based on patient self-reports of consuming <80% of the 
prescribed medications over a recall period of one week. Multiple logistic regression 
with backward stepwise likelihood ratio method was conducted to determine the 
association between study variables and inaccuracy of perceived GCR as well as MNA. 
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Results: The study found the prevalence of hypertension among women to be 35.2%. 
Although a majority (75.2%) of women had low risk (<10%) of developing CHD, about a 
quarter of the women (24.8%; n = 104) had high risk (≥10%) of developing fatal or non-
fatal CHD in the next five years. There was a low agreement between calculated and 
perceived GCR of women (Kappa ± SE) (0.137 ± 0.072); p = .05. More than half of 
women (52%) who were aware of their hypertension status were not able to estimate 
their CHD risk correctly. Diastolic hypertension (AOR = 3.09; 95% CI: 1.18–8.09; p = 
.02); age ≥48 years (AOR = 4.57, 95% CI: 1.75–11.93; p = .002); and poor knowledge 
level of CHD risk factors (AOR = 6.76; 95% CI: 2.60–17.63; p = <.001) were 
significantly and independently associated with the inaccurate perception of CHD risk.  
 
In this study, MNA was found in 51% of hypertensive women. The study showed 
women who were not satisfied with their antihypertensive treatment (AOR = 11.09; 95% 
CI: 2.33–52.87; p = .003); who had a duration of antihypertensive therapy for three 
years or less (AOR = 14.31; 95% CI: 2.40–85.18; p = .003); who were not given an 
explanation about the treatment regimen and side effects of medications by their 
doctors (AOR = 28.39; 95% CI: 4.50–178.40; p = <.001); who perceived their CHD risk 
as low (AOR = 153.65; 95% CI: 9.30–2539.43; p = <.001) and who were inaccurate of 
self-perception of the CHD risk (AOR = 188.087; 95% CI: 9.80–3606.47; p = .001) were 
significantly and independently associated with MNA. The result of the in-depth 
interviews also pointed towards the following barriers to antihypertensive treatment: 
women participants’ low awareness of the disease condition, an undesirable outlook 
toward antihypertensive medications, and dis-satisfaction with the attitude of health 
care providers and health care services provided. 
 
Conclusion: More than half of the hypertensive women in the study were unable to 
accurately perceive their GCR level and did not adhere to their antihypertensive 
treatment. The findings suggest the need of better communication between patients 
and health care professionals to address women’s lay beliefs about hypertension, its 
treatment and the risk of experiencing CHD events. The results can be used by policy 
makers in the design of culturally appropriate efficient programs to improve accuracy of 
perceived CHD risks and medication adherence to antihypertensive therapy in women 
living in low-income urban communities in order to prevent an increasing burden of 
CHD. 
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OPERATIONAL DEFINITIONS 
 
Drinker: 
Current-drinker: Participant who had consumed an alcoholic drink such as beer, spirits, 
wine, or other alcohol based drinks within the last 30 days. 
  
Former-drinker: Has consumed alcohol but who did not consume one or more drinks 
during the month preceding the survey. 
 
Non-drinker: Participants who had never drank alcohol in their life. 
 
Diabetes:  
In this study, patients were considered as diabetic if someone was taking insulin or oral 
hypoglycemic drugs during the time of the survey.1 
 
Family Type: 
Joint Family: A family in which parents and their male children with their families live 
together and are considered as a single unit.2 
 
Nuclear family: A family group consisting of a mother and father and their children.3  
 
Global CHD risk score:  
The absolute or global CHD risk score is defined as the probability of experiencing a 
coronary heart disease or cardiovascular-disease-related event within five years after 
the risk assessment.4 To estimate the global risk score of individual participants the 
NHANES non-laboratory–based risk prediction chart was used in this study.5  The 
variables used in the NHANES risk prediction charts were self-reported data (sex, age, 
current smoking status, diabetes status), anthropometric data (height, weight and 
systolic blood pressure), and calculated data (BMI).5 Because the prevalence of 
smokeless tobacco users in the study population was high, and based on the 
INTERHEART data, it was decided a priori to replace smoking with tobacco 
consumption in the NHANES.4 Based on the above-mentioned factors, the study 
women were stratified into low (<10%), moderate (10–20%) and high (>20%) risk of 
developing an adverse CHD event in the next five years.4  
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Hypertension:  
Elevation of blood pressure equal or above the treatment goal; that is, 140/90 mmHg6 
and/ or on antihypertensive treatment during the time of the survey. 
 
Level of CHD risk factor knowledge:  
A 10 item standardised questionnaire was used to assess knowledge of modifiable risk 
factors of CHD.7 Out of the 10 risk factors listed in the question, five were evidently 
known to cause CHD. These modifiable risk factors were smoking, hypertension, high 
cholesterol levels, diabetes and obesity. The response options were yes, no or ‘not 
sure’. Participants were instructed to say ‘yes’ only for risk factors that they felt definitely 
contributed to CHD, ‘no’ for factors that they were certain did not contribute, and 
otherwise to mark ‘not sure’. Correct identification of three or fewer risk factors was 
regarded as a poor level of knowledge while correct identification of four or more was 
considered as a good degree of knowledge.8  
  
Medication Adherence:  
In this study, medication doses consumed or missed, based on patient self-reports, was 
used to measure medication adherence.9 Patients were asked how often they missed 
their doses in the last seven days. The total number of doses that were supposed to be 
consumed in the past seven days was computed from the available current prescription, 
and when the prescription was not available, the medicine strips were used.10 A shorter 
recall period was used to obtain accurate responses to minimise recall bias. Adherence 
as a percentage was computed as follows:  
Number of pills the patient consumed in the last seven days x 1009 
Number of pills that were prescribed for that week)   
 
For analysis of adherence, a cut-off value of 80% was used for labeling patients as 
adherent or non-adherent. 9, 11 
 
Adherence to antihypertensive medications:  
Consuming ≥80% of the prescribed doses of medicine out of the total number of doses 
supposed to be consumed in the past one week.9 
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Non-adherence to antihypertensive medications:  
Consuming <80% of the prescribed doses of medicine out of the total number of doses 
supposed to be consumed in the past one week or stopped taking the medications after 
starting treatment at any point in the time following diagnosis in the past. 9, 11 
  
Metabolic syndrome:  
The cluster of the most dangerous heart attack risk factors: high blood pressure, 
diabetes and pre-diabetes, abdominal obesity and high cholesterol.12  
 
Obesity:   
Defined as Body Mass Index (BMI) ≥25 kg/m2.13  
   
Central or abdominal obesity: Abdominal obesity was defined as waist circumference 
(WC) ≥80 cm. A waist-to-hip ratio (WHR) of ≥0.85 for females was also considered to 
indicate abdominal obesity.13  
 
Overweight:   
Defined as BMI 23–24.9kg/m2.13 
 
Physical activity: 
High physical activity: Defined as minimum total physical activity of at least 3000 MET-
minutes/week.14 
 
Moderate physical activity: Defined as minimum total physical activity of at least 600 
MET-minutes/weeks.14 
 
Low physical activity: Defined as total physical activity score <600 MET-                        
minutes /week.14 
 
Perceived global CHD risk:  
Perceived risk was calculated in this study by asking research participants: ‘In the next 
five years, how many paisa in a rupee do you think is your risk of having heart disease 
compared to a woman of your age (if you make no changes in your current lifestyle 
such as tobacco use, diet, activity level, non-adherence to medication)?’. Participants 
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indicated their response by placing an X on a scale ranging from 0 paisa (no risk) to 
100 paisa (high risk) that was segmented at 10 paisa intervals. The 0–100 paisa 
response scale was selected to correspond with the risk estimates provided by the 
NHANES risk calculator. According to participants’ responses, participants were 
categorised into ‘low perceived risk’ (<10 paisa in a rupee), moderate perceived risk 
(10–20 paisa in a rupee) and high perceived risk (>20 paisa in a rupee). For study 
purposes, the variables for ‘moderate’ and ‘high perceived risk’ were collapsed into a 
single variable: ‘high perceived risk’. 
 
Perception of high blood pressure:  
Perceptions of high blood pressure were assessed with the valid and reliable Brief 
Illness Perceptions Questionnaire (BIPQ).15 The BIPQ asks patients to provide 
information about eight dimensions of illness (hypertension). Five dimensions are 
related to cognitive illness representations (the perceived consequence, timeline, 
personal-control, treatment-control and identity), two dimensions are related to 
emotional representations (respondents’ emotions and concerns about the illness) and 
one dimension is related to illness comprehensibility (coherence).15 Separate scores for 
the eight dimensions of illness perception and an overall score were calculated. The 
scores represent the degree to which the illness is perceived as threatening (high 
scores) or benign (lower scores). As suggested by authors of the BIPQ, the word illness 
was replaced by the wording ‘high blood pressure’. 
 
Response to BP medications:  
In this study, participants were asked whether their BP medications made them feel 
better and the response options were ‘yes’, ‘no’ and ‘can’t say’. For study purposes, 
those patients were further divided into two groups: feeling better (those who responded 
‘yes’) and not feeling better (those who responded ‘no’ and ‘can’t say’). 
 
Risk accuracy:  
Risk accuracy was defined as the ability of the participant to assign her likelihood of 
heart disease to the same category as her calculated risk.16 If the difference between 
an individual’s estimated risk and a personal perceived risk was a positive number, it 
indicated a pessimistic view in that participants see their own risk as greater than it is. 
Negative numbers would indicate an optimistic view in which participants understand 
21 
 
their risk as smaller than the calculated risk.17 According to participants’ responses, 
participants were dichotomised into participants with accurate perception and 
participants with inaccurate perception. Under-estimators were those women who 
perceived themselves to be at ‘low’ risk, but were actually at high risk16 (i.e. calculated 
by the NHANES non-laboratory-based risk score chart).  
 
Satisfaction with the BP treatment:  
In this study, participants were asked if they were satisfied with the benefit of the 
present medications. The response options were ‘satisfied’, ‘not satisfied’ and ‘can’t 
say’. For study purposes, patients were further divided into two groups: satisfied and 
not satisfied (those who responded ‘not satisfied’ and ‘can’t say’ with the BP treatment) 
 
Tobacco Users: 
Smoked tobacco user:  Participant who consumed smoked tobacco products such as 
cigarettes, bidis or hookah in the last month before the assessment. 
 
Current daily smoked tobacco user: Participant currently using smoked tobacco 
products such as cigarettes, bidis or hookah daily.  
 
Smokeless tobacco user: Participant who consumed chewable tobacco products such 
as gutkha, naswar, khaini or zarda paan in the last month before the assessment 
 
Current daily smokeless tobacco user: Participant currently using chewable tobacco 
products such as gutkha, naswar, khaini or zarda paan daily.1 
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CHAPTER 1 
INTRODUCTION AND OVERVIEW 
 
1.0 Introduction to the chapter 
This chapter describes the background to the study, specifies the research aim and 
objectives and outlines the thesis chapters. 
 
1.1 Overview of the background 
Non-communicable diseases (NCDs), also known as chronic illness, are the world’s 
number one killer, causing 60% of total deaths globally.18 NCDs are of long duration 
and slow progression. Worldwide, approximately 36 million people die every year from 
these silent killers.19 The four leading NCDs, in terms of burden of disease and 
mortality, are cardiovascular diseases (CVDs), cancers, chronic respiratory illness and 
diabetes.19 Together, NCDs are the foremost cause of death for women worldwide. 
They cause 65% of all female deaths, amounting to 18 million deaths each year.20 
CVDs account for most NCD deaths.18 CVDs are an assemblage of disorders of the 
heart and blood vessels and include: coronary heart disease (CHD), rheumatic and 
congenital heart disease, cerebro-vascular disease, hypertension, heart failure and 
peripheral vascular disease.20  
CHD, the largest contributor of the cardiovascular diseases, has emerged as the 
leading cause of death worldwide.21 The significant burden of CHD is already evident 
among populations living in low-income urban areas across India. Some studies in India 
have noted a high prevalence of CHD risk factors among urban, low-income people. 
Among these population groups, women are particularly vulnerable to developing CHD 
because of a higher prevalence of hypertension in middle-aged and older women 
compared to men.22-24 CHD is one of the most significant causes of disability and 
mortality in women during childbearing years.25 Regardless of race or ethnicity, the 
disease accounts for the death of one in three women worldwide, an estimated 3.4 
million women every year.26, 27 An analysis of global data reveals that of the women who 
will die from CHD, approximately 80% of the deaths will occur in low- and middle-
income countries,28 and is particularly common among people of low socioeconomic 
status.29  
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High blood pressure or hypertension is the one of the most important risk factors for 
cardiovascular disease and a leading cause of premature adult deaths worldwide.18 
Uncontrolled hypertension causes 50% of the CHD deaths globally.18 Since most 
deaths attributable to hypertension are the result of CHD, the primary objective in the 
management of hypertension is the prevention of CHD. As most hypertensive patients 
living in low-income urban areas are undetected, untreated or sub‑optimally treated, 
there is a significant treatment and prevention gap in CHD within this group.  
 
As clustering of CHD risk factors frequently occurs in hypertensive individuals, the 
global CHD risk (GCR) approach (on the basis of combined effect of multiple risk 
factors) is the most important target for hypertension treatment.30 GCR assessment 
more accurately identifies patients who will benefit from risk-reducing therapy, and such 
information may encourage patients and physicians to address CHD risk.30 To use 
available resources more efficiently, and to make treatment cost-effective at the patient 
level, the GCR approach is the preferred standard in CHD preventive management.31 
 
Studies show GCR varies among different sub-populations independent of the major 
risk factors.32, 33 In the setting of underserved communities, due to the rising incidence 
of hypertension, research policies should focus on CHD prevention strategies. 
Identification of patients at risk for CHD could facilitate the prevention of CHD events. 
There is a notable lack of published data on the stratification of CHD risk, particularly 
among vulnerable women residing in low-income urban settlements in India; as such, it 
becomes difficult to initiate CHD preventive and promotional activities. Primary 
prevention in terms of risk stratification is essential for accurate and early decision- 
making and action in the natural history of CHD.34 
 
Likewise, knowing the CHD risk perceptions of a population group is a prerequisite for 
planning and implementing focused and efficient CHD prevention strategies.35 As 
hypertension has no symptomatic external cues, it is important to ensure that 
individuals who live with hypertension have accurate perceptions of their CHD or heart 
attack risk in order to encourage preventive actions (i.e. medication adherence) against 
future heart attack risk. Women's perceived heart disease risk can significantly 
influence their decision-making process about healthcare choice.36 Evidence shows that 
only a small number of women recognise CHD as their greatest health threat.36 As a 
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result of the mistaken belief that CHD affects mainly males, there is a considerable gap 
between perceived and actual risk of CHD in women. These inaccurate perceptions 
may lead women to underestimate their likelihood of CHD so that they fail to look for 
early interventions to prevent avoidable morbidity and mortality.36  
 
Understanding the relationship between perceived risk of CHD in women and 
motivation to engage in health-promoting behaviour such as medication adherence is 
necessary to improve the health of women and prevent CHD.36 Although CHD risk 
perception has been studied in different parts of the world, the majority of the 
participants in these studies were Caucasian women.36 There was a limited 
representation of Asian and Pacific women in sample populations of these studies. 
Therefore, further studies need to be conducted with women of these regions on their 
perceptions of the risk for CHD.36  
 
One of the most important and least expensive ways of preventing CHD is to control 
hypertension by pharmacological treatment. Due to poor adherence to antihypertensive 
treatment, approximately 75% of diagnosed hypertensive patients do not attain 
optimum blood pressure control.9 Studies reveal that among women in developing 
countries such as India, the mean prevalence control of hypertension is only 16.2%.37 
Moreover, evidence suggests that despite the availability of free or low-cost 
antihypertensive medications at government primary care facilities, approximately 90% 
of people with hypertension residing in low-income settlements fail to achieve blood 
pressure control.38 
 
Although, poor adherence to antihypertensive treatment is a significant problem, studies 
intended at finding out the reasons for such non-adherence are very few in India.39 
Moreover, the majority of these studies were conducted in hospital and clinical 
settings.40 Studies carried out in low-income urban areas are extremely limited.10 
Overall, the non-adherence issue in hypertension control has received little public 
health attention in India. 
 
Therefore, to develop an effective CHD prevention program among hypertensive 
women in low-income urban settings, a comprehensive description of global CHD risk, 
perceived CHD risk and issues related to non-adherence to antihypertensive treatment 
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would be extremely valuable. This present study is expected to help fill the knowledge 
gap and inform the development of strategies for improving women’s perceived CHD 
risk, adherence to treatment and prevention of CHD. 
 
1.2 Aim and Objectives of the study 
The aim of the study was to examine hypertensive women’s global coronary heart 
disease risks, their perception of the global CHD risks and adherence pattern to 
treatment recommendations in a low-income urban area of Delhi, India. The study 
objectives were to: 
 
1. Objective 1: Assess and stratify global CHD risk among women living in a low-
income urban area of Delhi, India.   
2. Objective 2: Examine hypertensive women’s perceptions of their global CHD 
risks and evaluate its relationship with socio-demographic variables and their 
knowledge of CHD risk factors.   
3. Objective 3: Investigate prevalence and predictors of non-adherence to anti- 
hypertensive medications among hypertensive women in a low-income 
community. 
4. Objective 4: Explore the reasons underlying antihypertensive treatment 
adherence.  
5. Objective 5: Examine health care providers’ attitudes regarding women’s 
perceived global CHD risks and their adherence to antihypertensive treatment. 
 
1.3 Over-view of the thesis 
The present chapter has provided the background of the study, together with its aims 
and objectives.  
 
Chapter 2 explains the context of the increasing risk of coronary heart disease among 
low socioeconomic groups of people in India, the vulnerability of women and the 
management gap in CHD prevention. Poor adherence to antihypertensive treatment is 
a significant problem in CHD prevention. Understanding the relationship between the 
perceived risks of CHD in women and their motivation to engage in health-promoting 
behaviour such as medication adherence, is necessary to improve the health of women 
and prevent CHD. 
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Chapter 3 provides a literature review on the factors that affect treatment non-
adherence among hypertensive populations in developing countries with a special 
emphasis on urban women.  
 
Chapter 4 describes the research methodology and the conceptual framework 
underlying it. It details both the qualitative and quantitative arms of the study. Ethical 
considerations are also described. 
 
Chapter 5 contains the results from analysis of the quantitative data from the 500 
women participating in the present study. The data is of socio-demographic 
characteristics, behavioural and physiological profiles, knowledge of heart disease risk 
factors, dietary habits, family history of heart disease, and history of hypertension and 
its treatment. Detailed findings concerning CHD risk perception and medication 
adherence of the already-diagnosed hypertensive women are presented. 
  
Chapter 6 presents qualitative findings from hypertensive women and health care 
providers regarding their perceptions of the reasons that may hinder or assist 
antihypertensive medication adherence. It also describes women’s expectations 
regarding their hypertension management and physicians’ recommendations to improve 
medication non-adherence among hypertensive women from low-income communities. 
 
Chapter 7 discusses key study findings related to the study objectives in the light of the 
published literature and their implications for practice, policy and research. The chapter 
also makes recommendations, discusses the significance of the study and its 
limitations, and offers a concluding statement to the thesis. 
 
Appendices 1-15 contain ethical approvals from the HREC, Curtin University and 
Sigma International Review Board, India. They also include a supporting letter from the 
concerned NGO, the health behaviour model, lifestyle modifications and their effect on 
hypertension, the mechanism of action and adverse effects of common 
antihypertensive medications, participant information sheet, participant consent form, 
questionnaires, the semi-structured interview guide, the Hindi version of all participant 
related documents, a statement of accuracy of the Hindi translation, permission to use 
copyrighted questionnaires and overview of the included studies in literature review. 
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CHAPTER 2 
BACKGROUND 
 
2.0 Introduction to the chapter 
This chapter starts with an overview of the non-communicable diseases, especially 
cardiovascular disease, globally and in India. It then describes the prevalence of 
Coronary Heart Disease (CHD) in India, its risk factors and the management gap in 
CHD prevention. This is followed by the perception of global CHD risk and preventive 
behaviour. It then describes the rising burden of hypertension in India, its treatment 
management, medication adherence and health care services in India. 
 
2.1 Non-communicable diseases globally and in India 
Non-communicable diseases (NCDs), also known as chronic illness, are the leading 
causes of adult mortality and morbidity, causing 60% of all deaths globally.18 NCDs are 
of long duration and slow progression.18 The four main NCDs, in terms of burden of 
disease and mortality, are cardiovascular diseases (CVDs), cancers, chronic respiratory 
illness and diabetes.19 The most recent global estimates for NCD mortality are for the 
year 2008; they accounted for 36 million of the world’s 57 million deaths (please see 
Figure 1).27  
 
Figure 1: Global causes of death in 2008 19 
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Together, NCDs are also a significant cause of female deaths worldwide. They cause 
65% of all female deaths: 18 million deaths each year.41 The 2011 United Nations 
Assembly of Heads of States noted with concern that ‘the rapidly growing magnitude of 
NCDs affects people of all ages, gender, race and income levels, and … that poor 
populations and those living in vulnerable situations, in particular in developing 
countries bear a disproportionate burden’.42 
 
In India, NCDs accounted for an estimated 53% of all deaths in 200827, 43 (please see 
Figure 2). NCDs were also responsible for 44% of disability-adjusted life years (DALYs) 
lost in 2005.44 One quarter of all NCD-related deaths usually occur among people below 
the age of 60.19 Studies show that the leading NCDs will cost the world economy USD 
47 trillion over the next two decades and drive millions of people below the poverty 
line.4 In India, NCDs are creating more strain on health resources than that caused by 
communicable diseases and maternal health problems.45 In 2004, NCDs accounted for 
40% of all hospital stays and 35% of all outpatient visits.46 The World Bank estimates 
that health promotion and prevention initiatives could be used to avoid more than one 
half of the NCD burden.47 
 
 
Figure 2: Proportion of major causes of mortality in India in 2008
43 
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2.1.1 Cardiovascular disease  
Cardiovascular disease (CVD) is the single largest cause of morbidity and mortality 
worldwide. CVDs are a collection of disorders of the heart and blood vessels. CVDs 
include coronary heart disease (CHD), rheumatic and congenital heart disease, 
cerebrovascular disease, hypertension, heart failure and peripheral vascular disease.19 
CVD represents nearly 50% of NCD deaths.48 In 2012, an estimated 17.5 million people 
died from CVDs, representing 31% of all global deaths.21 CVD is also the number one 
killer of women worldwide 20 causing 9.1 million deaths annually (please see Table 1).28 
 
Table 1: The leading global causes of death among women, 200828 
Rank  Cause  Number of deaths % 
1 Cardiovascular diseases 9,127,416 33.2 
2 Infectious and parasitic diseases 3,811,044 13.9 
3 Cancer 3,566,128 13 
4 Respiratory disease  2,018,967 7.3 
5 Respiratory infections 1.812,342 6.6 
6 Unintentional injuries 1,408,698 5.1 
7 Per natal conditions 1,379,337 5.0 
8 Digestive diseases 865,847 3.1 
9 Diabetes mellitus 723,273 2.6 
10 Neuropsychiatric conditions 640,406 2.3 
 Total  27,501,236  
 
The majority of CVD deaths occur in low- and middle-income countries.49 Based on 
statistics from the Global Burden of Disease study, over 25% of CVD deaths in low- and 
middle-income countries come from the South Asia Region (SAR).50 The SAR consists 
of approximately 20% of the global population, with 1,470 million residents.50 In this 
region, India accounts for 75% of its inhabitants. CVD is responsible for over 25% of all 
deaths in the SAR.50 By 2030, the number of CVD deaths is expected to increase to 
23.6 million, from a total of 44 million NCD deaths.51 CHD is the most prevalent form of 
CVD, accounting for 90–95% of all CVD cases and fatalities.52   
 
CHD is one of the leading causes of disease burden in developing countries.50 In 2012, 
there were 7.4 million deaths due to CHD worldwide.21 The majority of global deaths 
and more than 80% of the total DALYs due to CHD take place in low- and middle-
income countries.50 It is expected that by 2020, the global burden of heart disease will 
rise, both in relative and absolute terms and that 34–37% of all deaths will be attributed 
to CHD.53, 54     
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2.2   Coronary Heart Disease in India 
As measured in 2010, CHD was the number one cause of mortality in India, replacing 
infectious diseases.45 There were more than 1.67 million deaths from CHD in 200827 
and CHD is expected to account for at least one-third (33.5%) of total deaths by the 
year 2015.55 
 
CHD has a greater incidence among Indians than any other ethnic group.56-58 The CHD 
risk of Indians is four times higher than that of Americans, six times greater than the 
Chinese and 20 times more than that among Japanese.57 The prevalence of CHD in 
urban India has risen four-fold over the last 40 years and has doubled in rural areas 
over the past 30 years.59 The prevalence of CHD is 7%–13% in urban populations and 
2%–7% in rural populations in India.60, 61 Approximately 31.8 million people are living 
with CHD in India.62 It is also estimated that only one-quarter of these individuals are 
aware of their condition and seek medical care.50 Despite this, nearly 25% of all medical 
admissions are due to CHD according to a survey carried out on hospital information in 
Delhi.62 Patients who do not solicit proper treatment die at a rate of 7%–8% per year.62  
 
More than 50% of CHD-related deaths in India occur in the age group of 35–64 years 
compared to around 22% of such deaths in the same age group in Western countries.63 
About 5%–10% of heart attacks or myocardial infarctions (MI) occur in Indian adults 
aged 40 years or below.64 The INTERHEART study suggested that the earlier age of 
heart attack in Asian Indians is likely due to the earlier onset of major CHD risk factors 
and a relative lack of access to the preventive and treatment interventions.65, 66 Earlier 
onset of risk factors is due to poor self-awareness and the failure to adopt healthy 
practices.66, 67 CHD affects Indians in their more productive years of age—at least 10–
15 years earlier than their western counterparts—effectively translating into a greater 
impact on the country’s economy.68, 69 In 2005, India experienced the ‘highest loss in 
potentially productive years of life’ worldwide.70 India lost USD9 billion in national 
income from premature deaths owing to heart disease, stroke and diabetes.70 These 
losses are expected to reach a cumulative total of USD237 billion over the next 
decade.58, 71   
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2.2.1 CHD and women 
Evidence shows that CHD is one of the most significant causes of disability and 
mortality in women during childbearing years.25 Regardless of race or ethnicity, the 
disease accounts for the deaths of one in three women.26 An estimated 3.4 million 
women die from CHD in each year worldwide.27 Women diagnosed with CHD 
experience greater morbidity and mortality than men. A higher proportion of younger 
women (52%) than men (42%) who experience a heart attack, die of sudden cardiac 
arrest before reaching a hospital.72 Likewise, 38% of women suffering a heart attack die 
within one year in contrast to 25% of men who die within one year.73 After a heart 
attack, heart failure occurs within six years in 46% of women compared to 22% for 
men.73 
 
It is estimated that, of the women who will die from CHD, 80% of the deaths will occur in 
low- and middle-income countries.28 Women in low- and middle-income countries living 
in poverty are particularly vulnerable to CHD. The report of the Registrar General of 
India on causes of death also stated CHD as the most significant cause of death among 
women in India.74 Evidence suggests that there is a greater proportion of women in 
India with CVD than men.75 A study found the prevalence of CHD among men was over 
6% and women over 10% in India.76 More than half of the 800,000 annual CHD deaths 
in women occur prematurely.74 Adult female mortality has considerable impact on 
household welfare. The impact encompasses food insecurity and increased mortality 
amongst small children, increased work burden on children as well as their forced 
detachment from school and ultimately overall loss of assets.77 
 
2.2.2 Aetiology and pathophysiology of CHD 
Atherosclerosis (formation of atheromatous or fatty plaques in the walls of blood 
vessels), which is the primary pathological process, leads to CHD, progresses gradually 
and is usually asymptomatic for a significant period. The rate of progression of 
atherosclerosis is subject to several modifiable CHD risk factors: hypertension, 
abnormal blood lipids, diabetes mellitus, tobacco use, an unhealthy diet and physical 
inactivity. Sustained exposure to these risk factors leads to further progression of 
atherosclerosis (calcification or hardening of the walls of blood vessels), narrowing of 
blood vessels and obstruction of blood flow to the heart muscle48 (please see Figure 3). 
The common clinical manifestations of CHD include angina pectoris, acute myocardial 
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infarction (MI) or heart attack, congestive heart failure, cardiomyopathies, inflammatory 
heart disease and sudden death.52, 78 
 
 
Figure 3: Heart with muscle damage and a blocked artery 79 
(Figure 3A shows a heart with damaged muscle caused by a heart attack or MI. Figure 3B 
shows a cross-section of a coronary artery with a blood clot and plaque accumulated). 
 
2.2.3 CHD risk factors and population in India 
Presence of a particular risk factor in an individual may increase the probability of 
developing a certain type of disease, but it does not suggest that the person will 
inevitably develop that disease.80, 81 CHD risk factors are divided into two broad 
categories: modifiable and non-modifiable. A modifiable risk factor is one which can be 
changed. In contrast, a non-modifiable risk factor cannot be amended. Major modifiable 
risk factors include hypertension or high blood pressure, smoking, abnormal lipid or 
dyslipidemia, diabetes, obesity, inadequate intake of vegetables and fruits, and physical 
inactivity. 
Non-modifiable risk factors include age, gender, ethnicity/race, family history and 
genetic disposition.80 The INTERHEART study evaluated the risk factors associated 
with a heart attack in 52 countries.72 Together, nine common risk factors (hypertension, 
abnormal lipids, smoking, diabetes mellitus, abdominal obesity, psychosocial variables, 
lack of consumption of fruits and vegetables, regular alcohol consumption and 
sedentary lifestyle) accounted for 90% of the population-attributable risk in men and 
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94% of women.72 Hypertension and elevated levels of cholesterol continue to be the 
primary causes of CHD where as tobacco use, lack of physical activity and obesity 
remain significant contributors.50 
 
The etiology and progression of CHD are related to a complex interplay of genetics and 
biological, behavioural, economic and social determinants.82, 83 The literature shows that 
the nine common risk factors mentioned earlier, explain more than 90% of the CHD in 
South Asian subjects.84 Findings from various studies have shown that, though genetic 
factors can perform a critical role, 80%-90% of people dying from CHD in India have 
one or more major modifiable lifestyle risk factors.49 Several epidemiological studies 
conducted in India have reported an increase in these CHD risk factors among adult 
Indians.60, 85-87 With demographic shifts, the epidemiological transition is principally 
responsible for the increase in CHD risk factors. Epidemiological change has been the 
result of rapid urbanisation, globalisation and intra-national migrations.88, 89 Rapid 
urbanisation leads to change in lifestyles such as increased unhealthy dietary practices, 
sedentary behaviours, tobacco use, alcohol intake and increased levels of stress along 
with reduced physical activity.88, 90 Changes in lifestyle increase the mean levels of 
blood pressure, serum cholesterol and blood glucose as well as a decrease in insulin 
sensitivity.88, 91 As a result, there are an increasing number of cases of hypertension, 
dyslipidemia, diabetes and obesity. Together, these factors have accelerated the 
growth and mortality levels of CHD diseases in India. Due to a lack of concerted policy 
directions aimed at CHD control in India, the prevalence of CHD is poised to accelerate 
even further.92 
  
2.2.4 CHD risk factors in Indian women 
A nationwide epidemiological study among women reported a greater prevalence of 
multiple CHD risk factors in urban women.93 Moreover, an analysis of nationally 
representative survey data94 and findings from recent studies indicate a higher 
prevalence of hypertension in middle-aged and older women as compared to men.23 
The second and third National Family Health Surveys (NFHS) point out that smokeless 
tobacco use is particularly high in women.95 Comparison of NFHS-2 and NFHS-3 shows 
that smoked tobacco use is also increasing among women, particularly among those 
with poor literacy or low socio-economic status.95 There is also an increasing trend of 
overweight and obesity in Indian women, which is of a greater magnitude than that 
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observed among men.96 Similarly, results from several studies demonstrate a higher 
prevalence of metabolic syndrome (it is a cluster of the heart attack risk factors: high 
blood pressure, diabetes and pre-diabetes, abdominal obesity and high cholesterol) and 
diabetes in women as compared to men.93  
 
2.2.5 CHD risk in people with low socioeconomic status 
In some developing countries, including India, the epidemiological transition has 
undergone a reverse social gradient with people of lower socioeconomic status 
suffering the highest rates of CHD and associated risk factors.97 Several studies from 
Sweden, USA, France and the UK, have investigated the relation between 
socioeconomic status (SES) and cardiovascular disease. Despite substantial regional 
differences between these studies, all found that lower SES is associated with higher 
CHD risk.98-100 Similarly, 30-day followup data of patients from the CREATE registry of 
acute coronary syndrome demonstrated significantly higher mortality rates in low SES 
groups compared to higher SES groups.68 Recent case-control studies of acute MI in 
India has also suggested a reversal of the social gradient with a significantly higher 
burden of CHD morbidity in low SES groups compared to higher SES groups.68, 101  
 
2.2.6 CHD risk in people living in low-income urban areas in India 
India is the world’s second most populous country. According to the 2011 Census of 
India, the total population is 1.21 billion.102 India has witnessed rapid and unplanned 
urbanisation in recent decades due to robust economic growth. However, the escalation 
in national wealth has not been equally distributed. As a result, there has been a 
dramatic growth of the low-income population in urban India. Indian cities are faced with 
an acute shortage of adequate housing, which has led to the growth of informal sub-
standard settlements in the form of slums or squatter settlements. About 30% of the 
Indian population now live in urban areas, while the population living in low-income 
urban settlements varies from 26%–55% of the total urban population.103 Informal 
settlements are typically set up illegally either on government land or private land in a 
haphazard manner. They are unplanned and violate most norms of civic planning.104 
These settlements suffer from various infrastructural inadequacies in water supply, 
sewerage, drainage, garbage disposal, schools, hospitals and roads.105, 106 The 
settlements are overcrowded with high levels of tenancy. Home-based manufacturing 
units are common in these areas, which accommodate tenants both for residential and 
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business enterprises.105 As these settlements are illegal, most lack not only essential 
facilities but also lawful rights of occupancy, even though some of them may have been 
in existence for a long time.106 An analysis of the 2005–2006 national survey data107 
found that the proportion of people living in poverty was smaller than the proportion of 
people residing in slums, signifying that not all people living in slums were poor, 
however, the majority of poor households were located in those slums. 
 
Due to lack of infrastructure and basic health facilities, slums and other vulnerable 
settlements are amongst the world’s most vulnerable environments.108 In fact, the urban 
poor face a ‘double burden’ with high incidences of acute communicable diseases (due 
to overcrowding and unhygienic living conditions) and growing rates of chronic NCDs 
associated  with rapid urbanisation.109 
 
Many studies in India have noted a high prevalence of CHD risk factors among people 
living in low-income urban areas.23, 110-114 They are generally more likely to have CHD 
than Indians living in affluent areas because of the high prevalence of CHD risk factors 
such as uncontrolled hypertension, tobacco use, low intake of fruits and vegetables, 
and obesity.23, 110-114 Recent case-control studies in India have reported that being 
illiterate or poor is an independent risk factor for acute MI.115 Lack of access to primary 
care is higher among the poor who are resident in vast urban slums or other 
substandard settlements leading to their conditions being undetected, untreated or 
undertreated. Consequently, they suffer avoidable complications that develop from 
NCD and CHD risk factors.116 Also, due to poor compliance and adherence to 
pharmaceutical treatment, they are more vulnerable to future CHD events.117, 118 
 
Among this population group, women are particularly vulnerable with higher prevalence 
of hypertension and other modifiable CHD risk factors compared to men.23, 119 Women 
living with cardiovascular diseases experience particular challenges in accessing cost-
effective prevention, early detection, diagnosis, treatment and care of cardiovascular 
diseases. The lack of knowledge and information regarding health, poor access to 
health care, family responsibilities, and poor economic, legal and political status worsen 
their situation.119 Furthermore, in some places, cultural restrictions make it difficult for 
women to avail health care from male health care professionals, but there is, at the 
same time, a scarcity of female health care providers.120 These issues are further 
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compounded by health systems that are often unable to respond to the particular 
requirements of women with CVDs.116  
 
2.3 CHD risk factors 
2.3.1 Major modifiable risk factors 
Hypertension 
Hypertension or high blood pressure (≥140/≥90mmof Hg) is the single leading risk 
factor for CHD and one of the most important causes of premature death worldwide.18 It 
has been estimated that hypertension causes 50% of CHD death globally.18 Among 
individuals aged 40–90 years, each 20/10mmHg rise in blood pressure (BP) doubles 
the risk of fatal coronary events.121 An analysis of global data reveals that more than 
80% of deaths from hypertension and associated CVDs now occur in low- and middle- 
income countries, with people of low SES particularly affected.29 A review of 
hypertension epidemiology demonstrated a high prevalence of hypertension in both 
urban and rural areas in India. High blood pressure is prevalent in 30%–40% of adults 
in larger Indian cities and 10%–20% in rural populations.109 These results are 
comparable with other regions of Asia and elsewhere where it has been reported that 
up to about 50% of all adult individuals have high BP at any given time.109 
 
Tobacco use 
Tobacco use causes a substantial number of preventable deaths from cardiovascular 
diseases.122 Tobacco contains many components that contribute to the initiation or 
progression of atherosclerosis or trigger clinical events such as MI and angina.123 
Tobacco smoking is the single most potent risk factor for atherosclerosis.124 It causes 
about 30% of CHD deaths globally.125 Research shows chewing tobacco has a similar 
cardiovascular risk as smoking.126 According to the Global Adult Tobacco Survey 
(GATS) 2009–2010, there were almost 275 million tobacco users in India.127 Over one 
third of the adult population (48% of males and 20% of females) use tobacco products 
in one form or another.  In India, a higher proportion of smoking tobacco users die from 
CHD than from any other diseases.128 
 
Dyslipidaemia 
Dyslipidaemia is characterised by elevated blood total cholesterol, triglyceride, low-
density lipoprotein cholesterol (LDL-C) concentrations and low levels of high-density 
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lipoprotein cholesterol (HDL-C) concentrations.129 According to the INTERHEART 
study, abnormal blood lipid is one of the most important risk factors for MI globally.72 
There is evidence of high prevalence of dyslipidemia among the urban slum population 
due to rapid acquisition of adverse lifestyles.130-132 A study conducted amongst urban 
slum-dwelling residents in northern India found that approximately 27% of the men and 
28% of the women had high levels of total cholesterol. Low HDL-C was seen in 16% of 
men and 17% of women, and high triglyceride in 17% of men and 12% of women.132 
 
Diabetes  
Diabetes or high blood glucose is an important risk factor for CHD. People with diabetes 
have a more than two-fold greater risk of fatal and nonfatal CHD compared to non-
diabetics.133 In 2001, approximately 1.49 million deaths from CHD globally (21% of all 
CHD deaths) were attributable to diabetes.134 India has been severely affected by the 
diabetes epidemic, particularly in urban areas.135 Although countrywide data are not 
available, smaller studies have been conducted in different states of India to investigate 
the prevalence of diabetes.136 The highest prevalence of diabetes is reported from 
Ernakulam in Kerala (19.5%) and the lowest from the Kashmir Valley (6.1%). Based on 
these studies, the national average for diabetes prevalence is just above 10%.136 Misra 
et al112 reported a 10.3% prevalence of diabetes in a slum area in Delhi. 
 
Overweight and obesity 
Obesity is the most visible manifestation of the global trend of sedentary lifestyles and 
excessive calorie intake.
137
 Epidemiological studies have shown that being overweight 
and obese confers a significantly elevated risk of CHD incidence and mortality. Also, 
obesity is an independent risk factor for CHD outcomes, such as congestive heart 
failure and sudden cardiac death.137-139  
 
Even in low- and middle-income countries where under-nutrition is still highly prevalent, 
overweight and obesity, especially among women, is a burgeoning issue.140 Body Mass 
Index (BMI) is used as an indicator of underweight, overweight, and obesity. BMI is 
calculated from height and weight measurements (weight in Kg/ height in metres). 
About 21% of global CHD risk is attributable to a BMI greater than 21 kg/m2.141 The 
health risks that are associated with overweight and obesity occur at lower levels of BMI 
in Asian populations in comparison to people in North America or Europe.142   
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Consequently, lower cutoff points for BMI are used to categorise overweight (BMI 
≥23)and obesity (BMI ≥25) conditions for the Asian populations.13 According to the 
National Family Health Survey-3 (NFHS-3) in India, the prevalence of overweight and 
obesity are three times higher in urban areas than in rural areas and are more frequent 
among women.107, 143 Similarly, in the New Delhi Birth Cohort study, obesity was found 
in 54% of men and 66 % of women using BMI >25 as the cut-off point. In this study, 
more than 80% were considered overweight.144 The prevalence of obesity is also on the 
rise among the population living in low-income settlements in India. A community-based 
cross-sectional study was conducted recently in a slum settlement in Chennai city. In 
this study, in women aged 20 years and above, the prevalence of overweight (BMI ≥23) 
and obesity (BMI ≥25) was found to be 27% and 20%, respectively.9  
 
However, BMI does not differentiate between body mass due to body fat, or muscular 
build.145 Abdominal obesity, (measured by waist circumference) appears to be a 
stronger predictor of CHD than BMI. It is suggested that abdominal obesity should be 
used as an indicator of obesity.146 For Indian population, waist circumference should be 
<90 centimetres for men and <80 centimetres for women.13 Another measure of central 
obesity is Waist to Hip Ratio (WHR), normally <0.85 for women and <0.95 for men.13  
 
Recent studies have also proposed that Percent Body Fat (PBF) indicates more 
accurately body composition than BMI and waist circumference. PBF is defined as the 
proportion of individual fat mass over body weight.147 Accurate determination of body fat 
could provide clinically useful guidance for physicians to assess CVD risks in patients 
with obesity and optimise preventive or therapeutic remedies for those patients.148 
However, due to cumbersome procedures of measurement and calculation for the PBF, 
BMI and waist circumference were used as diagnostic tools in the present study to 
identify weight problems of the participants. 
 
Lack of daily consumption of vegetables and fruits 
Vegetables and fruits are the primary resource of nutrients and phytochemicals, 
including fibre, B vitamins, vitamin C, antioxidants, potassium and flavonoids that 
support cardiovascular health.149 Phytochemicals are bioactive non-nutrient plant 
compounds that are linked to reducing the risk of CHD.149 People who eat more 
vegetables and fruits have a lower prevalence of major risk factors for CHD, such as 
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hypertension, diabetes, obesity and low levels of homocysteine.150 In the INTERHEART 
study,72 daily consumption of fruits and vegetables was estimated to be 30% for relative 
MI risk reduction. The daily fruit and vegetable intake of Indians is lower compared to 
the rest of the world (27% vs. 45%).72 A community-based cross-sectional study in 
central Delhi found that, in a typical week, the daily intake of fruits was only 1% among 
participants, despite its easy availability and affordability.151 
 
Lack of physical activity 
Physical activity is defined as any body movement produced by skeletal muscle that 
requires energy expenditure. It impacts upon metabolic and other pathways that 
positively affect CHD risk factors.152 It decreases body weight, lessens platelet 
aggregation, decreases BP, intensifies fibrinolytic activity, improves plasma lipid profile, 
decreases the resting heart rate, and enhances cardiac function and cardio-respiratory 
fitness.152 Physical inactivity has been consistently linked with an increased risk of CHD, 
with 22% of CHD deaths being attributable to a sedentary lifestyle worldwide.153 A 
Finnish study showed that regardless of other risk factors that may be present, 
moderate levels of physical activity was associated with a reduced risk of premature 
cardiovascular disease and mortality.152  
 
The World Health Organisation (WHO) recommends at least 30 minutes or more of 
moderate-intensity physical activity such as brisk walking on most or preferably all days 
of the week for adult Indians, which is consistent with the CDC recommendations.154  
Currently, the changing trend of work from physically demanding work to mainly 
sedentary office-based work has resulted in a lower level of physical activity.155 People 
from both developed and developing countries (60%-85% of the world’s population) do 
not carry out sufficient physical activity to gain health benefits.156  
 
2.3.2 Non-modifiable risk factors (age, genetic factors and ethnicity) 
The global risk of CHD increases with age as the result of a progressive accumulation 
of coronary atherosclerosis and is associated with ageing.82 Moreover, family history of 
CHD increases a person’s risk of developing CHD.157 The family history is considered 
positive if clinical CHD is documented in a first-degree male relative before the age of 
55 years, or first-degree female relative before the age of 65 years.158  
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The prevalence of CHD and levels of risk factors also differs across diverse ethnic and 
racial groups.159 For example, in comparison to the general population in the USA, the 
prevalence of CHD in Asian Indians is approximately four times higher.160 It is worth 
pointing out that Asians in the USA comprise several ethnic groups. Among them, the 
Chinese have the lowest rates of CHD, and Asian Indians have the highest rates.161 
 
A better understanding of the role of CHD risk factors has contributed a significant 
progress in the development of CHD prevention policies and programs. Moreover, the 
value of early detection and treatment of risk factors have been well acknowledged in 
the prevention of CHD and reduction of the disease consequences.157 
 
2.4 Prevention of CHD 
Evidence shows that control of risk factors has led to a 50%–80% decline in the 
incidence of cardiovascular diseases in high-income countries.58, 162 However, due to 
lack of appropriate preventive approaches, the prevalence of CHD risk factors are 
increasing in low- and middle-income countries.163 WHO has classified CHD prevention 
as population-based primordial, individual-based primary, and patient-based secondary 
prevention.58  
 
Primordial prevention: population based 
The population-based primordial approach is used to deal with behavioural risk factors 
at the community level. The success of this approach depends on population-wide 
education, partnerships with community organisations, the assertion of health services, 
policies regarding environmental changes, and legislative initiatives.164 In this approach, 
while the cumulative societal benefits are significant, individual benefits are relatively 
small. This approach does not provide an adequate response to the need to strengthen 
health care for people at high risk of CHD. Consequently, the CHD burden can be 
reduced considerably if the population-based approach is used in conjunction with 
health care interventions for individuals who either already have CHD or are at high risk 
of developing CHD.165-167  
 
Primary prevention: individual based 
In primary prevention, ‘the high-risk approach’ aims at identifying persons at the highest 
risk of diseases (that is, those with markedly elevated risk factors), focusing on 
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preventing the first occurrence of a clinical event.58 Interventions to reduce the risk 
factor levels might include, for example, use of blood pressure lowering medications or 
behaviour modification intervention in patients with hypertension, to prevent the earliest 
incidence of a heart attack. Hence, screenings for elevated blood pressure in at-risk 
groups are critical facets of CHD prevention guidelines.168 The high-risk approach for 
individuals is often pharmacological-based and relatively more expensive than the 
population-based approach, but its focus on projected individual risk and anticipated 
personal benefit can elicit greater motivation in patients.169 
 
Secondary and tertiary prevention: patient based 
Secondary prevention averts the recurrence of clinical events and also reduces 
mortality in patients with established CHD,157 whereas tertiary prevention incorporates 
appropriate treatment and rehabilitation approaches to slow the disease progression 
and reduce detrimental consequences.170  
 
At present, the primary focus of health care for cardiovascular and other chronic 
diseases in many low and middle-income countries including India is hospital-centred 
curative care. In the case of CHD, a large proportion of people with high risk remain 
undiagnosed,167 and even those diagnosed with the disease have inadequate access to 
treatment at the primary healthcare level.171 Chronic diseases are often diagnosed at a 
late stage when people are admitted to hospitals with acute symptoms, long-term 
complications of illness or disabilities.172, 173 In the advanced phase of the disease, 
treatment usually requires expensive high-technology equipment, health workers with 
specific skills, costly medications and tertiary hospital infrastructure.158 High-cost 
interventions increase out-of-pocket spending and incur gross expenditures that can 
drive families into poverty.46 Thus, to achieve a substantial impact on CHD, an 
approach is required to serve both the individual with overt disease and those with risk 
factors that predispose them to disease in later life.158 
 
2.4.1 Recent guidelines for CHD risk management 
Globally, treatments of CHD risk factors have resulted in a 50% decrease in deaths 
from CHD over the past 30 years.174 However, the concept of primary and secondary 
prevention is, in many ways, outdated.175 In a personal risk factor approach, a patient 
with modest levels of some risk factors may have a moderate or high total risk of a 
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CHD-related event, yet not be offered risk-reducing therapies.176 This approach takes 
into account the individual risk factor but not the degree of other strong risk factors 
including age. Accordingly, the high-risk approach often misclassifies millions of adults 
who could benefit from risk-reducing therapy.176 Ultimately, risk factor identification 
alone may not provide the physician adequate knowledge to make an appropriate 
decision about the use of pharmacologic agents for primary prevention. Therefore, 
preventive pharmacotherapy should take the patient’s global or absolute risk into 
consideration, and not just risk factors.30 
 
Global CHD risk (GCR) approach 
Recent guidelines for CHD risk management have emphasised the use of the global 
CHD risk approach. This method requires concomitant assessment and management of 
multiple risk factors for individuals.158, 177-180 Research has confirmed that CHD risk 
factors frequently occur in a cluster in an individual181 and that the danger of developing 
CHD is determined by the cumulative effect of multiple associated CHD risk factors.182 
When multiple risk factors are present (even mildly or moderately elevated levels) in an 
individual, as compared to someone with just one high-risk factor, the overall likelihood 
of CHD of that individual may substantially increase.183 The knowledge of the multi-
factorial nature of CVD has prompted the development of global CHD risk management 
systems based on ‘absolute risk’ of developing CHD. 
 
The typical clinical approach to primary prevention of CHD depends on identification 
and treatment of individual risk factors, such as hypertension and dyslipidaemia; in 
contrast, GCR is based on an empiric equation that combines all significant risk 
factors.182 GCR is a calculation of the total risk of having a CHD event over a given 
period, expressed in terms of the number of years (usually 5 or 10 years).30 The event 
can be ‘hard’ (e.g. myocardial infarction, sudden cardiac death) or ‘soft’ (e.g. chest 
pain). Epidemiological data suggests that incorporating risk factors into global scores is 
effective in computing an individual’s total cardiovascular risk with reasonable accuracy 
and accordingly, making possible a balanced approach to detrmine who should obtain 
treatment.158 The absolute, or global score, facilitates the intensity of interventions to be 
matched to the degree of total cardiovascular risk.158 
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Research has confirmed that CHD risk factor ‘clustering’ frequently occurs in 
hypertensive individuals, with about 40% of CHD events in men and 68% in women 
being attributable to the presence of additional two or more risk factors such as 
diabetes, obesity, left ventricular hypertrophy and dyslipidaemia.184 As hypertension is 
associated with other CHD risk factors, the GCR reduction is the most important target 
for hypertension treatment.30 Assessment of GCR helps to identify those at high CHD 
risk and formulate appropriate interventions that include changes in behaviour or 
prescribing medications to prevent the manifestation of CHD.158  As part of the effort to 
improve primary prevention of CHD, several national guidelines (such as the American 
Heart Association Guidelines; National Vascular Disease Prevention Alliance’s 
(NVDPA) Guidelines, Australia and National Clinical Guidelines, UK) have 
recommended estimating the patient’s GCR as a starting point.30  
 
Using the GCR to bring a hypertensive patient’s risk factors to a particular threshold has 
proven to be cost-effective, because it is a means of preventing hospitalisation and 
avoiding tertiary treatment costs.185 The WHO estimates that out-of-pocket health care 
expenditure of more than 15%–20% of total national health expenditure can lead to 
impoverishment; India’s proportion in 2013 was 58%.186 GCR assessments can help 
allocate preventive care to patients in need and restrict unnecessary drug treatment in 
low-risk patients.187 
 
An additional underlying goal of assessing GCR is the motivation of physicians to 
address a patient’s CHD risk. GCR assessment assists health professionals in 
communicating CHD risk with their patients in an effective manner.188, 189 Once doctors 
know a patient’s GCR, they are more likely to prescribe risk-reducing therapies such as 
antihypertensives, statins, and aspirin.30 Besides, patients who are aware of their risk 
level are more likely to initiate risk-reducing therapies.30 The literature indicates that 
assessment of GCR is particularly useful in young and middle-aged adults.32 Even 
though risk scores may not be high in younger patients, the long-term risk of developing 
CHD can be high with increasing age. Primary care physicians have the unique 
advantage of detecting and managing these patients. Management typically involves 
not only counselling and motivating patients to take on preventive behaviour but also 
empowering them to understand their CHD risk scores and respective treatment 
targets.190 Furthermore, measurement of population-level global CHD risk guides health 
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planners to make informed decisions regarding treatment, needs assessment, 
monitoring trends and evaluating the impact of preventive interventions to reduce the 
burden of disease in a high-risk population.191, 192 
 
Studies show GCR varies among different sub-populations, independent of the major 
risk factors.33 Risk scores provide a cost effective pragmatic solution to include people 
from diverse ethnic backgrounds in the primary prevention of CHD and, thereby, has 
the potential to reduce the enormous economic burden of health care in developing 
countries such as India.158 Research that explores the global CHD risk has now become 
crucial in order to focus prevention strategies on the settings of underserved 
communities.31 
 
2.4.2 CHD risk assessment tool or risk scoring chart 
There is some disagreement about the best approach for assessing global CHD risk. 
Depending on the requirement of the nature of risk factors, various versions of CHD risk 
measurement tools have been developed.158, 167 Most risk assessment charts have 
included patient’s age, sex, systolic blood pressure, smoking status, diabetes mellitus, 
and total cholesterol level.193-195 However, many variables that can confer risks are not 
included in these risk algorithms. Therefore, existing risk estimation tools simply allow a 
rough estimate of absolute risk and cannot accurately estimate total risk.196 For 
instance, family history is not included in most risk assessment tools. Patients with a 
family history of early-onset cardiovascular disease are likely to be at greater risk than 
the tools indicate.158 On the other hand, there is little evidence that adding additional 
variables (e.g. lipoprotein levels, a presence of left ventricular hypertrophy, C-reactive 
protein and homocysteine) in traditional CHD risk calculation tools, can improve overall 
predictive ability or inrease cost-effectiveness.197 Despite these shortcomings, existing 
CHD risk assessment tools are recommended for the evaluation of global CHD risk, as 
they are constructive, convenient and easy enough to be used in clinical settings. 202     
 
The non-laboratory-based method for the assessment of CHD risk 
Since developing countries have limited resources for prevention strategies that require 
laboratory testing, they can use a risk prediction method that does not need any 
laboratory tests.5 In addition to the overall predictive discrimination, a non-laboratory 
screening process can classify patients correctly at the thresholds that most prevention 
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guidelines choose for initiating treatment. Research shows that the non-laboratory-
based model correctly classifies most men and women at the 10% and 20% five-year 
risk thresholds and is not inferior to the laboratory-based model.5 
 
The non-laboratory-based method of risk prediction is less costly and more convenient 
than the laboratory-based method. Indeed, laboratory-based CHD risk prediction is 
inconvenient even in developed countries and is certainly too expensive and impractical 
in low-income countries with limited testing facilities. In developed countries, the added 
cost of cholesterol testing is about USD10 and an additional USD20–80 if an additional 
visit is needed. The rates for developing countries are USD1–4 for the test and USD3–7 
for an extra visit.198 For example, in India, a cholesterol test that costs USD2–4 would 
account for 5%–10% of the 2005 estimate of per capita health spending of USD40.199 
Recommended cholesterol screening to risk-stratify patients would require more than 
10% of the total Indian health care budget; besides, there is a modest or no additional 
benefit over non-laboratory means of risk stratification.5 Therefore, the additional costs 
of cholesterol testing would make screening with laboratory-based guidelines 
unaffordable. Further, in many low- and middle-income countries the personal cost of 
being seen at a health center can be rather high since to see the nurse or doctor, a 
patient frequently requires to take a day off work Finally, most developing countries do 
not have the required amenities or health care staff to implement such laboratory-based 
screening at the primary health care level.5  
 
The US National Health and Nutrition Examination Survey (NHANES) followup cohort 
demonstrated that a non-laboratory-based risk tool can predict CVD outcomes that 
were no different from the Framingham-based risk tool.5 To estimate global CHD risk, 
the NHANES non-laboratory-based risk chart includes age, systolic blood pressure, 
BMI, diabetes status and smoking status. The results of goodness-of-fit tests suggest 
that the non-laboratory-based model is well calibrated across a broad range of absolute 
risk levels and without changes in the classification of risk. It can be applied in one clinic 
visit with minimal equipment, and a prediction risk value apportioned with a treatment 
decision able to be made in the same 5–10-minute visit without the cost or the time 
needed to wait for laboratory results.5 The NHANES non-laboratory-based risk table 
differs from the World Health Organisation/International Society of Hypertension 
(WHO/ISH) chart, in that it includes the BMI, and it is based on a model that has been 
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validated against a laboratory-based model using a cohort that was followed 
prospectively.5 The WHO/ISH charts have not yet been validated, nor have they been 
compared to established laboratory-based scores.158  
 
However, risk profiling protocols lack universal applicability200, 201 and may be of limited 
applicability to developing countries, whose populations were not sampled for the 
Framingham and other studies.202, 203 Uncritical application of such protocols in hitherto 
untested populations may result in negative clinical and economic consequences.204 It 
has been suggested that until the region or country-specific scores are accessible, 
health providers could consider using the WHO/ISH non-laboratory-based risk table or 
the NHANES non-laboratory-based risk chart5 but health providers in those countries 
should recognise that the WHO/ISH chart and NHANES chart might miscalculate 
absolute risk. The probable inaccuracy in assessment would require to be considered 
against the health fatalities linked with no screening whatsoever.5 
 
2.5 Management Gap in CHD prevention 
Despite overwhelming evidence supporting the benefits of CHD preventive strategies, 
there has been a limited analysis of how extensively they are being implemented in 
health care. Several recently published studies in developed countries have shown 
substantial gaps in CHD risk management.205-208 Research has demonstrated that the 
following major obstacles often stand in the way of quality cardiovascular care: 
 
1. Physicians’ lack of understanding of GCR, sub-optimal and incorrect use of risk 
assessment tools and substantial underestimation of a patient’s risk.188 Studies 
in developed countries have shown a low use of risk prediction charts to 
estimate an individual’s 5–10 years GCR scores in primary practice (varying 
from 17%–47%).188, 209-211 Moreover, studies assessing the correspondence 
between physicians’ assessment of CHD risk at a primary practice and patients’ 
actual CHD risk, suggest the tendency of physicians to underestimate the 
patient’s risk.188, 212 As a result, those who qualify for drug therapy are not 
necessarily receiving it. Consequently, the quality gap in the treatment of CHD 
risk factors is striking among hypertensive patients with multiple risk factors. 
Evidence shows that there are sub-optimal uses of medicines, such as beta-
blockers (antihypertensive), statins (lipid-lowering drugs) and aspirin, for CHD 
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prevention in high CHD risk hypertensive people in India.213, 214 Furthermore, use 
of these drugs is significantly lower in women than in men.215  
2. Physicians may not have the required knowledge, attitude, and motivation to 
include preventive services into their practice.216 
3. Patients’ lack of eagerness and keenness to adhere to therapy and followup 
with their physicians.216 Perception of disease risk will influence individuals’ 
motivation and desire to change their risk behaviours, comply with treatment, 
and followup with their physicians. 
 
2.6 Perception of CHD risk and preventive behaviour 
2.6.1 Perception of risk 
The literature indicates that by influencing individuals’ perceptions and beliefs about a 
given risk, health providers can enhance the likelihood of people adopting healthier 
lifestyles.217-219 Individuals have a distinctive perception of their possibility of 
experiencing an undesirable health event and these attitudes differ commonly. It is, 
therefore, crucial to emphasise the importance of assessing individual risk perceptions. 
At the lower end of the scale, some individuals may disagree with the likelihood of 
meeting a particular health threat; those in the mid-range may acknowledge the 
statistical chance of disease vulnerability; at the other end of the scale, some may 
exaggerate their risk of the health threat and, thus, increase the danger of the disease 
impacting their lives.220  
 
2.6.2 Perception of global CHD risk and preventive behaviour 
Perceived global CHD risk (GCR) is defined as the perception of the likelihood of 
experiencing a premature CHD event.221 Evidence shows that CHD is preventable if 
people have an accurate perception of their risk of developing CHD. Inaccurate 
perception of GCR has important implications for CHD prevention, because people who 
do not perceive themselves as susceptible to CHD are less likely to adopt 
recommended behaviours to prevent it.222 Only a small number of women recognise 
CHD as their greatest health threat.36 As a result of the mistaken belief that CHD affects 
mainly male, there is a considerable gap between perceived and actual risk of CHD in 
women. These inaccurate perceptions may lead women to underestimate their 
likelihood of CHD so that they fail to look for early interventions to prevent avoidable 
morbidity and mortality.36  
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An accurate perception of a patient’s GCR by both the patient and the doctor is 
necessary, as this is one of the important components that determines health-related 
behaviour.223 Individual risk perception is a central construct in some health behaviour 
models including the Health Belief Model (HBM).224 The HBM proposes that patients 
weigh up a health-related behaviour (e.g. adherence to medications) by considering 
their perceived susceptibility to illness and the seriousness of the disease, as well as 
the benefits of the action. Perceived susceptibility is one of the strongest predictors of 
preventive health behaviours.225 
 
The HBM has been successfully applied and tested in many studies aimed at 
understanding patients’ adherence to treatment recommendations concerning CHD 
prevention. Ali226, 227 tailored the HBM’s major concepts to explain women’s participation 
in CHD prevention behaviours. This study included 178 women aged 50 years or older 
from three Midwestern churches in the USA, who did not have a history of heart 
disease. In Ali’s model, a woman’s perception consists of how susceptible she 
perceives herself to be at risk of CHD and how serious she perceives CHD to be. Using 
this model, Ali226 found that perceived susceptibility to CHD explained the majority of 
variances (50.7%) of CHD behaviour followed by knowledge of risk factors (explaining 
19.5%). These were also statically significant predictors of CHD preventive actions in 
women. Interestingly, Ali also found that perceived seriousness of CHD did not predict 
preventive behaviours for these women, although the majority of these women had at 
least one significant risk factor such as hypertension, diabetes, hyperlipidemia or family 
history. It appears that women do not personalise their risk of developing CHD despite 
their awareness of their risk factors. In another study, the HBM was used by Mirotzink 
et al. to explain attendance at a supervised community-based exercise program for 
CHD prevention.226 They found that two dimensions of the model were associated with 
attending the program: perceived benefit and perceived severity of CHD.  
 
Perceived GCR appears to be positively correlated with actual behavioural change and 
with a desire to make risk-reducing behavioural changes.228, 229 Successful primary 
prevention requires early identification of CHD risk factors and communication of GCR 
to patients. Assessment and communication of GCR are essential since it can help 
patients in developing more pragmatic perceived risks of CHD.230 A Cochrane review 
found that, in comparison to general risk communication, personalised communication 
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(i.e. presenting individualised risk scores) is associated with improved cognitive 
outcomes (i.e. increase knowledge, improved accuracy of risk perception and utilization 
of primary and secondary CHD prevention programs).231 A communication gap about 
absolute CHD risk and treatment targets during the consultation between health care 
providers and their patients can lead to hypertensive patients have an inaccurate 
perception of  GCR and, consequently, of the value of achieving treatment goals. The 
literature reveals that CHD risk factors alone do not necessarily assist a patient’s 
estimation of his or her risk.226 Other factors, including knowledge of CHD risk 
factors,221, 232, 233 perceptions of general health,189 and demographic variables such as 
age, education, personal income189 and family history, may be related to accurate 
perceptions of personal CHD risk and thereby indirectly influence treatment-related 
behaviour.189  
 
However, the association between behaviour change and risk perceptions is not linear. 
Furthermore, the optimal level of risk perceptions directing behaviour change is not 
clear.234 For instance, Wilcox and Stefani’s study failed to demonstrate a relationship 
between perception and knowledge of risk and following recommended CHD health-
promoting behaviours.232 Sometimes, even overestimated risk perceptions may lead to 
fatalistic or avoidance behaviours.234 Nevertheless, the literature suggests that, even 
though risk perception does not inevitably influence changes in behaviour, 
acknowledging one’s personal perception of risk may be the primary step toward CHD 
health promotion.235 236  
 
2.6.3 Measurement of perceived global CHD risk (GCR) 
Perceived GCR can be measured in several ways. The most fundamental risk 
measurement is to ask an individual’s perception of the likelihood that a CHD event will 
occur at some point in the future (i.e. personal risk).237 There are several approaches 
available for measuring risk perceptions including a percentage or numeric scale, 
verbally labelled scales and visual or graphic scales. There is no indication that any 
scale is consistently superior to another for measuring risk perceptions. Both numeric 
and verbally labelled scales are valid and reliable.238 If the goal of an investigation is to 
compare risk perception with actual statistics, a numeric scale can be used.239 Where 
comparisons with statistics are not planned, then a five- or seven-point verbally labelled 
scale can be used239 because ordinal scales permit the measurement of the degree of 
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variance but not the specific amount of difference.240 Frequently, ordinal scales are 
used as interval scales, but it is unclear if the distance between the response categories 
in ordinal scale is equivalent. Therefore, the mean cannot be calculated by these 
scales.240 
 
It has been suggested that a numeric scale is appropriate for use in cultures such as in 
India.241 In India, attitude measurement with a Likert-type scale has been problematic 
because the agreement categories, when translated into the local language, are open 
to subjective interpretations.241 The Likert scale typically consists of a five-point scale 
ranging from ‘strongly agree’ to ‘strongly disagree’ and is well accepted and tested in 
Western countries. In cross-cultural contexts, the applicability of the Likert scale is 
debatable242 because there is major problem with construct validity.243 Within the Indian 
culture and the Indian languages, there is no clear-cut difference between ‘strongly 
agree’ and ‘agree’ or ‘strongly disagree’ and ‘disagree’. Therefore, numeric response 
scales that provide more objective response categories may be more appropriate to 
overcome the subjective Likert response categories in countries such as India.242  
 
Information about actual total CHD risk is needed to investigate the accuracy of the 
study participants’ perception of their personal risk. A few earlier studies depended 
simply on epidemiological data to evaluate the accuracy of participants’ perception of 
CHD risk and did not refer to the participants’ total risk. However, the outcomes would 
be more precise if the participants’ calculaed total CHD risk was taken into account.230 
 
2.6.4 Discrepancy between individual’s perceived and absolute CHD risk 
Optimally, a patient’s perceived risk of developing CHD should match the patient’s 
actual calculated risk.230 However, several studies17, 223, 230 have found differences 
between perceived and calculated global risk. It appears that people can often be 
inaccurate in their risk estimates, and the bias tends to be towards either optimism or 
pessimism in risk accuracy.223 Inaccurate risk estimation has been confirmed in many 
different populations by both qualitative and quantitative research.17, 222, 230, 244, 245 That 
patients do not have an accurate understanding of their risk may be due to insufficient 
knowledge about CHD risk factors.230, 246 Patients often tend to have a dichotomous 
understanding of risk (e.g. ‘I have/do not have this risk factor’) rather than 
understanding risk as a continuum.223 
51 
 
Persons who accurately perceive their risk of cardiovascular diseases may be more 
likely to adopt behaviours that reduce their risk, compared to those who do not perceive 
themselves to be at risk.247 248-250 Evidence shows that older age,223, 245 smoking,245 
male gender,17 the presence of typical CV risk factors including obesity245 and high 
blood pressure,245 and higher education levels are associated with the accuracy of 
estimated CHD risk.245, 251 It  is believed that communication of the personal global CHD 
risk score (GCR) score can assist patients in developing a more realistically perceived 
GCR that, in turn, may motivate them to initiate and maintain appropriate treatment- 
seeking behaviour.32 On the other hand, perceived stress and lower personal income 
were found to be the strongest correlates of underestimation of risk.252 A mismatch 
between patients’ actual risk assessed by physicians and patients’ perception of their 
global CHD risk might lead to conflicts between the physician’s intended management 
and the patient’s expectations.246  
 
Understanding the relationship between women’s perceived CHD risk and health-
promoting behaviour is important to improve the health of women and prevent their risk 
of developing CHD.36 CHD risk perceptions were studied in women in different parts of 
the world. However, there is a lack of information about the perceived CHD risk of 
hypertensive women in India. Knowing the patients’ perceived risk and bringing them 
into line with the actual risk is a prerequisite for effective CHD prevention management. 
Hence, there is a fundamental need to develop interventions for enhancing an accurate 
perception of CHD risks.35  
 
2.7 Hypertension 
Hypertension is a chronic systemic disease and the leading risk factor for death and 
disability worldwide.253 Blood pressure (BP) is the force exerted by blood against the 
walls of arteries due to the pumping action of the heart. The peak and lowest pressures 
in the cardiovascular system correspond to the systolic blood pressure (SBP) and 
diastolic blood pressure (DBP) respectively.254 The optimal BP value for the general 
population is equal to or less than 120/80 mmHg. According to the Global Burden of 
Disease 2010 study (GBD 2010), hypertension is foremost among the top ten risk 
factors for the disease worldwide.255 In 2010, hypertension was accountable for 9.4 
million deaths and 7% of Disability-adjusted Life Years (DALYs) globally.255 Between 
the years 2000 and 2013, the number of deaths due to hypertension rose from 7.6 to 
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9.4 million.255 In the South East Asia region, one in three adults are estimated to have 
hypertension.256 
 
Hypertension is a most important risk factor for CHD and is also accountable for more 
deaths globally than any other CHD risk factor.257 It is directly responsible for 57% of all 
stroke deaths and 24% of all coronary heart disease deaths in India.258 Longitudinal 
population studies demonstrate that the relationship between high BP and increased 
risk of CHD events is constant, steady and independent of other risk factors.259  
 
Control of cardiovascular diseases requires modification of risk factors that have a high 
attributable risk or high prevalence or both, and where most or all of the risks can be 
reversed cost-effectively.258 Evidence shows that large proportions of most populations 
having non-optimal BP values, as well as most or all BP-related risks, appear to be 
reversible within a few years with inexpensive interventions. 260 
 
However, despite significant progress being made in diagnosis and treatment, 
hypertension remains largely uncontrolled worldwide. In the USA, hypertension still 
accounts for 30% of attributable risk for all-cause mortality and 40% of  cardiovascular 
disease-related deaths.261 Uncontrolled hypertension can cause severe long-term 
damage to the heart, kidneys, eyes and other organs.262 The presence of each 
additional risk factor compounds the risk from high BP. The higher the BP, the greater 
the chance of heart attack, stroke, and kidney diseases.263 
 
2.7.1 Rising burden of hypertension in India 
Hypertension is an important public health problem in India.264, 265 It is among the top 
four risk factors of global mortality and morbidity and accounts for the highest disease 
burden in India. Hypertension is directly responsible for 24% of all CHD deaths in 
India.86  
 
In India, the prevalence of hypertension in the adult population increased from 5% in 
the 1960s to nearly 12% in the 1990s, and more than 30% in 2008.256 A systematic 
review of studies published between 1969 and 2011 reported a rise in hypertension 
prevalence from 13.9%–46.3% in urban India and 4.5%–58.8% in rural areas.266 An 
urban study on hypertension and socioeconomic status in the year 2000 showed 
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hypertension rates of 54% in low-income groups and 40% in high-income groups of 
people.50 The number of hypertensive people in India is projected to increase from 118 
million in 2000 to 214 million in 2025.260  
 
Studies in India reveal the prevalence of hypertension rises with age in both genders.267, 
268. Besides, an analysis of nationally representative survey data94 and findings from 
recent studies in India indicate a higher prevalence of hypertension in middle-aged and 
older women compared to men.23 In population-based studies, Gupta et al.64 reported 
hypertension in Jaipur, northern India, in 30% of men and 33% of women aged ≥20 
years, Joseph et al.269 reported it in 31% of men and 41% of women in 
Thiruvananthapuram, southern India, while Gupta et al.22 reported hypertension in 44% 
of men and 45% of women in Mumbai, western India. The findings may be related to 
increasing family stress and obesity which is common in middle-aged women.270 The 
rates for hypertension are also projected to increase further in Indian females (23.6%) 
than Indian males (22.9%) by 2025.264 
 
2.7.2 Hypertension among people living in low-income urban settlements 
Socio-economically disadvantaged communities in large cities are more vulnerable to 
hypertension. The current prevalence of hypertension is between 15%–54% of people 
living in urban low-income settlements in India.110, 113, 271 Earlier studies have concluded 
that, despite the presence of free or low-cost government primary care facilities, the 
majority of hypertensive subjects remain undetected and the control of hypertension is 
also inadequate.39 A cross-sectional, population-based study was conducted recently in 
Delhi to assess awareness, treatment and control of hypertension in the population 
aged 20 years and above living in slum settlements.38 The study found a lack of 
awareness and inadequate treatment-seeking behaviour (regarding medication) as the 
backdrop to a high prevalence of hypertension in these communities. The study results 
reveal that only 41% of hypertensive people were aware of their hypertensive condition. 
Of those aware, only 59% were on medication, and of those treated, only 5% had 
controlled their hypertension.38 Moreover, a recent study among low-income settings in 
Delhi also revealed that awareness and knowledge about hypertension and its 
consequences were inadequate in these communities.272  
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2.7.3 Types of hypertension  
a. Primary hypertension  
In most patients, (over 90% of individuals) hypertension results from unknown patho- 
physiology.273 Although the reasons for this type of hypertension (also termed as 
primary or idiopathic  hypertension) are unknown, many lifestyle-related risk factors are 
thought to increase blood pressure such as obesity, smoked tobacco use, high alcohol 
intake, high salt intake, sedentary lifestyle and stress.274, 275  
 
b. Secondary hypertension   
In 5%–10% of individuals, hypertension is caused by underlying renal or adrenal 
disease and is termed secondary hypertension.6 Secondary hypertension is common in 
patients with resistant high BP.6 Resistant hypertension is defined as failure to achieve 
a BP goal in patients who adhere to an appropriate three drug regimen that includes a 
diuretic.6 Essentially, hypertension cannot be cured, although secondary hypertension 
can be cured if the cause can be identified.276 
  
2.7.4 Hypertension and CHD: the pathophysiological link 
It is critical for blood pressure to remain normal or healthy, as low BP leads to 
decreased tissue perfusion, hypoxia and cellular necrosis. High BP on the other hand, 
leads to increasing cardiac afterload, and may damage functional and structural 
vascular components of organs such as heart, kidneys, brain and eyes.277 To maintain 
equilibrium, several interconnected mechanisms such as vascular volume and 
peripheral resistance, autonomic nervous system, and renin-angiotensin systems play 
roles in regulating BP within normal limits.278 
 
Epidemiological data has shown that the risk of CHD rises with increasing BP levels in 
an active, independent, graded and continuous manner. Hypertension hastens the 
development and progression of atherosclerosis, and sustained elevation of blood 
pressure can destabilise vascular lesions and precipitate acute coronary events such as 
stroke or MI.  
 
Atherosclerosis 
Hypertension can cause endothelial damage. The damaged endothelium is responsible 
for impaired production and discharge of the effective vasodilator nitric oxide.273 The 
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endothelial injury also encourages the accumulation of reactive oxygen group and other 
inflammatory factors that promote the growth of atherosclerosis, thrombosis and 
vascular occlusion.273 This inflammatory progression is an important aspect in the 
pathogenesis of both hypertension and atherosclerosis.273 Besides, Angiotensin II (an 
octapeptide hormone in the blood that performs a fundamental role in cardiovascular 
homeostasis) assists development of atherosclerosis via vaso-constricting and vascular 
remodeling effects.254 
 
Increased afterload and left ventricular hypertrophy 
Increased afterload owing to high BP can result in left ventricular hypertrophy (LVH) 
significantly, which may weaken ventricular relaxation and compromise coronary blood 
flow during diastole.279 Research confirms that LVH reduces coronary flow reserve and 
alone can predict future CHD, heart failure and sudden cardiac death.280 
 
2.7.5 Benefit of hypertension control concerning CHD 
One of the most effective and least expensive ways of preventing MI is to control 
hypertension. Controlling hypertension is associated with the reduction of 20–25% of 
MIs and more than 50% of cases of heart failure.73, 281-284 If resources are limited, it is a 
preferred strategy to work on hypertension and not on other CHD risk factors such as 
lipid and diabetes, because of the lower CHD risk attributed to them.31 It has been 
estimated that just a 2 mmHg decrease in blood pressure can prevent 153,000 CHD 
deaths across India.285 
 
2.7.6 Management of hypertension 
The prevention and control of hypertension are significant public health challenges 
worldwide.286 Though challenging, hypertension is readily detectable and modifiable, 
and is manageable in the primary care setting. In high-income countries, early detection 
and treatment with inexpensive medications have considerably reduced mean blood 
pressure, contributing to a decline in deaths from heart disease.18 Effective treatment of 
hypertension can be achieved by non-pharmacological (diet and lifestyle modifications) 
as well as pharmacological means.287   
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a. Diagnosis of hypertension 
Individuals with severe hypertension may experience dizziness, blurred vision or 
headaches. Moderate hypertension, however, is asymptomatic and often detected only 
during a routine consultation.262 Since undiagnosed hypertension can cause grave and 
enduring harm to the heart, kidneys, eyes and other vital organs, it is vital that blood 
pressure is frequently assessed, mainly in persons above the age of 60 years.262  
 
b. Classification of hypertension 
According to the seventh
 
Joint National Committee on the Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure (JNC 7) in the USA,6 hypertension in 
adults over 18 years is classified as indicated in Table 2 below. 
 
Table 2: Classification of hypertension or high blood pressure 6 
BP classification  Systolic BP  
(mmHg)  
Diastolic  BP  
(mmHg)  
Normal  <120  and <80  
Pre-hypertension  120–139  or 80–89  
Stage I hypertension  140–159  or 90–99  
Stage II hypertension  ≥160  or ≥100  
          BP=blood pressure 
 
c. Treatment of hypertension 
Goals of Therapy 
One of the crucial public health goals of antihypertensive therapy is to reduce 
cardiovascular morbidity and mortality. The Joint National Committee (JNC 8) 
guidelines support treating hypertensive persons from 30–59 years of age to a blood 
pressure goal of less than 140/90 mmHg.253 The same thresholds and goals are 
recommended for hypertensive adults younger than 60 years who are diagnosed with 
diabetes or chronic kidney disease.253  
 
Non-pharmacological treatment: lifestyle modifications 
Lifestyle modifications should be the primary approach to hypertension management in 
all cases. Lifestyle treatments have the potential to improve BP control and even reduce 
medication needs.253 The literature suggests that lifestyle modifications such as weight 
reduction, a decrease in the dietary salt intake and alcohol consumption, adoption of a 
DASH (dietary approach to stop hypertension) eating plan and regular physical exercise 
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all lower blood pressure. The DASH diet recommends consuming a diet rich in fruits, 
vegetables and low-fat dairy products with a reduced content of saturated and total fat.6 
Please see Appendix 5 for details of lifestyle modifications and their effects on 
hypertension. 
 
However, a diet rich in vegetables and fruits can be expensive. Additionally, avoiding 
fatty foods, salt and sugar, refraining from alcohol and tobacco smoking, and 
maintaining a healthy body weight, all require continued hard work and a high level of 
self-motivation by the person. Effort and motivation tends to weaken over time in the 
absence of a collective approach and government support.288, 289 Although there is 
strong evidence of the benefit of lifestyle changes in persons at high risk, the proof of 
such interventions when implemented at a population level (including those at low risk) 
is less credible.187 
 
Although all patients with hypertension should be encouraged to adopt a healthy 
lifestyle, lifestyle change alone may be inadequate to control a patient's blood 
pressure.290 
 
Pharmacological treatments 
Research shows one of the easiest ways to deal with hypertension of at-risk CHD 
people is to continue antihypertensive therapy and achieve BP control. There is strong 
evidence showing a reduction in cardiovascular mortalities and morbidities on the 
application of antihypertensive therapy for controlling high blood pressure.291 Low-cost 
generic medications for lowering blood pressure are prescribed for controlling 
hypertension and preventing the development of complications throughout the world.292 
The JNC 8 recommends initiating pharmacologic treatment to lower BP at systolic blood 
pressure (SBP) ≥140mmHg and diastolic blood pressure (DBP) ≥90mmHg in the 
general population aged <60 years, and treat to a goal of SBP <140mmHg and DBP 
<90mmHg.253 JNC 8 also recommends initiating pharmacologic treatment to lower BP 
at SBP ≥150 mmHg or DBP ≥90 mmHg in the general population aged ≥60 years and 
treat to a goal of SBP <150 mmHg and DBP <90 mmHg.253  
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Antihypertensive drugs 
Many safe and effective drugs, well evidenced by large randomised clinical trials, are 
available for initial treatment of hypertension. Please see Appendix 6 for commonly 
used classes of antihypertensive medications, their mechanisms of actions and 
common adverse effects.  
 
About 50%–75% of patients with hypertension will not reach their BP target with a 
single drug, in which case combination (two or more drugs) therapy is advised.293 When 
blood pressure is more than 20 mmHg above systolic goal or 10 mmHg above diastolic 
goal, consideration should be given to initiate therapy with two drugs, either as separate 
or in fixed-dose combinations.294 In the ALLHAT study, 60% of those, whose BP was 
controlled to 140/90 mmHg received two or more agents, and only 30% were controlled 
on one drug alone.295  
 
Followup and monitoring 
Once antihypertensive drug therapy is started, patients should revisit for followup and 
modification of drugs if necessary, at monthly intervals or less, until the blood pressure 
goal is reached.296 Pharmacological treatment of hypertension requires that patients 
should adhere to their prescribed medications and revisit for a refill when medications 
are exhausted. They should maintain their schedules for followup visits with their health 
care professionals and implement health activities that are prescribed to reduce their 
high BP.297-299 The interval between followup visits can be extended if BP is within 
normal limits and stable. For instance, a review every three months for the next year 
and six-monthly after that is recommended.296 However, more frequent visits may be 
required for patients with stage two hypertension or with serious co-morbid 
conditions.296  
 
2.8 Uncontrolled hypertension in India 
Uncontrolled hypertension is the most significant problem of CHD prevention. Despite 
the identification and control of BP being prioritised by many national and global 
organisations and the availability of inexpensive and efficient medications BP is 
inadequately controlled in most hypertensive patients.300 In India, the situation is worse 
with very low levels of hypertension treatment and control.86 There is no national data 
on hypertension treatment and control available. However, many cross-sectional 
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studies carried out in different regions of India such as in the north (Delhi 10.5%), the 
south (Chennai 7.5%, Thiruvananthapuram 8.6%), in the east (Assam 18.1%) and the 
west (Mumbai 13.6%) concluded there was suboptimal BP control.266  
 
2.9 Adherence or compliance with therapy  
Compliance with treatment has a strong positive influence on health outcomes. 
Adherence and persistence are the two conventional measures of compliance.301 The 
WHO defines adherence to long-term therapy as ‘the extent to which a person’s 
behaviour—taking medication, following a diet, and/or executing lifestyle changes– 
corresponds with agreed recommendations from a health care provider.9 The term 
‘compliance to drugs’ may be defined as ‘the extent to which a patient acts in 
accordance with the prescribed interval and dose of the dosing regimen’, reported as a 
percentage of prescribed doses taken at the given time interval.302 Although variations 
exist, all these terminologies have been used interchangeably in most studies.303 
However, the term ‘adherence’ is preferred over ‘compliance’ because, in the latter, the 
patient is passive in the decision-making, which means that the patient has no choice 
as to follow treatment recommendations or not.304 Adherence refers to the extent of the 
patient’s agreement to, and implementation of, the recommendations of the health care 
provider about the regular treatment on the timing, dosage and frequency processes.305  
 
Adherence to pharmacological treatment of hypertension has a range of advantages for 
the individual, the society and the health care system as a whole. Antihypertensive 
medication adherence improves an individual's quality of life by preventing 
complications as well as untimely death from CHD.9 To the close family member, 
medication adherence reduces psychosomatic impact related with sudden death or 
living with a family member suffering from a chronic, unbearable and unremitting 
complication because of uncontrolled hypertension.306 It also preserves family 
resources that would have been otherwise used to get health care for complications.306 
To the society at large, adherence to drug treatment is a cost saving measure as it 
reduces the occurrence of complications such as CHD and the requirement for added 
medications.47 To the health care system, adherence has been associated with reduced 
hospitalisation rates and lower medical care costs,307 which is primarily essential in a 
publicly-financed but under-resourced health care system such as in India. 
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2.9.1 Medication non-adherence 
Medication non-adherence occurs when an individual’s health-seeking behaviour is not 
in accord with the agreed recommendations prescribed by a healthcare provider.308 
Non-adherence to medications may be defined when less than 80% of the doses of 
prescribed drugs is consumed out of the total number of doses supposed to be 
consumed, or the patient has stopped taking the medications after starting treatment at 
any point in the time following diagnosis in the past.9, 11, 73 More than one-half of patients 
under treatment discontinue their medications entirely within a year of diagnosis and, of 
those who remain on medication, only about half take 80% of their prescribed 
medication.9 In the USA, approximately 125,000 deaths per year were linked to 
medication non-adherence.309 Moreover, 33%– 69% of medication-related hospital 
admissions in the USA were due to poor adherence, with total cost estimates ranging 
from USD100–300 billion each year, including costs for additional physician visits, visits 
in hospital emergency, hospital admissions and extra medicines.310 
 
Approximately 75% of cases of antihypertensive treatment failure are attributable to 
poor adherence to medication.9  Achieving optimum hypertension control by improving 
adherence to antihypertensive treatment has now become a substantial challenge.311 
Medication adherence for hypertension control is influenced by multiple factors related 
to the patients, the health professionals, government and the health care system.312, 313 
Few studies on medication adherence have been carried out in Asian and other 
developing countries.308 More studies on antihypertensive medication adherence in 
these regions would be helpful to bridge the knowledge and practice gap and contribute 
to formulating strategies for countering non-adherence.308 
 
2.9.2 Methods of measuring medication adherence 
A range of direct and indirect methods can be used to evaluate or measure medication 
adherence, ranging from patient self-reporting to the use of sophisticated electronic 
medication monitors.314 There is no best-practice or ‘gold standard’ for precise 
measurement of adherence.314, 315 The methods available for measuring adherence can 
be classified into direct and indirect methods of measurement. 
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a. Indirect methods   
Indirect methods include patient self-reports, patient questionnaires, pill counts, rates of 
prescription refills, electronic medication monitors, measurement of physiologic 
markers, assessment of a patient’s clinical response as well as patient diaries.198, 316 
Indirect methods are convenient and inexpensive to obtain.317 
 
Patient self-report  
The most easy and low-cost method of measuring adherence is patient’s self-report.318 
Self-report defines the measurement of adherence using questionnaires or by 
interviewing patients directly about their medication-taking and lifestyle habits.319 A key 
benefit of self-report is the quick and simple application, with most non-adherent 
patients usually  admitting to not taking medications on certain days.320 These tools can 
identify non-adherence and factors that contribute to it.320 In community surveys, patient 
self-reporting seems to be more feasible than other indirect methods. One limitation of 
these tools is that some patients may give desirable, rather than truthful information.317 
Patients may prefer to ‘save face’ than admit non-adherence to taking medication to a 
health professional, who they may perceive to be judgmental or critical.319  
 
Monitoring clinic attendance  
The most important appeal of this method is that it is effortless and economical. 
However, the main disadvantage of this approach is that clinic attendance does not 
essentially show a relationship with taking medication or maintaining the suggested 
lifestyle.  
 
Pill counts  
Pill counting may involve visiting patients to count the number of leftover pills in the 
container. This method is attractive to many investigators due to its simplicity and 
directly observable nature. However, the method is not free from problems. For 
example, patients may discard pills and switch over to liquid medication in bottles 
before visits, in the pretense of having followed the regimen. For such reasons, pill 
counting is not a perfect measure of adherence.321, 322 Besides, this method does not 
give information on dose timing and medication holidays, where the medication has 
been discontinued on three or more consecutive days, both of which assist to decide 
clinical outcomes.124  
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Pharmacy refills records  
The number of refilling prescriptions received by a patient may be used to measure 
overall adherence in general in a closed pharmacy system (that is health maintenance 
organisations, military hospitals or countries with universal drug coverage), given that 
refills are measured at a number of points in that time. This method is comparatively 
low-priced and does not invade a patient's confidentiality.323 The main disadvantage of 
this practice, however, is that it does not essentially correlate with actual medication 
intake as other factors such as carelessness or forgetfulness may contribute 
considerably to non-adherence.323 
 
Medication events monitoring system (MEMS)  
The medication events monitoring system (MEMS) is an electronic pill bottle that 
encloses a microprocessor fixed in the bottle cap. The processor records the time and 
date the bottle is opened and by this means provides an objective method of evaluating 
adherence.324 In this method, it is understood that patients take the medication when 
the pack is opened. However, a study of adherence with the MEMS showed that in 
0.4% of patients the tool went wrong, and in 62% of patients there was a difference 
between the number of bottle openings and actual medication intake.325 Besides, 
electronic monitoring devices are very expensive and impractical for use in daily life.319  
 
b. Direct methods 
Direct methods of measuring medication adherence involve the assessment of serum 
and urinary concentrations of drugs or using biological markers incorporated into the 
tablets.315 Inspite of their higher sensitivity and specificity, pharmacological methods are 
not regularly used in clinical practice.315 This strategy is costly and not convenient for 
patients. Moreover, only a limited number of drugs can be examined in this way. Direct 
measurements are challenging in hypertension treatment since many patients are on a 
number of drug combinations. Dissimilar bioavailability, completeness of absorption, 
metabolism and excretion rate of various drugs are factors that make it complicated to 
correlate drug concentrations in blood or urine with adherence.326  
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2.10 Health care in India 
2.10.1 Government health care services 
Health care services in India are largely the responsibility of state governments. The 
health policy and planning framework are formulated by the central government.327 
Government health care facilities include teaching hospitals, secondary level hospitals, 
first level referral hospitals, dispensaries, primary health centres and sub centres, and 
health posts. In addition, there are public facilities (typically hospitals of different 
capacities, and dispensaries or clinics) for particular prefessional groups like the 
Employees State Insurance Scheme (ESIS), defence, and the Central Government 
Health Scheme (CHGS) etc.327 
 
The government health care system has three levels of care: primary, secondary and 
tertiary.328 Primary health care is the initial level of attention and contact point in the 
national health care system. It forms the foundation of the country’s health care 
delivery.328 Primary health care is concentrated on the wide-ranging provision of basic 
preventive, curative and rehabilitative services in the community aligned with the 
national primary health care strategy. Most of the government or public primary health 
services are free or low cost.328  
 
2.10.2 Nongovernment health care services 
Public health services in India are inadequate.327 It has been observed that with the 
increase in income, high purchasing power, and the growth of the middle class, urban 
India has witnessed a tremendous expansion in the private health care system.329 
Private health care is much more expensive and is mainly supported by direct out-of-
pocket payments. The private sector dominates ambulatory curative services. Over 
80% of ambulatory health care is supported through out-of- pocket expenses.327  
 
Private health care services usually are of two kinds: for-profit and not-for-profit. The 
former could be individual ownership, cooperative or corporate. The latter is generally a 
society or a trust, some of these also being identified as nongovernment organisations 
(NGOs). Private facilities also could be hospitals, clinics, dispensaries and diagnostic 
facilities of various sizes providing a variety of care.327   
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Studies also show that there is much heterogeneity among health care providers 
regarding qualifications, systems of medicine and practices in India. A large proportion 
of private health care providers are not qualified to provide modern health care since 
they are trained in another system of medicine or do not have any training. They include 
herbalists, indigenous and folk practitioners, compounders and others.330, 331 These 
practitioners-–being readily available and accessible locally-–are utilised extensively 
particularly by the poor. 327 
 
Though earlier studies have revealed the growing prevalence of NCD/CVD risk factors, 
health promotion and prevention of CVDs are yet to be adequately addressed in the 
country’s health system.332 Indeed, the literature indicates that health systems in India 
might not be prepared to deal with hypertension and other cardiovascular diseases 
even though cost-effective interventions are available.333 The so-called risk of a “double 
burden of disease” due to infections and NCDs poses a grave threat to the weak health 
system.333 A multiplicity of providers and extensive heterogeneity in the quality of 
clinical care result in individuals belonging to higher socioeconomic strata having 
access to the best possible, evidence-based care while, the poor lack access to even 
basic primary care.333  
 
However, the newly launched National Program on Prevention and Control of Diabetes, 
CVD and Stroke (NPCDCS) program has been initiated in 100 districts across 21 states 
during 2010–12 and it is anticipated to be implemented in 640 districts across the 
country under the twelfth 5-year plan (2013—2017) through selected institutions.334 
Primary activities under the program are yet to reach the urban poor communities. 
 
2.10.3 Health care services in Delhi  
At present, there are 509 dispensaries managed by the Delhi Government for providing 
primary care services. There are also 38 hospitals run by the Delhi Government for 
providing secondary and tertiary health care services.335 In addition, mobile health 
dispensaries are available to deliver curative and preventive health care services to 
disadvantaged people of Delhi living in slums and resettlement colonies. At present, 
there are 90 mobile health dispensaries in Delhi run by the Directorate of Health 
Services (DHS). The Mobile Health Service is a very crucial and important health 
support to the people who are not able to access the costly health facilities at private 
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clinics.335 Directorate of Health Services (DHS) is the technical wing of the Delhi 
Government. DHS is involved in coordination and implementation of various national 
and state health programs.336 Among other governmental agencies (local bodies) 
working for delivery of medical services to the citizens of Delhi, the most significant are 
the Municipal Corporation of Delhi (MCD), with its network of 403 dispensaries and 61 
hospitals, and the New Delhi Municipal Council (NDMC) with its network of 44 clinics 
and four hospitals. MCD organises the whole spectrum of public health services in 
Delhi.337 
 
Within the private sector, Delhi also has several non-profit organisations and charitable 
institutions that provide free health services or services at subsidised rates to the 
poor.338 Along with these NGOs, there are some private sector super-specialty 
hospitals, which receive patients referred from different parts of the country and from 
overseas.338 There are 883 medical hospitals or centres in Delhi with a capacity of 
42,698 beds. The hospital-bed-population ratio of 2.55 beds per 1000 Delhi residents in 
2011335 is far below the minimum 5 beds per 1000 population recommended by the 
WHO, but higher than the national average 0.7 beds per 1000 population.339  
 
Literature suggests that for primary level care, a substantial section of the population in 
both rural and urban areas access the services of individual private practitioners.340, 341 
Micro-level studies from Delhi, show that people prefer to use private practitioners as a 
first resort for acute conditions.330, 331 Poorer people unable to afford the doctor’s 
charges either choose government hospitals or go without care.342-344 
 
2.10.4 Utilisation of health care services by urban low-income communities 
The use of primary health care services is sub-optimal in urban low-income 
communities despite the supposed proximity of the latter to the medical services.336 
This is on account of their being ‘crowded out’ because of the meagerness of the urban 
health delivery system. Regardless of improved health care infrastructure, government 
primary health care services have not developed in proportion to the excessive growth 
of the urban population. Inefficient outreach and weak referral systems also restrict the 
access of the urban poor to public health care services. The Indian primary and 
secondary health care system is under-prepared to handle chronic NCDs, this leads to 
increased patient flow and patient load in tertiary care hospitals. Moreover, social 
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elimination and lack of information and assistance at the secondary and tertiary 
hospitals make low-income people uncomfortable and unfamiliar with the modern 
hospital environment, thus further restricting their access and utilisation.336 Also, the 
lack of economic resources confines their access to the obtainable private services.336 
The vast majority of the low-income population remains outside the purview or 
coverage of any type of insurance; 345, 346 the small minority that is covered; mostly 
belongs to the organized urban employment sector. 
 
The Indian government has recognised the inadequate availability and utilisation of 
existing health services in urban low-income settlements. This recognition was reflected 
in significant policy statements such as the National Population Policy 2000 and the 
Tenth Five Year Plan (2002–2007).336 To address the growing health care needs of the 
urban population, particularly urban poor, the National Urban Health Mission (NUHM) 
has been introduced by the Government of India in 2013, but it is yet to be 
implemented.332  
 
A continued neglect of the health care among overcrowded populations in urban low-
income areas will indeed lead to greater expenditure and diversion of medical 
resources in the long term. These additional expenses will be attributable to the 
management of end-stage complications of undetected or under-treated CHD risk 
factors among these populations.347 Health care systems should include this vulnerable 
group in their priority area. Therefore, there is an imperative to execute and assess low-
cost interventions for primary prevention of CHD in low-income urban areas to decrease 
the magnitude of CHD diseases in this stratum. More women-specific public health 
research is also required to deal with this issue, since most studies so far have been 
carried out on men.348 
 
2.11 Summary of the chapter 
CHD and its risk factors are greatly prevalent in urban and rural Indian populations and 
are increasing rapidly among the low socioeconomic stratum. This significant burden of 
CHD is driven by the growing prevalence of major cardiovascular risk factors among 
these groups. Women are more vulnerable among them due to the higher prevalence of 
CHD risk factors including hypertension. As most hypertensive patients living in low-
income urban areas are undiagnosed, untreated or sub-optimally treated, there is a 
67 
 
considerable management and prevention gap in CHD within this group. Women are 
more at risk due to lack of disease and treatment information, and low adherence to 
long-term treatment recommendations.  
 
As hypertension is associated with a grouping of other CHD risk factors, the GCR 
reduction is the most important target for hypertension treatment. Using available 
resources more efficiently and making treatment cost-effective, GCR becomes best–
practice in CHD preventive management. Research strategies aimed at considering the 
GCR is now essential in order to focus prevention strategies within the setting of 
underserved communities. Likewise, knowing the CHD risk perception of a population 
group is crucial for planning and implementing focused and efficient CHD prevention 
strategies. Poor adherence to antihypertensive treatment is a primary problem in CHD 
prevention. Achieving optimum hypertension control by improving adherence to 
antihypertensive treatment has now become a substantial challenge. Data on 
adherence to antihypertensive medications in India are extremely limited, particularly 
from urban low-income areas. Information on factors that influence CHD risk perception 
and non-adherence to antihypertensive treatment will help health care providers and 
clinicians to design effective interventions to reduce CHD risk burden among women in 
India.  
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3.0 Introduction to the chapter 
This chapter provides a literature review on the factors that affect treatment non-
adherence among hypertensive populations in developing countries with a special 
emphasis on urban women. The chapter ends with drawn conclusions and a summary. 
3.1 Rationale for reviewing medication non-adherence among 
hypertensive populations in developing countries  
High blood pressure or hypertension is the one of the most important risk factors for 
cardiovascular disease and a leading cause of premature adult deaths worldwide.18 
Uncontrolled hypertension causes 50% of the total coronary heart disease (CHD) 
deaths globally.18 An analysis of global data reveals that of the deaths from CHD, 
approximately 80% will occur in low and middle-income countries,28 and this is 
particularly common among people of low socioeconomic status.29 Findings from recent 
studies also indicate a higher prevalence of hypertension in middle-aged and older 
women compared to men in developing countries.22-24 CHD causes significant morbidity 
and mortality in women during childbearing years.25 Regardless of race or ethnicity, the 
disease accounts for the death of one in three women globally26 with an estimated 3.4 
million women dying from CHD every year worldwide.27 
 
Among all the WHO regions, the prevalence of hypertension is highest in the African 
Region (46%) and lowest in the region of the Americas (35%).256 One in three adults in 
the South East Asia region has hypertension.256 In developed countries, strong public 
health policies, multi-sectored preventive action and widely available diagnosis and 
treatment have led to an appreciable reduction in the prevalence of high blood pressure 
(BP).256 A systematic review of the studies published between 2001 to 2007 revealed 
that BP was poorly controlled among hypertensive population in developing countries, 
the mean proportion of control of hypertension among all hypertensive patients being 
only 13%.37 Poor medication adherence is one of the leading causes of failure to 
achieve BP control.349 Most of the studies on adherence have been undertaken in 
developed countries. However, health care access, cultural beliefs, education about 
chronic illnesses and the functions of medication, the nature of patient-physician 
interactions and social support, among many other factors, are very different in 
developing countries compared to developed countries and may profoundly affect rates 
of medication adherence.350, 351 The World Bank classifies all low- and middle-income 
countries as developing countries (however, this term is not intended to imply that all 
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economies in the group are experiencing similar development or that other economies 
have reached a preferred or final stage of development).352 In developing countries, the 
degree of non-adherence is assumed to be higher particularly due to the shortage of 
health resources and difficulties in access to healthcare.9  
 
Over the past decade, though some studies have been conducted in developing 
countries to explore the factors influencing medication adherence among hypertensive 
patients, little has been documented about medication non-adherence (MNA) and its 
determinants of hypertensive patients. This literature review was conducted to address 
this gap and examine the prevalence of MNA among hypertensive patients as well as 
investigate factors affecting MNA in this hypertensive population.  
  
3.2 Methods 
The literature search was conducted using the electronic databases: Proquest, 
PubMed, JSTOR and Science Direct for articles published during 2000-15. The online 
search engine, Google Scholar was also used to search for and identify likely papers. 
The search strategy included the following terms: adherence, compliance, treatment 
behaviour, hypertension, antihypertensive medications, non-adherence, persistence, 
belief, perception, high BP, women, and developing countries. 
 
3.2.1 Study selection 
From the initial search, 1425 titles and abstracts were identified. Duplicates were 
removed. Abstracts and titles were screened for relevance, and an initial list of 124 
relevant articles was made (please see Figure 4). The full-texts of these articles were 
then examined to determine eligibility for inclusion in this literature review using the 
following selection criteria: 
1) measured adherence to antihypertensive medications in developing countries 
2) identify factors related to medication adherence with the antihypertensive 
treatment 
3) enrolled hypertensive adults (18 years and older) 
4) published in English as a peer-reviewed full-text article 
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Figure 4: Result of screening process 
 
Studies were excluded that measured adherence of other chronic diseases or were 
conducted in developed countries and published in a non-English language. 
 
3.2.2 Data extraction and analysis  
The total number of relevant articles meeting the above criteria was 47, consisting of 45 
peer-reviewed journal articles and two thesis papers: 40 were on quantitative studies, 
five on qualitative studies and two were mixed methods studies. To check the quality of 
quantitative studies the National Collaborating Centre for Methods and Tools’ quality 
assessment tool for quantitative studies was used.353 Qualitative studies were checked 
based on NICE guidelines.354 
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A standardised data extraction form was used to record the citation details, 
methodology and objectives, and main findings of each paper. The following information 
was extracted and tabulated by the researcher: author name, date of publication, the 
country in which research was conducted, sample size, sampling method , study 
design, sex (% female), the adherence measure used, key findings and any statistical 
information (odd ratios, 95% CI p-value, correlation coefficients). A summary of the 
studies reviewed was provided in Appendix 15. A meta-analysis of the findings was not 
possible due to the heterogeneity in important aspects of methodology of the selected 
studies including sampling procedure (random/ purposive) population ages, study 
settings (hospital/ clinic/ community), study design (Cross sectional/ 
longitudinal/qualitative) and measurement of medication adherence. Descriptive 
analysis of studies examining similar variables and any association observed were 
considered to offer a simple indication of the level of evidence. Summary ranges of 
quantitative proportions and measures relating to prevalence and factors associated 
with MNA were compiled and presented. The evidence from the studies was 
synthesised and presented in a narrative review. The review followed the PRISMA 
reporting guidelines.355  
 
3.3 Results  
3.3.1 Description of the studies 
The selected studies were conducted in developing countries in Asia (22) Africa (17), 
the Middle East (4), South America (2), and Europe (1). Among the 42 quantitative 
studies, the majority (33 studies [78.57%]) were conducted in urban hospital or clinic 
settings, with only nine studies were carried out in community settings (five in India and 
one each from Bangladesh, Nepal and Nigeria). Most of the studies (34 studies) were 
cross-sectional quantitative in type. A study from Nigeria was mixed methods in type, 
comprising both quantitative and  qualitative methods for data collection.356  A summary 
of the characteristics and the aim of each study are shown in Appendix 15. 
 
The five qualitative studies were from India (1), Pakistan (1), Congo (1), Malaysia (1) 
and Nigeria (1). Three studies used one-to-one qualitative interviews, one study used 
focus group discussion, and one used a combination of these methods. Further details 
of the study designs are presented in Appendix 15. 
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In all of the studies, the study population included both males and females. Overall 
women comprised 55.98% of study participants.  
 
3.3.2 Reported adherence to antihypertensive treatment   
To measure medication adherence, 21 (50%) of the quantitative studies used the 
Morisky Medication Adherence Scale’. Other scales used in the four different studies 
were: Medicines Team Questionnaire-Qualiaids (QAM-Q) (1); Beliefs about Medicine 
Questionnaire (BMQ) (1); Hill-Bone Adherence to Blood Pressure Therapy Scale (1); 
Drug Attitude Inventory (DAI-10) (1);  One study used Medication Event Monitoring 
System (MEMS) and one used pill count to measure adherence.  The remaining studies 
used questionnaires. Among them, eleven studies used structured questionnaires with 
established reliability and or validity, while eight studies (33%) did not cite information 
on their reliability or validity. The rate of MNA among hypertensive population ranged 
from 23.8%-86.76% with the mean being 47.34%.  
 
3.3.3 Factors impacting on adherence 
The identified factors related to MNA in the reviewed studies can be categorised into 
seven domains: demographic; psychosocial; perceptions regarding hypertension and its 
severity; perceptions regarding antihypertensive treatment; perceived barriers to 
treatment adherence; treatment and disease related factors; and health care services. 
 
Demographic factors 
Sixteen studies reported significant associations between demographic variables (such 
as age, sex, level of education, types of family, household income, occupation, type of 
family, comorbidities, and use of herbal preparations) and MNA to hypertensive therapy 
(please see Table 3). 
 
Age 
The effect of age on medication adherence showed conflicting results. Younger age 
was found to be significantly associated with MNA to hypertensive medications in India 
(≤57 years) (OR = 3.348; 95% CI: 1.665–6.732),357 Palestine (<45 years) (OR = 0.40; 
95% CI: 0.157–0.99)358 and Pakistan (≤51years) (OR= 1.0; 95% CI: 1.00–1.04). The 
mean age of hypertensive patients who were not adherent to medications was 54.5 ± 
13.2 years while those who were adherent had a mean age of 60.9 ± 12.1 years (p       
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<0.001) in Ghana and Nigeria.359 On the other hand, a significantly lower level of 
adherence was identified in a study with elderly patients in Serbia. In that study younger 
than less than 65 years of age were found to be more likely to adhere to their 
prescribed treatment, compared to older patients (AOR = 6.0; 95% CI: 2.76–13.04).360 
 
Table 3: Summary of variables under the domain of demographic factors 
 
Domain Variables 
being 
investigated 
Study  Measurement  of 
medication 
adherence 
Setting and sample 
size (N) 
Demographic 
factors 
Age  Boima  et al
359
 MMAS 8 Ghana and Nigeria; 
N=357 
Nagarkar et al
357
 MMAS 8 India; N=174 
Bilal et al
361
 Questionnaire Pakistan; N=113 
Lalic et al
360
 MMAS 8 Serbia; N=170 
  
Sex 
 
Khanam et al
362
 
 
Questionnaire 
 
Bangladesh; 
N=29,960 
Praveen et al
363
 Questionnaire India; N=804 
Ismael et al
364
 Questionnaire  Iraq; N=200 
Bilal et al
361
 Questionnaire Pakistan; N=113 
Joho et al
365
 Questionnaire Tanzania; N=135 
  
 
Level of 
education 
 
 
Khanam et al
362
 
 
 
Questionnaire  
 
 
Bangladesh; 
N=29,960 
Bhandari et al
366
 MMAS 4 Nepal; N=154 
Boima et al
359
 MMAS 8 Ghana and Nigeria; 
N=357 
  
Household 
income and 
employment 
 
Hussain et al
367
 
 
Questionnaire 
 
Bangladesh; N=120 
Gelaw et al
368
 Questionnaire  Ethiopia; N=91 
Bilal et al
361
 Questionnaire Pakistan; N=113 
  
Type of 
family 
 
Nagarkar et al
357
 
 
MMAS 8 
 
India; N=174 
  
Comorbidities  
 
Hareri et al
369
. 
 
Questionnaire  
 
Ethiopia; N=365 
Khanam et al
362
 Questionnaire  Bangladesh; 
N=29,960 
Ambaw et al
370
 MMAS 4 Ethiopia; N=384 
Al-Ramahi et al. 
358
 
MMAS 8 Palestine; N=450 
  
Use of herbal 
preparation 
 
Boima et al
359
 
 
MMAS 8 
 
Ghana and Nigeria; 
N=357 
Saleem et al
371
 Qualitative  Pakistan 
Odusola et al
372
 Qualitative Nigeria 
Key: MMAS=Morisky Medication Adherence Score 
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Sex 
Being female was independently and significantly associated with poor adherence in a 
study in India (AOR = 2.95; 95% CI: 1.39–6.24) with hypertensive women 2.95 times 
more likely to be non-adherent to their medications than men.363 A study in Iraq also 
revealed that female hypertensive patients (61.7%) were more non-adherent than male 
(30.3%) patients.364 On the other hand, MNA was significantly associated with male 
gender in Pakistan (p = .008),361 Tanzania (p = .044),365 and Bangladesh (AOR = 1.67; 
95% CI: 1.42–1.97).362 However, several studies359, 366, 367, 373, 374 found no significant 
association between gender and MNA among hypertensive patients. Thus, the effect of 
gender on MNA showed conflicting results across countries. 
 
Level of education 
Hypertensive patients in Nepal who were illiterate almost five times less likely to be 
adherent to medications than those who were literate (AOR = 5.34; 95% CI: 1.23– 
23).366 Similarly, a lower level of education was significantly associated with MNA 
among hypertensive patients in Bangladesh (OR = 6.34; 95% CI: 1.65–24.41).367 On 
the other hand, formal education was associated with MNA (p = .001) in Ghana and 
Nigeria.359 A study in India found that educational level was not a significant contributing 
factor to non-adherence.39 These results suggest that educational level may not always 
be a good predictor of MNA. 
 
Household income, employment and type of family 
Hypertensive patients with low monthly income (AOR = 11.60; 95% CI: 3.77–35.65) in 
Bangladesh367 and Ethiopia (p = .04)368 were more non-adherent to their medications. In 
Pakistan,361 the likelihood of MNA was also found to be higher among unemployed 
persons (p = .002) and people with low socioeconomic status (p = .046). Hypertensive 
patients who had private businesses were 72% less likely to adhere to medication 
compared to government employees (AOR = 0.28, 95% CI: 0.130–0.60) in Ethiopia.375 
Hypertensive patients living in a nuclear family setup in India were more likely to have 
lower adherence to medication as compared to staying in the extended family (OR = 
2.67; 95% CI: 1.38–5.18).357 
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Comorbidities  
Hypertensive patients with comorbidities were 50% less likely to be adherent to their 
medications compared to patients with no comorbidity (AOR = 0.50; 95% CI: 0.29– 
0.89) in Ethiopia.369 In Bangladesh, hypertensive patients with cardiovascular 
comorbidity were significantly associated with MNA (AOR = 0.79; 95% CI: 0.64– 
0.97).362 A study in north-west Ethiopia370 also found that patients with no comorbidity 
and one co morbidity were more likely to adhere to their treatment than those with two 
(AOR = 2.50; 95% CI: 1.01–6.21) or more than two co-morbidities (AOR = 2.68; 95% 
CI: 1.07–6.71). However, having no other chronic disease (p = .009) was a significant 
factor influencing MNA among hypertensive patients in Palestine.358  
 
Using traditional or herbal preparation 
In Ghana and Nigeria, patients who used herbal preparations for the treatment of 
hypertension were more likely to show MNA (p = .014).359 In a qualitative study in 
Pakistan,371 almost all the hypertensive patients surveyed firmly supported the 
utilisation of traditional or herbal remedies for the control of their high BP and confirmed 
that only in the case of failure of these therapies would they seek help from modern or 
biomedical health care providers. A qualitative study in Nigeria found some patients 
with low medication adherence substituted or complemented prescribed pills with herbal 
remedies on their own without informing their doctor.372 
 
Psychosocial factors 
Seven studies reported significant associations between psychosocial variables (such 
as family support, depression and use of social drugs) and MNA to hypertensive 
treatment (please see Table 4). 
 
Family support 
An absence of household support had a strong negative effect on adherence among 
hypertensive patients in Ethiopia (AOR = 0.170; 95% CI: 0.03–0.90)376 and Nigeria 
(p<0.05).377 Likewise, studies373, 378 in Congo reported that patients who received no 
reminder from family members about taking their medications were likely to be more 
non-compliant than the others. A qualitative study in Congo378 found that there was a 
perception among some family members that the hypertensive patient had brought the 
condition upon himself or herself by being a bad person:  
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‘They say I developed hypertension because I killed her sister (through 
witchcraft).’  
 
Table 4: Summary of variables under the domain of psychosocial factors 
 
Domain Variables 
being 
investigated 
Study  Study design  Study setting and 
sample size 
Psychological 
factors 
Family support Hussain et al
367
 Questionnaire  Bangladesh; 
N=120 
Nsitou et al
373
 Questionnaire   Congo; N=212 
Lubaki et al
378
 Qualitative  Congo 
Ali et al
376
 MMAS 8 Ethiopia; N=121 
Olowookere et al
377
 Questionnaire  Nigeria; N=420 
  
Depression  
 
Boima et al
359
 
 
MMAS 8 
 
Ghana and 
Nigeria; N=357 
  
Use of social 
drugs 
 
Khanam et al
362
 
 
Questionnaire 
 
Bangladesh; 
N=29,960 
  Ahmed et al
379
 MMAS 8 India; N=334 
Kamran et al
380
 MMAS 4 Iran; N=671 
Bhandari et al
366
 MMAS 4 Nepal; N=154 
Key: MMAS=Morisky Medication Adherence Score 
 
Though family cohesion is very high in Bangladesh, lack of an accompanying person to 
go to the physician or hospital was a significant factor in determining non-adherence to 
antihypertensive treatment (OR = 3.54; 95% CI: 1.04–11.99).367 This lack of support 
may be due the family members lacking knowledge about the disease process. 
 
Depression 
When patients are depressed, they are less likely to follow health care providers’ 
treatment plan for hypertension. In Ghana and Nigeria359 MNA occurred in patients who 
had varying degrees of depression (𝑟 = −0.208, p <.001) (𝑟 = Pearson’s correlation 
coefficient).  
 
Use of social drugs 
A World Health Organisation report observed that alcohol abuse and tobacco smoking 
were important modifiers of compliance behaviour. Patients’ habit of alcohol 
consumption,362, 379 tobacco chewing,379 and smoking362, 379, 380 were strongly associated 
with poor adherence to antihypertensive treatment in studies in India, Iran and Ethiopia. 
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In contrast, a study in Nepal did not find any significant association between tobacco 
use and alcoholism with MNA among hypertensive study participants.366 
 
Perceptions regarding hypertension and its severity 
Four studies reported significant associations between variables related to perceptions 
of hypertension and MNA to hypertensive medications. These factors included: 
awareness, knowledge and belief of hypertension and knowledge of the severity of 
hypertension. 
 
Researchers found that poor understanding and belief in high blood pressure were 
significant factors associated with MNA in Bangladesh (AOR = 12.90; 95% CI: 1.65– 
100.63)367 and in Ethiopia (p <.01).368 A qualitative study in Pakistan371 revealed that 
patients, when achieving control of their high BP, tended to discontinue their 
medications. Those patients with an inadequate knowledge of hypertension-related 
complications were also more likely to be non-adherent with the treatment regimen, as 
found in a study in Bangladesh (OR = 23.71; 95% CI: 3.38–166.46)367 and Congo (OR 
= 2.9; 95% CI:1.61–5.29).373 Diagnosed hypertensive patients who lacked  knowledge 
regarding the severity of hypertension were also more likely to be non-adherent to 
medications in Bangladesh (AOR = 23.71; 95% CI: 3.38–166.46)367 and Congo (AOR = 
0.34: 95% CI: 0.13–0.94).373   
 
Perceptions regarding antihypertensive treatment 
Eight studies found significant associations between variables related to 
antihypertensive treatment and MNA (please see Table 5). 
 
Studies in Bangladesh (AOR = 24.50; 95% CI: 6.28–95.58),367 Congo (AOR = 0.36; 
95% CI: 0.15–0.83),373 and Ethiopia368 (p <.01) reported that patients’ lack of knowledge 
about hypertension management was significantly associated with non-adherence to 
therapy. A significant correlation between beliefs about medication and MNA was found 
among hypertensive patients in Ghana and Nigeria;359 patients who were worried about 
the adverse effects of antihypertensive drugs less likely to be adherent to their 
medications (𝑟 = −0.0347, p = .002). Qualitative studies in Pakistan371 and Malaysia381 
also found patients hesitated to take medications continuously due to their lack of belief 
in medications. As one hypertensive patient in Pakistan commented: 
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‘Medications are hot (warm) in nature. They enter the stomach and increase 
temperature, which interferes with digestion.’ 
 
Table 5: Variables summarised under the domain of perceptions regarding 
antihypertensive treatment 
Domain Variables  
investigated 
Study Measurement 
of medication 
adherence  
Study setting 
and sample size 
Perceptions 
regarding 
antihypertensive 
treatment 
Knowledge 
about 
hypertension 
management 
Hussain et al
367
 Questionnaire  Bangladesh; 
N=120 
Nsitou et al
373
 Questionnaire  Congo; N=212 
Gelaw et al
368
 Questionnaire  Ethiopia; N=91 
 
Belief about 
medication  
 
Boima et al
359
 
 
MMAS 8 
 
Ghana and 
Nigeria; N=357 
Saleem et al
371
 Qualitative  Pakistan  
Shima et al
381
 Qualitative Malaysia 
Al-Ramahi et al
358
 MMAS 8 Palestine; N=450 
 
Avoiding side 
effect of 
medications 
 
Campbell et al
374
 
 
MMAS 4 
 
Nigeria; N=262 
Hareri et al
369
 Questionnaire Ethiopia; N=365  
Praveen et al
363
 Questionnaire  India; N=804 
 
Do not 
understand 
drug regimen 
well 
 
Gelaw et al
368
 
 
Qualitative  
 
Ethiopia  
Odusola et al
372
 Qualitative  Nigeria  
Key: MMAS=Morisky Medication Adherence Score 
 
A study in Palestine found that patients with hypertension were not adhering to their 
medication due to the fear of dependency on medicines (AOR = 8.00; 95% CI: 2.44– 
26.19).358 Similarly, avoiding side effects of drugs (AOR = 3.0; 95% CI: 1.4–6.7) was an 
important reason for non-adherence to a treatment regimen among hypertensive 
patients in Nigeria.374  
 
Hypertensive patients who did not understand their drug regimen well, were poorly 
adherent to their prescribed medications (AOR = 4.06; 95% CI: 1.01–16.32) in India363 
and Ethiopia (AOR = 0.12; 95% CI: 0.26–0.58).369 Gelaw et al.368 found that insufficient 
information about the consequence of non-adherence to hypertension treatment 
contributed to the non-adherence of hypertensive patients in Ethiopia. In Nigeria, a 
qualitative study also found ignorance about regular use of medication was an 
important contributor to medication non-adherence.372 
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Perceived barriers to adherence  
Sixteen studies found significant associations between aspects related to perceived 
barriers and MNA. These perceived barriers were: the cost of medications, the number 
of pills that needed to be taken on a daily basis, forgetfulness, side effects of 
medications, duration of therapy, satisfaction with the treatment and health services 
provided, and distance from a health care centre (please see Table 6) 
 
Table 6: Variables investigated under the domain of perceived barriers to 
adherence 
Domain Variables being 
investigated 
Study  Measurement of 
adherence 
Study setting 
and sample 
size 
Perceived 
barriers to 
adherence 
Cost of 
medications 
Bhandari et al
366
 MMAS 4 Nepal; N=154 
Nsitou et al
373
 Questionnaire  Congo; N=212 
Eizubier et al
382
 Pill count Sudan ; N=198 
Praveen et al
363
 Questionnaire  India; N=804 
  
Number of pills 
 
Bhandari et al
366
 
 
MMAS 4 
 
Nepal; N=154 
Srikanth et al
383
 MMAS 8 India; N=304 
Olowookere et al
377
 Questionnaire  Nigeria; N=420 
Ramli et al
384
 The hill bone 
adherence to BP 
scale and MMAS 8 
Malaysia; N=653 
Bilal et al
361
 Questionnaire  Pakistan; N=113 
Srivastava et al
385
 Self-report and 
MMAS 4 
India; N=440 
 Forgetfulness  Campbell et al
374
 Moisky Green Nigeria; N=262 
Al-Ramahi et al
358
 MMAS 8 Palestine; 
N=450 
 Side effect of 
medicine 
Lalic et al
360
 MMAS 8 Serbia ; N=170 
Shima
381
 Qualitative  Malaysia 
Odusola
372
 Qualitative Nigeria 
  
Duration of 
therapy 
 
Bhandari et al
366
 
 
MMAS 4 
 
Nepal; N=154 
Hareri et al
375
 Questionnaire  Ethiopia; N=286 
Lalic et al
360
 MMAS 8 Serbia; N=170 
Bilal et al
361
 Questionnaire Pakistan; N=113 
Hu et al
386
 Questionnaire China; N=318 
  
Distance from  
health care 
facilities 
 
Gelaw et al
368
 
 
Questionnaire 
 
Ethiopia; N=91 
Al Ramahi
358
 MMAS 8 Palestine; 
N=450 
Ambaw et al
370
 MMAS 4 Ethiopia; N=384 
Key: MMAS=Morisky Medication Adherence Score; BP=Blood Pressure 
 
Studies showed a link between patients’ perception of the high cost of treatment with 
poor adherence. In non-adherent patients surveyed in Nepal, a significantly greater 
proportion of patients considered the price of medications to be too high (AOR = 5.14; 
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95% CI: 1.1–23.9)366 and a reason for not taking medications (AOR = 0.143; 95% CI: 
0.02–0.78). The cost of medicine was also a significant factor associated with MNA 
among patients in Congo (OR = 1.84; 95% CI: 0.93–3.64).373 Similarly, the inability to 
buy medications (p <0.001) was positively and significantly related to MNA in Sudan.382 
Even being able to afford only some of the prescribed antihypertensive drugs (AOR = 
3.70; 95% CI: 1.81–7.59) was also significantly related with MNA in India.363  
 
Number of pills 
In Nepal, non-adherence was significantly associated with therapy requiring more than 
one pill per day (AOR = 5.33; 95% CI: 1.19–23.70) compared to patients prescribed 
only one pill per day.366 MNA was also greater among patients with higher pill intake in 
India,383 Nigeria,377 and Malaysia384 (p <.05). On the other hand, a couple of studies361, 
385 found that when patients had to take multiple medications, they were less likely to 
fail to remember to take them, compared to having only one pill. A study in Pakistan361 
found non-adherence was higher among those patients who were on mono-therapy and 
di-therapy compared to patients using 3 or >3 drugs (p = .02).  
 
Forgetfulness 
Patients also often forget to take even once-daily medications. Studies in Nigeria (OR = 
14.8; 95% CI: 3.9–54.8)374 and Palestine (AOR = 5.12; 95% CI: 3.12–8.41)358 found 
significant correlation between forgetfulness and non-adherence among hypertensive 
patients. 
 
Side effects of medications 
Hypertensive patients who experienced side effects of their medications were less 
adherent to their medication than those who did not experience side effects in Palestine 
(AOR = 4.58; 95% CI: 1.87–11.25) and Serbia (OR = 7.95; 95% CI: 1.48–42.60).358, 360 
Qualitative studies in Malaysia381 and Nigeria372 also found perceived side effects were 
inhibitors of antihypertensive medication adherence. In India, however, Praveen et al.363 
did not find any correlation between adverse drug events and non-adherence.  
 
Duration of therapy 
Patients who had had a diagnosis of hypertension of five or more years were less likely 
to adhere to treatment than those who had been diagnosed for less than five years in 
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Nepal366 (OR = 2.98; 95% CI: 1.73–5.14) and Ethiopia (AOR = 0.11, 95% CI: 0.01– 
0.95).375 Lower levels of adherence in elderly patients in Serbia was correlated with 
longer duration of antihypertensive therapy.360 On the other hand, patients with shorter 
duration of hypertension were less likely to be adherent to treatment in Pakistan (<5 
years) (AOR = 0.11; 95% CI: 0.01–0.96)361 and China (<3 years) (AOR = 3.31; 95% CI: 
1.91–5.72; p <.001).386 
 
Distance from health care facilities 
Distance from health care facilities was a significant barrier for adherence to treatment. 
Being further away from medical centres contributed to MNA of hypertensive patients in 
Ethiopia.368 In the same way, those living in rural areas had poorer adherence to 
hypertensive medications in Palestine than those living in urban areas (AOR = 1.79; 
95% CI: 1.10–2.92).358 As the remoteness from the hospital decreased, adherence to 
hypertension treatment improved (AOR = 2.02; 95% CI: 1.19–3.43) in Ethiopia.370 
 
Treatment or disease related factors  
Eleven studies found a number of treatment or disease related factors associated with 
MNA. These included absence of disease symptoms, complication, irregular followup, 
family history of hypertension and poor BP control (please see Table 7). 
 
Absence of disease symptoms  
The absence of symptoms significantly contributed to poor compliance to hypertensive 
therapy in Nigeria (AOR = 3.3; 95% CI: 1.3–8.0)374 and India (OR = 0.414; 95% CI: 
0.19–0.89).357 Qualitative studies in Congo378 and India387 also found hypertensive 
medications were more likely to be taken when the patient experienced symptoms of 
hypertension.  
 
Presence of hypertension-related complications 
The presence of hypertension-related complications such as heart diseases (AOR = 
21.73; 95% CI: 1.57–418.42; p = .000) was found to be associated with decreased 
medication adherence among patients in Ethiopia.376 In contrast, a study in Pakistan 
found that cases suffering from hypertension-related complications were more likely to 
be adherent to medications.388 
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In Nepal, those with no family history of hypertension were less adherent to their 
medications compared to those with a family history of high BP (OR = 4.46; 95% CI: 
1.21–16.40; p = 0.024).366 
 
Table 7: Variables summarised under the domain of treatment and/or disease 
related factors investigated by the studies 
Domain  Variables  
investigated 
Study  Measurement of 
medication 
adherence 
Study setting 
and sample 
size 
Treatment and 
disease related 
factors 
Absence of  
symptoms 
Campbell et al
374
 Morisky Green Nigeria ; N=262 
Nagarkar et al
357
 MMAS 8 India; N=174  
 Lubaki et al
378
 Qualitative  Congo  
 Kusuma et al
38
  Qualitative  India  
 Odusola et al
372
 Qualitative  Nigeria  
 
Presence of 
hypertension 
related 
complications 
 
Ali et al
376
 
 
MMAS 8  and 
patient 
medication chart 
 
Ethiopia; N=121  
Hashmi et al
388
 History of pill 
taken & MMAS 4 
Pakistan  
 
Family history 
of hypertension 
 
Bhandari et al
366
 
 
MMAS 4 
 
Nepal; N=154 
 
Irregular follow 
up 
 
Bhandari et al
366
 
 
MMAS 4 
 
Nepal; N=154 
Praveen et al 
363
. Questionnaire India; N=804 
 
Blood pressure 
control 
 
Boima et al
359
 
 
MMAS 8 
 
Ghana and 
Nigeria; N=357 
Lalic et al
360
 MMAS 8 Serbia; N=170  
Ramli et al
384
 The hill bone 
adherence to BP 
and MMAS 8 
Malaysia;N=653 
Ali et al
376
 MMAS 8 Ethiopia; N=121 
Key: MMAS=Morisky Medication Adherence Score; BP=Blood Pressure 
 
Irregular followup 
Frequent meetings or appointments provide better monitoring of blood pressure levels, 
as well as the opportunity to have more access to information and can serve as the 
basis for adherence to antihypertensive medication management.389 Irregular followup 
(AOR = 6.39; 95%CI: 1.22–33.30),366 was significantly associated with MNA in Nepal. 
Similarly, an Indian study reported that a longer time since the previous visit to a doctor 
for advice (AOR = 7.26; 95% CI: 2.65–19.86) was significantly related with non-
adherence to hypertensive medications.363 
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Blood pressure (BP) control 
Poor BP control was significantly associated with MNA in Ghana and Nigeria (p = 
.006).359 BP values over 140/90 mmHg were also reported in 59.1% of non-adherent 
patients and 21.4% of adherent patients, (χ2 = 19.84; p <.01; OR = 5.30; 95%, CI: 
2.39–11.85) in Serbia.360  Similarly the average systolic and diastolic blood pressure for 
non-adherents was significantly higher (p = .05) than that in adherents in Malaysia.384 In 
contrast, a study in Northern Ethiopia376 found that patients at the pre-hypertension 
level (BP values below 140/90 mmHg) (AOR = 0.026; 95% CI: 0.003–0.242) were less 
adherent to their medications.  
 
Health care services  
Four studies found ‘dissatisfaction with the health services and treatment provided’ 
significantly influenced MNA among hypertensive patients (please see Table 8).  
 
Table 8: Variables summarised under the domain of health care services 
 
Domain  Variables being 
investigated 
Study  Measurement 
of medication 
adherence 
Study setting 
and sample size 
Health Care 
services 
Dissatisfaction 
with the health 
care services 
received  
Barreto et al
390
 Morisky- Green  Brazil; N=68 
Lubaki et al
378
 Qualitative  Congo  
Kusuma et al
387
 Qualitative  Delhi  
 Odusola et al
372
 Qualitative  Nigeria  
  
Inadequate 
information from 
health care 
Centre 
 
Hussain et al
367
. 
 
Questionnaire 
 
Bangladesh; 
N=120 
  
Dissatisfaction 
with treatment  
 
Al-Ramahi et al
358
. 
 
MMAS 8 
 
Palestine; N=450 
  
Fewer 
Interaction with 
physicians 
 
Hussain et al
367
 
 
Questionnaire 
 
Bangladesh; 
N=120 
Key: MMAS=Morisky Medication Adherence Score 
 
A study conducted in Brazil confirmed the high correlation between MNA and 
dissatisfaction with health services.390 Hypertensive individuals who were dissatisfied 
with the care received in primary public health services (such as reception service, 
scheduling appointment and care received from the health team) were more likely to not 
adhere to the proposed medication treatment. Inconvenient clinic operating hours, long 
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waiting time and under-dispensing of medications were found to be inhibitors of 
adherence in a qualitative study in Nigeria. Studies in Congo378 and India387 found that 
antihypertensive medication was sometimes not readily available at health care centres. 
Patients waited for long periods to receive medications once they had been prescribed. 
Rude or unsympathetic behaviour and attitudes by staff members at the health clinics 
was the other reason found for the dissatisfaction of the patients in Congo.378 
 
In Bangladesh, inadequate information from health care professionals about 
hypertension and its treatment (AOR = 5.16; 95% CI%:1.13–23.66) were significantly 
associated with MNA.367 Also in Palestine, patients dissatisfied with treatment were less 
likely to adhere to prescribed hypertensive medications than those satisfied with their 
treatments (AOR = 2.93; 95% CI: 1.22–7.02).358 Due to fewer interactions with the 
physicians, those receiving treatment at government hospitals had a 30 times greater 
chance of being non-adherent than those treated at private hospitals or clinics (AOR = 
35.29; 95% CI 9.76–127.63) in Bangladesh.367  
 
3.4 Discussion 
Though non-adherence to antihypertensive treatment is a significant problem in CHD 
management few studies on medication adherence have been conducted in developing 
countries.308 Moreover, the majority of these studies were conducted in hospital and 
clinical settings. Studies carried out in low-income urban areas extremely limited. 
Despite the higher prevalence of hypertension and its poor control among women in 
developing countries, this researcher did not find any studies that focused specifically 
on this vulnerable population.  
 
This review found that although there was substantial heterogeneity in methods and 
populations across studies, approximately half (49.64%) of the participated 
hypertensive population both male and female 18 years and older did not adhere 
properly to the treatment for hypertension as prescribed by their doctors. Women in 
developing countries living with chronic non-communicable diseases such as 
hypertension experience particular challenges in accessing cost-effective prevention, 
early detection, diagnosis, treatment and care. The lack of knowledge and information 
regarding health, poor access to healthcare, family responsibilities, and poor economic, 
legal and political status further worsen their situation.119   
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From 25 studies, significant factors were identified associated with MNA. A limitation of 
the selected studies was the fact that factors associated with MNA were not examined 
for gender differences. However, a  study in Brazil reported reasons for non-adherence 
to medication and non-medication regimen in patients’ opinion according to gender.391 
Considering the magnitude of inadequately treated or controlled hypertension among 
women in developing countries, studies that explore factors affecting MNA in this 
vulnerable population are urgently needed.  
  
While recognising these limitations, the findings do provide insight into factors 
influencing MNA of hypertensive patients. Factors related to demography, barriers for 
adherence and treatment and disease related factors were the most commonly 
examined among the studies reviewed while factors related to perceptions regarding 
hypertension and its severity were the least examined. Associations of MNA with 
demographic and psychosocial factors such as age, gender, ethnicity, level of 
education, co-morbidities, duration of therapy, the number of medicines, use of social 
drugs, were often varied and not consistent. Factors affecting MNA consistently were: 
low socioeconomic status and low monthly income, family support, the use of traditional 
herbal preparations, knowledge and belief regarding hypertension and its management, 
cost of medications, avoiding side effect of medications, forgetfulness, absence of 
symptoms, distance from health facilities, irregular followup, and dissatisfaction with the 
treatment and health services provided.  
 
3.4.1 Implications for hypertension management and research 
The present review reveals that gender may not be a good predictor of non-adherence 
because of inconsistent conclusions. However, it is conceivable that women with low 
socioeconomic status and lower level of education are more vulnerable. Their lack of 
adherence might be due to their inability to buy medicines, and lack of access to free 
health facilities as governments in developing countries spends comparatively less of 
their budgets on health than developed countries. The importance of cost-related 
factors should be considered against the background of the relatively high out-of-pocket 
payments for most treatments in developing countries especially in South Asia and 
Africa.  
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The review also found that fear of side effects make some hypertensive patients stop 
their medications or reduce their daily doses without consulting their health care 
providers. Therefore, information tailored to patient’s literacy level about the side effects 
of prescribed medications and how to manage these should be provided to all patients. 
From the review, it appears that educational level may not be a good predictor of MNA. 
However, sceptical attitudes towards antihypertensive treatment even among educated 
participants necessitate the health education on hypertension and its treatment to all 
hypertensive patients irrespective of the patients’ educational status. Understanding 
potential complications of hypertension could be a motivating factor for adherence to 
treatment. For this to happen, patients need to be aware of the seriousness of their 
condition and all risks involved without being worried unnecessarily.392 To better deal 
with these problems, educational interventions are required that recognise patients’ 
apprehension and perceptions. In particular, patients should be provided an explanation 
of the benefits and adverse effects of treatment. The safety of long-term use of drugs 
needs to be discussed, including the information that treatment does not cause physical 
dependence irrespective of the length of treatment. 
 
The review indicated that adherence to antihypertensive medication treatment would be 
improved if patients experience positive encounters with their doctors or health care 
providers regarding adequate and accurate advice on achieving control of their high 
blood pressure.393  
 
Among the selected studies, there was a general lack of assessment of individual risk 
perceptions of hypertension complications such as CHD. This is an unfortunate 
omission given the importance of such risk perceptions in medication adherence. 
Earlier studies in developed countries have shown that patients who accurately 
perceive their risk of cardiovascular disease are more likely to be adherent to 
medications and guidelines compared to those who do not perceive themselves to be at 
risk.247-250 Women's perceptions of their risk for heart disease can significantly influence 
their decision-making process concerning health care choice.394 
 
The studies in the review did not examine in depth psychological issues, in particular 
those relating to self-efficacy (i.e. the belief that one can perform a particular behavior 
under differing conditions) which can greatly impact on medication adherence. Cultural 
88 
 
restrictions make it difficult for women to seek medical care from male health care 
providers,120 but there is, at the same time, a shortage of female health professionals.120 
These issues are compounded by health systems that often fail to respond to the 
particular needs of women with NCDs such as hypertension.116 Weak health systems 
have been identified as major obstruction in effectively responding to the rising burden 
of chronic conditions such as hypertension in developing countries.395 In spite of the 
need for research on health systems, little attention has also been given to the role of 
local health systems in the delivery of care for the control of hypertension. 
 
Moreover, belief-laden factors including confidence in the physician’s knowledge or 
ability, belief of control over one’s health and illness perception were all found to be 
significantly related to medication adherence in developed countries.396 Studies in 
developing countries especially at community settings on these factors influencing 
adherence would be helpful to address the knowledge gap and contribute to global 
strategies for addressing non-compliance among hypertensive patients. 
 
3.4.2 Strengths and weaknesses of the review 
We have included studies from 20 developing countries (27.40% of all developing 
countries). Having study population from less than one third of the developing countries 
incorporated in the analysis, the conclusions of this review might not be extrapolated to 
the whole population of the developing countries. 
 
Most of the studies in this review that met inclusion criteria were quantitative in type. 
Only half of the quantitative studies (20) chose study participants using simple or 
systematic random sampling techniques. Eight studies used purposive sampling 
method, thus their results may not be necessarily generalisable to the wider population. 
The remaining studies selected all eligible hypertensive patients from clinics or 
hospitals or communities as their study participants. 
 
The review followed the PRISMA reporting guidelines for identifying, reporting, and 
synthesising research. The results of the review are robust. Most of studies selected for 
the review were judged to be of moderate to strong quality in terms of research rigour, 
reliability and validity. A large number of MNA related factors were consistently 
identified across different countries. However, this review was subject to a few 
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limitations. This study included only English peer-reviewed journal articles. The majority 
of the studies relied solely on self-reported adherence, which may be subject to self-
presentation and recall bias. Among the selected quantitative studies, only two 
prospective cross-sectional studies were found. Longitudinal assessment is desirable to 
differentiate between chronic and occasional non-adherence and related barriers that 
may contribute to non-adherence.  
 
3.5 Conclusion 
This literature review examined the prevalence of MNA among hypertensive population 
as well as investigated factors affecting MNA. Approximately half of hypertensive men 
and women were found to be non-adherent to their medications. Among the selected 
studies, very few studies were conducted in low-income community settings. MNA was 
influenced by a range of factors including socio-economic status, knowledge of 
hypertension and its management, medication side effects, costs of medication, and 
dissatisfaction with the treatment and health services provided. There was a general 
lack of consideration of cultural barriers, role of health system in health care delivery, 
self-efficacy and perceived individual risk of hypertension complications. Policymakers 
and health service providers should take these factors into account to design 
intervention strategies that are relevant and appropriate for the target population, in 
order to enhance adherence among hypertensive patients. There is also a lack of 
gender-specific research, which is necessary given the social and economic 
vulnerabilities faced by women in developing countries that may affect adherence to 
antihypertensive medications.  
 
3.6 Summary of the chapter 
This chapter has reviewed the key factors that impact on the medication adherence 
status of the hypertensive populations in developing countries. The next chapter 
describes the research methodology used in the study.  
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CHAPTER 4 
RESEARCH DESIGN AND METHODS 
 
4.0 Introduction to the chapter 
This chapter describes the research methods used in the study. The chapter begins 
with the conceptual framework, and it then describes the quantitative arm of the study, 
focusing on sampling procedures, the survey questionnaire used, and the methods of 
quantitative data analysis. It is followed by a description of the qualitative arm, 
describing the methods of qualitative data collection and analysis. Finally, it documents 
ethical considerations involved in this study. 
 
4.1 The conceptual framework, theoretical model and study variables 
This study used as its conceptual framework the Health Belief Model (HBM)397 (please 
see Appendix 4).397 The HBM framework helped inform the selection of the research 
variables, and the development of the hypothetical model and the data collection 
instruments.  
 
4.1.1 The Health Belief Model (HBM)  
The HBM was initially developed by Rosenstock to clarify and predict individuals’ health 
behaviours, and has been subsequently modified by Becker to integrate illness role 
behaviours as well.398 According to the HBM, the following five key elements determine 
an individual’s adherence to treatment: 
1. Threat of the illness: perceived susceptibility to the illness. 
2. Positive outcome expectancy:  the patient’s perceived benefits from treatment. 
3. Barriers to using the treatment: the patient’s expected disadvantages of the 
treatment. 
4. Intent: the patient’s intention to adhere to their treatment regimen. 
5. Self-efficacy: the patient’s belief in their ability to adhere to the course of 
therapy. 
 
Perceived susceptibility  
Perceived susceptibility refers to the patients’ perception of the possibility of having an 
illness such as hypertension or the complications of uncontrolled hypertension.220 
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Perceived susceptibility to CHD is defined as the perception of the likelihood of 
experiencing a premature CHD event.221 In several studies, perceived susceptibility was 
determined to be an indicator of an individual’s inclination to take part in risk-reducing 
behaviours for the prevention of heart disease.229, 399  
 
According to the HBM, a person who believes susceptible to hypertension and its 
sequel such as heart attack, kidney failure or stroke, would more likely adhere to 
treatment than those who do not hold this belief.220 Such a perception is usually derived 
from good knowledge of the disease. Patients with proper understanding regarding the 
pathophysiology of hypertension and likely risks associated with non-adherence to 
treatment; would possibly perceive themselves vulnerable to the disease and its 
complications. Persons, who consider that they are not vulnerable to hypertension or 
oppose the existence of hypertension, may not realise the requirement for consumption 
their medications as advised or modify their lifestyle. For example, a study400 in Finland 
reported that 66% of hypertensive respondents did not believe they had hypertension 
and did not follow through with their treatment.  
 
Perceived severity  
Perceived severity is one’s belief about the gravity of a medical condition. According to 
the HBM, people who understand hypertension to be a severe disease would be more 
adherent with prescribed medicines and lifestyle changes than those who do not hold 
such a perception.220 
 
Perceived threat 
Carpenter401 defines perceived threat as ‘the anticipation of harm that is based on the 
cognitive appraisal of an event or cue that is capable of eliciting the individual's stress 
response’. The explanation emphasises three issues: first, the expectation of harm, 
which involves that individuals have needs, and ambitions they desire to attain in life; 
whatever jeopardises these requirements and aspirations constitutes a danger. Second, 
the anticipated threat, results in cognitive evaluation of the relevance or irrelevance of 
the risk. Third, action is taken, which demands appraisal of the resources available to 
deal with the risk and the method(s) of doing so.401  
 
92 
 
Different socio-demographic, socio-psychological and structural variables could 
together influence persons’ judgment outcomes. Perceived susceptibility and perceived 
severity also influence their perception of hypertension as an intimidation.402 For 
patients suffering from uncomplicated asymptomatic hypertension, a permutation of 
these factors would decide their response to the prescribed treatment and advice given 
on lifestyle modifications.402 
 
Perceived benefits  
The HBM assumes that patients who perceive benefits from implementing specific 
health behaviour are more likely to exhibit the requisite health behaviour than those 
who do not.403 For instance, those patients who believe that consuming 
antihypertension medications and adopting lifestyle changes would benefit them would 
be more likely to be adherent than those who do not have such a perception. Such 
perceptions are influenced by knowledge of the disease and its consequences if 
untreated. 
 
Perceived barriers 
Perceived barriers refer to potential obstacles to taking a recommended health 
action.403 Such barriers are related to physical and psychological costs of taking health 
action. Patients with a greater perception of barriers are less likely to adhere to their 
treatment than those who believe that the benefits outweigh the barriers.403 Potential 
barriers for hypertensive people to take prescribed medication may include: inadequate 
knowledge about hypertension and its treatment, fear of getting side effects from 
medicines, fear of addiction from long term use of drugs, and financial expenses.404 A 
qualitative study in the UK393 identified many suspicions that patients had regarding 
antihypertension medications. Several participants stated the need to discontinue a 
medication in order not to become addicted whereas others preferred alternatives to 
medicines. A number of patients expressed an apprehension of the unseen threat 
associated with lifelong drug consumption whereas others questioned the justification 
behind taking antihypertensive medications even in the absence of any disease 
symptoms.  
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A cue to action 
A cue is defined as a spontaneous influence that makes the person consider the 
necessity to act.403 Cues to action may be internal or external. Internal factors may be 
the appearance of the symptoms of the illness.220 Peoples’ beliefs about illness and the 
symptom of illness perform as internal cues to adherence behaviour.405 External factors 
could be, for instance, effective counselling on CHD risk management by health care 
providers.220 These cues can perform a key function in adherence behaviour by 
reminding or encouraging patients to consume their medications regularly. 
 
Self-efficacy 
Self-efficacy is defined as the confidence or self-belief to adopt health action and 
perform a health action. The self-efficacy construct states that, for a successful change, 
confidence in medication efficacy and lifestyle alteration is essential. It has been 
documented that patients adhere well when they can manage the treatment regimen, 
and when they believe in medication efficacy.406 
 
Modifying factors  
Several modifying factors, together with socio-demographic, socio-psychological and 
structural factors, are known to have considerable influences on health behaviour. The 
HBM postulates that modifying factors influence health behaviour, as indicated in the 
literature review in chapter 3. 
 
Likelihood of compliance behaviour  
The HBM suggests that low perceived barriers, a high perceived threat, and a high-
perceived benefit would result in the probability of demonstrating adherence behaviour. 
Nevertheless, the final outcome decision would be determined by the interaction of 
several demographic, psychosocial and structural factors surrounding the individual and 
the cues to action to which they are exposed.407 
 
4.1.2 Theoretical model and study variable 
All the constructs of HBM are important factors for examining medication adherence to 
hypertension medication.408 Knowing what aspects of HBM are influencing medication 
adherence in a given population, can help health care providers and policy makers to 
design appropriate interventions to improve adherence among hypertensive patients. 
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For example, if a patient is unaware of his or her risk factors for developing CHD we 
can direct teaching to make the patient aware of his or her personal CHD risk factors. 
Consequently, based on the HBM constructs, a theoretical model (please see Figure 5) 
was developed by the researcher to examine factors influencing medication adherence 
to pharmacological treatment measures of hypertensive women and to suggest 
recommendations that might improve treatment adherence.  
    
 
INDIVIDUAL PERCEPTIONS     MODIFYING FACTORS          LIKELIHOOD OF ACTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: The theoretical model based on the Health Belief Model398 
 
The hypothetical model consisted of variables based on the research objectives. These 
variables were primarily identified from the literature and classified as independent and 
dependent variables. Details of the study variables are summarised in Table 9.  
 
Perceived benefits  
MINUS  
Perceived barriers  
 E.g. satisfaction with benefit 
of treatment,  number of 
antihypertensive drugs, 
frequency of dose, 
medication cost, duration of 
treatment, medicine side 
effects and drugs availability 
 
 
Susceptibility and 
severity 
 
Illness perception of  
hypertension  
Likelihood of taking 
action 
 
CHD prevention 
behaviour 
Demographic variables  
 E.g. age, gender, marital status, 
         income, education, religion 
Psychological variables 
 E.g. depression 
Structural variables 
 E.g. knowledge of CHD risk  
        factors 
Health care related factors 
 E.g. Relationship with doctors; 
        Health care facilities 
 
Cue to action 
 
E.g. family history of CHD 
advice from physicians 
 
Perceived threat  
 
Self-perceived global 
CHD risk 
Medication 
Adherence 
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Table 9: Overview of the study variables 
 
Independent variables 
Socio-demographic  Age, religion, level of education, marital status, work status, per 
month household income in INR, co-existing chronic illnesses, 
knowledge of greatest health for women in India and knowledge 
level of CHD risk factors 
 
Psychosocial  
 
Perceived global CHD risk and hypertension perception 
 
CHD risk factors 
 
Tobacco use, alcohol consumption, dietary habits, physical 
activity, systolic and diastolic BP, self-reported diabetes, family 
history of heart disease, the BMI, physical activity and abdominal 
obesity 
 
Hypertension and its 
related treatment 
 
History of high BP, treatment duration,  number of prescribed pills 
per day, side effects of drugs, cost of medicine, availability of 
prescribed drugs locally, feeling better with medication, and 
satisfaction with the treatment 
 
Health care provider-  
Related 
 
Doctor explains the treatment regimen and the likely side effects of 
medication, doctor explains the reason for carrying out the medical 
test, and doctor treats in a friendly and courteous manner 
 
Dependent variables 
 
Medication adherence  
 
4.2 Study design 
Based on the need for a better understanding of the medication adherence of urban 
low-income women in India, a mixed methods design was chosen for the present 
research. The purpose of using mixed methods in this study is to look for 
complementarities and convergence. Complementarities refer to the use of different 
data sources to obtain alternate or overlapping views of phenomena. Convergence 
refers to reaching shared conclusions from data collected by the various methods 
thereby increasing the validity of outcomes.409 
 
Mixed-methods research involves collecting, analysing, and integrating (or mixing) 
quantitative and qualitative research (and data) in a single study.136 The rationale for 
this form of research is that both qualitative and quantitative research, in combination, 
can provide a better understanding of a research problem or issue than either research 
approach alone.410 In this research study, complementarities were accomplished using 
both quantitative and qualitative research methods. The findings from the dominant 
method type (whether quantitative or qualitative) can be enhanced or clarified by results 
from another method type (quantitative or qualitative).411 The dominant component in 
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the present study was quantitative while the less dominant, or supplementary 
component, was qualitative. Quantitative and qualitative data was collected 
concurrently and sequentially, the mixed pattern of timing being appropriate for 
investigating convergence and complementarities. Using the Morse notation system, 
this multi-strand, mixed dominant-less dominant design can also be depicted as ‘QUAN 
(qual)’.136, 412  
 
Phase one of the study consisted of the QUAN strand, whereby a survey was carried 
out among 500 households in a low-income urban settlement in Delhi. It was designed 
to collect information on the characteristics of individuals and determine associations 
between the key independent variables and dependent variables. Phase two of the 
study consisted of the qual strand to assist in gaining a deeper understanding of the 
treatment adherence among hypertensive women in low-income areas and the 
contextual factors that either facilitate or hinder medication adherence. Both 
hypertensive women and health care providers were interviewed in the qualitative 
phase of the study. A purposeful sample of 30 hypertensive women participants were 
selected from phase one of the study and nine physicians were chosen from different 
government and non-government health care centres in Delhi. 
 
In each strand, there were four stages:  
 Conceptualisation stage: the research question was formulated 
 Methodological stage: the data was collected  
 Analytical stage: collected data was analysed  
 Inferential stage: inferences were made. 
 
The conceptualisation of the research questions, data collection and analysis of both 
the qualitative and quantitative phases occurred independently of each other. 
Inferences were made based on the data from each phase and then findings from the 
QUAN and qual phases were converged for a shared conclusion.413 
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4.3 Study site 
4.3.1 Delhi 
Delhi, the national capital of India, is the eighth largest metropolis in the world with an 
estimated population of approximately 16.75 million.102 Delhi is spread over an area of 
around 1483 square kilometres.102 It is the fastest growing and densely populated city in 
India. The UN-Habitat’s  study shows that the average annual growth rate in most of the 
large cities in developing countries was 1.8% in the 1990s414 while Delhi’s was 4.23% 
for the same period.415 Delhi’s population growth is accounted for by natural increase 
and net in-migration. With Delhi being a hub for trade and employment for the whole of 
northern India, migration has averaged 1.3 times the natural growth of Delhi.416 The 
bulk of the migrant population is from the northern states such as Uttar Pradesh, 
Haryana and Bihar. 417 This disproportionate growth has had a severe impact on the 
city’s physical and societal infrastructure, besides creating an acute shortage of 
housing.418  
 
 
Figure 6: Map showing Delhi, India419 
 
Delhi’s citizens have a higher economic status overall to other parts of the country. 
Contrarily, due to unequal distribution of natural wealth, the proportion of Delhi’s 
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population living below poverty line has increased from 1.55 million (1999–2000) to 2.29 
million (2004–2005) which was 14.7% of the total population in Delhi. This means, the 
population living below the poverty line grew by 87% in just five years.420 Therefore, 
Delhi has two faces: one accommodates the richer population and the other 
accommodates a large number of poor people, whose numbers continue to increase.104 
Explosive population growth and low-income contribute to the proliferation of 
uncontrolled informal urban settlements in Delhi. More than half of Delhi’s population 
resides in these settlements.104 
 
Delhi is divided into nine administrative districts. Each district is headed by a Deputy 
Magistrate and has three subdivisions. A Subdivision Magistrate directs each 
subdivision. The culture of Delhi is characterised by the assimilation of cultural traits of 
different states of India bordering the Union Territory of Delhi, especially Rajasthan, 
Punjab, Haryana and Uttar Pradesh. The language spoken in Delhi is primarily Hindi, 
the national language.421 It is also the mother tongue of most of the people living in 
Delhi, Bihar, Haryana, Uttar Pradesh, north-eastern Madhya Pradesh and Rajasthan. 
English enjoys the status of subsidiary official language but is the most important 
language for national, business-related and political communication.422 A majority of the 
city’s population is of the Hindu religion (82%) followed by Muslims (11.7%), Sikhs (4%) 
and Christians (0.9%), while the remaining are Jains, Buddhist and others.423 A 
disproportionately large number of Muslims in urban India experience miserable 
poverty.424 The demographic profile of Delhi State in Table 10 is from the 2011 census. 
 
Table 10: Demographic profile of Delhi State102 
Indicator  Delhi 
Total population  16,787,941 
Male (M) 8,976,410 
Female (F) 7,776,825 
Sex ratio (per thousand) 
Population growth 
866 F per 1000 M 
21.21% 
Area (square kilometre) 1,483 
Density per square kilometre 11,320 
Average literacy 86.21% 
Female literacy 68.85% 
Male literacy rate  90.95% 
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4.3.2 Study area   
The study was conducted at Sarai Kale Khan locality (Chand Bibi camp, near Nafisa 
masjid and T86 areas), a low-income urban settlement425 located behind Nizammudin 
Railway station and under the jurisdiction of South Delhi Municipal Corporation.425 
 
This research site had a population of approximately 25,000 people, covering an area 
of less than a square kilometre. The majority of the population were from Muslim and 
Hindu religious groups and Hindi was the most commonly and widely spoken language. 
This area was largely inhabited by migrants from the neighbouring states of Uttar 
Pradesh and Rajasthan. The problems of continued access to livelihoods, education, 
healthcare and other basic amenities were quite prevalent in low-income settlements in 
Delhi, and this particular area was not an exception. The majority of the people earned 
their living through manual labour, small businesses and menial jobs. Women were 
mainly responsible for managing households.   
 
There was no government health facility within this locality. The nearest government 
primary health centre that provided free outpatient care was located about a kilometre 
away. In contrast, there were about 15 private health service facilities in the area with 
medical doctors trained in modern allopathic medicine or in Indian Ayurvedic, 
Homeopathic and Unani complemenatary medical systems, who offered mostly primary 
care services on a fee-for-service basis. Furthermore, there were many private 
pharmacies and several medical diagnostic laboratories in this locality. 
 
This locality was selected because a Mobile Health Unit from the ‘Hope Project’ 
Charitable Trust, an NGO where the primary researcher had previously been employed, 
provided weekly health care support to this community. The NGO was one of the 
stakeholders in the study and assisted the research team by providing: 
 research assistants for data collection purposes  
 logistic support during data collection 
 the mobile van, for the transportation of study participants to the nearby 
government hospital for further evaluation, treatment and followup  
 office premises to train research staff and for carrying out research related work. 
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4.4 Quantitative arm of the study: Phase 1 
4.4.1 Conceptualisation stage 
The literature search was conducted by searching the following databases: PubMed, 
Proquest, Science Direct, Ovid, Cochrane Database, and JSTOR. Keywords included: 
CHD, India, absolute or global CHD risk, perceived CHD risk, low socio-economic 
areas, women, health behaviour, antihypertensive treatments and medication 
adherence. The retrieved literature was examined in depth and scrutinised in detail.  
 
a. Data collection tool: Questionnaire 
An interviewer-administered structured questionnaire was used after some modification. 
Interviewer administration was chosen mainly because of the low literacy rate among 
the target population. The 81-item structured questionnaire was divided into six sections 
(please see Appendix 9). It was developed from reliable and validated questions used 
in previous studies. Table 11 below provides an overview of the questionnaire and the 
various validated questionnaires used for the study. The variables in the questionnaire 
for individuals reflected the research objectives and represent health behaviours, 
beliefs, attitudes and health status of the respondents.  
 
All interactions with study participants were conducted in Hindi (the primary language 
spoken in Delhi). The entire questionnaire, consent form and other study materials were 
translated from English into Hindi by the primary researcher (please see Appendix 12). 
The Hindi translation was cross-checked with all discrepancies resolved (please see 
Appendix 13 for the statement of the accuracy of Hindi translation).  
 
Cultural adaptation of the intervention was accomplished by incorporating survey and 
interview terminology that are aligned with Indian culture. Moreover, the researcher had 
worked in the past with the NGO in the broad study area. She also had extensive 
clinical work experience as a physician and public health professional in teaching 
hospitals and nongovernmental health programmes in Delhi, India where the study was 
conducted. Furthermore, to check for understandability and clarity of the questions, the 
data collection was pre-tested in a pilot study of 10 community women who were not 
included in the final analysis.  
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Table 11: Overview of the questionnaire 
Sections Variables No. of 
items 
Source of validated 
questions or scale 
1: Socio-demographic 
information 
 
Age, gender, level of 
education, religion, marital 
status, monthly income and 
work status 
9 WHO STEPS
426
 
  
2: Behavioural 
measurements 
 
Tobacco use (4Qs),  
Alcohol consumption (2Qs)  
 
 
6 
 
WHO STEPS
426
 
Diet and nutrition  20 Adapted from NFHS-3, 
India
107
 
History of last seven days 
physical activity 
 
6 IPAQ
14
 
3: Assessment of 
knowledge of CHD risk 
factors 
 
Knowledge of CHD risk 
factors 
10 Standardised 
questionnaire
7
 
4: Assessment of 
knowledge of women’s 
health problem and family 
history of heart attack 
 
Greatest health problem for 
women in India 
 
1 Adapted from AHAS
427
 
Family history of premature 
CHD 
1 BRFSS
428
, 
5: History of high BP and 
its treatment 
History of hypertension, 
other co- morbidities, 
medication adherence, 
treatment belief and 
satisfaction, medication 
information satisfaction  
18 Developed by the 
present researcher 
from published 
literature 
1, 9, 318
 
 6: Assessment of CHD 
risk perception 
CHD risk perception  
 
1 
 
Developed by the 
present researcher 
from Pachod Paisa 
scale (numerical 
scale)
17, 237, 238, 241, 429
. 
 
7: Assessment of illness 
perception for high blood 
pressure 
Illness perception for 
hypertension scale 
9  BIPQ
15
 
KEY: WHO STEPS=Stepwise approach to surveillance; NFHS=National Family Health survey; IPA=: 
International physical activity questionnaire; BRFSS=Behavioural Risk Factor Surveillance System 
(BRFSS); AHAS=American Heart Association Survey; IPQ: Illness perception questionnaire 
 
b. Instrument reliability and validity 
Reliability of a research instrument refers to the consistency with which it measures a 
particular attribute.
430
 The validity of an instrument refers to the degree to which it 
measures what it is intended to measure in the context of the phenomenon of 
interest.
431
 The following instruments, which are in the public domain (excluding the  
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Brief Illness Perception Questionnaire) and validated in previous studies, were included 
in the questionnaire: 
 
The WHO STEPS426 instrument for non-communicable disease risk factors: This is a 
standardised instrument and protocol for collecting, analysing, disseminating data in 
WHO member countries. Questions on demography, tobacco and alcohol consumption 
were adopted from the WHO STEPS. 
 
NFHS-3: National family Health Survey (2005–06), India 
Questions regarding diet and nutrition were adapted from NFHS-3107. Consumption of 
food was assessed by asking, ‘How often do you eat the following food items: daily, 
weekly 3–4 times, weekly, occasionally or never?’ related to cereals consumption, milk 
or milk products, pulses or beans, green leafy vegetables, fruits, eggs, fish, chicken or 
meat, and junk foods. Participants were also asked regarding the total amount of salt 
and oil consumption (in Kg) in their household in a month.  
 
IPAQ: Questions on physical activity followed those in the International Physical Activity 
Questionnaire (IPAQ).14 The IPAQ has standard measurement properties for utilisation 
in several settings and languages, and is appropriate for national population-based 
prevalence studies of participation in physical activity.432 The short version consisted of 
three distinct activities: walking, moderate-intensity activities and vigorous-intensity 
activities. Besides, there was also a question of sitting activity as an indicator of the 
time that was used for sedentary activities, but it was not incorporated in the 
computation of the total physical activity score. 
 
BRFSS from CDC: The Behavioural Risk Factor Surveillance System (BRFSS) 
questionnaire, was developed by the Centre for Disease Control and Prevention 
(CDC).428 A review of results from numerous other studies suggests that measures 
included in the BRFSS are both reliable and valid. The question related to family history 
of heart disease was taken from BRFSS. 
 
AHAS: American Heart Association Survey (AHAS): What is the greatest health 
problem of women in India? This question was modified from AHAS.427 
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The Pachod Paisa scale: It is a valid, newer numeric response scale that is supposed to 
be a culturally sensitive altrnative to the Likert-type scale.241 The scale has cultural 
resemblance within the South Asian regions as the ‘paisa’ reference is a typically used 
analogy in every parts of the area. Lack of education also does not become an 
impediment when using the scale given that everybody, educated or non-educated, 
deals with money and can relate to an amount of agreement thereby enabling a higher 
level of precision in measurement.241 The Pachod Paisa scale is based on the monetary 
currency in India, the ‘rupee’ (INR) which is comprised of ‘100’ paisa (100 paisa = 
INR1). The scale elicits agreement in ‘paisa’ thereby providing the researcher with a 
continuous variable ranging from ‘0–100’. Several examples demonstrate that this scale 
can be used effectively to a numeric estimate of attitude, perception, cultural belief, and 
quality of life in clinical and community settings.241 In this study the Pachod Paisa scale 
was used to develop a question to calculate the perceived CHD risk of the participants.  
 
The Brief Illness Perception Questionnaire (BIPQ) 
The Brief Illness Perception Questionnaire is a standardised nine-item tool developed to 
measure cognitive and emotional illness depictions.15 BIPQ has been validated and 
available in different languages, including Hindi.433, 434 BIPQ has been used for a variety 
of conditions such as hypertension, diabetes and HIV.  
 
Permission from the researcher was obtained to use this copyrighted questionnaire in 
this study, in Hindi, via email (please see Appendix 14). 
 
4.4.2 Conducting the study  
a. Study population  
The study population was defined as all households (approximately 4000) in the 
selected low-income urban settlement in Sarai Kale Khan, Delhi, India. Household, in 
the Indian context, is defined as a group of individuals living together and sharing a 
common kitchen.435  
 
b. Study participants’ selection criteria 
Inclusion criteria:  
 All women residing in the selected settlement  
 Age: 35–59 years 
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 Women who had the ability to give informed consent 
Exclusion criteria:  
 Not willing to participate  
 Acutely ill  
 History of a past CHD event (based on documentary evidence such as 
physician certified angina pectoris, acute myocardial infarction, congestive heart 
failure, cardio-myopathies, and inflammatory heart diseases),  
 Pregnant women  
 Cannot converse in Hindi (local language in Delhi). 
 
c. Sample size determination  
By using the formula: 
N=2zP(1-P)/(d2(1-α/2)436 
and considering a hypertension prevalence of 40%,437 precision 0.05 and CI 95%, the 
minimum sample size was calculated to be 369. By adding 15% to account for 
incomplete questionnaires, the total number was rounded up to 500. 
 
d. Sampling technique  
Data was collected in a cross-sectional survey over three months, from August to 
October, 2015, in the selected community. The study participants were selected using a 
multi-stage random sampling technique. At the first stage of sampling, 10 lanes or 
gallies were selected randomly out of approximately 27 gallies of the settlement. In the 
second stage, 500 households were randomly chosen from the identified 10 lanes of 
the study area as the secondary sampling units. For selecting households, in the 
beginning, a sampling frame was developed by listing all the residential buildings in the 
selected gallies. Subsequently, the research team visited those residential buildings 
and updated the household list to include only eligible households. For the enrolment, a 
household needed to have (a) at least one female member aged between 35 and 59 
years and (b) that female member residing in the area at the time of the survey. 
 
Each of the selected households was then given a distinctive number. Using the 
updated households list and a unique random number table the research team selected 
500 households for interviews. An invitation and an information sheet about the study 
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were delivered to each of the selected households. The invitation messages included 
the time and date of the proposed home visit.   
 
e. Recruitment process 
In the last stage of sampling, one eligible woman from each household was selected for 
the study. Research staff visited the selected households at a predetermined date and 
time. Only one eligible adult woman was recruited from each household. If a selected 
household had more than one eligible adult woman, the team member in attendance 
used a Kish table438 to select one woman for participation in the study. The Kish 
selection table is a commonly-used method in research that enables interviewers to 
select individuals by following simple and rigorous rules for deciding one person to 
interview among household residents. The method involves creating a list of eligible 
individuals at a particular address, ordered by age, and then selecting according to the 
serial number of the address itself. The method is planned so that all individuals in a 
household have an equal chance of selection.439 If a selected person was not eligible 
for the study, the research team proceeded to the next household. 
 
The research team had two groups. One group conducted the interviews, and the other 
took the necessary anthropometric and clinical measurements including height, weight, 
waist, hip circumference and blood pressure. The interviewing group comprised two 
female interviewers with several years’ experience as community health educators and 
counsellors in reproductive health, HIV/AIDS, communicable diseases and 
immunisations. The second group taking the physical measurements comprised two 
female health workers with several years’ experience as paramedics in the health 
department of the NGO. 
 
Prior to formal data collection, the interviewing team attended a training workshop 
conducted by the researcher to ensure consistent and accurate data collection. 
Similarly, the measurement group was trained by the researcher in performing basic 
anthropometric and clinical measurements including height, weight, waist, hip 
circumference and blood pressure according to standard guidelines. The researcher 
conducted two 7-hour training workshops using the existing resource materials, 
developed by national and international agencies. At the end of each session of the 
workshop, the researcher tested the participants’ knowledge and understanding of the 
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subjects that had been taught during each session.  
  
The researcher closely supervised data collection and the collected data were checked 
on the day of compilation for errors, missing information and inconsistent responses in 
order to ensure data quality. Where necessary, research staff revisited a study 
participant to clarify any erroneous information. 
 
f. Data collection procedures 
The research staff informed participants of their ethical rights and obtained written 
informed consent from participants before starting interviews. 
 
First stage: The interviewers in the team collected information from the participants 
using a standardised structured questionnaire. Patients were also asked about details 
of their prescribed medication regimen. Prescriptions, available at the time of the 
interview, were used in getting reliable data. Wherever prescriptions were not available, 
the medicine or drug strips used by the respondents were inspected and noted. Each 
interview lasted between 20 and 30 minutes.  
 
Second stage: Upon completion of the face-to-face interview, physical measurements 
were taken from the participants in the following order: BP then heart rate then height 
then weight then waist circumference and finally hip circumference, using a standard 
guideline.440 All physical measurements were conducted in a separate room or 
screened-off area in the interviewee’s house. The separate areas provided privacy for 
waist and hip circumference measurements as measures were taken with participants 
wearing minimal clothing and were without shoes (Table 12 documents the physical 
measurement procedures).  
 
Physical mesurements were followed by basic health education related to CHD risk 
factors, including hypertension. All the hypertensive women, irrespective of their blood 
pressure level, were referred to nearby designated government health centres for 
further evaluation, treatment or followup. They were provided with contact details of the 
local government hospitals that provide free health care to the community. Contact 
details of private health care providers also were made available to participants. 
 
107 
 
Table 12: Overview of the physical measurement procedures 
Measurements  Instruments  Procedures  
 
Blood pressure 
(BP) 
 
Omron digital 
automated blood 
pressure monitor 
(OMRON HEM 
7111, Omron 
Healthcare Co. Ltd. 
Uk-Ku, Kyoto, 
Japan).   
The left arm of all participants was used for the BP 
measurement. An appropriate-sized cuff (cuff 
bladder encircling at least 80% of the arm) was 
used for accurate reading. Three BP measurements 
were taken in a sitting position, three minutes apart. 
During data analysis, the average of the second 
and third readings was calculated.  
 
Weight  
 
 
Equinox BR-9201 
analogue weighing 
machine (Microlife 
AG Swiss 
Corporation,  
Switzerland). 
 
The device was placed on a smooth concrete 
surface. The participants were asked to remove 
their shoes and all external heavy clothes. A display 
panel showed 0.0 before the participants stood on 
the scale. This was followed by the participants 
being asked to stand straight with their feet aligned 
in the centre of the weighing machine with arms 
hanging relaxly by their sides, and head facing 
forward. The measurements were recorded to the 
nearest 100g. 
 
Height  
 
 
Non-stretchable 
measuring tapes 
(Jonson Tapes Ltd. 
Delhi, India) 
 
The participants were asked to remove their shoes 
so as to obtain a precise measurement. While 
standing with their feet straight together against the 
flat wall, they were asked to keep their back as 
straight as possible with arms hanging relaxled by 
their sides, and facing forwards. The height was 
recorded in centimetres (cm).  
 
Waist 
circumference  
(WC) 
Non-stretchable 
measuring tapes 
(Jonson Tapes Ltd. 
Delhi, India) 
WC was measured at the central point amid the 
lower margin of the last palpable rib and the top of 
the iliac crest (hip bone) in the mid-axillary plane, 
without any outfits; that is, directly over the skin or 
over light clothing.
440
 Measurement was read to the 
nearest centimetre on the tape, while ensuring to 
keep the measuring tape at ease without causing 
any tightening of the skin.  
 
Hip 
circumferences 
(HC) 
 
Non-stretchable 
measuring tapes 
(Jonson Tapes Ltd. 
Delhi, India) 
 
HC was measured at the widest part of the 
buttocks, with the tape parallel to the floor.
441
 
Measurement was read to the nearest centimetre 
on the tape. 
 
 
4.4.3 Analytical stage 
All data collected from the questionnaire were entered into the Statistical Package for 
Social Sciences (SPSS) (Version 19 for Windows).442 Data cleaning was performed to 
check for accuracy and consistency. There were no missed values during entry. The 
cleaned data was then used for statistical analysis. Distributions of data were explored 
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using the histogram with normality curve. Recoding of variables was also done, mainly 
to convert continuous variables into ordinal and nominal data to ease data analysis. The 
median value was taken as the cutoff for conversion of the continuous variables into 
binary ones. 
 
Study objective 1: the prevalence of CHD risk factors 
Descriptive statistics was used in describing patients’ characteristics, CHD risk factors, 
and prevalence of global CHD risk, health behaviours, knowledge of risk factors and the 
degree of medication adherence. Mean and standard deviation were computed for all 
continuous data. Frequencies (with percentages) were calculated for categorical and 
binary variables.  
 
Study objective 2: the prevalence of inaccurate perception of global CHD risk and its 
predictors 
Kappa analysis (weighted kappa) was carried out to study the agreement between 
perceived and calculated risk. Socio-demographic, behavioural and physiological and 
variables were compared using the non-parametric chi-squares test and t test between 
the accurate and inaccurate perception of CHD risk group. Chi-square tests were used 
to determine the association between categorical variables and the t test for continuous 
variables. Pearson’s chi-square was used to find out any statistically significant 
associations during bivariate analysis, however, in the two-by-two tables, Yates’ 
Correction for Continuity was used which compensates for the overestimation of the 
chi-square when used with a two-by-two table. Fischer’s Exact Test was used if 20% or 
more cells had an expected value of less than 5. 
 
Logistic regression analysis was performed to identify the factors that were associated 
with inaccurate perception of CHD risk. All variables identified in the bivariate analysis 
with a p-value <.05 was entered into multiple regression models. Multiple logistic 
regression analysis using the backward stepwise likelihood ratio method was conducted 
to determine whether the factors could significantly predict inaccuracy of CHD risk. 
Odds ratio (OR) and corresponding 95% confidence interval (CI) are reported. A p– 
value of less than .05 was considered to be statistically significant for all analyses.  
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Study objective 3: the prevalence of medication non-adherence and its predictors 
For analysis of adherence, a cut-off value of 80% was used for labeling patients as 
adherent or non-adherent.9 Socio-demographic, behavioural and physiological variables 
were compared using the non-parametric chi-squares test and t test between 
adherence and non-adherence group. Chi-square tests were used to determine the 
association between categorical variables and t test for continuous variables. Pearson’s 
chi-square and Fisher’s exact tests were used to find out any statistically significant 
associations during bivariate analysis.  
 
Logistic regression analysis was performed to identify the factors that were associated 
with medication non-adherence to hypertensive treatment. All variables identified in the 
bivariate analysis with a p-value <0.05 were entered into multiple regression models. 
 
Multiple logistic regression analysis using the backward stepwise likelihood ratio 
method was conducted to determine whether the factors could significantly predict non-
adherence. OR and corresponding 95% CI are reported. A p value of less than .05 was 
considered to be statistically significant for all analyses. 
 
4.5 Qualitative arm of the study: Phase 2 
4.5.1 Conceptualisation stage 
For the qualitative interviews, semi-structured guides were developed based on an 
extensive review of the relevant literature. A search of the literature was conducted by 
using PubMed, Proquest, Science Direct, Ovid, Cochrane Database, and JSTOR. Key 
words included: CHD, India, CHD risk, low socioeconomic areas, women, health 
behaviour, antihypertensive treatments and medication adherence. The retrieved 
literature was examined in depth and scrutinised in detail. 
 
4.5.2 Methodological stage 
a. Interviews with the hypertensive women  
Recruitment of the participants 
The selection of the women hypertensive participants for the in-depth qualitative 
interview depended on their willingness to communicate freely regarding their medical 
condition and its management, so as to provide sufficient information.443 Another 
criterion was women who had at least one-year experience of living with hypertension. 
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For a sample size in qualitative interview studies, the number of participants is 
adequate if interviews with new members do not yield new themes.444 Guest445 
suggests that 12 participants in homogenous groups are generally enough to achieve 
saturation. With these considerations and the inclusion criteria, a purposeful sample of 
30 hypertensive women participants from the phase one of the study was invited. None 
declined the qualitative interview. 
 
Interviews were conducted over four week period during October–November, 2015. 
Training sessions were held with the research team before conducting the interviews to 
introduce the interview guide, the information sheet, the digital voice recorder, and how 
to conduct the interview. Each question was discussed with the interviewers, and an 
explanation given regarding how to present the question, followup issues, how not to 
lead the participants and how to make the participants relaxed. The interviewers were 
also asked to take notes that would help the researcher later during the transcribing of 
the interviews. 
 
Interviews 
The patients’ interviews were conducted in participants’ homes with prearranged 
appointments adjusted to the participants’ schedules. Interviews with the participants 
lasted between 15 and 30 minutes and were audio recorded. Before the interviews, the 
participants were informed of their ethical rights. After informed consent had been 
obtained, interviews were conducted with help of the semi-structured guide (please see 
Appendix 7). The guide was developed in English and translated into Hindi by the 
researcher, as interviews with participants were conducted in Hindi. The Hindi 
translation was cross-checked with all discrepancies resolved (please see Appendix 10 
for the statement of the accuracy of Hindi translation).  
 
Cultural adaptation of the intervention was accomplished by incorporating interview 
terminology that is aligned with Indian culture. The interview guide was also pretested 
with five hypertensive women, not included in the study, for its relevance, 
appropriateness and ease for delivery in community settings. 
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To ensure confidentiality, the in-depth interviews were all carried out face-to-face in a 
private room, which was out of hearing range of other family members and neighbours. 
The interviews mainly focused on participants’: 
 knowledge regarding hypertension treatment 
 beliefs about antihypertensive medications  
 reasons for medication non-adherence 
 factors related with high medication adherence 
 nature of interaction with health care personnel 
 expectation regarding their hypertension treatment management. 
 
Moreover, to draw out in‑depth views, at the end of the interview the patients was given 
freedom to express any further views and comments. 
 
b. Interviews with the health care providers  
Recruitment  
Individual semi-structured interviews were conducted in health care settings in Delhi. 
Physicians were selected using purposive sampling techniques from government and 
nongovernment health care centres that were directly involved in providing health care 
services to a large number of patients with hypertension from low-income urban areas 
in Delhi. 
 
Before the interview, each participant was contacted by phone. The researcher briefly 
described the aim of the interview and sent an information sheet to the potential 
participant. The sampling procedure allowed for a variety in physicians’ characteristics 
in order to obtain diversity on risk perception and medication adherence. In all, 12 
physicians were approached on the basis of gender, experience, their association with 
private practices, practices at government health facilities and their association with 
nonprofit organisations. These characteristics are known to have an impact on the 
management of care and risk perception.446 Three of the 12 physicians did not respond 
to the contact. The researcher made an appointment with the nine physicians who 
responded and interviews were conducted in the month of October, 2015. 
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Data collection 
As in Phase 1, participants were informed of their ethical rights and their informed 
consent obtained before the start of the interview, which lasted between 15 and 35 
minutes and was audio recorded. A separate semi-structured interview guide was 
developed for this purpose (Appendix 8). Themes for the guide were identified through 
a review of the literature and centred on CHD risk perceptions and medication 
adherence by hypertensive women.  The interviews mainly focused on physicians’:  
 perception of hypertensive women’s perceived CHD risk  
 medication adherence characteristics of their women hypertensive patients  
 factors related to high level of medication adherence 
 factors related to lower levels of medication adherence 
 strategies for addressing medication non-adherence.  
The in-depth interviews were all conducted face-to-face in a private room in the health 
clinic after the physician had completed seeing their patients. The interviews were 
conducted by the researcher. In order to draw out in-depth views, at the end of the 
interview the physicians were given freedom to express additional views and comments 
they might have to make.  
 
c. Data recording and transcribing of the interview data 
The researcher audio recorded interviews to ensure there was an accurate and 
complete verbatim recording of both the interviewer’s questions and participant’s 
responses. The researcher listened to the recordings and transcribed the audio 
recordings into English with an assistant. Transcripts were verified by the researcher for 
their accuracy by repeated listening to the audio interview data. 
 
4.5.3 Data analysis 
Thematic analysis,294 the most widely used method in qualitative studies, was used in 
this study to identify prominent perspectives on non-adherence. Data were analysed by 
the researcher in two stages. 
 
First stage 
Analysis of the data began with repeated readings of the whole transcripts and 
interview notes line-by-line to gain familiarity with the data from the answers to each of 
the research questions. Sections of text from the transcripts were coded, paying 
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attention to the relevant words, phrases or sentences related to the research questions. 
This coding process was done manually, by writing notes on the texts and by using 
highlighters or coloured pens to indicate possible patterns and was thus inductive.294  
 
Second stage 
After coding each transcript, themes were created by grouping the coded transcripts 
around related research questions. The transcripts were reviewed again to determine 
the sub-themes and then collated to form major themes. The list of themes was then 
grouped into several categories. Thus, a coding framework was drawn up to identify 
dominant themes and sub-themes relating to four categories: factors inhibiting 
medication adherence, factors facilitating medication adherence, women’s expectations 
related to their hypertension management, and suggested strategies to improve 
women’s medication adherence to antihypertensive treatment. The results are 
presented in detail in chapter 6. 
 
4.5.4 Ensuring rigor in the research 
Steps were taken throughout the data collection and analysis processes to establish the 
trustworthiness of the methods and credibility of the collated qualitative data and 
findings.447 These steps included verification strategies such as systematic checking of 
data and on-going interpretation of data to enhance reliability and validity. Methods and 
data were documented (audio recording, followed by transcription of interviews) so that 
the analysis of the data could be confirmed.448 Moreover, throughout the research 
process, the research methodology, findings, and documentation were consulted with 
the supervisors of the present researcher. 
 
4.6 Ethical Issues 
Ethical approval was sought from the Curtin University Human Ethics Committee, Perth, 
Western Australia and from the Sigma Institutional Ethical Review Board, Delhi, India. 
Sigma, a research and consulting organisation actively engaged in the social and 
development sector research in India since its inception in 2008. Sigma has sensitivity 
for research ethics in Indian society and culture, with vast experience research 
conducted throughout India. Necessary permission to carry out the research was also 
obtained from the community leaders where the data collection procedure was 
performed.  
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Informed consent 
Before the interviews, trained research team members explained the study intervention 
to potential subjects verbally and provided all pertinent information (purpose, data 
collection procedures, risks, benefits, participants’ rights, confidentiality and anonymity). 
They read out the translated information sheet and consent form to the participants.  
The research team members allowed the potential subjects ample opportunity to ask 
questions to clarify any ambiguities and obtain additional information. They were also 
provided an opportunity to discuss their participation with someone at home (for 
example, husband or in-laws) who could support them in making a decision to 
participate. Interviewers obtained informed consent from those who agreed to 
participate. If a prospective participant was unable to give written informed consent due 
to lack of literacy, the participant’s verbal consent was taken down, and a thumb 
impression was obtained in the appropriate space of the consent form. In such cases, 
the entire procedure was completed in the presence of an independent witness who 
was selected by the participant and had no connection with the research team. The 
witness signed and dated the consent form. The interviewer reviewed and 
countersigned each consent form. All study participants were provided with a copy of an 
‘Information Sheet’ and a ‘Consent Form’ with the contact details of the researcher for 
their personal records ( please see Appendices 4 and 5).  
 
Right to withdraw 
Participants were informed about their ethical rights. As their participation was 
voluntary, they were free to not answer any particular question(s) or refuse any physical 
procedures such as measurement of blood pressure, body weight and waist 
circumference. They had the right to withdraw from the study at any phase without 
compromising the regular services they received from the NGO or other health care 
services.  
 
Confidentiality  
Participants were assured of full confidentiality with regards to their responses in the 
interviews. No information about participants was accessible to other study participants 
or the general public. The interviewers held all meetings in the privacy of the 
participants’ homes. Individual identifiers were removed permanently from all the data. 
Data, without any personally identifiable information, were entered into a computer 
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database for analysis so that individual participants could not be identified in any 
publications associated with the study.  
 
Minimisation of harm 
The researcher was very much aware of the possibility of psychological harm because 
of hypertension labeling, since the study involved an examination of individuals’ blood 
pressure status. To prevent adverse psychological consequences, research staff (the 
counsellor-interviewer) was trained to provide such information in an empathic and 
neutral manner to the study participants. The research team followed the advice of Dr. 
Thomas Pickering: 
‘When we diagnose and treat patients with hypertension, we should 
emphasise the positive aspects of care. Our message to the public should 
not be that hypertension is the ‘silent killer’ but that it is a risk factor that can 
be readily controlled by an ongoing partnership between patients and their 
health care providers’.410 
 
Addressing unequal relationship 
The researcher was acutely aware that the study women, who were disadvantaged due 
to gender, poor socio-economic status and poor access to health care in the Indian 
social and cultural context, were in an unequal power relationship with the health care 
staff of the NGO, which provided weekly services to them. To minimise impacts of such 
unequal relationship, only those interviewers were selected from the NGO who were 
not associated with providing direct health services to the study participants. 
 
Dissemination of the findings 
The thesis will be open access and will be uploaded on the Australian Digital Thesis 
website, which is a mandatory requirement of the Australian government. An abridged 
report in English and Hindi will be made available to the NGO and will also be uploaded 
to the School of Nursing, Midwifery and Paramedicine, Curtin University website. The 
findings will also be submitted for publication in peer-reviewed journals so that the 
results can be shared with the global academic community. The report will also be 
launched at a community event in New Delhi with the NGO and participants. 
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4.7 Data storage 
All paper records, audio recordings, questionnaires, printed transcripts, interview notes 
and code sheets are stored in a secured cabinet in the Research Hub of Curtin 
University. Before transfer of the data by the researcher to Australia, the survey 
information, including participants' consent forms, were placed in sealed envelopes and 
locked in cupboards in a secure location at the researcher's residence in Delhi. All 
electronic data is password protected. Data will be stored seven years after the thesis 
has been submitted, after which it will be destroyed as required by legislation. 
 
4.8 Summary of the chapter 
This chapter has described the methods of data collection and analysis used in the 
quantitative and qualitative arms of the present study as well as ethical considerations. 
of the study. The next chapter presents the quantitative findings of the study. 
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CHAPTER 5 
QUANTITATIVE RESULTS 
 
5.0 Introduction to the chapter 
This chapter presents quantitative findings from the survey questionnaire. They include 
socio-demographic characteristics, behavioural and physiological profiles, knowledge of 
heart disease risk factors, dietary habits, knowledge of greatest health problem of 
women, family history of heart disease and history of hypertension, and treatment 
obtained. The findings concerning CHD risk perception and medication adherence of 
hypertensive participants are then presented in the form of univariate, bivariate and 
multivariate statistics. 
 
5.1 Description of the survey participants  
The 500 eligible community women were approached for structured quantitative 
interviews. None declined the interview. The researcher closely supervised data 
collection and the collected data were checked on the day of compilation for errors, 
missing information and inconsistent response in order to ensure data quality. Where 
necessary, research staff revisited a study participant to clarify any erroneous 
information. All data collected from the questionnaire were entered into the SPSS 
(Version 19). There were no missing values during data entry (please see page 107, 
chapter 4.4.3 for details of the data analysis procedure).  
 
5.1.1 Socio-demographic characteristics of the participants 
This section summarises the socio-demographic characteristics of the 500 community 
women of the low-income urban settlement in Delhi, who participated in this study. 
These are presented in summary form in Table 13 (age, average household members, 
education, religion, marital status, work status, type of family and average household 
income). 
 
The mean age of the study women was 45.8 years (± SD 6.5) (range 35–59 years). The 
median age was 45 years. The majority of the women were Muslim (56.8%; n = 284) 
followed by the Hindu faith (39.6%; n = 198). Most of the women (89.4%; n = 447) were 
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married while 3.4% (n = 17) were never married and rest 6.6% (33) were divorced, 
separated, or widowed at the time of the survey. 
 
Table 13: Socio-demographic characteristics of survey participants, N=500 
Socio-demographic factors 
 
Females  
 N 
Percent  
   % 
Mean ± SD 
Age (years)       45.8 ± 6.57 
Age grouping    
     ≤45years 260 52  
     >45 years 240 48  
Number of household members 
Education  
      5.1 ± 1.8 
      No schooling (can’t sign) 133 26.6  
      Primary school = 0 to <5 years  
      (can sign only) 
119 23.8  
      Primary school completed (5 years) 120 24  
      Secondary school completed(10 years) 66 13.2  
      Higher secondary school completed 46 9.2  
      College/university completed 16 3.2  
Religion    
      Hindu  198 39.6  
      Muslim 293 58.6  
      Christian  6 1.2  
      Sikh  3 0.6  
Marital status    
     Never married 20 4  
     Currently married 447 89.4  
     Separated  18 3.6  
     Divorced  12 2.4  
     Widowed  3 0.6  
Work status     
      Government employee 14 4  
      Nongovernment employee 70 14.8  
      Self-employed  53 10  
      Unskilled manual labour 58 12.2  
      Homemaker  298 58  
      Retired  5 1  
      Unemployed  2 0.4  
Type of family    
      Nuclear  422 84.4  
      Joint  78 15.6  
Co-existing illnesses 127 25.4  
Monthly household income (INR)                                         9000
a
(median) 9,404.17±  
4,283.83 
a
INR 9000=AUD187 
Over half of the women (52%; n = 251) were found to be illiterate, and this included 115 
women (23%) who could sign their names but not read or write. Only a quarter of the 
participating women (24%; n = 120) had up to primary education, whereas 22.4% (n = 
128) had received 10 years or more of formal education. The majority of the women 
(84.4%; n = 422) lived in nuclear families with an average family size of 5.1 (± SD 1.8) 
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members. Above half (59.6%; n = 298) of the families were having more than four 
members. Nearly a quarter of the women (25.4%; n = 127) had self-reported history of 
co-existing chronic illnesses. 
 
Regarding employment status, over half of the study women (58%; n = 298) were 
homemakers and not engaged in any formal work, while 18.8% (n = 84) were employed 
in government or nongovernment organisations. About 12.2% (n = 58) were in manual 
labour jobs and a tenth (n = 53) were self-employed. The remaining (1.4%; n = 7) were 
unemployed or retired persons. The average monthly family income of them was INR 
9,404.17 (± SD 4,283.83) with a median of INR 9,000 (USD 135). 
 
5.1.2 Dietary habits  
Table 14 shows the frequency of consumption of each of the food groups represented 
on the food frequency questionnaire. All of the participants consumed cereals (chapati, 
rice, daliya, suji, bajra, jowar, ragi etc.) daily. Vegetables were eaten daily by more than  
 
Table 14: Dietary habits of survey participants, N=500 
Food groups Frequency of consumption n (%) 
Daily  3-4 days in 
a week 
Weekly Occasionall
y  
Never  
 
Cereals  
 
500 (100) 
 
- 
 
- 
 
- 
 
- 
Milk or milk products   145 (29.9) 131(26.2) 66 (13,2) 100 (20) 58 (11.6) 
Pulses or beans   156 (31.2) 145 (29) 174 (34.8)            25 (5) - 
Green leafy vegetables 81 (16.2) 180(36) 208 (41.6) 30 (6) 1 (0.2) 
Roots and tubers  77 (15.4) 292 (58.4) 126 (25) 5 (1) 1 (0.2) 
Other vegetables   126 (25.2) 264 (52.8) 107 (21.4)           3 (0.6) - 
Fruits   51 (10.2) 132 (26.4) 181 (36.2) 127 (25.4) 9 (1.8) 
Eggs   5 (1) 29 (5.8) 155 (31) 229 (45.8) 82 (16.4) 
Fish   9 (1.8) 13 (2.6) 60 (12) 237 (47.4) 181 (36.2) 
Chicken or meat   6 (1.2) 147 (29.4) 149 (29.8) 81 (16.2) 117 (23.4) 
Nuts and oilseed   5 (1) 2 (0.4) 8(1.6) 136 (27.2) 346 (69.2) 
Fats and oils    497 (99.4) 3 (0.6) - - - 
Sugar and Jaggery   315(63) 103 (20.6) 32 (6.4) 44 (8.8) 6 (1.2) 
Fried foods    4(0.8) 122 (24.4) 38.6 (193) 153 (30.6) 28 (5.6) 
Junk foods  - 2 (0.4) 28 (5.6) 221 (44.2) 249 (49.8) 
Sweets   1 (0.2) 11(2.2) 139 (27.8) 301 (60.2) 48 (9.6) 
Aerated drinks    6(1.2) 11 (2.2) 119 (23.8) 264 (52.8) 99 (19.8) 
(soft drinks) 
Monthly individual salt consumption (mean ± SD) 220.18 ± 50 mg 
Monthly individualcooking oil intake( mean ± SD) 1.30 ± 0 .32 kg 
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half of the participants (56.8%) though green leafy vegetables were eaten daily by only  
16.2% (n = 81) of the women. Approximately one-tenth of the study women (10.2%; n = 
5) had eaten fruits daily in the preceding one month. Only 36.2% (n = 181) and 41.6% 
(n = 208) reported eating fruit or green leafy vegetables weekly respectively in the last 
month.  Less than a third (29.9%; n = 145) of the women reported consumption of milk 
products daily.  
 
Just under a third (29.4%; n = 147) of the women consumed chicken or meat three to 
four days per week. The consumption of eggs and fish was quite infrequent, with 5.8% 
(n = 29) of women eating eggs and 2.6% (n = 13) eating fish 3–4 days a week. Very few 
women reported eating chicken or meat (1.2%; n = 6), fish (1.8%; n = 9) and eggs (1%; 
n = 5) daily. Eggs were consumed less often daily than chicken or meat, or fish. Of the 
participants, more than one-third (36.2%; n = 181) never ate fish. The 126 women 
(25.2%) who reported eating fried foods (poori, pakora, vada, samosa, tikki, etc) did so 
either 3–4 days a week, or more. The mean consumption of salt and cooking oil per 
month, per household member, was 220.18 mg (± SD 50.04) and 1.30 kg (± SD 0.32) 
respectively. 
 
5.1.3 Knowledge of modifiable CHD risk factors and greatest health problem of 
women     
In section 3 of the questionnaire, participants were asked several questions to measure 
their knowledge of CHD risk factors. The findings are summarised below in Table 15.  
 
Table 15: Knowledge of CHD risk factors among survey participants, N=500 
 
Items  Response frequency 
 Yes  
  n (%) 
No  
n (%) 
Don’t know  
n (%) 
Smoking/tobacco use 255 (51) 129 (25.8) 116 (23.2) 
Weight loss 181 (36.2)  210 (42) 109 (21.8) 
Obesity  347 (69.4) 100 (20) 53 (10.6) 
Depression  250 (50) 148 (29.6) 100 (20.4) 
Hypertension 417 (83.4) 28 (5.6) 55 (11) 
High cholesterol 295 (59) 87 (17.4) 118 (23.6) 
Daily exercise  112 (22.4) 218 (43.6) 170 (34) 
Stress 355 (71) 64 (12.8) 81 (16.2) 
Sleeping too much 104 (20.8) 241 (48.2) 155 (31) 
Diabetes mellitus 187 (37.4) 96 (19.2) 217 (43.4) 
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Among the participants, hypertension, obesity, high cholesterol and smoking were 
identified as modifiable risk factors of CHD by 83.4 % (n = 417), 69.4% (n = 347), 59% 
(n = 295), and 51% (n = 255) respectively. Only 37.4% (n = 187) knew that diabetes 
mellitus was a modifiable risk factor of CHD. Overall, the majority (74.8%) of 
participants lacked ‘good’ level of knowledge about modifiable risk factors of CHD, 
where ‘good level’ was defined as correctly knowing four or more major modifiable CHD 
risk factors. Only a quarter (25.2%; n = 126) had a good level of knowledge about 
modifiable CHD risk factors. 
 
The majority of the women (32.2%; n = 161) identified cancer as the greatest health 
problem followed by AIDS (14.2%; n = 71) and diabetes (13.6%; n = 68) for women in 
India. A tenth of the study women (10.4%; n = 52) considered heart diseases or heart 
attack as the greatest health problem for women while 3.8% could not give a response 
regarding the greatest problem. 
 
5.1.3 Behavioural and physiological CHD risk factor among survey women 
This section summarises behavioural and physiological risk factors of the study women. 
The statistics for tobacco use, alcohol consumption, physical activity, history of 
diabetes, family history of heart disease, and physiological parameters (blood pressure, 
height, weight, waist and hip circumference) are summarised in Table 16. 
 
 Of the 500 women studied, some of them indulged in unhealthy lifestyles such as 
tobacco use and alcohol consumption. The overall prevalence of current tobacco users 
was 28.2% (n = 141). Among the study participants, the prevalence of smokeless 
tobacco users (17.8%; n = 89) was higher than that of smoked tobacco users (10.4%; n 
= 52). Only three women (0.6%) consumed alcohol in the past 30 days. 
 
A low level of physical activity was observed in 190 women (38.4%) while 279 women 
(55.8 %) were moderately active and 29 women (5.8%) were highly active. The overall 
prevalence of overweight and obesity (BMI ≥23 kg/m2)13 among the participants was 
52.6% (n = 263). A higher proportion of women had abdominal obesity (66.4% 
assessed by waist circumference and 82.8% by waist-hip ratio).  
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Over one-third of the study women were identified as having hypertension (35.2%; n = 
176). Among them, 102 (58%) women were aware of their hypertensive status, 82 
women (46.6%) were currently on antihypertensive medication, and only 28 women 
(15.9%) had achieved blood pressure (BP) control. 
 
Table 16: Prevalence of CHD risk factors among survey participants, N=500 
  
 
Of all study women, 11% (n = 55) had self-reported diabetes. Nine percent (n = 45) had 
a family history of heart disease as diagnosed by health care providers. Although the 
majority (75.2%: n = 376) were in the low risk category (<10% risk) of developing CHD, 
about a quarter (24.8%; n = 124) had ≥10% risk of developing fatal or non-fatal CHD in 
the next five years (please see Table 17). 
 
 
CHD risk factors Number  Percent        Mean ± SD 
Use smoked tobacco daily                                         51 10.2  
Use smokeless tobacco daily 90 18  
Current drinker 3 0.6  
Physical activity score 
(MET-minutes/week) 
       830.24 ± 935.05 
Physical activity level    
       Low activity 192 38.4  
       Moderate activity 279 55.8  
       High activity  29 5.8  
Hypertensive  176 35.2  
       On current medication 82 46.5  
       Not on treatment  20 11.5  
       Not aware of hypertensive state 74 42  
Self-reported diabetics 55 11  
Height (cm)    150.02 ± 5.19 
Weight (kg)    55.31 ± 12.47 
Body Mass Index (BMI)    24.53 ± 4.87 
       <18.5 kg/m
2 
21 4.2  
       18.5–22.9kg/m2 216 43.2  
       23–24.9kg/m2 68 13.6  
       ≥25kg/m
2 
195 39  
Waist circumference (WC)    86.94 ± 11.94 
        WC<80 cm 167 33.4  
        WC ≥80 cm 333 66.6  
Hip circumference (cm)     97.98 ± 11.54 
Waist and Hip Ratio (WHR)     1.06 ± 3.98 
        WHR ≥0.85 414 82.8  
        WHR <0.85 86 17.8  
Family history of heart disease 45 9  
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Table 17: Global five-year risk of CHD among survey participants according to 
NHANES non-laboratory-based risk prediction chart, N=500 
 
 
 
 
 
5.2 Description of the hypertensive respondents 
This data was collected only from those respondents who were hypertensive (n = 176). 
The data analysis was conducted in two phases. At the first step, descriptive 
analysis of all variables related to socio-demography, psychosocial, CHD risk 
factors, CHD risk factor knowledge, global CHD risk, CHD risk perception, 
hypertension perception, and antihypertensive treatment of the hypertensive women 
was performed. In the second step, relationships of independent variables with CHD 
risk perception and medication adherence status were examined. 
 
5.2.1 Socio-demographic characteristics of hypertensive women  
The statistics on socio-demographic characteristics of the hypertensive women are 
summarised in Table 18 (age, household members, education, religion, marital status, 
work status, type of family, co-existing illness, and average household income). 
 
The mean age of the participants was 46.3 years (SD ± 6.9) (range 35–59 years). The 
median age was 48 years. The majority of the participants were of the Muslim faith 
(59.7%; n = 105) followed by Hindus (39.8%; n = 70). Over half of the participants 
(51.1%; n = 90) were illiterate, among whom 21.6% (n = 38) could sign their names. A 
quarter of the participants (25%; n = 44) received only five years of formal education; 
just under a quarter (23.9%; n = 42) completed 10 years or more of formal education. 
Most of the study women (89.8%; n = 158) were married while 11 (6.2%) were divorced, 
separated, or widowed. Seven women (4%) never married. One-third of the women 
(34.1%; n = 60) had a self-reported history of co-existing chronic illnesses. 
 
The majority of the women (58.5%; n = 103) were homemakers followed by government 
or non-government employees (15.4%; n = 27) and self-employed (13.1%; n = 23). A 
tenth of the women (10.8%; n = 19) were in manual labour jobs. Most of the women 
Global CHD risk                                         Number                              Percent 
         High risk >20% 35 7 
         Moderate risk 10–20% 89 17.8 
         Low risk <10% 376 75.2 
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(80.7%; n = 142) lived in nuclear families with an average family size of 5.3 (± SD 2.2) 
members. The average monthly family income of the study population was Rupees 
10,065 (± SD 5,117) with a median of INR 9,000 (USD 135). 
 
Table 18: Socio-demographic characteristics of the hypertensive women, N = 176 
 
5.2.2 Food habits of the hypertensive women 
Table 19 shows the frequency of consumption of each of the food groups represented 
on the Food Frequency Questionnaire. All of the study women consumed cereals 
(chapati, rice, daliya, suji, bajra, jowar, ragi etc.) daily. Fruit and green leafy vegetables 
(GLVs) were eaten more than three days in a week by 40.3.1% (n = 71) and 42.1% (n = 
Socio-demographic factors 
 
Females  
n 
Per cent  
% 
Mean ± SD 
Age (years)    46.36 ± 6.93 
Age grouping    
       ≤46 years 96 54.5  
       >46 years 80 45.5  
Number of household members    5.34 ± 2.21 
Education % (n)    
        No schooling (can’t sign) 52 29.5  
        Primary school = 0 to <5 years)  
        (can sign only) 
38 21.6  
        Primary school completed (5 years) 44 25  
        Secondary school completed (10 years) 20 11.4  
        Completed higher secondary school 16 9.1  
        College/university completed 6 3.4  
Religion     
        Hindu  70 39.8  
        Muslim 105 59.7  
        Christian  1 0.6  
Marital status    
       Never married 7 4  
       Currently married 158 89.8  
       Separated  5 2.8  
       Divorced  5 2.8  
       Widowed  1 0.6  
Work status     
       Government employee 4 2.3  
       Nongovernment employee 23 13.1  
       Self employed  23 13.1  
       Unskilled manual labour 19 10.8  
       Home maker  103 58.5  
       Retired  4 2.2  
Type of family    
       Nuclear  142 80.7  
       Joint  34 19.3  
Co-existing illnesses 60 34.1  
Monthly household income (INR)                                  9000 (median)         10,065 ± 5,117 
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74) of women respectively. Over half of the women reported eating fruit (59.7%; n = 
105) and green leafy vegetables (58%; n = 102) weekly or occasionally. Only 28.4% (n 
= 50) of the study women consumed milk products daily, whereas, 13.1% (n = 23) 
never had milk or any dairy products in the previous month. 
 
The majority of women (42.6%; n = 75) had eaten chicken or meat on more than three 
days a week. Eggs were consumed less often than chicken or meat. Of the participants, 
approximately one third (33%; n = 58) never ate fish. Forty five women (25.6%) 
reported eating fried foods three to four times weekly. The mean consumption of salt 
and cooking oil per month, per household member, was 218.37 mg (± SD 50.13) and 
1.32 kg (± SD .31) respectively. 
 
Table 19: Dietary habits of hypertensive women, N = 176 
Food groups Frequency of consumption n (%) 
Daily  3-4 times in 
a week 
Weekly Occasionally  Never  
Cereals 176 (100) - - -                 - 
Milk or milk products 50 (28.4) 45 (25.6) 24 (13.6) 34 (19.3) 23 (13.1) 
Pulses or beans 17 (9.7) 92 (52.3) 62 (35.2) 5 (2.8) - 
Green leafy vegetables 4 (2.3) 70 (39.8) 89 (50.6) 13 (7.4) - 
Roots and tubers 18 (10.2) 103 (58.5) 54 (30.7) 1 (0.6) - 
Other vegetables 36 (20.5) 108 (61.4) 31 (17.6) 1 (0.6) - 
Fruits 9 (5.1) 62 (35.2) 57 (32.4) 44 (25) 4 (2.3) 
Eggs 1 (0.6) 9 (5.1) 59 (33.5) 77 (43.8) 30 (17) 
Fish 1 (0.6) - 23 (13.1) 94 (53.4) 58 (33) 
Chicken or meat - 75 (42.6) 60 (34.1) 12 (6.8) 29 (16.5) 
Nuts and oilseed 1 (0.6) -  4 (2.3) 49 (27.8) 122 (69.3) 
Fats and oils  175 (99.4) 1 (0.6) - - - 
Sugar and Jaggery 93 (52.3) 44 (25) 16 (9.1) 22 (12.5) 2 (1.1) 
Fried foods  - 45 (25.6) 72 (40.9) 46 (26.1) 13 (7.4) 
Junk foods  - - 9 (5.1) 67 (38.1) 100 (56.8) 
Sweets 2 (1.1) - 47 (26.7) 105 (59.7) 22 (12.5) 
Aerated drinks  1 (0.6) 3 (1.7) 37 (21) 87 (49.4) 48 (27.3) 
Monthly individual salt consumption (mean ± SD ) 218.37 ± 50.13 mg 
Monthly individual cooking oil  intake (mean ± SD ) 1.32 ± 0.31kg 
 
5.2.3 Knowledge of modifiable CHD risk factors and prioritisation of health 
problems by hypertensive women  
In section 3 of the questionnaire, participants were asked several questions to measure 
their knowledge of CHD risk factors. The results are summarised in Table 20. Among 
the participants, hypertension, obesity, high cholesterol and smoking were identified as 
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modifiable risk factors of CHD by 86.9 %( n = 153), 69.9% (n = 123), 64.8% (n = 114), 
and 49.4% (n = 87), respectively. Only 47.2% (n = 83) knew that diabetes mellitus is a 
modifiable risk factor of CHD. Just over half (52.3%) of participants lacked ‘good’ level 
of knowledge about modifiable risk factors of CHD, where ‘good level’ was defined as 
correctly knowing four or more major modifiable CHD risk factors, while the remaining 
47.7% (n = 84) had a good level of knowledge.  
 
The majority of the women (42.6%; n = 75) considered cancer as the greatest health 
problem for women in India, followed by diabetes (13.6%; n = 24) and hypertension 
(13.1%; n = 23). Only 4.5% (n = 8) women recognised heart diseases or heart attack as 
the greatest health problem for women in India. Nine women (5.1%; n = 9) could not 
say what was the greatest health problem for Indian women. 
 
Table 20: Knowledge of CHD risk factors among hypertensive women. N = 176 
 
CHD risk factors                             Response frequency                            
 Yes 
 n (%) 
No  
n (%) 
Don’t know 
 n (%) 
Hypertension 153 (86.9) 8 (4.5) 15 (8.5) 
Obesity  123 (69.9) 33 (18.8) 20 (11.4) 
Stress 118 (67.0) 26 (14.8) 36 (20.5) 
High cholesterol 114 (64.8) 26 (14.8) 36 (20.5) 
Depression  91 (51.7) 44 (25.0) 41 (23.3) 
Smoking/tobacco use 87 (49.4) 46 (26.1)               43 (24.4) 
Diabetes mellitus 83 (47.2) 33 (18.8) 60 (34.1) 
Weight loss 64 (36.4) 73 (41.5) 39 (22.2) 
Daily exercise  46 (26.1) 61 (34.7) 69 (39.2) 
Sleeping too much 33 (18.8) 93 (52.8) 50 (28.4) 
 
5.2.4 Behavioural and physiological CHD risk factors of the hypertensive women 
This section summarises the behavioural and physiological risk factors of the 
hypertensive women. The statistics on womens’ tobacco use, alcohol consumption, 
physical activity, history of diabetes, family history of heart disease, and physiological 
parameters (blood pressure, height, weight, waist and hip circumference) are 
summarised in Table 21. 
 
Among hypertensive women, the prevalence of current tobacco users was 26.1% (n = 
46). The prevalence of smokeless tobacco users (17.6%; n = 31) was higher than that 
of smoked tobacco users (8.5%; n = 15). Among the hypertensive study women, the 
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prevalence of systolic hypertension was 68.2% (n = 120) while the prevalence of the 
diastolic hypertension was 54% (n = 95). The mean systolic blood press (SBP) was 
143.95 ± 18.36 mmHg, and it ranged from 100 to 206 mmHg. The average diastolic 
blood pressure (DBP) was 88.09 ± 9.70 mmHg, and ranged from 62 to 108 mmHg. 
Almost one-fifth of the hypertensive women (18.2%; n = 34) had co-existing self-
reported diabetes.  
 
Of the hypertensive women studied, 44.3% (n = 78) reported low physical activity, while 
54.5 % (n = 96) were moderately active and 1.1% (n = 2) were highly active. The overall 
prevalence of overweight and obesity (BMI ≥23 kg/m2) was 70.5% (n = 124). A higher 
proportion of women had abdominal obesity (82.4% assessed by waist circumference 
and 93.2% evaluated by waist-hip ratio) compared to obesity defined in terms of BMI. 
Twenty-four women (13.6%) had a family history of heart disease as diagnosed by 
health care providers. The majority of women (79%; n = 139) said that someone 
accompanied them during their clinic visits most of the time. 
 
Table 21: Prevalence of CHD risk factors among hypertensive women. N = 176 
CHD risk factors Number  Percent  Mean ± SD 
Use smoked tobacco daily                                         15 8.5  
Use smokeless tobacco daily 31 17.6  
Current drinker 0.6 1  
Physical activity score (MET minutes/week)   728.67± 550.461 
Level of physical activity    
      Low activity 82 46.6  
      Moderate activity 72 40.9  
      High activity  22 12.5  
Systolic hypertension 120 68.2  
Diastolic hypertension 95 54  
Self-reported diabetics 32 18.2  
Body Mass Index (BMI)   26.37 ± 5.12 
   <18.5 kg/m
2 
2 1.1  
     18.5–22.9kg/m
2 
49 28.4  
      23–24.9kg/m
2 
30 17  
    ≥25kg/m
2 
93 53.4  
Waist circumference (WC)   91.75 ± 11.77 
     WC ≤80 cm 32 18.2  
     WC >80 cm 144 81.8  
Hip circumference (cm)   102.11 ± 12.00 
Waist and Hip Ratio (WHR)   0.89 ± 0.03 
     WHR ≥0.85 164 93.2  
     WHR<0.85 12 6.8  
Family history of heart disease 24 13.6  
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5.2.5. Global five-year CHD risk of hypertensive women 
Of all hypertensive women, 14.8% (n = 26) had high risk and 27.3% (n = 48) had 
moderate risk of developing fatal or non-fatal myocardial infarction or stroke in the next 
five years, as assessed with the NHANES non-laboratory-based prediction chart5 
(please see table 22). 
 
Table 22: Global five-year CHD risk of hypertensive women according to the 
NHANES non-laboratory-based risk prediction chart, N = 176 
 
 
5.3 Hypertensive womens’ perceptions of coronary heart disease risk 
This data was collected only from those hypertensive women (n = 102) who were aware 
of their hypertensive condition before the survey. As the first step, descriptive analysis 
of all the variables related to perceived and global CHD risk was carried out. In the 
second step, associations and inferences of variables with inaccurately perceived 
CHD risk status were performed. 
 
Perceived CHD risk was calculated in this study by asking research participants ‘In the 
next five years, how many paisa in a rupee do you think is your risk of having heart 
disease compared to a woman of your age (if you make no changes in your current 
lifestyle such as tobacco use, diet, activity level, non-adherence to medication)?’. 
Participants indicated their response by placing an X on a scale ranging from 0 paisa 
(no risk) to 100 paisa (high risk), segmented at 10 paisa intervals. The 0–100 paisa 
response scale was selected to correspond with the risk estimates provided by the 
NHANES risk calculator. According to participants’ responses, participants were 
categorised to ‘low perceived risk’ (<10 paisa in a rupee), moderate perceived risk (10–
20 paisa in a rupee) and high perceived risk (>20 paisa in a rupee). For research 
purposes the variables ‘moderate’ and ‘high perceived risk’ were collapsed into a single 
variable, ‘high perceived risk’. Risk accuracy was defined as the ability of the participant 
to assign her likelihood of heart disease to the same category as her calculated risk.16 If 
the difference between an individual’s estimated risk and a personal perceived risk was 
a positive number, it indicated a pessimistic view in that participants saw their own risk 
  Global CHD risk                                               Number                     Percentage 
 
            High risk >20% 26 14.8 
           Moderate risk 10–20% 48 27.2 
            Low risk <10% 102                 58.0 
129 
 
as greater than it is. While negative numbers would indicate an optimistic view in which 
participants understand their risk as smaller than the calculated risk.17 According to 
participants’ responses, participants were dichotomised to participants with accurate 
perception and participants with inaccurate perception. Under-estimators were those 
women who perceived themselves to be at ‘low’ risk, but were actually at high risk,16 as 
calculated by the NHANES non- laboratory-based risk score chart. 
 
The mean score for CHD risk perception of these hypertensive women was 22.9 (± 
SD 28.4; median 10) indicating that the participants had low CHD risk perception 
overall. The distribution of the scores was positively skewed (skewness = 1.17 and SE 
.24) indicating that responses were clustered around the lower end. Figure 7 illustrates 
this. The majority of the women (58.8%; n = 60) perceived their CHD risk as low 
while 28.4% (n = 29) viewed it as moderate and only one-tenth (9.8%; n = 10) 
perceived their CHD risk as high.   
 
Figure 7: Distribution of perceived CHD risk score among hypertensive women 
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On the other hand, NHANES non-laboratory-based prediction chart indicates 20.6% (n 
= 21) of all hypertensive women had high risk, and 31.4% (n = 32) and 48 (49%) had 
moderate and low risk of fatal or non-fatal myocardial infarction or stroke in five years, 
respectively. 
 
Thus, women tended to underestimate their moderate and high risks of CHD. The 
statistics on perceived and global CHD risk of these women are summarised in Table 
23. Kappa analysis showed low agreement449 (Kappa ± SE: 0.137 ± 0.072; p = 0.05 
between Global CHD risk as assessed with the NHANES chart and perceived CHD risk 
of the women. 
 
Table 23: Agreement between perceived and absolute CHD risk of hypertensive 
women, N=102 
 
 Perceived CHD risk n (%)*       Total 
      High        Moderate              Low   
Total 
five-year 
CHD risk 
High risk 4 (3.9) 7 (6.9) 10 (9.8) 21 (20.6) 
Moderate risk  9 (8.8) 9 (8.8) 14 (13.7) 32 (31.4) 
Low risk            0 13 (12.7) 36 (35.3) 49 (48.0) 
                       Total                     13 (12.7)          29 (28.4)           60 (58.8)       102 (100) 
    * Kappa=0.137 
 
5.3.1 Prevalence of accuracy of self-perception of CHD risk 
In statistical analysis, more than half (52%; n = 53) of women who were aware of their 
hypertension status were not able to estimate their CHD risk correctly while 48% (n = 
49) could do so correctly. Under-estimation of their CHD risk was observed in 31 
women (30.4% of the total aware hypertensive women and 58.49% of the inaccurate 
women participants), while over-estimation was observed in only 22 women (21.6% of 
the aware hypertensive women; 41.50% of the inaccurate women participants).  
 
5.3.2 Comparing the socio-demographic, other chronic illnesses, CHD risk factor 
knowledge and CHD risk factors profile of the hypertensive women based on the 
accuracy of their CHD risk perception 
Table 24 summarises the statistics comparing data on socio-demographic factors, other 
chronic illnesses, monthly household salt consumption, monthly use of household 
cooking oil, CHD risk factor knowledge, knowledge of greatest health problem of 
women in India, and CHD risk factors profiles of hypertensive women who were 
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accurate in their CHD risk perception with those who were not accurate. Socio-
demographic factors include age, religion, marital status, educational status, work 
status, type of family, and monthly household income. The CHD risk factors profile 
includes data on daily tobacco use, mean systolic blood pressure (SBP), mean diastolic 
blood pressure (DBP), systolic hypertension, diastolic hypertension, BP control, BMI, 
physical activity, abdominal obesity, self-reported diabetes and family history of heart 
disease. 
 
Among the participants, the following proportions reported the following as risk factors 
for heart attacks: 80.4% of participants for obesity, 76.55% for high cholesterol, 53.9% 
for diabetes and 52.9% for smoking. Women who perceived their CHD risk accurately 
were younger than women who perceived their CHD risk inaccurately (mean age ± SD 
45.8 ± 7.1 versus 50.2 ± 7.2; p = 0.003). A significantly higher proportion of women with 
inaccurate risk perceptions were aged 48 years or more in comparison to women with 
accurate risk perceptions: 66% versus 34.7% respectively (p = 0.003).  
 
Regarding the overall level of CHD risk factor knowledge, there was a significant 
difference between hypertensive women who estimated their risk correctly with those 
women who did not. A higher proportion of women who perceived their CHD risk 
accurately had a good level of CHD risk factor knowledge in comparison to women with 
inaccurate risk perceptions: 71.4% versus 30.2% respectively, (p = .0000). Of those 
women with inaccurate CHD risk perception, 28.3%, 32.1%, 56.6%, and 60.4% did not 
know that obesity, high cholesterol, smoking and diabetes increase the risk of having a 
heart attack respectively. Though the higher proportion of women with inaccurate risk 
perception unable to identify hypertension as a risk factor for heart attack, in 
comparison to those women who correctly perceived their CHD risk (17% versus 6.1% 
respectively), the difference was not significant (p = 0.12).  
 
A non-significant higher proportion of women with inaccurate perception of CHD risk 
were illiterate and homemakers, than those who perceived their risk accurately: 52.8% 
versus 47.2% and 66% versus 34% respectively. In univariate analysis, there were no 
significant differences between women who perceived their CHD risk accurately and 
those who perceived their risk inaccurately for characteristics such as religion, marital 
status, type of family, monthly household income, fruits and vegetable consumptions, 
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and monthly household salt and oil consumption. There were also no significant dif-
ferences between women who perceived their CHD risk accurately and those who 
perceived their risk inaccurately for household cooking oil use per month, other chronic 
illness and knowledge of greatest health problem of women in India.  
 
Average BP was significantly higher among women with inaccurate CHD risk 
perceptions (SBP 152 mmHg [± SD 20.8] and DBP (89.1 mmHg [± SD 10.4]) than those 
with accurate risk perceptions (SBP 138 mmHg [± SD 14.6] and DBP 84.1 mmHg [± SD 
9.1]), with p values less than 0.000 and 0.014, respectively. Similarly, a greater 
proportion of women who inaccurately perceived their CHD risk had BP above the 
treatment goal (i.e. ≥140/90 mmHg) in comparison to those women who correctly 
perceived their CHD risk: 84.9% versus 59.2% respectively (p = 0.004). 
 
The univariate analysis showed no significant differences between women with 
accurate CHD risk perceptions and those with inaccurate perceptions with regards to 
CHD risk factors such as daily tobacco use, BMI, self-reported diabetes, physical 
activity and family history of heart disease. However, hypertensive women with 
accurate risk perceptions had a higher rate of abdominal obesity compared to those 
with inaccurate perceptions, although this did not quite reach statistical significance: 
98% versus 86.8% respectively (p = 0.06). 
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Table 24: Socio-demographic, CHD risk factor knowledge and risk factor profile of hypertensive women compared 
with their CHD risk perceptions 
 
Variables  Total  
(N = 102)  
n (%) 
Accurate PCR  
(N = 49) 
n (%)     
     Inaccurate PCR  
(N = 53) 
n (%) 
p value* 
Socio-demographic 
Age(mean ± SD) 
 
48.08 ± 7.44 
 
45.83 ± 7.15 
 
50.16 ± 7.16 
 
0.003 
Age group    0.003 
    <48 years 50 (49) 32 (65.3) 18 (34.0)  
    ≥48 years 52 (51) 17 (34.7) 35 (66.0)  
Religion    0.839 
     Hindu  38 (37.3) 19 (38.8) 19 (35.8)  
     Muslim 64 (62.7) 30 (61.2) 34 (64.2)  
Marital status    0.51 
     Currently married 92 (90.2) 43 (87.8) 49 (92.5)  
     Currently not married 10 (9.8) 6 (12.2) 4 (7.5)  
Educational status    1.00 
     Illiterate 54 (52.9) 26 (53.1) 28 (52.8)  
     Literate 48 (47.1) 23 (46.9) 25 (47.2)  
Work status    0.417 
     Homemaker 63 (61.8) 28 (57.1) 35 (66)  
     Not housewife 39 (38.2) 21 (42.9) 18 (34)  
Type of family    1.00 
      Nuclear 81 (79.4) 39 (79.6) 42 (79.2)  
      Joint   21 (20.6) 10 (20.4) 11 (20.8)  
Monthly household income    0.32 
    ≤INR8,000  52 (51) 22 (44.9) 30 (56.6)  
    >INR8,000 50 (49) 27 (55.1) 23 (43.4)  
Family members    0.83 
     ≤5 67 (65.7) 33 (67.3) 34 (64.2)  
     >5 35 (34.3) 16 (32.7) 19 (35.8)  
Consumption of vegetables    0.55 
    ≥3–4 days/week 53 (52)            27 (55.1) 26 (49.1)  
    <3–4 days/week 49 (48) 22 (44.9) 27 (50.9)  
Consumption of fruits    0.67 
     ≥3–4 days/week 31 (30.4) 16 (32.7) 15 (28.3)  
     <3–4 days/week 71 (69.6) 33 (67.3) 38 (71.7)  
    . 
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Household salt consumption (mg)/month  1.3 ± 1.09 1.2 ± 0.721 1.4 ± 1.34 0.291 
Household Cooking oil use (kg)/month 6.6 ± 2.54 6.8 ± 2.52 6.3 ± 2.55 0.345 
Other chronic illness    0.68 
          Yes  36 (35.3) 16 (32.7) 20 (37.7)  
          No  66 (64.7) 33 (67.3) 33 (62.3)  
 
CHD risk factor knowledge 
   
Level of  CHD risk factors knowledge            <.001 
         Good level of knowledge 51(50) 35 (71.4) 16 (30.2)  
         Poor level of knowledge 51(50) 14 (28.6) 37 (69.8)  
Smoking increase the risk of heart attack    0.05 
         Yes  54 (52.9)            31 (63.3)        23 (43.4)  
          No  48 (47.1)            18 (36.7) 30 (56.6)  
Obesity increase the risk of heart attack    0.02 
         Yes 82 (80.4)            44 (89.8) 38 (71.7)  
          No  20 (19.6) 5 (10.2) 15 (28.3)  
Hypertension increase the risk of heart attack    0.12 
        Yes  90 (88.2) 46 (93.9) 44 (83)  
         No  12 (11.8) 3 (6.1) 9 (17)  
Cholesterol increase the risk of heart attack    0.03 
         Yes  78 (76.5) 42 (85.7) 36 (67.9)  
          No  24 (23.5) 7 (14.3) 17 (32.1)  
Diabetes increase the risk of heart attack    0.003 
          Yes  55 (53.9)          34 (69.4) 21 (39.6)  
          No  47 (46.1) 15 (30.6) 32 (60.4)  
Heart attack is women’s greatest health problem                        0.71 
         Know  8 (7.8) 3 (6.1) 5 (9.4)  
         Don’t know 94 (92.2) 46 (93.9) 48 (90.6)  
 
Presence of CHD Risk factors 
    
Use smoked tobacco daily    0.36 
       Yes  5 (4.9) 1 (2) 4 (7.5)  
       No  97 (95.1) 48 (98) 49 (92.5)  
Use smokeless tobacco daily    0.48 
       Yes  22 (21.6) 9 (18.4) 13 (24.5)  
       No  80 (78.4) 40 (81.6) 40 (75.5)  
Systolic hypertension    0.001 
       Present  70 (68.6) 26 (53.1) 44 (83)  
       Absent  32 (31.4) 23 (46.9) 9 (17)  
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Diastolic hypertension 0.029 
       Present  45 (44.1) 16 (32.7) 29 (54.7)  
       Absent  57 (55.9) 33 (67.3) 24 (45.3)  
BP control    0.004 
       Yes  28 (27.5) 20 (40.8) 8 (15.1)  
       No  74 (72.5) 29 (59.2) 45 (84.9)  
Self-reported diabetes    0.109 
        Yes  24 (23.5) 8 (16.3) 16 (30.2)  
        No  78 (76.5) 41(83.7) 37 (69.8)  
BMI    0.597 
       Obese  70 (68.6) 36 (73.5) 34 (64.2)  
       Overweight  15 (14.7) 6 (12.2) 9 (17)  
       Normal   17 (16.7) 7 (14.3) 10 (18.9)  
Physical activity    0.324 
       Active  30 (61.2) 30 (61.2) 27 (50.9)  
       Low active 19 (38.8) 19 (38.8) 26 (49.1)  
Abdominal obesity     0.06 
       Yes  48 (98.0) 48 (98.0) 46 (86.8)  
        No  1 (2.0) 1 (2.0) 7 (13.2)  
Family history of heart disease                                                                                   . 1.00 
        Yes       24 (23.5)         12 (24.5)        12 (22.6%)  
         No      78 (76.5)         37 (75.5)         41 (77.4%)  
PCR=Perceived CHD risk; * p values calculated using Yates Correction for Continuity chi-square or Fisher’s Exact Test where 
appropriate; BP=blood pressure; SBP=systolic Blood pressure; DBP=diastolic blood pressure.
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5.3.3 Factors associated with inaccurate perception Of CHD risk among 
hypertensive women 
5.3.3.1 Bivariate analysis 
Bivariate analysis was conducted to determine the factors associated with inaccurate 
perception of CHD risk among hypertensive women and the results are summarised in 
Table 25. The variables included in the model were sociodemographic factors (i.e. age, 
religion, marital status, educational status, work status, type of family, number of family 
members, monthly household income, and monthy household consumption of fruits, 
vegetables, salt, and cooking oil), level of CHD risk factor knowledge and presence of 
CHD risk factors (i.e tobacco use, systolic hypertension, diastolic hypertension, BP 
control, self-reported diabetes, BMI, physical activity, abdominal obesity, and family 
history of heart disease). The factors significantly associated with inaccurate perception 
of CHD risk on bivariate analysis at the p<0.05 levels were: age, level of CHD risk 
factors knowledge, systolic hypertension, diastolic hypertension and BP control level of 
the participants.  
  
The participants who were aged ≥48 years, the median age of the study population, 
were almost four times more likely (OR = 3.7, 95% CI: 1.6–8.30; p = 0.02) to have an 
inaccurate perception of risk compared to participants aged <48 years. Women’s lack of 
knowledge or awareness of various CHD risk factors was significantly associated with 
inaccurate perceptions of their CHD risk. As shown in Table 25 these factors included 
smoking, obesity, high cholesterol and diabetes. In general, hypertensive women in the 
study who had a poor level of CHD risk factors knowledge, were almost six times (OR = 
5.8; 95% CI: 2.5–13.6; p = <0.001) more likely to have an inaccurate perception of their 
CHD risk compared to those with a good level of knowledge. 
 
The participants who had systolic hypertension were four times more likely to be 
associated with inaccurate perception of CHD risk compared to those who had no 
systolic hypertension (OR = 4.3; 95% CI: 1.7–10.7; p = 0.002). The participants who 
had diastolic hypertension were 2.5 times more likely to be linked with inaccurate 
perception of CHD risk than those who had no diastolic hypertension (OR = 2.5; 95% 
CI: 1.1–5.6; p = 0.02). Similarly, the women with uncontrolled BP were approximately 
four times more likely to be associated with inaccurate CHD risk perception compared 
to participants with BP under control (OR = 3.9; 95% CI: 1.5–9.9; p = 0.005). 
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Table 25: Bivariate analysis of factors associated with inaccurate perception of CHD risk among hypertensive 
women. N=102 
 
Characteristics  Total  
N 
Inaccurate PCR 
n (%)  
OR (95% CI) P* value   
Socio-demographic      
Age     
       ≥48years 52 35 (67.3) 3.66 (1.61–8.29) 0.02 
       <48 years 50 18 (36.0) Reference  
Religion     
        Hindu  38 19 (50.0) 0.88 (0.39–1.97) 0.76 
        Muslim 64 34 (53.1) Reference  
Marital status     
        Currently married 92 49 (53.3) 1.70 (0.45–6.46) 0.42 
        Currently not married 10 4 (40.0) Reference  
Educational status     
         Illiterate 54 28 (51.9) 0.99 (0.45–2.15) 0.98 
         Literate 48 25 (52.1) Reference  
Work status     
         Homemaker 63 35 (55.5) 0.17 (0.77–3.86) 0.18 
         Not housewife 39 18 (46.1) Reference   
Type of family     
         Nuclear 81 42 (51.8) 0.76 (0.29–2.02) 0.59 
         Joint   21 11 (52.4) Reference  
Monthly household income     
        ≤INR 8,000  52 30 (57.7) 1.60 (0.73–3.50) 0.23 
        >INR 8,000 50 23 (46.0) Reference  
Family members     
         ≤5 67 34 (50.8) 1.41 (0.64–3.10) 0.39 
         >5 35 19 (54.3) Reference  
Consumption of vegetables     
         ≥3–4 days / week 53 26 (49.1) 0.80 (0.36–1.71) 0.55 
        <3–4 days / week 49 27 (55.1) Reference  
Consumption of fruits     
        ≥3–4 days / week 31 15 (48.3) 0.81 (0.35 –1.89) 0.63 
        <3–4 days / week 71 38 (53.5) Reference  
 
Monthly household salt consumption (mg)  
 
1.3 ± 1.0 
 
1.4 ± 1342.4 
 
1.00 (1.00–1.00) 
 
0.30 
Monthly household cooking oil use/ (kg) 6.6 ± 2.5 6.3 ± 2.5 0.90 (0.79–1.08) 0.34 
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Heart attack is women’s greatest health problem 
          Know   8 5 (62.5) 1.59 (0.36–7.06) 0.53 
          Don’t know 94 48 (51.1) Reference   
 
CHD risk factors knowledge 
    
Level of CHD risk factors knowledge     
        Poor level of knowledge 51 37 (72.5) 5.80 (2.5–13.6) <.001 
        Good level of knowledge 51 16 (31.4) Reference  
Smoking increase the risk of heart attack     
         No  48 30 (62.5) 2.20 (1.01–4.97) 0.04 
         Yes  54 23 (42.6) Reference  
Obesity increase the risk of heart attack     
         No  20 15 (75.0) 3.50 (1.15–10.44) 0.02 
         Yes 82 38 (46.3) Reference  
Hypertension increase the risk of heart attack     
         Yes  90 44 (48.9) 0.30 (0.08–1.25) 0.102 
         No  12 9 (75.0) Reference  
Cholesterol increase the risk of heart attack     
         No  24 17 (70.8) 2.80 (1.05–7.59) 0.039 
         Yes  78 36 (46.1) Reference  
Diabetes increase the risk of heart attack     
         No  47 32 (68.1) 3.40 (1.52–7.84) 0.003 
         Yes  55 21 (38.2) Reference  
Other chronic illness     
          No  66 33 (50.0) 1.30 (0.59–2.83) 0.51 
          Yes  36 20 (55.5) Reference  
 
Presence of CHD Risk factors 
    
 Smoked tobacco users daily     
           No  97 49 (50.5) 3.91 (0.42–36.33) 0.22 
          Yes  5 4 (80.0) Reference  
Non smoked tobacco users daily      
           No   80 40 (50.0) 1.84 (0.69–4.86) 0.219 
           Yes  22 13 (59.1) Reference  
Systolic hypertension     
           Present  70 44 (62.8) 4.32 (1.74–10.74) 0.002** 
           Absent  32 9 (28.1) Reference  
Diastolic hypertension     
            Present  45 29 (64.4) 2.49 (1.11–5.58) 0.02 
            Absent  57 24 (42.1) Reference  
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BP control     
          No  74 45 (60.9) 3.87 (1.51–9.96) 0.005** 
          Yes  28 8 (28.6) Reference  
Self-reported diabetes     
        Yes  24 16 (66.7) 2.22 (0.85–5.70) 0.104 
         No  78 37 (47.4) Reference  
BMI     
         Overweight  15 9 (60.0) 0.80 (0.02–3.24) 0.75 
         Obese  70 34 (48.6) 0.70 (0.24–2.05) 0.51 
         Normal  17 10 (58.9) Reference  
     
Physical activity     
          Low active 45 26 (57.8) 0.77 (0.35–1.69) 0.51 
          Active  57 27 (47.4) Reference  
Abdominal obesity      
          No  8 7 (87.5) 7.30 (0.86–61.70) 0.06** 
          Yes  94 46 (48.9) Reference  
Family history of heart disease    
           No  78 41 (52.6) 1.10 (0.44–2.76) 0.82 
           Yes  24 12 (50.0) Reference   
PCR=perceived CHD risk; CHD=coronary heart disease; OR=odds ratio; CI=confidence interval; INR=Indian Rupees; BMI=Body Mass 
Index;* p values calculated using Yates Correction for Continuity chi-square or Fisher’s Exact Test where appropriate; ** Due to small cell 
size (less than 10) not included in multivariate logistic model 
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There was also an association between inaccuracy of self-perception of CHD risk and 
abdominal obesity (≤80cm). That is, participants who had no abdominal obesity were 
7.3 times more likely not to have an accurate perception of CHD risk, although this did 
not quite reach statistical significance (OR = 7.3; 95% CI: 0.9–61.7; p = 0.06). 
 
5.3.3.2 Multivariate analysis  
The factors that were significantly associated with inaccurate perception of global CHD 
risk on binary logistic regression were used in a multivariate logistic model, using the 
backward stepwise likelihood ratio method. Multiple logistic regression analysis was 
conducted to determine whether the variables could significantly predict inaccurate 
perception of CHD risk. The variables included in the model were age of the 
participants; women’s awareness of smoking, obesity, high cholesterol and diabetes 
increase the risk of heart attack; level of CHD risk factors knowledge; and diastolic 
hypertension. Due to small cell size (less than 10) variables such as systolic 
hypertension, BP control, and abdominal obesity were not included in the multivariate 
logistic model. On regression, diastolic hypertension, age of the participants and level of 
CHD risk factor knowledge remained significantly associated with inaccurate perception 
of global CHD risk among hypertensive women (please see Table 26). 
 
Diastolic hypertension 
The study women with diastolic hypertension were three times more likely to be 
associated with inaccurate CHD risk perception compared to the women who had no 
diastolic hypertension (AOR = 3.0 ; 95% CI: 1.2–8.0; p = 0.02).  
 
Age  
The women participants who were aged ≥48 years were almost five times more likely to 
have an inaccurate perception of CHD risk than those women who were <48 years old    
(AOR = 4.6; 95% CI: 1.8–11.0; p = 0.002). 
 
Level of CHD risk factor knowledge 
Hypertensive women who had a poor level of CHD risk factor knowledge were 
approximately seven times more likely to have an inaccurate perception of CHD risk 
than those women with a good level of knowledge (AOR = 6.8, 95% CI: 2.6–17.6; p = 
<0.001).  
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Table 26: Multivariate logistic regression analysis of factors associated with 
inaccurate perception of CHD risk among hypertensive women 
 
Variable 
 
  P value        AOR           95% CI for OR 
DBP 0.022 3.09 1.18 8.09 
Age  0.002 4.57 1.75 11.92 
Level of CHD risk factors knowledge <0.001 6.76 2.59 17.63 
AOR= Adjusted odd ratio; CI=confidence interval; CHD=coronary heart disease; DBP=diastolic blood 
pressure. Variables entered in initial model: age of the participants; women’s awareness of smoking, 
obesity, high cholesterol and diabetes increase the risk of heart attack; level of CHD risk factors 
knowledge, and prevalence of DBP. 
 
5.4 Hypertensive womens’ perception of hypertension 
This data was collected only from those hypertensive women (n = 102) who were aware 
of their hypertensive condition before the survey. Table 27 shows that hypertensive 
study women had a lower score on items such as emotional response (less affected 
emotionally), identity (fewer symptoms) and consequence (less affect on life), with 
emotional responses having the lowest score of 3.17 (± SD 1.76). There was a higher 
score for items such as treatment control (treatment was more helpful), timeline (longer 
time), personal control (more control) and understanding (more illness understanding), 
with treatment control having the highest score of 7.07 (± SD 2.24). After reversing the 
score for personal control, treatment control and illness understanding, the total illness 
perception score was 32.55 (± SD 4.72). 
 
Table 27: Descriptive statistics of hypertension perception among women who 
were aware their hypertensive status, N = 102 
 
 
 
 
 
Variables  Score 
Mean   SD Median 
Consequences  3.99 2.63 4 
Timeline  6.35 3.31 6 
Personal control 6.03 1.77 6 
Treatment control 7.07 2.24 7 
Identity 3.51 2.28 3 
Concern  4.49 1.47 4 
Understanding  5.78 2.74 5.50 
Emotional response  3.17 1.76 3 
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Perceived cause of hypertension  
Table 28 shows that the majority of the hypertensive women (n = 65; 63.7%) ranked 
stress as the number one perceived cause of their hypertension followed by lifestyle (n 
= 31; 30.4%) and heredity (n = 6; 5.9%). 
 
Table 28: Perceived causes of hypertension by the hypertensive women, N=102 
 
 
 
 
 
 
 
5.5 Adherence status to antihypertensive medications among women 
This data was collected only from those hypertensive women (n = 102) who were aware 
of their hypertensive condition before the survey. For the first step, descriptive analysis 
of all the variables related to medication adherence was carried out. For the second 
step, associations and inferences of variables with medication non-adherence were 
performed. 
 
5.5.1 Prevalence of adherence and non-adherence to antihypertensive 
medications 
Among the hypertensive women the mean adherence score was 79.45 (± SD 21.82). At 
the 80% cutoff level, about half (51%; n = 52) of the women were found to be non-
adherent and the other half (49%; n = 50) adherent to their treatment. 
 
5.5.2 Comparing the socio-demographics, CHD risk factor knowledge and CHD 
risk profile of the hypertensive women based on their medication adherence 
status 
Table 29 summarises the statistics comparing data on socio-demographic factors, other 
chronic illnesses, monthly household salt consumption, monthly household cooking oil 
use, CHD risk factor knowledge, knowledge of greatest health problem of women in 
India and CHD risk factors profile of the hypertensive women who were adherent and 
who were not adherent to their antihypertensive treatment. Socio-demographic factors 
Rank order  Frequency  % 
Stress, lifestyle, heredity 56 54.9 
Stress, heredity, lifestyle 9 8.8 
Lifestyle, stress, heredity 29 28.4 
Lifestyle, heredity, stress 2 2.0 
Heredity, lifestyle, stress 2 2.0 
Heredity, stress, lifestyle 4 3.9 
Total  102 100 
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included age, religion, marital status, educational status, work status, type of family, 
monthly household income. CHD risk factors included data on daily tobacco use, mean 
SBP, mean DBP, systolic hypertension, diastolic hypertension, blood pressure control, 
BMI, physical activity, abdominal obesity and family history of heart disease. 
 
It was interesting to identify literate women as being more likely to be non-adherent to 
medications than non-literate women: 59.6% versus 40.4% respectively (p = 0.01). 
Lower monthly household income (INR ≤8,000) was also significantly associated with a 
higher medication non-adherence (MNA) in comparison to higher monthly household 
income (>INR 8,000): 61.5% versus 38.5% respectively (p = 0.04). 
 
A univariate analysis, found no significant differences in socio-demographic 
characteristics such as age, work status, family type and family members between 
women who were adherent to their hypertensive medications and those who were non-
adherent.  
 
Similarly, there was no difference in knowledge of CHD risk factors between these two 
groups. However, women living in nuclear families were more likely to be medication 
non-adherent than those living in joint family structures, although this did not quite 
reach statistical significance: 86.5% versus 13.5% respectively (p = 0.08). 
 
Regarding presence of CHD risk factors, a univariate analysis, found no significant    
differences between women who were adherent to their hypertensive medications and 
those who were non-adherent. Women who were adherent to their medication had a 
non-significant higher rate of obesity (76% versus 61.5%), low physical activity (50% 
versus 38.5%), abdominal obesity (96% versus 88.5%), and family history of heart 
disease (28% versus 19.2%) compared with those who were non-adherent. 
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Table 29: Socio-demographics and CHD risk factor profile of hypertensive women compared with their medication 
adherence status 
 
Variable Total  
(N = 102) 
     n (%) 
Adherence  
 (N = 50) 
n (%) 
Non-adherence  
(N = 52) 
n (%) 
P* value 
Socio-demographic     
Age (mean ± SD) 48.08 ± 7.44 49.06 ± 7.12 47.15 ± 7.70 0.19 
Age group    0.17 
      <48years 50 (49) 21 (42) 29 (55.8)  
      ≥48 years 52 (51) 29 (58) 23 (44.2)  
Religion    0.84 
       Hindu  38 (37.3) 18 (36) 20 (38.5)  
       Muslim 64 (62.7) 32 (64) 32 (61.5)  
Marital status    1.0 
      Currently married 92 (90.2) 45 (90) 47 (90.4)  
      Currently not married 10 (9.8) 5 (10) 5 (9.6%)  
Educational status    0.01 
       Illiterate 54 (52.9) 33 (66.0) 21 (40.4)  
       Literate 48 (47.1) 17 (34) 31 (59.6)  
Work status    1.0 
       Housewife 63 (61.8) 31 (62) 32 (61.5)  
       Not housewife 39 (38.2) 19 (38) 20 (38.2)  
Type of family    0.08 
       Nuclear 81 (79.4) 36 (72) 45 (86.5)  
       Joint   21 (20.6) 14 (28) 7 (13.5)  
Monthly household income    0.04 
       ≤INR8,000  52 (69.6) 20 (40) 32 (61.5)  
       >INR8,000 50 (30.4) 30 (60) 20 (38.5)  
Family members    1.0 
        ≤5 67 (65.7) 33 (66) 34 (65.4)  
        >5 35 (34.3) 17 (34) 18 (34.6)  
Consumption of vegetables    0.69 
        ≥3–4 days/week 53 (52) 27 (54) 26 (50)  
       <3–4 days/week 49 (48) 23 (46) 26 (50)  
Consumption of fruits           0.393 
         ≥3–4 days/week 31 (30.4) 13 (26) 18 (34.6)  
        <3–4 days/week 71 (69.6) 37 (74) 34 (65.4)  
Monthlyhousehold salt consumption 1.33 ± 1.09 1.22 ± 483 1.44 ± 1.45 0.306 
Monthly household cooking oil use 6.58 ± 2.54 7.01 ± 2.74 6.18 ± 2.28 0.101 
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 INR=Indian Rupees; CHD=coronary heart disease; BMI= Body Mass Index* p values calculated using Yates Correction for Continuity 
chi-square or Fisher’s Exact Test where appropriate.
Knowledge of CHD risk factors    0.553 
         Good level of knowledge 51 (50) 27 (54) 24(46.2)  
         Poor level of knowledge 51 (50) 23 (46) 28 (53.8)  
Heart attack is women’s greatest health problem               1.0 
        Know 8 (7.8) 4 (8) 4 (7.7)  
        Don’t know 94 (92.2) 46 (92) 48 (92.3)  
Other chronic illness    1.0 
        Yes  36 (35.3) 18 (36) 18 (34.6)  
        No  66 (64.7) 32 (64) 34 (65.4)  
 
Presence of CHD Risk factors  
    
Smoked tobacco users daily    0.36 
        Yes 5 (4.9) 1 (2) 4 (7.7)  
         No 97 (95.1) 49 (98) 48 (92.3)  
Non smoked tobacco users daily    0.47 
        Yes  22 (21.6) 9 (18) 13 (25)  
         No  80 (78.4) 41 (82) 39 (75)  
BMI    0.26 
         Obese  70 (68.6) 38 (76) 32 (61.5)  
         Overweight   15 (14.7) 5 (10) 10 (19.2)  
         Normal  17 (16.7) 7 (14) 10 (19.2)  
Self reported diabetes    1.00 
         Yes  24 (23.5) 12 (24) 12 (23.1)  
          No  78 (76.5) 38 (76) 40 (76.9)  
Physical activity    0.31 
           Active 57 (55.9) 25 (50) 32 (61.5)  
            Low active 45 (44.1) 25 (50) 20 (38.5)  
Abdominal obesity     0.27 
           Yes  94 (92.2) 48 (96) 46 (88.5)  
            No 8 (7.8) 2 (4) 6 (11.5)  
Family history of heart disease                                                                                      0.35 
            Yes  24 (23.5) 14 (28) 10 (19.2)  
            No  78 (76.5) 36 (72) 42 (80.8)  
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5.5.3 Hypertension and antihypertensive treatment characteristics among women 
The descriptive analysis of all the variables related to hypertension, antihypertensive 
treatment and health care provider behaviour are summarised in Table 30. 
 
Among the hypertensive women (n = 102), the mean duration of hypertension since 
diagnosis was 57.9 months (±SD 48.7 months; median 48 months). Approximately 45% 
of the women were on antihypertensive treatment for more than three years with an 
average duration of 50.6 months (± SD 36 months) (range 5–180 months). Treatment 
duration was associated with medication adherence with those on treatment for more 
than three years (36 months) less likely to be to be non-adherent than those with 
treatment duration of three years or less: 34.6% versus 65.4% respectively (p = 0.04). 
 
At the time of the study, women who were non-adherent were more likely to have 
systolic hypertension than those who were adherent: 92.3% versus 44% respectively (p 
= .000). Similarly, women who were non-adherent to medication were more likely to 
have diastolic hypertension than those who were adherent: 59.6% versus 28% 
respectively (p = 0.002). Therefore, it was not surprising that most of the women 
(94.2%) who were non-adherent to their antihypertensive treatment had uncontrolled 
BP. Only about 6% of the non-adherent women had controlled BP (p = <0.001). 
 
In this study, non-adherent women were more likely to believe that their medications 
were not available at their local pharmacy than adherent women: 29% versus 4% 
respectively (p = 0.001). It was seen that the mean cost of antihypertensive medicines 
per month was less in non-adherence women compared to adherent women: INR113.6 
(± SD 89) versus 117.1 (± SD 95) respectively. Among the hypertensive women, 74.5% 
(n = 76) had been prescribed a single pill by their health care provider and the majority 
(89.2%; n = 91) were on a single dose regimen.  A greater proportion of non-adherent 
women were prescribed a single pill per day than adherent women: 82.7% versus 66% 
respectively (p = 0.063). 
 
Of the twomen who were under current treatment, 75.5% (n = 77) reported feeling 
better with BP medications. A significantly higher proportion of adherent women in 
comparison to non-adherent women reported feeling better on their antihypertensive 
medications: 86% versus 65.4% respectively (p = 0.02). Likewise, a higher proportion of 
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adherent women in comparison to non-adherent women had no complaints of 
medications side effects: 98% versus 67.3% respectively (p = <0.001). Regarding 
treatment satisfaction, just 47.1% women were satisfied with their antihypertensive 
treatment. A significantly lower proportion of non-adherent women in comparison to the 
adherent women were satisfied with their antihypertensive treatment: 32.7% versus 
62% respectively (p = 0.005). 
 
Only half of the total women (52%; n = 53) stated that their treating doctor had treated 
them in a friendly and courteous manner. A considerably lower proportion of non-
adherent women in comparison to the adherence women reported that doctors treated 
them in a friendly manner: 32.7% versus 64% respectively (p = 0.003). 
 
A significantly higher proportion of non-adherent women were not provided 
explanations by the doctor regarding the treatment regimen and its likely side effects, 
compared to adherent women: 73.1% versus 40% respectively (p = 0.001). Likewise, a 
greater proportion of non-adherent women in comparison to adherent women did not 
receive an explanation for a medical test by their doctors: 82.7% versus 68% 
respectively (p = 0.05). 
 
Regarding lifestyle advice, doctors’ instructions on salt restriction, losing weight and 
doing more physical activity were reported by 81.4%, 54.9% and 70.6% of the 
hypertensive women respectively. Doctors’ advice regarding lifestyle changes showed 
no statistical difference in women’s medication adherence characteristics. Surprisingly, 
no one reported a doctor suggesting they stop tobacco use.  
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Table 30: Hypertension and its treatment characteristics of adherent and non-adherent hypertensive women: 
history of hypertension, antihypertensive medications and health care providers’ behaviour 
 
 Variables  Total 
 (N = 102) 
n (%) 
Adherence  
(N = 50) 
n (%) 
Non-adherence  
(N = 52) 
n (%) 
*p value 
History of hypertension     
Hypertension duration     0.112 
      ≤4 years  54 (52.9) 22 (44) 32 (61.5)  
      >4 years 48 (47.1) 28 (56) 20 (38.5)  
Duration of  therapy     0.04 
      ≤3 years 56 (54.9) 22 (44) 34 (65.4)  
      >3 years 46 (45.1) 28 (56) 18 (34.6)  
SBP    <0.001 
      Present 70 (68.6) 22 (44) 48 (92.3)  
      Absent 32 (31.4) 28 (56) 4 (7.7)  
DBP    0.002 
      Present 45 (44.1) 14 (28) 31 (59.6)  
      Absent 57 (55.9) 36 (72) 21 (40.4)  
BP under control    <0.001 
      Yes 28 (27.5) 25 (50) 3 (5.8)  
      No  74 (72.5) 25 (50) 49 (94.2)  
 
Antihypertensive medications 
   
Number of tablets/day    0.063 
       1 76 (74.5) 33 (66) 43 (82.7)  
     >1 25 (24.5) 17 (34) 8 (15.4)  
Dose frequency/day    0.20 
       1 91 (89.2) 47 (94) 44 (84.6)  
     >1 11 (10.8) 3 (6) 8 (15.4)  
Side effect    <0.001 
     Yes  18 (17.6) 1 (2) 17 (32.7)  
     No  84 (82.4) 49 (98) 35 (67.3)  
Easy availability     0.001 
     Yes  85 (83.3) 48 (96) 37 (71.2)  
     No  17 (16.7) 2 (4) 15 (28.8)  
Feeling better    0.02 
     Yes  77 (75.5) 43 (86) 34 (65.4)  
     No  25 (24.5) 7 (14) 18 (34.6)  
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SBP=systolic blood pressure; DBP= diastolic blood pressure; * p values calculated using Yates Correction for Continuity chi-square 
or Fisher’s Exact Test where appropriate.
Treatment  satisfaction    0.005 
      Yes  48 (47.1) 31 (62) 17 (32.7)  
      No  54 (52.9) 19 (38) 35 (67.3)  
Cost per month (INR)(mean ±SD) 115.34 ± 92 117.10 ± 95 113.65 ± 89 0.85 
 
Health care providers 
Doctor explains treatment and medication side 
effects 
                 
0.001 
       Yes  44 (30) 30 (60) 14 (26.9)  
       No  58 (20) 20 (40) 38 (73.1)  
Doctor treat in a friendly manner    0.003 
       Yes  49 (48) 32 (64) 17 (32.7)  
       No  53 (52) 18 (36) 35 (67.3)  
Doctor explain medical test    0.05 
      Yes  25 (24.4) 16 (32) 9 (17.3)  
       No  77 (75.7) 34 (68) 43 (82.7)  
Non-pharmacological advice by doctors   
Reducing salt    0.80 
       Yes  
       No 
83 (81.4) 
19 (18.6) 
40 (80) 
10 (20) 
43 (82.7) 
9 (17.3) 
 
Losing weight    0.327 
       Yes  
       No 
56 (54.9) 
46 (45.1) 
30 (60) 
20 (40) 
26 (50) 
26 (50) 
 
 
Do more exercise    0.30 
       Yes  72 (70.6) 37 (74) 35 (67.3)  
       No 30 (29.4) 13 (26) 17 (32.7)  
Stop tobacco use nil Nil nil  
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5.5.4 Characteristics of perceived CHD risk and hypertension perception of 
adherent and non-adherent hypertensive women 
This data was collected only from those hypertensive women (n = 102) who were aware 
of their hypertensive condition before the survey. The descriptive analysis of all the 
variables related to perceived CHD risk and hypertension perception are summarised in 
Table 31. 
 
There was a significantly higher proportion of non-adherent women with low perceived 
CHD risk in comparison to those women who were adherent to their hypertensive 
treatments: 78.8% versus 38% respectively (p = <0.001). There was also a significant 
difference between the adherent and non-adherent hypertensive women, with a higher 
proportion of non-adherent women having an inaccurate self-perception of CHD risk 
than adherent women: 65.4% versus 38% respectively (p = 0.01). Regarding the 
perception of hypertension, the mean Brief Illness Perception Questionnaire (BIPQ) 
score of non-adherent participants was not significantly lower than the mean score of 
the adherent participants: 32.0 ± 5.3 versus 33.1 ± 4.0. The lower score would translate 
into the lower level of medication adherence. 
 
Table 31: CHD risk perception, accuracy of CHD risk perception, and 
hypertension perception of adherent and non-adherent hypertensive women 
 
Variables Total 
N=102 
n (%) 
Adherence 
N=50 
n (%) 
Non-adherence 
N=52 
n (%) 
*p 
value 
CHD risk perception    <0.001 
          Low  60 (58.8) 19 (38) 41 (78.8)  
          High  42 (41.2) 31 (62) 11 (21.2)  
Accuracy of CHD risk perception   0.01 
         Accurate 49 (48) 31 (62) 18 (34.6)  
         Inaccurate 53 (52) 19 (38) 34 (65.4)  
Hypertension perception  
(mean BIPQ score)  
32.55 ± 4.72 33.12 ± 4.01 32.01 ± 5.30 0.241 
CHD=coronary heart disease; BIPQ=Brief Illness Perception Questionnaire; * p values 
calculated using Yates Correction for Continuity chi-square or Fisher’s Exact Test where 
appropriate 
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5.5.5 Factors associated with non-adherence to antihypertensive medications 
among women 
5.5.5.1 Bivariate analysis  
Bivariate analysis was conducted to determine the factors associated with non- 
adherence to medications among hypertensive women (Table 32). The factors 
significantly associated with non-adherence to antihypertensive medications on 
bivariate analysis at the p<.05 level were participants’ educational status, monthly 
household income, systolic hypertension, diastolic hypertension, blood pressure control, 
duration of therapy, number of pills, availability of medications, treatment satisfaction, 
feeling better with medication, explanation by the doctor regarding the treatment 
regimen and its side effects, treating doctor friendly, perceived CHD risk and accuracy 
of self-perception of CHD risk. 
 
The participants who were literate were almost three times more likely to be non-
adherent than those women who were without an education (OR = 2.9; 95% CI: 1.3–
6.4; p = 0.01). Those women who were living in families with an average monthly 
income of ≤INR 8,000 were 2.4 times more likely to be non-adherent compared to those 
living in households with average monthly income of >INR 8,000 (OR = 2.4; 95% CI: 
1.0–5.3; p = 0.03). 
 
The participants who had a duration of  three years or less of antihypertensive therapy 
were two times more likely to be non-adherent than those who had more than three 
years (OR = 2.4; 95% CI: 1.0–5.3; p = 0.031) of therapy. Those who were non-adherent 
were more likely to have higher average SBP (OR = 15.3; 95% CI: 4.8–48.8; p = 
<0.001) and DBP (OR = 3.8; 95% CI: 1.6–8.7; p = 0.002). 
 
A prescription for only a single tablet or pill daily had a significant association with non-
adherence, with an odds ratio of nearly three times compared to the prescription of 
more than one pill per day (OR= 2.5; 95% CI: 0.97–6.2; p = 0.06). Women participants 
who believed that medications were not easily available had an almost 10 times higher 
chance of being non-adherent to their treatment than those who believed that 
medications were readily available (OR = 9.8; 95% CI: 2.1–45.2; p = 0.004). Women 
who had no complaints of the side effects of antihypertensive drugs were about 24 
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times more likely to be non-adherent than those who had complaints (OR = 23.8; 95% 
CI: 3.0–187.2; p = 0.003). 
 
The women who were not satisfied with their hypertension treatment were 3.4 times 
more likely to be non-adherent than those who were satisfied (OR = 3.4; 95% CI: 1.5–
7.6; p = 0.004). Similarly, the women who reported not feeling better because of their 
antihypertensive medications were 3.3 times more likely to be non-adherent than those 
who reported feeling better (OR = 3.3; 95% CI: 1.2–8.7; p = 0.01). 
 
Women who reported the treating doctor as not friendly had a significantly higher 
chance of being non-adherent to their treatment (OR = 3.7; 95% CI: 1.6–8.3; p = 0.002). 
The women who were not explained the treatment regimen and its side effects by their 
doctors were four times more likely to be non-adherent (OR = 4.0; 95% CI: 1.8–9.4; p = 
0.001) than those whose doctor gave exlanations. 
  
Those women who perceived their CHD risk as low had a significantly higher chance of 
being non adherent to their treatment (OR = 6.0; 95% CI: 2.5–14.6; p = <0.001) than 
those who perceived their CHD risk as high. Women who had an inaccurate self-
perception of CHD risk were three times more likely to be non-adherent than those with 
accurate self- perception (OR = 3.0; 95% CI: 1.4–6.9; p = 0.006). 
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Table 32: Bivariate analysis of factors associated with non-adherence to antihypertensive medications among 
women. N=102 
 
Variable   Total 
                    n 
Non-adherence 
n (%) 
OR (95% CI) *p value 
Socio-demographic      
Age (years)(mean ± SD) 48.08 ± 7.44 47.15 ± 7.70 0.57 (0.26 –1.25) 0.166 
Age      
    <48years 50 29 (58.0) 0.52 (0.24 –1.16) 0.164  
    ≥48 years 52 23 (44.2) Reference   
Religion     
      Hindu  38 20 (52.6) 1.11(0.49–2.48) 0.79 
      Muslim 64 32 (50.0) Reference   
Marital status     
     Currently married 92 47 (51.0) 1.044(0.28 –3.85) 0.94 
     Currently not married 10 5 (50.0) Reference   
Educational status     
        Literate 48 31 (64.6) 2.86 (1.28–6.41) 0.01       
        Illiterate 54 21 (38.9) Reference  
Work status     
      Homemaker/housewife 63 32 (50.8) 0.98 (0.44 –2.18) 0.96 
      Not housewife 39 20 (51.3) Reference   
Type of family     
      Nuclear 81 45 (55.5) 2.50 ( 0.91–6.84) 0.07 
      Joint   21 7 (33.3) Reference  
Monthly household income     
      ≤INR 8,000  50 32 (64.0) 2.40 (1.08–5.31) 0.03 
      >INR 8,000 52 20 (38.5) Reference  
Family members     
      ≤5 67 33 (49.2) 0.97 (0.43 –2.20) 0.94 
      >5 35 17 (48.6) Reference  
Consumption of vegetables     
      ≥3–4 days/  week 53  26 (49.1) 1.17 (0.53 –2.55) 0.69 
      <3–4 days / week 49  26 (53.1) Reference  
Consumption of fruits     
        ≥3–4 days / week 31  18 (58.1) 1.51 (0.64–3.53) 0.346 
       <3–4 days / week 71  34 (47.9) Reference  
Other chronic illness     
        Yes  36 18 (50.0) 0.94 (0.42–2.12) 0.88 
        No  66 34 (51.5) Reference  
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Knowledge of CHD risk factors     
       Good level of knowledge 51 27 (52.9) 0.99 (0.45–2.16) 0.99 
       Poor level of knowledge 51 25 (49.01) Reference  
Heart attack is women’s greatest health problem   
       Know  8 4 (50.0) 0.95 (0.22–4.06) 0.95 
       Don’t know 94 48 (51.1) Reference  
Monthly household salt consumption 1.33 ± 1.09 1.44 ±1.450 1.00 (1.00–1.00) 0.319 
Monthly household cooking oil use 6.58± 2.54 6.18± 2.28 .87 (0.74–1.02) 0.103 
     
Presence of CHD risk factors     
Smoked tobacco users daily     
       Yes  5 4 (80.0) 1.46 (0.23–9.17) 0.68 
        No  97 48 (49.5) Reference  
Non smoked tobacco users daily       
       Yes  22 13 (59.1) 1.51 (0.58–3.95) 0.39 
       No   80 39 (48.7) Reference  
BMI     
      Obese  70 32 (45.7) 0.59 (0.20–1.72) 0.335 
      Overweight  15 10 (66.7) 1.40 (0.33–5.93) 0.64 
      Normal  17 10 (58.9) Reference  
Self reported diabetes     
Yes  24  12 (50.0) 0.95 (0.38–2.37) 0.91 
No  78  40 (51.3) Reference   
Physical activity     
       Active  57 32 (56.1) 1.6 (0.73–3.51) 0.24 
       Low active 45 20 (44.4) Reference  
Abdominal obesity      
       Yes  94 46 (48.9) 0.32 (0.06–1.66) 0.17 
       No  8 6 (75.0) Reference  
Family history of heart disease     
       Yes  24 10 (41.7) 0.61 (0.24–1.54) 0.29 
       No  78 42 (53.8) Reference  
 
Hypertension 
    
Hypertension duration      
      ≤4 years 54 32 (59.2) 2.04 (0.92–4.48) 0.078 
      >4 years 48 20 (41.7) Reference  
Duration of  therapy      
      ≤3 years 56 34 (60.7) 2.40 (1.08–5.34) 0.031 
      >3 years 46 18 (39.1) Reference  
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SBP     
       Present 70 48 (68.6) 15.27 (4.77–48.85) <0.001** 
       Absent 32 4 (12.5) Reference  
DBP     
      Present 45 31 (68.9) 3.79 (1.65–8.70) 0.002 
      Absent 57 21 (36.9) Reference  
BP under control     
        No     74 49 (66.2) 16.33 (4.49–59.38) <0.001** 
       Yes  28 3 (10.7) Reference  
 
Related to  antihypertensive medications 
   
Number of tab daily     
         1 76 43 (56.6) 2.46 (0.97–6.21) 0.057** 
       >1 26 9 (34.6) Reference  
Dose frequency     
        1 91 44 (48.3) 0.35 (0.08–1.40) 0.14 
      >1 11 8 (72.7) Reference  
Side effect     
        No  84 35 (41.7) 23.8 (3.02–187.28) 0.003 
        Yes  18 17 (94.4) Reference  
Easy availability      
       No  17 15 (88.2) 9.73 (2.09–45.22) 0.004 
       Yes  85 37 (43.5) Reference  
Feeling better     
       No  25 18 (72.0) 3.26 (1.21–8.68) 0.01 
       Yes  77 34 (44.1) Reference  
Treatment  satisfaction     
       No  54 35 (64.9) 3.36 (1.49–7.57) 0.004 
      Yes  48 17 (35.4) Reference   
Cost per month (mean ±S D) 115.34 ± 92.07 113.65 ± 89.06 1.00 (0.99–1.00) 0.849 
 
Health care related factors 
    
Treating doctor friendly     
       No 53 35 (66.0) 3.66 (1.61–8.29) 0.002 
       Yes  49 17 (34.7) Reference   
Doctor explain the treatment regimen     
and its side effects 
    
      No  58 38 (65.5) 4.07 (1.77–9.37) 0.001 
      Yes  44 14 (31.9) Reference  
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Doctor explain medical test     
      No  77 43 (55.9) 0.44 (1.75–1.13) 0.089 
      Yes  25 9 (36.0) Reference  
Non-pharmacological advice by doctors     
Reducing salt     
     Yes 
     No 
83 
19 
43 (51.8) 
9 (47.4) 
1.19 (0.44–3.24) 
Reference 
0.727 
Losing weight     
     Yes  
      No 
55 
46 
26 (47.3) 
26 (56.5) 
0.67 (0.30–1.46) 
Reference 
0.331 
Do more exercise     
     Yes  
      No  
72 
30 
35 (48.6) 
17 (56.7) 
0.72 (0.30–1.70) 
Reference  
0.459 
 
Individuals perception  
    
Perceived CHD risk    . 
      Low  60 41 (68.3) 6.08 (2.53–14.61) <0.001 
      High  42 11 (26.2) Reference  
Accuracy of the CHD risk perception     
      Inaccurate 53 19 (35.9) 3.08 (1.374–6.91) 0.006 
      Accurate 49 31 (63.7) Reference  
OR=odd ratio; CI=confidence interval; INR=Indian Rupees; BMI=Body Mass Index; SBP=systolic blood pressure, DBP=diastolic 
blood pressure, BP=blood pressure; CHD=coronary heart disease; *p values calculated using Yates Correction for Continuity chi-
square or Fisher’s Exact Test where appropriate; ** Due to small cell size (less than 10) not included in multivariate logistic model.
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5.5.5.2 Multivariate analysis  
Multiple logistic regression analysis using the backward stepwise likelihood ratio 
method was conducted to determine whether the factors could significantly predict 
medication non-adherence. Factors significantly associated with medication non-
adherence on bivariate analysis at p <0.05 level were used in a multivariate logistic 
model. The variables included in the model were participants’ literacy level, monthly 
household income, duration of the antihypertensive therapy, diastolic hypertension, 
feeling better with BP medication, treatment satisfaction, perceived CHD risk level, 
friendly doctor, explanation by the doctor regarding the treatment regimen and its side 
effects, and accuracy of self-perception of CHD risk. 
 
A multivariate analysis revealed the factors that remained significantly associated with 
non-adherence to antihypertensive medications among women included the duration of 
the antihypertensive therapy, explanation by the doctor regarding the treatment regimen 
and its side effects, treatment satisfaction, perceived CHD risk level and accuracy of 
self-perception of CHD risk (Table 33). Literacy level, monthly household income, 
diastolic blood pressure, friendly doctor and feeling better with BP medication no longer 
remained significantly associated with non-adherence after the multivariate analysis 
was conducted. 
 
Treatment satisfaction 
The women who were not satisfied with their antihypertensive treatment were 11 times 
more likely to be non-adherent than those who were satisfied (AOR = 11; 95% CI: 2.3– 
52.9; p = 0.003). 
 
Duration of the antihypertensive therapy 
The participating women who had antihypertensive therapy for three years or less were 
14.3 times more likely to be non-adherent than those women who had therapy for more 
than three years (AOR = 14.3; 95% CI: 2.4–85.2; p = 0.003). 
 
Doctor explained treatment regimen and side effects 
The women who were not given an explanation of the treatment regimen and its side 
effects by their doctors were 28.3 times more likely to be non-adherent than those  
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Table 33: Multivariate logistic regression analysis of factors associated with non-adherence to 
antihypertensive medications among women 
  
Variables    P value                AOR                 95% CI for OR 
Treatment satisfaction 0.003 11.08 2.33 52.87 
Duration of therapy 0.003 14.31 2.40 85.18 
Doctor explains treatment regime and side effects <0.001 28.34 4.50 178.40 
Perceived CHD risk level <0.001 153.65 9.29 2539.43 
Accuracy of the self-perception of the CHD risk 
 
0.001 188.08 9.80 3606.47 
AOR=Adjusted odd ratio; CI=confidence interval; CHD=coronary heart disease. 
Variables entered in initial model: prevalence of diastolic blood pressure, participants’ literacy level, monthly household income, feeling better 
with BP medication, treatment satisfaction, doctor friedly, doctor explain treatment regime and side effects, accuracy of the self perception of 
CHD risk, perceived CHD risk lvel and duration of therapy. 
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women who had received such explanation (AOR = 28.3; 95% CI: 4.5–178.4; p = 
<.001). 
 
Perceived CHD risk level  
Hypertensive women who perceived their CHD risk as low, were 153.6 times more 
likely to be non-adherent than those who perceived their CHD risk as high (AOR = 
153.6; 95% CI: 9.3–2539.4; p = <0.001). 
 
Accuracy of the self-perception of the CHD risk 
Women with inaccurate self-perception of CHD risk were 188 times more likely to be 
non-adherent to their hypertensive medication than those women with accurate self-
perceptions (AOR = 188; 95% CI: 9.8–3606.5; p = 0.001). 
 
5.6 Conclusion  
The majority of the previously diagnosed hypertensive study participants who were on 
treatment were found to be inaccurate in the estimation of their global CHD risk (GCR), 
as well as being non-adherent to their antihypertensive treatment. This study identified 
several factors influencing the inaccurate perception of global CHD risk and non-
adherence to antihypertensive medications. Factors that were significantly and 
independently associated with medication non-adherence among hypertensive women 
are: shorter duration of the antihypertensive therapy, non-satisfaction with the 
treatment, not receiving an explanation of the treatment regimen and side effects by the 
physician, low perceived GCR and the inaccurate estimation of perceived GCR. Older 
age, poor level of CHD risk factors knowledge, and diastolic hypertension was 
associated with inaccurate CHD risk perception of hypertensive women. 
 
5.7 Summary of the chapter 
This chapter described the socio-demographic characteristics, behavioural and 
physiological profiles, knowledge of heart disease risk factors, and history of 
hypertension and its treatment obtained from the 500 participants in a low income 
community in Delhi. It also presented the results regarding CHD risk perception and 
medication adherence among hypertensive women. The next chapter reports the 
results of the qualitative data from interviews undertaken with 30 hypertensive women 
and nine health care providers. 
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CHAPTER 6 
QUALITATIVE RESULTS 
 
6.0 Introduction to the chapter 
This chapter presents the analysis of the qualitative data from interviews with 30 
hypertensive women and nine health care providers. Major themes were drawn from 
the analysis using thematic analysis. The presentation of the themes is enhanced with 
interview quotes that best highlight the issues presented. Participants have been 
identified by a number to maintain confidentiality.  
6.1. Characteristics of the participants 
6.1.1 Characteristics of the hypertensive women participants  
The selection of the women hypertensive participants for the in-depth qualitative 
interview depended on their willingness to communicate freely regarding their medical 
condition and its management, so as to provide sufficient information.443 Another 
criterion was women who had at least one-year’s experience of living with hypertension. 
With these inclusion criteria, a purposeful sample of 30 hypertensive women 
participants from the phase one of the study was invited. None declined the qualitative 
interview. 
 
Table 34 summarises the socio-demographic characteristics of the 30 hypertensive 
women. The mean age was 48 years with an age range of 35–59 years. Of the 
participants, 16 had completed five or more years of education. Eighteen of the 30 
women were homemakers and did not work.  
 
The duration of their hypertensive state varied from 1 to 14 years (mean of 6 years); 
only nine women had treated and controlled BP. The participants in this study 
experienced symptoms during their diagnoses such as dizziness, headaches and 
palpitation. Among all the women, two were first diagnosed during their routine 
antenatal check-up, one during a hospital visit due to an accident, another during a 
hospital visit due to a surgical procedure, while others were identified when they sought 
medical attention for their symptoms. Almost all the women participants knew the risk of 
heart attack connected with high BP. 
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Table 34: Characteristics of the hypertensive women interviewed 
Participants  Age  Education 
completed 
Occupation Duration 
of HTN 
(years) 
BP control 
P1 49 Can sign only UL 1 Yes  
P2 53 Year 12 NGE 5 Yes 
P3 54 Year 12 Homemaker  6 No 
P4 57 Can sign only UL 5 Yes 
P5 59 Illiterate  UL 12 No 
P6 46 Primary school Homemaker 1 No 
P7 35 Can sign only Homemaker 1 Yes 
P8  55 Can sign only Homemaker  12 No 
P9 40 Illiterate  Homemaker 5 No 
P10 55 Illiterate Homemaker  10 No 
P11 55 Can sign only  Homemaker  11 No 
P12 59 Can sign only  Homemaker  10 No 
P13 46 Year 10 Homemaker 5 Yes  
P14  58 Can sign only Homemaker  12 No 
P15 59 Illiterate  Homemaker  4 No 
P16 49 Year 12 NGE 1 Yes 
P17 35 Year 10 Homemaker  3 No 
P18 58 Year 12 Pensioner  1 No 
P19  44  Year 10 Homemaker  10 Yes 
P20 40 Can sign only UL 7 Yes 
P21 42 Year 10 Homemaker  5 No 
P22  44 Primary school NGE 1 No 
P23  38 Year 10 Homemaker  14 No 
P24 51 College NGE 8 No 
P25  45 Year 10 NGE 3 No 
P26 45 Can sign only Homemaker  8 No 
P27  35 Year 10 NGE 1 No 
P28 40 Primary school Homemaker 1.5 No 
P29  59 Illiterate  Homemaker 4 No 
P30  59 Year 12 NGE 12 Yes 
NGE=Nongovernment Employee; HTN=hypertension; BP=Blood Pressure; UL=Unskilled 
Labourer. 
6.1.2 Characteristics of the health care providers   
For qualitative interviews, health care providers or physicians were selected using 
purposive sampling techniques from government and nongovernment health care 
centres that were directly involved in providing health care services to a large number of 
patients with hypertension from low-income urban areas in Delhi. Before the interview, 
each participant was contacted by phone. In all, 12 physicians were approached on the 
basis of gender, experience, their association with private practices, practices at 
government health facilities and their association with nonprofit organisations. Three of 
the 12 physicians did not respond to the contact. The researcher made an appointment 
with the nine physicians who responded and interviews were conducted in the month of 
October, 2015. 
162 
 
Among the nine physicians, six were female and three were male. Seven physicians 
were general medicine specialists and two were cardiologists. Three physicians worked 
for government health facilities, three for private health facilities and two were self -
governing private practitioners. They had an average of 16 years of clinical experience 
after their training (range, 7–25 years) (please see Table 35) 
 
Table 35: Characteristics of the health care providers interviewed 
Participants  Sex  Health facility Years of 
experience  
Ph1 Female  Private  12 
Ph2 Female   Private  10 
Ph3 Female  Private  23 
Ph4 Female Government  15 
Ph5 Female  Government  18 
Ph6 Female  Private  20 
Ph7 Male  Government  7 
Ph8 Male  Private  14 
Ph9 Male  Private  25 
 
6.2 Summary of the hypertensive women and health care providers’ 
responses  
Present study aimed at finding out the hypertensive women and health care providers’ 
perspective on women’s medication adherence behaviour in hypertension 
management. From the analysis of hypertensive women and health care providers’ 
responses, this study identified several themes which were organised under four 
categories:  
1. factors inhibiting medication adherence  
2. factors facilitating medication adherence 
3. women’s expectation related to their hypertension management 
4. suggested strategies to improve women’s medication adherence.  
 
6.2.1 Factors inhibiting medication adherence 
Even though almost all participating women were aware of the complications of 
uncontrolled hypertension, such as heart disease and stroke, 14 of the participants said 
that they did not always take their antihypertensive medications as prescribed. Factors 
that inhibited women from using their medications as prescribed could be classified into 
three major themes: patient related, issues with health care providers, and issues in 
health care service delivery. The reasons for non-adherence identified by physicians 
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were patient related and health system connected. An overview of themes and related 
sub-themes under the category ‘factors inhibiting medication adherence’ are 
summarised in Table 36. 
 
Table 36: Reasons for non-adherence 
 
Categories  Themes       Related sub-themes  
      (patients’ perspective) 
    Related sub-themes  
    (health caeproviders’ 
    perspective) 
Factors 
inhibiting 
medication 
adherence  
 
 
 
Patient 
related 
  
Perception of  
disease and  
health belief 
 Knowledge of hypertension 
and its management 
 Views on personal CHD 
risk  
 Feeling good physically 
 Belief regarding 
hypertension and its 
management 
 Perceived CHD risk 
 Lack of education  
 
Treatment  
perception 
 
 
 Lack of knowledge about 
hypertension treatment 
(treatment duration, 
medication side effect, how 
it works) 
 Medication satisfaction 
 
 Treatment belief 
 Treatment 
duration 
 Multiple medicine 
prescription 
 
 
Family or 
social  
Support 
 
 Lay belief of hypertension 
 Family crisis  
 Domestic works 
 Lack of companion to visit 
health facilities 
 
 
 Lack of family cooperation 
 Lack of companion to visit 
health facilities 
 Family commitments 
 Less prioritiy 
 Tendency for saving 
money for other reason 
 
Forgetfullness   
 
 Busy schedule 
 
 
 Being too lazy to have 
medications 
Issues with 
health care 
providers 
 
 Physicians attitude 
 No explanation of 
treatment regimen 
 Lack of risk communication  
 
- 
 
 
 
Issues with 
health care 
service 
delivery 
 
Government service 
 Non-availability of medicine 
 Quality of medicine 
 Long waiting time to 
procure medicine 
 Distance and travel cost 
 Ill-mannered staff 
Private service 
 Cost of medicine 
Government service 
 Frequent visit to collect 
medications 
 Non-availability of 
medications 
 Inflexible hospital timing 
 
Private service 
 Cost of medicine 
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6.2.1.1 Patient related factors  
This section presents findings related to patients’ knowledge of hypertension, 
perceptions of treatment and CHD risk, family support, and forgetfulness. 
 
Knowledge of hypertension and its management, perceived CHD risk and health beliefs 
In the interviews, women participants were asked about their perceptions of the most 
important factors to control high BP. Five of the women did not consider taking 
medication as a priority to control their BP. They believed that they could control their 
blood pressure more effectively through drinking lots of water. As one woman stated,                                      
‘The most important thing is to increase my intake of water. As many older 
people told me that more water intake helps in lowering the BP more 
effectively.’ (P24) 
 
Another woman commented, 
‘In my opinion, drinking lots of water is the most important thing to control 
my high BP. Taking medicines is also important, but it would have been 
great if one does not require using the medicines.’ (P21) 
 
Two women considered consuming less salt and taking morning walks as the most 
important;  
‘Consuming less salt is most important. In my view, medication is less 
important than salt. If my dietary restrictions fail to control my high BP, then 
I have to use medications as the last option’. (P7) 
 
One woman felt that refraining from eating oily and fried food was the most important 
factor to control her BP; another woman felt losing weight was the most important task 
to control high BP. 
 
In the interviews, hypertensive women were asked about their risk of having a heart 
attack. Patients’ perceived risk motivated them to make life style changes and engage 
in prevention after receiving advice from family and friends. Some non-adherent women 
believed that if they had a heart attack then it is God’s will. As one illiterate older woman 
commented,  
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‘I never think that I may encounter that chance associated with heart attack. 
I leave everything on GOD’s mercy.’ (P5) 
 
Anther younger women who completed primary school said, 
‘If I have to die I will die! Nobody could stop that. Since it is Almighty’s will! ’   
(P6)  
 
Three women associated their heart disease risk with the intensity of high BP 
symptoms. One woman who was a home maker said,  
‘When my physical problem increases such as palpitation due to high BP, I 
feel that I may have a heart attack.’(P9) 
 
In the study, some physicians reported disappointment with their efforts to improve 
patients’ CHD risk perception. According to the physicians, in spite of their counselling, 
women patients did not understand the seriousness of heart disease risk as a 
consequence of their uncontrolled BP. The physicians attributed this to women’s low 
level of education, and misconceptions. As one physician working in a private primary 
care health facility commented,  
‘Many of them (women) don’t take their heart disease risk seriously ... they 
feel that the consequences of uncontrolled hypertension will never happen 
with them. I don’t know why they have this notion ... they believe that getting 
a heart attack is the God’s wish. If someone is supposed to get a heart 
attack, nobody can prevent it. So these women don’t bother to take 
precautions for getting a heart attack.’ (Ph1) 
 
Another physician working in a government health care facility said, 
‘I think … among women who do not adhere to their treatment, most of 
them do not know the risk involving a heart attack as a consequence of 
uncontrolled high BP.’ (Ph7) 
 
Seven women stated that they did not take their medications when they had felt well.  
The comments of two women serve as examples: 
‘When I feel better, I think my BP is under control; I stop taking the 
medication on my own. When I feel sick, I simply restart my medication. I 
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don’t like to take the pills every day. Let’s see what will happen if I skip my 
medication! (P5)  
 
‘If I remain to stabilise for couple of weeks, I usually consume half of my 
prescribed medicines on my own, without consulting my doctor; this is my 
personal decision. It has nothing to do with the doctor. Whenever I feel 
better, I simply discontinue my medication’. (P16) 
 
Some of the participating physicians also recognised the asymptomatic nature of 
hypertension related to MNA. As one physician commented,  
‘When they are being diagnosed to be suffering from high blood pressure ... 
we start their treatment. After some time, once they become symptoms free 
and when they come to know that their BP has become normal; they feel 
that they need not to continue their medication for the extended period. 
They stop taking their medication abruptly on their own.’ (Ph5) 
 
Treatment perceptions:  
Concerns and fear were expressed by some women regarding the use of their 
antihypertensive medications regularly. Among them, two women expressed the 
opinion that the long-term continuous use of medications would have an impact on 
important organs of the body and body system.  
‘Doctor prescribed me three drugs per day. But my husband told me not to 
take these BP medications daily as these drugs may increase my usual 
temperature. That’s the reason I avoid taking the medications daily.’ (P4)  
 
Another woman even expressed fear of becoming addicted to using antihypertensive 
medicines.  
 ‘I don’t want the medications to affect my kidneys nor would I like to 
become addicted to these medications.’ (P20)  
 
Similarly, one physician stated,  
‘Some of the patients believe that if they start taking medicines, their body 
will become habituated to it and eventually they will need to take these 
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medications regularly on a life-long basis. So they think if they use other 
ways to control BP that will be a better option for them.’ (Ph5)  
 
A long duration of treatment affects treatment adherence. Two participants expressed 
their concern regarding the long duration of antihypertensive treatment;  
‘I have been using medicines for my BP for fourteen years and at this point, 
I do not feel like to continue my medications.’ (P23) 
 
‘I do not prefer to prolong treatment by the doctors. I believe by God’s 
blessing my treatment may get shorter.’ (P5) 
 
Physicians also recognised prolonged treatment duration as one of the reason for MNA. 
As one physician commented, 
 ‘Patients generally don’t want to go for medicine for a longer period of time 
... When they are symptom-free; they don’t bother to take medications 
anymore.’ (Ph1) 
 
Prescription of multiple medications due to comorbidities such as diabetes, thyroid, and 
high cholesterol was frequently reported by the participating physicians as treatment-
related factors associated with MNA of hypertensive women. One physician 
commented,  
‘As per my experience, poor adherence is linked to multiple medicines on 
the daily basis. I don’t see simple hypertension cases. Most of the 
hypertensive patients have other problems too. Like diabetes, thyroid, etc. 
So, we are also helpless, but we need to prescribe multiple medicines.’ 
(Ph6) 
 
Among the non-adherent participants, four women stated that, as they were not 
satisfied with their current treatment, they hesitated to take medications continuously. 
Uncontrolled BP was perceived by them as one of the reasons for not being satisfied 
with the medication. For example, two women commented: 
‘I am not satisfied with my current medicine for high BP ... it is still high. I 
visited my doctor for this purpose and asked him to change the medicine ... 
But he did not bother to say anything further in these contexts. He only 
168 
 
advised me to minimise the intake of my salt consumption in my diet, refrain 
myself from greasy and fatty foods and I have to lose my weight.’ (P2) 
 
‘I am not satisfied with my BP medications; it does not work effectively on 
me. Infrequently, some physical problems happen with me due to my high 
BP’. (P17) 
 
Family support and forgetfulness: 
Five participants stated that they had non-supportive family members. Perceptions of 
hypertension were very much responsible for non-support of the family members. 
These conceptions were expressed in the following comments: 
‘Most of my family members feel since I underwent an operation in the past 
and I have had many domestic problems, and they think … these 
circumstances are responsible for my high BP.’ (P3) 
 
‘My family members do not take my problem of high BP acutely. They don’t 
care about the risk involved in high BP neither they care whether I live or 
die. Even if I die today, they are least concerned about me!’ (P23)  
 
Two participants also claimed that, as they were busy with their work and daily life 
commitments in the family they often forgot to adhere to their medications. 
 
6.2.1.2 Issues with health care providers 
The majority of the women with low-adherence were not satisfied with the way 
physicians dealt with them. They indicated that they were not able to discuss their 
health status freely with the doctor since the consultations were hurried.  
‘Whatever we say to doctors, they simply do not listen to our wordings. They 
only advise, since we have high BP, just keep on taking the medications. 
Most of the doctors are mannerless, and they use foul language. As a 
result, I avoid asking them anything ... If we could have found any good 
doctor who sympathises with us, we would have shared our medical 
problems with him or her as we could easily relate to them.’ (P17)  
 
169 
 
Only two women said that their doctor informed them that they might experience some 
side effects at the time of the initial diagnosis. Five participants stated their doctor did 
not make them aware of the prolonged duration of the treatment or the need to keep 
taking medicines on a regular basis, without fail. One woman stated, 
‘No, the doctor did not say to continue my medicine lifelong. He wrote 
nothing in my prescription.’(P3) 
 
Another woman said, 
‘If my family doctor could have said that I have to take my BP medications 
daily, then I may continue to take my medicines on a regular basis ... its 
doctor’s fault! The doctor should have told me that I have to take my 
medications regularly and lifelong. If I already do so many things, I don’t 
mind taking extra medications for my high BP to save my life!’ (P8) 
 
Regarding lack of information about the risk associated with uncontrolled BP, one 
participant commented,  
‘If I could have been aware of the risks such as heart attack, paralysis or 
brain haemorrhage involved with high BP, I must have been taking the 
medicines daily without fail ... Doctor never told me any such risk associated 
with high BP.’ (P3)  
 
This study has found that none of the participating physicians used CHD risk 
assessment tools (a detail of CHD risk assessment tools has been explained in chapter 
2) to communicate the individualised CHD risk to the women they were treating. They 
claimed they found the risk scoring tool difficult to use daily in a clinical context. The 
main reasons for not using risk scoring tools, as acknowledged by the physicians were 
workloads, not interested, lack of staff, work protocol and lack of staff to assist them. A 
physician at a government health facility stated,  
‘For treatment of the patients, we follow the standard guidelines. It is 
important to calculate the risk, but no one could have helped us to do that. 
We explain patients their risk according to the circumstances and advise 
them for a followup regularly. And I believe this is being followed in private 
practices also.’ (Ph5) 
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A physician at a private health care facility commented,  
‘No, that is not possible at the busy centre like ours. Workloads on doctors 
are so high that it is not feasible to calculate the actual risk by using charts. 
For that, we need to keep a separate group of staff who can sit, calculate 
and maintain those records. At present, what we do is the proper treatment 
that is more important than calculation’. (Ph2) 
 
Most of the patients reported having blood tests performed to assess their blood sugar, 
cholesterol levels or other blood tests. They did not understand the reason for the test. 
A few assumed that they had been tested for their heart disease risk even if their 
physicians had not mentioned it. No patients interviewed recalled having had 
information conveyed by their physicians concerning their personal CHD risk after tests 
or physicians explaining their results to them. 
 ‘My doctor advised me for some tests. But he has never mentioned these 
tests were meant for measuring heart attack risk or not.’ (P11) 
 
6.2.1.3 Issues with health care facilities and service delivery 
Consistent with the participants’ experiences, health care facilities and delivery of the 
services had some influence on hypertensive treatment adherence. Fiive patients 
preferred government health facilities and the others preferred private health facilities. A 
common reason given for going to government health facilities was free medications for 
hypertension. In spite of the availability of free medications, the majority of the women 
did not prefer government services. Also, government health services were either not 
available in their locality or participants were not aware of the services.  
 
The reasons given by the participants for not preferring government health services 
were: long distances, ill-mannered staff, poor quality of medicines, unavailability of 
drugs, long queues, lack of a companion to visit health facilities, overcrowding, uncaring 
doctors, and doctors not giving much time to the patients. Some patient comments 
regarding the health care system were: 
‘I had a bad experience at a government hospital. As the medical staff 
there, at large are very impolite and manner less. Once they threw my OPD 
registration card at my face. That’s the reason I prefer going to private GP.’ 
(P14) 
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 ‘I prefer to go to government hospitals as they provide free medicines. But 
the major problem is that there are always long queues to register you at 
general OPD. After that even for getting myself scheduled at doctors 
chamber there is all the time another long line. That’s the reason I have to 
spend the whole day in simply standing in the lines. And at times, while 
standing in the lines my turn does not come up.’ (P16) 
 
The conversations also revealed that patients were unlikely to continue private 
treatment because they could not afford it, due to their economic status. As one patient 
commented,  
‘My whole day gets wasted in procuring my medications from government 
hospital.  So I go to private medical doctor for my treatment even though it 
is expensive. That's why; I am forced to quit my treatment whenever I feel 
better.’ (P11) 
 
Health system factors that were related to MNA highlighted in the physicians’ interviews 
were: need frequent visits to the government health facilities to collect medications, 
non-availability of subsidised medication, and the cost of private medications. Some 
physicians’ comments regarding health systems associated factors were:  
‘The women need to come repeatedly for collecting the drugs which itself is 
a time-consuming task. Most of the health facilities provide 7–15 days 
medicine only.’ (Ph3)  
 
‘They (working women patients) simply cannot afford to lose their daily 
earnings for collecting medications.’ (Ph9)  
 
‘Occasionally medicines are not available in the government health facilities. 
Some women from low-income areas cannot afford to buy these medicines 
from private chemist shops’. (Ph4) 
 
However, one physician did not think that medication cost was a significant factor in low 
adherence to medications,  
‘Yes sometimes I don’t feel so … cost of medicine is an important cause of 
non-adherence. In our dispensary we at times give free medicine to the 
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patients who are unable to buy … still they would like to avoid taking 
medicine!’ (Ph1) 
 
6.2.2 Factors facilitating medication adherence 
Sixteen of the participants stated that they were taking their antihypertensive 
medication as prescribed. Participating women and physicians suggested four themes 
of factors that motivated women to use their medications as prescribed: remain 
physically fit, trust in medicine and physician, family and social support, and integrating 
routine to aid medication adherence (please see Table 37). 
 
Table 37: Motivating factors for adherence 
 
Categories  Themes  Related sub-themes 
(patient’s perspective) 
Related sub-themes 
(health providers’ 
perspective) 
Factors 
facilitating 
medication 
adherence 
Remain  
physically fit 
 
 
 
 
 Avoiding physical 
manifestations  
 Fear of getting heart 
attack and even death 
 Past event in the family 
 
 Awareness of risk 
 Young kids to look 
after 
 Family history 
 Trust in 
physician 
 Belief in the benefits of 
medication 
 Young age 
 Education  
 
 Family and 
social support 
 Supportive family  
 Family responsibilities 
 Considerate health care 
providers  
 
 Supportive family 
 Family history 
 Domestic work  
 
  
Integrating 
routine to aid in 
medication 
adherence 
 
 Fixed timing to have 
medications 
 
- 
 
6.2.2.1 Remain physically fit 
Eight women commented that they took their medicine regularly to stay physically fit 
and to avoid symptoms of hypertension.  
 
Fear of a heart attack 
The fear or knowledge that they could suffer from a heart attack or stroke and even 
death if they do not control their high BP was a significant reason for medication 
adherence.  
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‘If I do not take my high BP medications I feel a severe headache and pain 
in my neck. Even there is a risk of heart attack or paralysis. If I die of a heart 
attack, the life is over but If I have to live with this disease throughout my 
life, who will look after my family and me ... That’s the question I am worried 
about. So I am taking my medications as advised by my doctor.’ (P15)
  
‘I fear that I may have a heart attack; even death at times. So I always take 
my medications regular basis.’ (P18) 
 
Past event in the family 
Two participants had a family history of heart attack and stroke. So, they made sure to 
take their medications on a daily basis to prevent their future heart attack risk. One 
woman said, 
 ‘In the past, my sister had some heart problems, and my father had brain 
haemorrhages due to uncontrolled high BP. Because of these instances, I 
feel afraid that it may happen to me anytime ... this invisible fear motivates 
me to continue my medications. (P13) 
Another woman commented, 
‘My father had thrice heart attack and ultimately he died of heart attack ... 
If I do not take my high BP medications...there is a risk of heart attack or 
paralysis. Hence, I am taking my medications as advised my doctor’. (P15) 
 
Participating physicians also acknowledged that family history of heart attacks could 
make patient serious about their heart disease risk. As one physician commented, 
‘If they (hypertensive women) have a previous family history of the heart 
attack then they think their heart attack risk seriously. Otherwise, they do 
not appreciate.’ (Ph9) 
 
Family commitments 
The family commitment was also perceived by four participants as another factor for 
taking high blood pressure medication on a regular basis. Family obligation included 
responsibility for household work and looking after young unmarried children. As one 
woman commented,   
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‘Since I have to do lot of household works, if I do not take my medication 
regularly, am afraid it will affect my health ... so I have to take my medicine 
daily.’ (P10)  
 
 Another woman commented, 
 ‘I take my medication daily. I have family responsibilities ... as my 
unmarried children have to be married in time.’ (P19) 
 
6.2.2.2 Trust in physician and medicine 
Belief in medicine and the physician affects medication adherence. One participant 
expressed her feeling about the relationship with her physician,  
‘I have full faith in my doctor, and I believe him; I am dependent on him 
regarding my treatment. I have full confidence in him that he will never give 
me too many medicines unnecessarily.’ (P30) 
 
Physicians reported that young age and education level of participants were related to 
good medication adherence. As one physician commented,  
‘I tell them to take medicine continuously as advised. Old and middle aged 
women are not worried. Young and educated women have faith on us, if 
they are hypertensive, they want to come out of it; they are willing to take 
medicine. Especially, aged women do not understand the importance of 
taking medicine.’ (Ph1) 
 
6.2.2.3 Family and social support 
For taking antihypertensive medication properly, five participants did get support and 
motivation from their family members. One woman stated, 
‘Family members are very caring and supportive about my high BP problem. 
They always enquire whether I have taken my medication on time or not.’ 
(P28) 
 
Most physicians also identified supportive family and awareness of the consequence of 
high BP as an important factor associated with high medication adherence. As one 
physician stated,  
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‘When we describe them the consequences of uncontrolled hypertension … 
and if their family is supportive then they become strict to their regime’. 
(Ph1) 
 
6.2.2.4 Integrating routine in daily life to aid in medication adherence 
Adherence to treatment was easier if the medication was taken in the morning. In this 
case, the majority of participants had associated their medication with their breakfast or 
had invented different tricks to remember it. For example, participants commented: 
‘I put down all my medicines in a box, and this box is being kept in kitchen’. 
(P25).  
 
‘I take my medications just after having my breakfast’. (P21) 
6.2.3 Expectation regarding hypertension management  
When women were asked about their expectation regarding hypertension management, 
most expressed their desire for caring and sympathetic physicians who should educate 
them on hypertension and its management without getting annoyed. Some of the 
women further stated that awareness programs by health educators should be 
implemented at the household level so that the majority of the women can get benefits. 
Apart from the education, participants expected their prescribed antihypertensive drugs 
should be useful and efficient to control their BP. Private practitioners should prescribe 
cheap and effective medicine.  
 
Some women conveyed willingness to get a regular supply of free, good quality 
medicine from government health facilities. They stated that this would help them to 
control their condition. Patient comments regarding their wishes for disease 
management were: 
 ‘I wish I could have persons who may sympathise with me, ask me whether  
I have taken my regular medications and done medical tests then perhaps I 
would have felt happy and would have recovered from my medical problems 
sooner.’ (P17) 
 
‘I wish there could be some real and effective drugs available which may 
stabilise my high BP and perhaps some medical test which can precisely 
predict why my BP simply cannot be under control?’ (P1) 
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“I wish if I could have a good supply of quality medicines regularly in 
government facilities then I could have visited goernment hospital for my 
medications.’ (P11)  
 
6.2.4. Strategies to improve women’s medication adherence 
In this study, physicians suggested strategies related to counselling and education, and 
health service delivery. Physicians recommended that counselling should be continuous 
and regular every time a patient made a clinic visit, and include the patient’s spouse 
and other family members. They echoed the importance of communicating with the 
patients and expressed that it was largely their job to educate them. However, they 
pointed out that additional staff is always necessary for them for regular health 
counselling and followup the patient. Some physicians’ comments regarding the 
counselling were: 
‘First of all, we have to educate them, not only them but also their children 
or husband. We have to teach them that hypertension is a long term 
disease, and it needs to be managed on a long-term basis.’ (Ph4) 
 
‘One sitting of counselling in our chamber is not sufficient for the patient. It 
should be continuous and regular process.’ (Ph1) 
 
To improve MNA, some physicians recommended outreach services to teach women at 
community level and for health care services delivery. One physician commented,  
‘If the government takes an initiative and trains community health workers to 
visit women at their house to measure their BP, provide them subsidised 
medicines and arrange for a blood test when need in a fundamental way … 
I think this procedure can help to control BP of these group of women and 
prevent their future heart attack risk.’ (Ph8)  
 
The physicians also recommended that, if possible in their busy schedule, doctors 
should explain the prescribed medication in patients’ languages as well as write 
detailed instructions on prescriptions. Private practitioners should prescribe cheap and 
effective medicines. Apart from this, they also suggested the free supply of medication 
from government facilities be for a longer period of, at least, 15–30 days as a shorter 
duration of medication supply causes non-adherence. As one physician commented,  
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‘Most of them (women patients) are working. They do not get leave from 
their workplaces to collect medications at regular interval. Their work 
schedules interfere with their medications adherence behaviour.’ (Ph3) 
 
6.3 Conclusion  
In conclusion, the present study identified several issues relevant to the medication 
adherence of women patients with hypertension. The results indicated that barriers to 
medication adherence for antihypertensive treatment included: low awareness of the 
conditions of the disease, an undesirable outlook toward antihypertensive medications 
and dissatisfaction with the attitude of health care providers and health care services. 
 
6.4 Summary of the chapter 
This chapter described the characteristics of 30 hypertensive women and nine health 
care providers who were interviewed. It presented the analysis of participants’ 
responses. The next chapter describes an overview of the study design, discussion of 
the findings for each objective, recommendations and a concluding statement. 
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CHAPTER 7 
DISCUSSION, SIGNIFICANCE, RECOMMENDATIONS AND 
CONCLUSIONS 
 
7.0 Introduction to the chapter 
This chapter describes the study design and discusses the findings for each objective. 
The chapter also makes recommendations, discusses the significance of the study, 
notes limitations of the study and makes a concluding statement.  
 
7.1 The overview of the study design 
Based on the need for a better understanding of medication adherence of urban low-
income women in India, a mixed-method design was chosen for the research study. 
The rationale for this form of research is that using both qualitative and quantitative 
research methods, can provide a better understanding of a research problem or issue 
than either of the research approaches alone.410 In this study, complementarities were 
accomplished using both the approaches together. In such a combined approach, the 
dominant research mode can be enhanced by results from the other method type.411  
 
In present study, the dominant component was quantitative with the supplementary 
component being qualitative. Quantitative and qualitative data were collected both 
concurrently and sequentially.411 The quantitative survey provided information on how 
many women were hypertensive, how many were on antihypertensive treatment, how 
many perceived their global CHD risk inaccurately and how many women were not 
adherent to their antihypertensive treatment, and finally factors that were associated 
with these results. The qualitative semi-structured interviews explored the perceptions 
of hypertensive women and health care providers about the reasons that hamper or 
facilitate antihypertensive medication adherence.  
 
The two methods used together allowed a more holistic understanding of medication 
non-adherence (MNA) in this population. The mixed-method approach helped offset the 
weakness in one approach with a more nuanced understanding given by the other, and 
in the process assisted with explanation and contextualisation of the findings. Table 38 
summarises some of the examples of the complementarities (i.e explanation and 
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context) of the mixed methods approach in this study, followed by explanation on some 
aspects of offsetting the weaknesses. 
 
Table: 38 Examples of complementarities of the mixed methods approach in this 
study 
 
Quantitative findings 
 
Qualitative findings Pragmatic explanation of 
issues raised 
Inaccuracy of the self-
perception of the CHD risk 
was significantly associated 
with MNA of the hypertensive 
women 
Some non-adherent women 
believed that heart attack risk 
was due to divine will while 
others associated their risk 
with the 
severity level of their 
hypertensive symptoms 
Explanation:  
Most of the women did not 
understand the seriousness 
of the condition due to 
misconceptions and 
inadequate knowledge of 
CHD risk factors, treatment 
and consequences of MNA 
 
Women who had not been 
explained the treatment 
regimen and side effects of 
medications by their doctors 
were significantly more likely 
to be non-adherent 
 
Concerns and fear were 
expressed by the low adherent 
women about the long term 
use of regular medicines. 
Some even expressed fear of 
dependence on 
antihypertensive medicines 
 
Explanation:  
Hypertensive women had 
lay beliefs regarding 
hypertension, its treatment 
and management. The 
qualitative findings explain 
the inadequate knowledge 
and belief of women in the 
study 
 
Women with shorter duration 
of hypertension were 
significantly less likely to 
adhere to treatment 
 
In response to the mild 
symptoms of high BP, some 
patients stopped or reduced 
their daily doses without 
consulting their health care 
providers 
 
Context:  
Recent diagnosis may be 
associated with mild 
hypertension, fewer 
symptoms and fewer 
complications, which leads 
to complacency among 
patients 
 
Women who were not 
satisfied with their treatment 
were more non-adherent 
than those who were 
satisfied 
 
Uncontrolled BP was one of 
the important reasons that 
women were not satisfied with 
the medication 
 
Context:  
Poor BP control might be 
attributable to inadequate 
medication therapy. When 
physicians assess patient’s 
global risk of CHD, they are 
more likely to recommend 
risk-reducing therapies 
 
Offsetting the weaknesses 
Mixed methods are used in some studies because the weaknesses of one method can 
be compensated by the strengths of another.450 One of the central constructs in the 
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quantitative arm of the study—medication adherence—was measured using a single 
item with a binary response. Participants were expected to answer ‘yes’ or ‘no’ to the 
question of whether they had missed any of their doses for high BP in the last seven 
days. Unlike the structured interview, the qualitative interviews were able to extensively 
explore the underlying issue of not taking the drugs and the impact it has on patients’ 
medication adherence behaviour.  
 
It should be noted that the Health Belief Model (HBM) was used to help inform the 
selection of the variables related to the research objective, the development of the 
hypothetical model, and the design and construction of the questionnaires (please see 
chapter 4). The model is useful in predicting the likelihood of a person taking 
recommended preventive health action and to understand an individual’s motivation 
and decision-making about seeking health service. In this respect, the model has been 
found to correlate well with medication adherence.408 A major feature of this model 
holds that the patients have choices and can make reasonable decisions regarding their 
health.397  
 
7.2    Discussion of findings and response to study objectives 
7.2.1 Objective one: Assess and stratify global CHD risk among women living in a low-
income urban area of Delhi, India 
 
This section discusses the findings of the prevalence of major CHD risk factors among 
women in a low-income urban area in Delhi. This is followed by a discussion of the 
findings regarding the stratification of global CHD risk among this population using the 
NHANES non-laboratory-based risk score. 
 
Hypertension 
The study found the prevalence of hypertension of 35.2% among women in a low-
income community in Delhi. This is similar to hypertension prevalence among urban 
women found in other Indian studies where they ranged from 21%–48.2%.64, 267, 269, 437, 
451-453 In the current study among hypertensive women, 58% were aware of their 
hypertensive status, 46.5% were currently on treatment, and only 15.9% had BP under 
control. These results closely reflect those from a population-based cross-sectional 
study spread across Delhi of hypertensive women aged 20–59 years, where 60.8% 
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were aware of their diagnosis, 49.7% were taking treatment, and only 14% had 
controlled BP.451 
 
Diabetes 
Among participating women the prevalence of self-reported diabetes was 11%. This 
prevalence was found to be high, given the fact that an enormous number of patients 
with diabetes mellitus frequently remain unaware of their diabetic status.85 Conversely, 
this rate of prevalence was lower considering the estimates using bio-medical 
diagnostic tools for diabetes (range: 12.1%–14%) from different parts of the country.454, 
455 This difference between measured and self-reported diabetes prevalence suggests a 
high burden of undiagnosed diabetes. 
 
Coexistence of hypertension and diabetes 
Hypertension may precede the onset of diabetes. People with co-existing diabetes and 
hypertension are at increased risk of developing atherosclerosis and coronary heart 
disease.456 In the present study, nearly one-fifth of the hypertensive women (18.2%) 
had co-existing self-reported diabetes, which demonstrated that the substantial burden 
of diabetes and hypertension is on the rise in India. This result was consistent with 
India’s Twin Epidemic (SITE) cross-sectional study conducted in 10 Indian states where 
diabetes and hypertension were co-existent in 20.6% patients.457 
 
Physical activity level 
Approximately 38% of the women studied had a low physical activity score (MET-
minutes per week), comparable to recent studies conducted in 11 cities across India458 
and a slum in Brazil106 where the physically inactive rate among women was 46% and 
27.3% respectively. Household chores and transportation may represent a substantial 
proportion of women’s total activity in the low-income area. However, studies that 
include all social classes had reported a higher level of physical inactivity. The 
prevalence of physical inactivity was reportedly higher (66.8%) among women in a 
study conducted in Chandigarh, capital of India’s prosperous state Punjab.458 
 
Overweight and obesity 
The mean Body Mass Index (BMI) in the present study was 24.53 ± 4.87, which was 
comparable to the mean BMI 25.0 ± 4.9 among women reported in a study in north 
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India.459 It was found that in the current study, more than half of the women (52.6%) 
were overweight and had obesity (BMI≥23 kg/m2). CHD risk and metabolic syndrome 
begin to increase above BMI 23 kg/m2. 
460 This result was comparable to a five-city 
study in India by Singh et al. where 51.6% of women had overweight and obesity.460 
 
Among the studied women, abdominal or central obesity was more prevalent than 
generalised obesity defined by BMI. In the present study, an analysis based on waist- 
circumference (WC ≥80 cm) and waist-hip ratio (WHR ≥0.85) showed that 66.6% and 
82.8% of women respectively had abdominal obesity. These results were consistent 
with studies in North India459 and Kerala461 where abdominal obesity was found among 
women at a rate of 74.8% by WC and 85.6% by WHR respectively. It was also 
comparable to another study conducted among women in a Mumbai slum, where 
57.1% and 72.2% of the women had abdominal obesity using WC and WHR 
respectively.462  
 
In the current study, an estimated two-thirds of the women had abdominal obesity as 
assessed by multiple parameters, which was of considerable concern because 
abdominal obesity is one of the key determinants of insulin resistance, an important 
component of metabolic syndrome and the major CVD risk factor in all populations. 
Traditional explanations for the increase in obesity include reduced physical activity and 
consumption of high-fat diets.463   
 
Tobacco use 
Among the study participants, the prevalence of tobacco users was 28.2%; the 
prevalence of smokeless tobacco users (17.8%) was higher compared to the smoked 
tobacco users (10.4%). These results are consistent with previous studies. According to 
the Global Adult Tobacco Survey (GATS) report 2009–2010, 18.4% of females were 
current smokeless tobacco users in India.127 Studies in urban slums in Delhi and 
Haryana found self-reported smoked tobacco use among women 10.3% and 9.1% 
respectively.464  
 
In the present study, 9% of women had a family history of heart disease as diagnosed 
by a health care provider which was comparable to a study where 6% of urban women 
had a first-degree relative with a history of heart disease.465 The high prevalence of 
CHD risk factors in the current study confirms a reverse social gradient of CHD risk 
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factors in that people from lower socioeconomic groups and women suffer the highest 
rates of CHD and levels of various risk factors.97 
 
Stratification of global CHD risk  
In the present study, using the NHANES non-laboratory-based risk score alone, it was 
found that 7% of the study population were at high risk (>20%) of developing a fatal or 
nonfatal CHD event over the next five years. The finding was consistent with an 
observational study carried out in Bangladesh, Guatemala, Mexico, and South Africa. 
Across all sites, of the 4049 community members who had completed NHANES 
screening, it was found that 6% had a five-year CHD risk of >20%.466 The prevalence of 
high CHD risk in the current study was comparable to studies that reported the 
prevalence of high CHD risk (>20% chance of developing a CHD event over 10 years) 
in other countries such as Pakistan (10%)467, Malaysia (6%)468 and Seychelles 
(5.1%).469 The present study, disturbingly, estimated one-fourth of the women (24.8%) 
had ≥ 10% risk of developing fatal or non-fatal CHD in the next five years. This is a 
stark indication of the high burden of CHD diseases that can be expected in the near 
future to arise in the low income urban Indian population. 
 
7.2.2 Objective two: Examine hypertensive women’s perceptions of their global CHD 
risks and evaluate its relationship with socio-demographic variables and their 
knowledge of CHD risk factors 
 
This section discusses the findings related to women’s level of accuracy in estimating 
their perceived global CHD risk (GCR). This is followed by a discussion of the results 
about predictors of inaccurate perception of CHD risk. In the current study, a five-year 
risk was chosen, rather than ten-year risk, to assess the perceived GCR because it was 
thought to reflect more realistic expectations about near future events, based on current 
state of health.16 
 
Inaccurate estimation of global CHD risk 
In the current study, there was a low agreement between calculated and perceived 
GCR of women, which was in line with other studies.16, 470 More than half (52%) of the 
studied hypertensive women of the low-income community were inaccurate in 
assessing their GCR (heart attack) in the next five years. The result is comparable with 
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a study outcome in the Netherlands done by Frijling et al.17 where the researchers 
compared calculated to perceived GCR in 1194 patients with diabetes mellitus and 
hypertension. The rate of inaccuracy was 42% for a heart attack. In another study in 
North Carolina, where Kreuter et al. compared perceived risk with calculated heart 
attack and stroke risks in a sample of 1317 participants, 65% of participants had an 
inaccurate perception of their risk.247 In the current study, a majority of the inaccurate 
participants under-estimated their CHD risk (rather than overestimation), which was 
consistent with other studies.246, 247, 471, 472  
 
Accurate understanding of the CHD risk 
In this present study, approximately 45% of hypertensive women at medium and high 
risk of a heart attack had an accurate understanding of their risk. Also, nearly 73% of 
low-risk women accurately identified their low-risk status. However, the study by 
Christian et al.230 revealed slightly different results. She found 71% of ethnic women 
with medium and high likelihood of heart attack had an accurate understanding of their 
risk, but only 52% of low-risk women accurately identified their low-risk status. 
 
Predictors of inaccurate CHD risk perceptions 
In this study, backward multiple regression analysis demonstrated that age, knowledge 
level of CHD risk factors and diastolic hypertension were the significant predictors of 
inaccurate perceptions of CHD risk of hypertensive women. 
 
Older age 
In this study, older age predicted inaccuracy of the perceived GCR. This result is 
consistent with three other studies245, 251, 473 where older age had led to decreased 
accuracy in estimation of risk. On the other hand, studies by Hussein et al.16 
established that younger age, not older age, was independently related to the 
inaccurate perception of GCR. Similarly, two other studies245, 247 also reported that 
younger participants were more likely to have an optimistic bias (underestimation of 
risk) to a heart attack. However, age was not seen to be associated with the ability to 
perceive risk in some studies.252, 474 
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Poor knowledge level of CHD risk factors 
In the present study, inaccurate perception of GCR was significantly higher in women 
with a poor knowledge level of major modifiable CHD risk factors. The result is in line 
with the studies474, 475 of other populations, such as adults with type 2 diabetes, where 
greater CHD risk factor knowledge was associated with higher perceived CHD risk. 
However, in a study of HIV-infected adults,252 CHD risk factor knowledge was not 
related to perceived GCR. It is possible that HIV-infected adults did not personalise the 
general knowledge that they had about heart disease.252  
 
In the current study, most of the women were not able to recognise heart attack as the 
greatest health problem for women in India. Like a previous study,472 this study also 
showed that women perceived cancer as a higher risk than CHD. The lower level of 
women’s risk perceptions for heart disease in the present study corresponded to a 
frequent misperception found in earlier studies, which revealed that the general public 
perceived heart disease primarily as a health problem for men.36, 476 These 
misperceptions may lead women to underestimate their risk of CHD and fail to seek 
early interventions to prevent unnecessary morbidity and mortality.36 
 
Diastolic hypertension 
Studies have shown that high BP increases the accuracy of perceived risk.245 However, 
in this study, inaccurate perception of the GCR was higher with the hypertensive 
women with increased diastolic BP. This high BP might be due to the result of women’s 
underestimation of risks for their heart disease, which likely inhibited them from 
practicing preventive behaviour such as medication adherence to the hypertensive 
treatment. Persons who accurately perceive their risk of cardiovascular diseases may 
be more likely to be adherent in practices to reduce their risk, compared to those who 
do not perceive themselves to be at risk.247-250  
 
7.2.3 Objective three: Investigate the prevalence and predictors of non-adherence to 
antihypertensive medications among hypertensive women in a low-income community 
 
This section discusses findings regarding the prevalence of MNA among hypertensive 
women. This is followed by a discussion of findings related to the predictors of non-
adherence in this population. 
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Prevalence of MNA 
In this study, the prevalence of MNA among hypertensive women was 51%, similar to 
the studies in another part of India and in Pakistan where the rate of MNA was found to 
be 49.67%39 and 51.7% respectively.379 The rate was lower than studies in Ghana and 
Nigeria (66.7%),359 Pakistan (68.4%),361 and a multicentre study in Bangladesh and 
India (90%).404 However, MNA was higher than what has been reported from Ethiopia 
(26.4%),376 Congo (32.5%)373 and other parts of India (45.8%).477 This inconsistency of 
data could be due to measurement of adherence based on different criteria, along with 
variations in the subset of the population that served as the study sample, and sampling 
and monitoring periods. Besides, most of the previous studies were hospital-based 
whereas the current study was community-based. 
 
Predictors of MNA 
Shorter duration of hypertension 
In the present study, women who had hypertension for less than three years were less 
likely to adhere to treatment. Recent diagnosis may be associated with milder 
hypertension, fewer symptoms and fewer complications and might lead to complacency 
among the participants. This result was consistent with a study in China,386 Pakistan361 
and another part of India.10 The result also emphasised the fact that a shorter duration 
of the disease hinders the patient in accepting the diseased state as well as adapting to 
the adherence behaviour. However, in contrast to this finding, lower levels of adherence 
with a longer duration of antihypertensive therapy were found in studies in Serbia360 and 
Nepal.366   
 
Lack of knowledge about hypertension treatment, medication information and 
consequence of medication non-adherence 
The current study found a significant relation between knowledge of hypertension 
treatment, medication information and adherence to medications. Women whose 
doctors had not explained the treatment regimen and the possible side effects of 
medications were more likely to be non-adherent than those women who had been 
given such an explanation by their doctors. Similar observations were noted in other 
studies363, 369 where hypertensive patients who did not properly understand their drug 
regimen were poorly adherent to their prescribed medications. Knowledge about 
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hypertension and its management creates a clear understanding and avoids confusion 
about the treatment and the disease condition.  
 
Perceived low and inaccurate CHD risk 
In this study, non-adherence was significantly higher when women perceived their CHD 
risk as low. Those who perceived their risk as high were more adherent to their 
hypertensive treatment. The study result was in line with Ali’s study in the USA,226, 227 
which explained women’s participation in CHD prevention behaviours such as 
medication adherence. Ali226 found that perceived susceptibility to CHD explained the 
majority of variances (50.7%) and was a statistically significant predictor of CHD 
preventive actions in women. Similarly, in other studies, the perceived CHD risk 
appeared to be positively correlated with actual behaviour change, and with a desire to 
make risk-reducing behavioural changes.228, 229 The current study also found that 
inaccuracy of the self-perception of the CHD risk was significantly associated with MNA 
of the studied women. A similar observation was noted in previous studies222, 245 where 
persons who accurately perceive their cardiovascular disease risk may be more likely to 
engage in reducing their risk, compared to those who do not perceive themselves to be 
in danger.247  
 
7.2.4 Objectives four and five: Explore the reasons underlying antihypertensive 
treatment adherence; to examine health care providers’ attitudes regarding women’s 
perceived global CHD risks and their adherence to antihypertensive treatment    
 
This section discusses findings related to hypertensive women and health care 
providers’ perception of the reasons that may influence adherence to prescribed 
antihypertensive medication.  
 
The current study results suggest that patient-related factors such as their knowledge 
and beliefs about hypertension and its management, Support from family members and 
family accountability, health care provider related issues and issues related to health 
facilities and service delivery were perceived as important reasons for not being 
adherent to medications. The result also revealed that to remain physically healthy, 
trust in physician, and family and social support, were the motivating factors for 
medication adherence. Integrating routine concerning taking regular medicine helped 
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aid medication adherence. In general, these results are consistent with findings from 
other qualitative studies on antihypertensive medication adherence.371, 478, 479  
 
Knowledge and beliefs in hypertension and its management 
In this study, it appeared that knowledge and beliefs in hypertension were inadequate 
among hypertensive women. In response to mild symptoms of high BP, some patients 
stopped or reduced their daily doses without consulting their health care providers. The 
participants who had discontinued medication due to ‘feeling well’ physically, resumed 
taking it again on their own accord when they felt unwell. Patient’s perception that 
hypertension is a temporary condition and antihypertensive medications may no longer 
be required once symptoms disappear, contributed significantly to the non-adherence to 
medications. Other studies reported similar findings of feelings and beliefs of wellness 
concerning adherence.371, 378, 480 Evidence shows that inadequate knowledge of patients 
on their disease management is associated with their poor education level.481 482, 483 In 
the current study, over half of the women (53%) were found to be illiterate; some (30%) 
could sign their names but could not read or write. The lack of education leads to the 
poor conceptual understanding of hypertension as a silent cause of death. In 
developing countries poverty is a significant contributory factor to low levels of 
education.378 
 
In the present study, some patients believed that heart attack risk was God’s will; as a 
result they perceived less need for medication. This misconception was also reported in 
earlier studies.484 Perceived CHD risk appears to be positively correlated with actual 
behaviour change, and with a desire to make risk-reducing behavioural changes.228, 229 
 
In previous studies, one of the reasons for non-adherence given by patients was 
medication side effects, however, none of the hypertensive women in the current study 
perceived this as a cause for MNA. In this study, some perceived that barriers to 
medication adherence were patients’ beliefs and knowledge about hypertension 
treatment, fear of dependence, forgetfulness and being busy, which were consistent 
with the experiences of participants in previous research.478, 485-487  
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Support of family members and family accountability 
Some participants in the study who were non-adherent to their antihypertensive 
medications experienced an adverse attitude from their family members and relatives, 
who regarded the hypertensive person as being responsible for their condition, as 
reported in other studies.378 Family roles or accountability i.e household activities also 
deprived some women by limiting their mobility to access healthcare. This finding was 
also consistent with earlier study.488  
 
Factors related to health care providers 
In this study, there was a lack of communication between patients and health care 
providers concerning the nature of treatment, drug use, medications side effects and 
the consequence of MNA. Very few women reported that their doctors had alerted them 
to the possibility of side-effects at the time of the initial diagnosis. Moreover, a number 
of women stated that they were not made aware by their doctors about the prolonged 
duration of the treatment as well as taking medicines on a regular basis without fail. 
Such inadequate communication and negative attitudes by healthcare providers 
towards patients from low income communities were responsible for poor access to 
satisfactory health care to a number of participating women, as reported in other 
studies.488 
 
Inadequate communication may be due to physicians’ time constraints. Government 
health care facilities are often crowded; and as a result, physicians’ consultation times 
with patients are typically very brief. According to a World Bank report in 2012, the total 
number of physicians per 1000 population in India was 0.7.489 Also, there is no 
appropriate patient followup and referral system in most government health care 
facilities in India.490 In the present study women perceived that trust in a doctor and a 
good patient-doctor relationship facilitated adherence to the treatment. This finding was 
consistent with earlier research.356, 478, 485  
 
Uncontrolled BP was highlighted by non-adherent women in the present study as one of 
the reasons for dissatisfaction with the antihypertensive medications. The literature 
shows that poor hypertension control results in part from failing to intensify or step up 
medication therapy.491 When physicians make out a patient’s global risk of CHD, they 
are more likely to recommend risk-reducing therapies.30 In this study, none of the 
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participating physicians used CHD risk assessment tools. A qualitative study in 
Australia also confirmed that general practitioners do not routinely perform global CVD 
risk assessments of their patients.492 Other studies have shown the suboptimal use of 
such tools in primary practice, varying from 17 to 47%.209-211 Surprisingly, in the present 
study, none of the participating physicians identified their actions in providing care as 
contributing to poor medication adherence and control of BP.  
 
Standard guidelines require physicians to use CHD risk score of hypertensive patients 
which can assist health professionals in communicating CHD risk with their patients 
effectively.188, 189 A Cochrane review reports that, compared to general risk 
communication, personalised communication such as presenting individualised risk 
scores has been related to improved cognitive outcomes related to good health care 
seeking behaviour (i.e. increased knowledge, improved the accuracy of risk perception 
and uptake of primary and secondary CHD prevention programs).231 Although CHD risk 
assessment tools are simple enough to use in clinical settings,5, 493 physicians in this 
study identified some barriers in utilising risk assessment tools including lack of time 
during the consultation, low patient levels of education and lack of helping hands. 
These findings were consistent with previous studies.494, 495 
 
Factors related to health care facilities and service delivery  
According to the perception of the hypertensive women, travel expenses incurred in 
visiting the government health care facilities, long waiting times to procure medicines, 
and the lack of medicines at the hospital dispensary were inhibiting factors for taking 
medications regularly. These findings were also credible in the light of other studies.378, 
387, 487, 488 Moreover, the drugs that were available at the government dispensaries were 
viewed by some women patients with suspicion regarding their effectiveness. Women 
believed that the drugs obtained at private clinics were of a higher quality than the ones 
they were receiving at the government’s health facilities, as reported in other studies.378 
Financial constraints and treatment costs were perceived as barriers to seeking private 
health care in the current study. A study investigating the association between the free 
supply of medication for hypertension and adherence among patients in Ghana found 
that the financial support itself did not act as a reason for improving medication 
adherence and satisfactory BP control.483 In this current study, physicians were aware 
of these obstacles for MNA among women in low-income communities. To improve 
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medication adherence among female patients, they suggested the free supply of quality 
medicines from government health facilities at regular intervals for a longer period. 
 
7.3 Recommendations 
The study results are expected to be helpful in devising strategies to improve perceived 
GCR and antihypertensive medication adherence among women in low-income 
communities to prevent CHD risk burden among them. The recommendations from the 
study can be categorised as: 1) educational and behavioural interventions, 2) 
recommendations for health care providers, 3) recommendations for the health system 
and policy makers. 
 
7.3.1 Educational and behavioural intervention  
At the patient level 
Health care providers should address the hypertensive women’s lack of basic 
knowledge about hypertension and its treatment. In addition to giving appropriate 
treatment to women, physicians need to perform as a competent patient mentor. 
Education should be targeted at the consideration that hypertension is usually 
symptomless with long-term sequela if left untreated. The body will adapt to high BP so 
that the complications will gradually manifest with no specific symptoms.6 
Understanding potential complications of hypertension could be in itself a motivating 
factor for adherence to treatment. For this to happen, patients need to be aware of the 
seriousness of their conditions and all risks involved with it, without being worried 
unnecessarily.392  
 
Educational interventions should recognise women’s apprehension and perceptions 
regarding antihypertensive medications. Clinicians should spend time with women 
patients to allay these fears and explain the benefits and adverse effects of treatment. 
The women need to be educated about the distinctive differences between curing 
hypertension and managing and treating it with medication.371 The safety and side 
effects of long-term use of drugs needs to be discussed, including the information that 
treatment does not cause physical dependence irrespective of the length of treatment. 
They should be made aware of the risk of complications arising from poor adherence to 
treatment. This information is necessary for patient adherence and has been 
acknowledged in many studies.478, 479, 487  
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There is also a need for educational interventions to develop hypertensive women’s 
knowledge about CHD risk factors to improve the accuracy of their perceived global risk 
of CHD. A lack of awareness of cardiac risk factors translates into an underestimation 
of personal cardiac risk. An inaccurate understanding of CHD risk contributes to low 
levels of perceived susceptibility, urgency and self-efficacy in initiating the behavioural 
changes for CHD prevention.264, 496 Educational programs on CHD and risk factor 
control, specially designed for hypertensive patients, should be part of each patient’s 
visit with health educators. Education and counselling should be continuous and 
regular. Aims to increase CHD risk factor knowledge and, more importantly, to link risk 
factor knowledge to risk perception and health-related consequences, are required for 
behaviour change.252 According to the present study results, recently detected 
hypertensive women with inaccurate or low perceived GCR deserve particular attention 
as they are more non-adherent to their antihypertensive medications. 
 
At the family level 
For better family support, adequate information should also be provided to women’s’ 
husbands or children to regarding hypertension and its treatment. Female patients 
usually come to the health clinic with their children and husband. At the health clinic, 
health educators can utilise this opportunity to educate patients’ family members. 
 
At the community level 
A well-planned educational program, especially at the low-income community level is 
also recommended to educate patients, their family members as well as neighbours to 
address misconceptions regarding hypertension and its management. Adherence is 
influenced by community members where patients live.16, 497 Community level education 
has been effectively used in developed countries. The education must be delivered by 
community health educators who are trained and competent as well as those who are 
known, trusted, culturally competent and confident in the language of the target 
community.372 
 
For this purpose, health educators can be selected from each community and need-
based training can be provided to them. In India, under the Revised National 
Tuberculosis Control Programme (RNTCP) if a patient fails to collect their medicine 
form their local DOT (Direct Observation Therapy) centre, then community health 
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workers follow them up by visiting their houses to ensure they take their medications.498 
Likewise, to control blood pressure and future CHD risk among hypertensive women in 
low income communities, the government could take similar proactive measures to train 
community health workers to followup patients at their homes, if necessary, to ensure 
BP control and medication adherence. At the same time, they can also provide them 
with subsidised medicines and arrange for laboratory tests if indicated.  
 
At the national level 
Continued education and awareness at the national level is imperative for all women 
about modifiable CHD risk factors including hypertension, CHD being the leading cause 
of women’s deaths. Dissemination of educational content, screening and early detection 
of CHD risk factors by public health agencies can help to shift women’s attitudes and 
improve outcomes. In this regard, physicians and public health agencies can play an 
important advocacy role to raise awareness at the highest political levels, so that 
government action can result. 
 
7.3.2 Recommendation for health care providers 
Improving communication with patients 
There is a need to enhance health care providers’ communication with patients. Most of 
the women felt that the doctor should spend more time to explain the prescribed 
medication, including its side effects, how long to use medication and the risks 
associated with not continuing the medication. A physician who spends quality time with 
their patients in explaining about the disease and treatment contributes significantly to 
patients’ medication adherence.393, 479, 487 Physicians also need to check on patients’ 
understanding of the information concerning their illness and treatment.371 Effective and 
formal communication skills’ training is required for medical professionals for this 
purpose. Unfortunately such organised training courses for medical professionals are 
not available in India.499 Structured training courses regarding these issues should be 
mandated for medical students in their curriculums to ensure that they are adequately 
skilled, and that patients get the satisfactory care. 
 
Some women indicated that they were not able to discuss their health status freely with 
the doctor since the consultation is typically done in a hurried manner. To overcome the 
time limits of physician consultations in addressing individual needs at primary care, a 
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practical solution could be the integration of group visits into the primary care routinely. 
A group visit brings together a group of patients with similar medical requirements or 
conditions for therapeutic care in an extended appointment with a physician or health 
care provider.500 The meeting of several patients with the primary care physician at the 
same time allows a more efficient use of the physician’s consultation time and better 
interaction with patients, as the group approach may facilitate communication, sharing 
concerns with the doctor and, therefore, adherence.501 Shared medical appointments 
are shown to have a positive impact on tackling misconceptions and concerns about 
hypertension.502, 503 Implementing such a measure however requires consideration of 
possible privacy concerns, although this should not be a significant obstacle as 
hypertension does not carry the same sensitivity concerns as conditions like HIV/AIDS 
or sexually transmitted infections which are associated with stigma and discrimination. 
 
A good relationship between patients and health professionals underpins the treatment 
adherence and may persuade the patient to take care of her health.504, 505 A number of 
hypertensive women expressed their preferences for caring and sympathetic 
physicians. Uncaring communications also contributes to patients’ lower levels of recall 
of the information presented to them by health care providers and increase the risk of 
medication non-adherence (MNA). When patients are satisfied with their medical visits, 
they tend to experience better recall of information.504 Adherence to antihypertensive 
medication treatment will be improved if patients experience positive encounters with 
their health care providers about receiving adequate information to control high BP. 
There is also a need to identify and work collaboratively with patients in addressing the 
reasons related to non-adherence to improve BP control among hypertensive women. 
 
Accurate assessment and effective communication of CHD risk to the patient  
It is vital that physicians, particularly at the primary level of care, should counsel their 
patients about their CHD risk in an individualised manner using a CHD risk assessment 
tool. Lack of communication between women and their health care providers adds to 
the misperceptions of uncontrolled hypertension risk in women. Individualised advice 
about CHD risk should come from a physician. Risk communication interventions have 
positive beneficial effects and are most productive when they include personalising risk 
estimates in the discussion between professional and patient.506 If physicians are not 
using risk assessment tools to assess CHD risk, their estimations will not be accurate. 
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In line with international standard guidelines, indeed, the National Program on 
Prevention and Control of Diabetes, Cardiovascular Diseases and Stroke (NPCDCS) 
program in India requires physicians to use a CHD risk score for accurate assessment 
of patients’ CHD risk.507 
 
It is essential that physicians not only take the opportunity to discuss CHD risk with their 
hypertensive women patients when they can but also give accurate advice and present 
it in a way that the patient understands the risks.223 The simple way of repeatedly 
conveying CHD risk information to a patient has been shown to improve the accuracy of 
risk perception.223  
 
Overcoming clinical inertia for effective blood pressure control 
Inspite of adherence to antihypertensive treatment, one important reason for 
uncontrolled blood pressure is clinical inertia.508 Physicians need to overcome clinical 
inertia to treat hypertensive patients. Despite knowing the patient is not achieving BP 
control, failure to titrate or combine medications represents clinical inertia.509 Physicians 
often lack appropriate aggressiveness in the use of antihypertensive medications, which 
can lead to prescription of suboptimal antihypertensive therapy.295 When physicians can 
evaluate a patient’s global risk of CHD, they are more likely to recommend risk-reducing 
therapies.30 
 
7.3.3 Health system and policy 
At the higher health system and policy levels, the following considerations should be 
taken into account when formulating national strategies to tackle hypertension. 
 
Strategies for early diagnosis and prompt treatment of hypertension 
The higher prevalence of undiagnosed hypertension among the low-income women 
points out the need to devise a comprehensive strategy for early identification and 
prompt treatment of hypertension to prevent its end-stage complications such as CHD; 
thus reducing the burden on health systems and the need for management at tertiary 
care institutes. 
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Recognising MNA as a modifiable risk factor for complications of hypertension 
The NPCDCS should address the issue of non-adherence to medication and recognise 
it as one of the modifiable risk factors for complications of hypertension.477 By 
addressing this risk factor, the quality of life for individuals with hypertension can be 
improved and will reduce the overall CHD morbidity and mortality among women. 
 
Availability of free or low-cost medications 
The health system needs to be strengthened to ensure steady, regular supply of free, 
quality medicines for a longer period to patients at the government health facilities. 
Shorter duration of medication supply or irregular supply of drugs should not be a cause 
for medication non-adherence among hypertensive women. Apart from this, private 
practitioners should prescribe inexpensive but effective medicines to prevent non-
adherence among hypertensive women of low-income communities. 
 
7.4 Future research 
This study generated valuable findings regarding women’s perceived global risk and 
medication adherence characteristics. However, more research is needed to evaluate 
how such results can be used for the control of hypertension as well as prevention of 
CHD at the community level. The development of efficient methods for dealing with 
treatment non-adherence among hypertensive women patients of urban low-income 
communities should be a priority for future research in India.  
 
This study was not able to examine all factors that impact on the CHD risk perceptions 
and adherence to long-term hypertensive therapy among women in low-income 
communities. There is a need for extensive targeted research to identify cultural factors 
and patients’ self-efficacy that could have an effect on these outcomes. Research also 
needs to be conducted to explore the use of multiple adherence assessments, which 
could be equated and combined to obtain a single adherence estimate. 
  
There is also a need to conduct systematic evaluation of psychosocial factors as part of 
a standard cardiovascular risk assessment as per the European Society of Cardiology 
risk assessment guideline recommendations.510  
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7.5 Significance of the study  
This study was significant for several reasons. These are briefly discussed below. 
 
One, there have not been many comprehensive studies done in India that demonstrate 
the probability of major cardiovascular events (heart attack or stroke) among population 
sub-groups using existing CHD risk factors. To this researcher’s knowledge, this is the 
first study that has estimated the prevalence of CHD risk factors among women in a 
low-income urban community in India and classified the population using the NHANES 
non-laboratory-based risk prediction chart. This information is crucially important for 
public health authorities to plan for allocation of health resources to vulnerable 
population sub-groups such as the women in this study. 
 
Two, despite the rising incidence of hypertension in women little is known about the 
level of CHD risk perception and its determinants in hypertensive women in India. It was 
important for this study to assess perceived GCR in hypertensive women and 
investigate its relationship with socio-demographic variables and women’s knowledge of 
CHD risk factors. This information is critical because a CHD risk perception that is not 
appropriate to actual risk may prevent women from accepting and relating to CHD risk 
reduction behaviour.  
 
Three, although non-adherence to antihypertensive treatment causes significant 
problems in CHD prevention, it is inadequately addressed as a public health problem in 
India. Studies aimed at finding out the reasons for non-adherence to hypertensive 
medications have been very few in India.39 Moreover, studies on women, particularly in 
low-income urban areas, are scarce. Therefore, this study, which provides insights into 
the prevalence and determinants of non-adherence to antihypertensive treatment 
among women in a low-income urban area, is a crucial step towards filling the 
knowledge gap. The study findings in this regard can help inform the formulation of 
strategies to address barriers to medication adherence. 
 
Fourth, the present study has focused on specifically vulnerable, neglected and 
disempowered population sub-group in India, namely poor urban women. According to 
India’s constitution, women have equal rights with men. However, because of socio-
cultural fators in a predominantly patriarchal and male dominant society, Indian women 
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suffer enormously. Higher prevalence of hypertension in middle-aged and older women 
compared to men as reported by recent studies in India are related to increasing family 
stress and domestic violence especially common among middle aged women.511 
According to a recent report by the United Nations Population Fund (UNFPA), 
approximate two third of married Indian women are victims of domestic violence and as 
many as 70% of married women in India between the age of 15 and 49 are victims of 
beating or forced sex.511  
 
Economic, social, legal and political fators drastically affect women's health. In the 
current study, several women said that they interrupted their daily dose of 
antihypertensive medications due to financial constraints. In addition, our study finding 
on women’s forgetfulness about medication usage was connected with their 
prioritisation of expected gender-based family roles of females. Stringent domestic 
responsibility negatively affected participating women’s medication adherence by 
restricting their freedom of movement and authority. The role of gender is widely 
recognised to affect women’s health and healthcare in general, including treatment of 
chronic conditions.512 
 
There is a considerable gap between male and female literacy rates in India. According 
to Census 2011, the male literacy rate is 82.14% and the female literacy rate is 
65.46%.102 In the current study, the majority of the research participants were 
uneducated women. The lack of education leads to poor conceptual understanding of 
hypertension, its complication and treatment adherence. In our study, some women 
believed that heart attack risk was God’s will; as a result, they perceived less need for 
medication. These findings suggest a need for interventions that contribute to promoting 
societal norms enhancing women’s status and self-sufficiency within families and 
society. Additionally, Muslim women have distinctive beliefs, attitudes, and perceptions 
that may directly impact healthcare received within a modern health care system.513 In 
this  study, the majority of the women participants were Muslims and some of them 
acknowledged during their interviews that they sometimes interrupted their daily doses 
of medications and follow-up investigations due to religious practices (for example, 
during the month of Ramadan, Muslims are not permitted to eat or drink from dawn until 
dusk). Our study findings highlight the need to understand the religious beliefs of 
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Muslim women to effectively develop interventions and programmes that meet the 
health care requirement of this community.  
 
The lack of knowledge and information about health and health care access can worsen 
women’s health. Women experience particular challenges in accessing cost-effective 
primary care leading to their conditions being undetected, untreated or undertreated. 
Consequently, they suffer avoidable complications that develop from NCD and CHD 
risk factors. Our study reveals the gender factor influence adherence of CHD prevention 
medications. The study findings can be used by the health policy makers in the design 
of effective interventions to prevent the rising burden of CHD among low income urban 
women in India and other South Asian populations. 
 
7.6 Limitations of the study 
This study had several limitations. These are outlined below. 
 
First, for the quantitative survey, the sample size calculation was based on the 
prevalence of hypertension (i.e. 40%) in Indian Women. In addressing the first objective 
of the study: ‘Assess and stratify global CHD risk among women living in a low-income 
urban area of Delhi, India’- the sample size may have been underestimated. Preferably, 
the sample size should have been calculated based on the prevalence of CHD in Indian 
women (i.e. over 10%). Assuming even about 15% prevalence of CHD in Indian women 
would require double of the sample size of the present study undertaken. In the current 
study, this approach (prevalence of hypertension) was taken principally keeping in mind 
the study time, the logistics and available budget for the research. 
 
Second, the data collected from interviews may have been affected by recall and 
courtesy bias. Interviewer bias was another possible limitation due to differences in the 
attitudes of interviewers. However, the researcher believes that this latter bias should 
be minimal as interviewers were not only provided intensive training in data collection 
procedures but also had field experience among the population. 
 
Third, CHD risk estimation in the study was based on a simple application of a 
NHANES non-laboratory-based risk algorithm in line with other recent studies where 
assessment of the CHD risk category was based on self-reported history of diabetes 
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mellitus, whereas studies in India have shown that only 60–70% of diabetics are 
actually aware of their diabetic status.455, 514 Also, the NHANES tool uses a BMI cut-off 
of 25, whereas the revised cut-offs in the Indian population classify BMI 23 as 
overweight. These factors, integral features of the NHANES tool, could have led to 
some degree of inaccurate classification of the CHD risk among the study population.515 
For a novel way of measuring ‘risk’ discordance in cross-sectional studies, powerful risk 
assessment tools such as atherosclerosis imaging techniques can be used to calculate 
the actual burden of disease.516 Otherwise, risk can be measured directly in prospective 
studies. However, laboratory-based CHD risk prediction is inconvenient even in 
developed countries and is too expensive and impractical in low-income countries with 
limited testing facilities.198 
 
A fourth limitation of this study was that self-reported adherence was assessed only 
once. Point prevalence of adherence may not reflect actual adherence to medication(s) 
for a chronic condition such as hypertension.517 Longitudinal assessment may be 
required to differentiate between chronic and occasional non-adherence and related 
barriers that may contribute to the nature of non-adherence. In the present study, the 
decision for one time data collection was due to the limited study time, resources and 
budget.  
 
Also, the study participants were recruited from a low-income urban community within 
Delhi; therefore, the scope of generalisability to the entire population is limited except 
for those patients with a similar background. 
 
7.7 Concluding statement 
There is a high prevalence of hypertension among women in urban low-income areas in 
Delhi, India. The majority of the diagnosed hypertensive study participants who were on 
treatment were found to be inaccurate in their estimation of their global CHD risk 
(GCR), as well as being non-adherent to their antihypertensive treatment. This study 
identified several factors influencing the inaccurate perception of global CHD risk and 
non-adherence to antihypertensive medications. Older age, poor level of CHD risk 
factors knowledge, and diastolic hypertension were associated with inaccurate CHD 
risk perception of hypertensive women. Factors independently associated with 
medication non-adherence among hypertensive women included a shorter duration of 
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the antihypertensive therapy, dissatisfaction with the treatment, not receiving an 
explanation of the treatment regimen and side effects by the physician, low perceived 
GCR and the inaccurate estimation of perceived GCR. The result of the in-depth 
interviews found that barriers to medication adherence to antihypertensive treatment 
included low awareness of the disease condition, an undesirable outlook toward 
antihypertensive medications, and dissatisfaction with the attitude of health care 
providers and health care services provided. 
 
Overall, to improve MNA, the study has specified the need for better communication 
between patients and health care professionals to address women’s lay beliefs about 
hypertension, its treatment and the risk of experiencing CHD events. Primary level 
health care providers are in an excellent position to assess the women’s accuracy of 
risk perception and should consider this factor when providing education and 
counseling interventions. Physicians also need to identify and work collaboratively with 
women to address the barriers related to non-adherence to hypertensive medications to 
improve their BP control. This study result can be used by policy makers at national and 
international levels and health organisations at the local level, in the design of effective 
programs to improve medication adherence to antihypertensive therapy in women living 
in low-income urban communities and to prevent the rising CHD burden among them. 
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Appendix 4:  The Health Belief Model (HBM)397 
 
   Individual perceptions         Modifying factors           Likelihood of Action 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Age, sex, 
ethnicity, 
personality, 
socioeconomic, 
knowledge 
Perceived 
Benefits  
minus  
Perceived 
Barriers 
Perceived 
Susceptibility/ 
Perceived 
Severity 
Perceived 
Threat 
Likelihood of 
Behaviour 
Cues to 
Action 
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Appendix 5: Life style modifications and their effect on 
hypertension6 
KYE: BMI=Body Mass Index; SBP=Systolic Blood Pressure 
 
 
 
 
 
 
 
Modification  Recommendation Approximate SBP 
reduction (range) 
1.Weight reduction Maintain normal body weight   
(BMI 18.5-24.9 kg/m
2
) 
5-20 mmHg/ 10 kg 
weight reduction 
2. Adopt the DASH 
eating plan 
Consume a diet rich in fruits, 
vegetables, and low-fat dairy products 
with a reduced content of saturated 
and total fat 
8-14 mmHg 
3. Dietary sodium 
reduction 
Reduced dietary salt intake to  
<2400mg sodium per day or 
<6000 sodium chloride per day 
2-8 mmHg 
4. Moderation of 
alcohol consumption 
Limit alcohol consumption to no more 
than 2 drinks (e.g. 24 oz bear, 10 oz 
wine or 3 oz 80-proof whiskey) per 
day in men  and to no more than one 
drink per day in women and lighter 
weight persons 
2-4 mmHg 
5. Physical activity Engage  in regular aerobic exercises 
such as brisk walking at least 30 
minutes per day most of the week 
4-9 mmHg 
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Appendix 6: Common antihypertensive medications, their 
mechanism of action and adverse effects518 
Antihypertensive Mechanism of action 
 
Adverse effects 
Angiotensin 
Converting Enzyme 
inhibitors e.g. 
Lisinopril  
Blocking the conversion of angiotensin-1 
to angiotensin-11, a potent 
vasoconstrictor and thereby leading to 
reduced vascular resistance 
Hypotension 
Persistent dry cough 
Angioedema 
Impotence  
Alopecia 
Diuretics:    
Thiazides  
e.g. Bendrofluazide 
 
Increasing fluid loss from the body. 
Inhibiting sodium reabsorption at the 
distal convoluted tubules 
Hyperuricemia (gout) 
Hyponatraemia 
Postural hypotension 
Impotence 
 
Loop Diuretics  
e.g Frusemide  
 
Inhibiting potassium re-absorption at the 
ascending limb of the loop of Henle in 
the renal tubule. 
 
Hypokalemia 
Hyponatraemia 
Hypomagnesaemia 
Hypochloraemic alkalosis 
 
Potassium Sparers  
e.g. Spironolactone 
Antagonising aldosterone and potassium 
sparing diuresis. 
Hyponatremia 
Hyperkalemia 
Gastro-intestinal (GI)tract 
disturbances 
Impotence 
Menstrual irregularities 
 
Beta adrenoceptor 
blockers  
e.g. Atenolol  
Blocking beta-adrenoceptors in the 
heart, peripheral vasculature, pancreas, 
liver, bronchi. 
GI tract disturbances 
Bradycardia 
Hypotension 
Bronchospasm 
Calcium channel 
blockers  
e.g. Amlodipine  
Blocking the inward flow of Ca+ ions 
through active cell membranes 
Bradycardia 
A-V block 
Hypotension 
Sleep disturbances 
Pedal oedema 
Angiotensin II 
receptor antagonists  
e,g. Valsartan  
Blocking angiotensin-II receptors Anemia 
Neutropenia 
Cough 
Headache 
Alpha adrenergic 
blockers  
e.g. Prazosin  
Blocking post-synaptic adrenoceptors 
producing vasodilation. 
Postural hypotension 
Drowsiness 
Palpitations 
Priapism 
Urinary incontinence 
Centrally acting 
drugs  
e.g. Methyldopa  
Stimulating alpha-adrenergic receptors 
in the brain thus inhibiting the 
sympathetic nervous system 
GI tract disturbances 
Stomatitis 
Hypersensitivity- reaction 
Impotence 
Failure of ejaculation 
Decreased libido 
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Appendix 7: Participant Information Sheet 
 
 
International Heath Program 
School of Nursing, Midwifery and Para medicine 
Faculty of Health Science 
Participant Information Sheet 
 
PhD research project title:  
“Perceptions of global coronary heart disease risk, and adherence to anti-
hypertensive treatment among low income urban women in Delhi, India” 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Background: Coronary heart disease (Disease of the Heart/ Heart attack) is one of the 
leading causes of death in India. The causes of heart attack include high blood 
pressure, high cholesterol, diabetes (high blood sugar), tobacco smoking, unhealthy 
diet, obesity, physical inactivity and high tobacco use.  In most cases theses can be 
controlled or treated. Women who have any one of the above causes, especially high 
blood pressure, have a high risk of developing heart disease. Controlling high blood 
pressure will bring down the risk of having heart disease and make the individuals’ life 
better. 
 
Purpose: The purpose of this PhD research study is to find out total coronary heart 
disease risks, perceptions of their total risks, and adherence to treatment 
recommendations of women with high blood pressure living in a low income urban area 
of Delhi, India. 
PhD student and Researcher 
Dr. Lipi Dhar 
International Health Programme, 
School of Nursing, Midwifery& Para medicine, 
Curtin University 
Kent Street, Western Australia 6102 
Email:lipi.dhar@postgrad.curtin.edu.au 
Mobile: +61426239050 
 
Associate supervisor 
Dr. Supreet Kaur 
PhD (nutrition) 
All India Institute of Medical Sciences 
Telephone: +91-9717387654 
Email:supreetaiims@gmail.com 
Principal Investigator 
                    Professor Jaya Earnest 
Building 401, Curtin University 
Kent street, Western Australia 6102 
Telephone: +61 89266 4151 
Email: J.Earnest@curtin.edu.au  
webhttp://www.curtin.edu.au/ 
 
Co-Investigator 
Dr. Mohammed Ali 
Building 401, Curtin University 
Kent street, Western Australia 6102 
Telephone: +61 892663974 
Email: M.Ali@curtin.edu.au  
webhttp://www.curtin.edu.au 
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What the project will involve:  
The first part of the research project involves a personal interview where trained and 
experienced health workers of our research team will ask you questions about your 
age, education, employment, income, tobacco use, drinking habits, fruit and vegetable 
intake, physical activity and medical history of high blood pressure. If you have high 
blood pressure, they will also ask some more specific questions about your health and 
treatment in the last two weeks.  The interview will take about 30-45 minutes.  
 
The second part of the study involves clinical and physical measurements; where 
research staff, after interviewing you, will measure your blood pressure (BP), height, 
weight, waist and hip circumference. These measurements will take approximately 10-
15 minutes.  
 
Possible benefits: 
 Taking part in this study will enable you to know your risks of developing heart 
disease. If you are at such risk, we will refer you to the appropriate health care 
provider at the nearest government hospital (Safdarjung Hospital). They can 
carry out the necessary medical tests, advise you of various ways in which to 
control or reduce your risks of developing heart disease, and prescribe you 
medications that can control your high blood pressure or any complications that 
you may have developed as a result of high blood pressure. 
 Some of the risk factors for heart disease are also common for other health 
conditions such as diabetes, cancers and lung disease. For example, smoking 
can cause both cancers and lung disease, and overweight or sedentary lifestyle 
can make you more likely to develop diabetes and certain cancers. Thus, by 
becoming aware of these risk factors, you can take the appropriate steps to 
manage these risk 
 Your participation in this study will help us understand more about how to 
reduce the risk of heart disease among women living in low income urban 
settlements in Delhi. 
 
Possible Risks: No physical harm or financial burden will result from your involvement 
in this study. 
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Voluntary participation and withdrawal from the project: Please note that your 
participation is voluntary. You are free to refuse to answer any particular question(s) or 
any physical procedures. You have the right to withdraw yourself at any phase of the 
study procedure even after having initially agreed to participate, without prejudice or 
any negative consequences; non participation will not affect your rights/access to usual 
services you receive from the NGO or other health care services. 
 
Confidentiality: Information that is obtained from you will be completely confidential 
and will not be revealed to others. You will not be identified in the resulting report.  
 
Reimbursement: You will not be paid for participating in this study. As a token of 
appreciation for your participation and time, you will be provided a kitchen utensil. 
 
Questions or concerns: You can find out more about the study, if needed, or you have 
any further questions/concerns regarding this study please contact Dr. Lipi Dhar (mobile 
no: +918586893522) or Dr. Supreet Kaur (mobile no: +91-9717387654). If you have 
any ethical concerns regarding the study you can contact:  Dr U V Somayajulu, The 
Secretary, Sigma IRB member secretary, Sigma Research and Consulting Private 
Limited (Contact no: +91 11 4619 5555) 
 
Do you understand what I have just explained or should I explain again? 
 
 
THANK YOU VERY MUCH FOR PARTICIPATING IN THE STUDY 
 
 
This study has been approved by the Curtin University Human Research Ethics Committee (Approval 
Number HR42/2015). The committee is comprised of members of the public, academics, lawyers, 
doctors and pastoral carers. Its main role is to protect participants. If needed, the verification of 
approval can be obtained either by writing to the  Curtin University  Human  Ethics Committee, c/- 
office of research and Development, Curtin University, GPO Box U1987, Perth, 6845 or by telephoning 
92662784 or by emailing hrec@curtin.edu.au 
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Appendix 8: Participant Consent Form                          
                                                                                                                         
          
International Heath Program 
         School of Nursing, Midwifery and Para medicine 
                                                                                                                                                    Faculty of Health Science                                                                                                            
Participant Consent Form 
 
I ………………………………………………………... agree to participate in the research 
project entitled, 
“Perceptions of global coronary heart disease risk, and adherence to anti-
hypertensive treatment among low income urban women in Delhi, India” 
 
In giving my consent I acknowledge that: 
1. I have been given an Information Sheet about this study and have been given 
time to consider whether I want to take part.  
2. The procedures required for the project and the time involved have been 
explained to me, and any questions I have about the project have been 
answered to my satisfaction. 
3. I have been told about the possible advantages and risks of taking part in the 
study and I understand what I am being asked to do.   
4. I know that I do not have to take part in the study and that I can withdraw at any 
time during the study without it any way affecting my medical care.  
5. I understand that my involvement is strictly confidential. I understand that any 
research data gathered from the results of the study may be published however 
no information about me will be used in any way that is identifiable.  
 
-----------------------                   ---------------------------                        -------------------- 
Name of Participant                 Signature of Participant      Date  
 
If participant with low literacy  
(A literate witness must sign) 
I have witnessed the accurate reading of the consent form to the potential participant, 
and the individual has had the opportunity to ask questions. I confirm that the individual 
has given consent freely.  
Name of witness_____________________                Thumb print of participant 
Signature of witness __________________ 
Date _____________  
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Appendix 9: Questionnaire 
                                                                         
International Heath Program 
School of Nursing, Midwifery &Para medicine 
Faculty of Health Science 
Perceptions of global coronary heart disease risk, and adherence to anti-
hypertensive treatment among low income urban women in Delhi, India 
 
No of questionnaire  
 
  
    
Code of the household  
 
  
    
Code of the participant  
 
  
    
 
Full name of the participant 
 
 
 
--------------------------------------- 
 
 
Full address of the household 
 
 
-------------------------------------- 
  
 --------------------------------------- 
 
 
 
Contact number: 
 
 
--------------------------------------- 
 
 
--------------------------------------- 
 
Date 
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Section 1  *Demographic information 
Please provide your response to the following questions by giving Tick (√) in the box or answer in 
space provided 
 
Questions                                            Response  
 
Q1 
 
How old are you in years?  
 
Years                   ---------------------------- 
 
 
Q2 
 
 
What is the highest level of education you 
have completed? 
 
Illeterate   
Can sign only   
Primary school completed                     
(up to year 5) 
 
Completed year 10  
Completed year 12  
College/University completed  
Other (specify)  
Don’t know/ can’t remember  
 
 
Q3 
 
 
What is your religion? 
 
Hindu 
 
 
Muslim  
 
 
Christian 
 
 
Sikh 
 
 
Other     ----------------------------------- 
 
 
 
 
 
Q4 
 
 
 
 
What is your marital status? 
Never married 
 
 
Currently married 
 
 
Separated 
 
 
Divorced 
 
Widowed  
 
 
 
 
 
Q5 
 
 
 
 
Which of the following best describes 
your main work status over the past 12 
months? 
 
 
Government employee 
 
 
Nongovernment employee 
 
 
Self-employed 
 
 
Unskilled/manual labourer 
 
 
Homemaker 
 
 
Retired/ pensioner 
 
 
Unemployed  
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Other   ------------------------------------- 
 
 
 
 
Q6 
 
What were the average earnings of your 
entire house hold (per month) in the past 
12 months? ( in INR) 
 
 
Don’t know 
 
 
Q7 
 
Type of family: 
 
Nuclear  
 
Joint  
 
Others: (specify)------------------------ 
 
 
 
Q8 
 
No. of household members: (specify) 
 
 
---------------------------------------- 
 
Q9 
Does anybody come with you if you need 
clinic visits in generally? 
 
                             Yes                          no                                  
 
 
Q14 
 
Have you ever consumed an 
alcoholic drink such as beer, wine, 
spirits, or other alcohol-based drink 
 
 
Q15 Have you consumed alcohol within the past 30days? 
 
 
 
 
Section 2  Behavioural measurements 
Now I am going to ask you some questions about various health behaviours. This includes things 
like tobacco use, drinking alcohol, eating fruits and vegetables and physical activity**. 
 
Questions                                                                                                                                      
Response 
                                                                                                                                                 Yes               
No 
 
Q10 
 
Did you consume smoked tobacco in the last 
one month? 
 
                                                      
                     
 
Q11 
  
Do you currently use smoked tobacco product 
daily? 
 
 
Q12 
 
Did you consume any smokeless tobacco such 
as gutkha, naswar, khaini, zarda paan, betel in 
the last one month? (use show card) 
 
 
  
 
Q13 
 
Do you currently use smokeless tobacco 
product daily? 
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Q. 16 
Over the last one month 
how often you eat the 
following food items: 
daily, weekly, 
occasionally, or never? 
DAILY 3-4 
TIMES/ 
WEEK 
WEEKLY OCCASIONALLY NEVER 
A 
Cereals 
(Chapati, rice, daliya, suji, 
bajra, jowar, ragi etc.) 
 
  
  
B 
Milk or milk products 
(Curd, chach, lassi, paneer, 
khoa, tea, coffee etc.) 
 
  
  
C 
Pulses or beans 
(All dals like arhar, moong, 
rajma, chana, urad etc)and 
soyabean 
 
  
  
D 
Green leafy vegetables 
(Palak, sarson, cholaiy, soya, 
methi etc.) 
 
  
  
E 
Roots and tubers 
(Potato, sweet pototo, 
colocasia, yam etc) 
 
  
  
F 
Other vegetables 
(All other vegetables 
excluding above mentioned) 
 
  
  
G 
Fruits 
(Apple, grapes, mango, 
guava, banana, melons, 
papaya, berries etc.) 
 
  
  
H Eggs 
 
  
  
I 
Fish 
(Fish and other seafood)  
  
  
J Chicken or meat 
 
  
  
K 
Nuts and oilseed 
(almonds, cashew nut, raisin, 
apricot, peanut etc.) 
 
  
  
L 
Fats and oils  
 
(All fats used in cooking) 
 
  
  
M Sugar and Jaggery 
 
  
  
N 
Fried foods  
(Poori, pakora, samosa, 
cutlet, tikki, parantha, vada, 
kachori, mathri etc.) 
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17. How much salt (in Kg) is consumed in your household in a month?                ----------------- --Kg 
18. How much cooking oil in total is used in your household during last one month?  
(Refined oil (all types), mustard oil, coconut oil, fish oil, Dalda, desi ghee)       -------------------Kg  
 
**Physical activity 
 
Think about all the vigorous activities that you did in the last 7 days.  Vigorous physical activities 
refer to activities that take hard physical effort and make you breathe much harder than normal.  
Think only about those physical activities that you did for at least 10 minutes at a time 
 
Q19a 
 
During the last 7 days, on how many days 
did you do vigorous physical activities like 
heavy lifting, digging, construction work, 
running,or fast bicycling? 
 
Days per week     --------- 
 
None                                          if none  go  
                                                   to Q21a 
 
Q19b 
 
How much time did you spend doing 
vigorous physical activities on one of 
those days? 
 
 
 
Hours per day             ------ 
 
 
 
Minutes per day          ------  
 
Unsure/ don’t know  
 
Refused  
 
 
 
Think about all the moderate activities that you did in the last 7 days.  Moderate activities refer to 
activities that take moderate physical effort and make you breathe somewhat harder than normal.  
Think only about those physical activities that you did for at least 10 minutes at a time 
 
Q20a 
 
During the last 7 days, on how many days 
did you do moderate physical activities  
 
(carrying light loads <20kg, various sports, 
household and domestic chores,carrying 
buckets of water or loads of laundry to and 
from wells - Do not include walking) 
 
 
Days per week       --------- 
 
None                                        if none go 
                                                 to Q22 
 
Q20b 
 
How much time did you usually spend 
doing moderate physical activities on one 
of those days? 
 
 
 
Hours per day           ---------- 
 
 
 
Minutes per day         ---------  
Unsure/ don’t know  
 
Refused   
 
O 
Junk foods 
(Burger, pizza, noodles, 
pasta, patties, French fries 
etc.) 
 
  
  
P Sweets 
(Indian and other sweets)  
  
  
Q 
Aerated drinks 
(Carbonated beverages)  
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Think about the time you spent walking in the last 7 days.  This includes at work and at home, 
walking to travel from place to place, and any other walking that you have done solely for 
recreation, sport, exercise, or leisure. Think only about walking that you did for at least 10 minutes 
at a tim 
 
Q21a 
 
During the last 7 days, on how many days 
 did you walk for at least 10 minutes at a 
time?   
 
 
Days per week             ------------ 
  
None                                                                     
 
 
Q21b 
 
 
 
How much time did you usually spend 
walking on one of those days? 
 
 
Hours per day               ------------  
 
Minutes per day            -----------  
 
 
 
Unsure/ don’t know 
 
 
Refused 
 
 
 
Section 3  *Assessment of heart disease risk factors knowledge 
Please provide your response to the following questions by giving Tick (√) in the box or answer in 
space provided 
Q.22 Which of the following increase the risk of having a heart 
attack?  
Yes No Not sure 
a) Smoking cigarettes    
b) Weight loss    
c) Obesity     
d) Depression    
e) Hypertension    
f) High cholesterol level in the blood    
g) Daily exercise    
h) Stress    
i) Sleeping too much    
j) Diabetes Mellitus    
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Section 4 Assessment of Knowledge of women’s greatest health problem 
and family history of heart attack 
Please provide your response to the following questions by giving Tick (√) in the box or answer in 
space provided 
 
Q23  *Which of the following do you consider the 
greatest health problem for women in India? 
 
AIDS 
Cancer (general) 
Diabetes 
Heart disease/Heart attack 
Drug addiction/Alcoholism 
Obesity  
Hypertension 
Smoking 
Stroke 
Don’t know 
Other 
Please specify---------------------- 
 
 
Q24  **To the best of your knowledge, do you have a 
parent, brother or sister, or child related by blood, who 
has been diagnosed with heart disease by a health care 
provider? 
 
 
Yes 
No  
Don’t know/ Not sure 
Refused 
 
 
 
 
Section 5  History of hypertension and its treatment 
 
 
Q25 
 
Have you ever been told by a doctor or other health worker that you have high blood 
pressure or high BP?                                                            Yes                      No  
                                                                                     
 If no go to Q no 38    
                                                                                       
 
Q26 
 
 
How long have you had high BP?                                  Years ----------------------months 
 
 
Q27 
 
Are you currently on medication for your high BP?            Yes               No                                           
 
                                                                                                                    If no go to Q 38 
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Q28 
 
How long are you on medication for high BP?                          Years____        Months-------- 
 
 
Q29 
 
Is your BP medications helps you feeling better?   
                                                                          Yes                  No          Can’t say 
                                                                                                             
 
Q30 What was your BP the last time you had it measured?                                                                                
 
Systolic ---------- mmofHg                Diastolic ----------mmofHg      Don’t Know  
 
Q31 Are you satisfied with the benefit of your present BP treatment?              
 
                                    Satisfied                     Not satisfied             Can’t say 
 
Q32 Descriptions of the prescribed BP medicine(s): 
   
  
Medicine name 
  
 How many times 
does it need to be 
taken/day 
 
If you feel any side 
effects  
Yes  No  
I. a     
II. b     
III. c     
IV. d     
V. e     
 
 
Q33a Did you miss any of your doses for high BP in the last seven days?    Yes                No  
 
             If yes, which medicine(s) was it? ------------------------------ 
 
 
Q33b.    How many times did you miss your doses in the last seven days?    No.------------------------- 
 
 
Q34.Is your medication(s) for high BP easily available?   
 
                                                                    Yes                  No                      Don’t know 
 
 
Q35.      What is the medicine cost per month for your high BP?   INR------------------------/ month 
 
 
Q36.     Have you ever been advised by your doctor about the following advice?                                 
                  
                                                                                                                   Yes           No                                   
 
 
 
a. To reduce salt intake 
  
 b.  to lose weight 
 
  
 
 
c. to stop tobacco use 
 
 
 
 d. to start or do more exercise 
 
 
  
Q37
.  
If yes, which of the above advice are you currently following?   
please circle one 
a)             b)               c)              d) 
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Q38.        At present do you have any other illness (es)? (For ex: Diabetes, high cholesterol, kidney 
disease, arthritis, lung disease or any other chronic diseases) 
                                                                                                      Yes                              No 
               if yes please specify  the name of the disease   ------------------------------------ 
 
  
Q 39.     Are you currently on medication for the above disease(s)   Yes                     No 
 
 
Q40.      Did your doctor treat your high BP in a friendly and courteous manner?   
 
                                                                     Yes                          No                 Cannot say 
 
 
Q 41.     Did your doctor explain the treatment regimen (i.e: what, when, why, how and how long) 
and likely side effect of medication for your high BP? 
                                                                                                        Yes                       No 
 
 
Q 42.    If yes, are you satisfied with the medication information for high BP provided by your doctor? 
 
                                                                                                            Yes                      No 
 
 
Q 43.       Did your doctor explain the reasons for carrying out any medical tests?                
 
                                                                                                             Yes                      No 
 
 
 
Section 6 Assessments of CHD risk perception and the Illness perception 
 
 
*Assessment of CHD risk perception 
Q 44.   In the next 5 years, how many paisa in a Rupee do you think is your risk for developing heart 
disease compared to a woman of similar age as you? (If you make no changes in your current lifestyle 
such as diet, medication adherence level, physical activity level and tobacco use)  
Make an X on the line 
                                                                                                                        
 
 
         
0 Paisa   10             20         30              40       50Paisa     60          70          80          90       1Rupees    
(No risk)                                                                                                                                  (High risk)  
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**Assessment of The Illness Perception for high blood pressure 
 
Q 45. For the following questions, please circle the number that best corresponds to your views: 
 
I.   
How much does 
high BP affect 
your life? 
 
0--------1--------2------3-----4------ -5--------6--------7-----8--------9-------10 
No affects at all                                                                                     
Severely affect                                                                                                                                                    
my life 
II.  How long do you 
think hypertension 
or high BP will 
continue? 
 
0-------1------ -2-------3-----4--------5--------6--------7----- 8--------9-------10 
A very short time                                                                            Forever 
 
III.  How much control 
do you feel you 
have over your 
high BP 
 
0------ 1-------- 2------3------4---- --5--------6--------7------8-------9--------10 
Absolutely no control                                                                     Extreme  
                                                                                amount control 
IV.  How much do you 
think your 
treatment can help 
your high BP? 
 
0---- --1--------2------3-------4---- --5--------6-------7-------8--------9--------10 
Not at all                                                                                        Extremely 
                                                                                                          Helpful 
V.  How much do you 
experience 
symptoms from 
your high BP 
 
0------ 1-------2-------3-------4-------5--------6-------7-------8--------9-------10 
No symptoms at all                                                                  Many severe  
                                                                                                     symptoms 
VI.  
How concerned 
are you about 
your high BP? 
 
0------1----- --2-------3-------4--------5-------6-------7-------8-------9--------10 
Not at all concerned                                                                   Extremely 
                                                                                                     Concerned 
 
VII.  
How well do you 
feel you 
understand your 
high BP? 
 
0-------1-- ----2--------3-------4-------5-------6--------7------8-- ----9-----10 
Do not understand                                                                   Understand 
                                                                                                 very clearly 
 
VIII.  How much does 
your high BP 
affect you 
emotionally? (e.g. 
does it make you 
angry, scared, 
upset or 
depressed? 
 
0-------1------ 2--------3-- ----4-------5-------6--------7------8------ 9------10 
Not at all affected emotionally                                                     Extremely  
                                                                                     affected emotionally 
 
Please list in rank-order the three most important factors (Stress, lifestyle, heredity) that you 
believe caused your high BP. The most important causes for me:- 
1. __________________________________ 
2. __________________________________ 
3. __________________________________ 
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Section 7: Clinical  and Physical Measurements 
 
 
Clinical Measurements  
 
 
BP 
Reading 
1 
 
Systolic ( mmHg) -------------------- 
 
Diastolic (mmHg)                     -------------------- 
 
BP 
Reading 
2 
 
Systolic ( mmHg) ------------------- 
 
Diastolic (mmHg)                     -------------------- 
 
BP 
Reading 
3 
 
Systolic ( mmHg)------------------- 
 
Diastolic (mmHg)                     -------------------- 
 
Heart rate  ( per minute) 
Reading 1 
 
Reading 2 
 
Reading 3 
 
 
Physical  Measurements 
 
1 
 
Height  
 
Cm                             ------------------- 
 
2 
 
Weight  
 
kg                               ------------------- 
 
3 
 
Waist circumference 
 
Cm                             ------------------- 
 
4 
 
Hip circumference 
 
Cm                             ------------------- 
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Appendix 10: Interviewer Guide- for hypertensive women 
 
                                                                                                                                                                              
 
Perceptions of global coronary heart disease risk, and adherence to anti-
hypertensive treatment among low income urban women in Delhi, India 
Introduction including informed consent 
I want to thank you for taking the time to meet with me today.  
We are undertaking a research project that aims to guide policy planners in the 
development of interventions to reduce heart attack risk among women with 
hypertension living in low income urban area in India.  
I am-----------------------------------------, I would like to talk to you about your high blood 
pressure, its treatment, medication use and your expectation from health care providers 
regarding treatment. You are being invited to participate in this study because your 
participation will help us to understand more about how to reduce the risk of heart 
attack among hypertensive women.  
The interview will take 30 to 60 minutes. I will be taping the session because I don’t 
want to miss any of your comments. Because we’re on tape, please be sure to speak 
up so that we don’t miss your comments. I can assure that full confidentiality and 
anonymity will be maintained and you will not be identified in the resulting report.  
Remember, you don’t have to talk about anything you don’t want to and if you wish you 
can withdraw during the interview at any time without prejudice or any negative 
consequences; non participation will not affect your rights/access to other services/care.   
Are there any questions about what I have just explained? 
Are you willing to participate in this interview? 
_________________            __________________          __________ 
Interviewee                                  Witness                            Date 
 
  
International Heath Program 
     School of Nursing, Midwifery and Para medicine 
Faculty of Health Science 
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Questions: 
The condition 
1. How did you find out that you had high blood pressure? 
2. Has high BP influence your quality of life? 
3. How much do you experience symptoms from your high BP? 
Understanding of risk, own vulnerability to heart disease 
4. What are the risks connected with high BP? 
5. Do you feel you are at risk of heart disease? Why/why not? 
6. What do you do to stay healthy and lower your risk of heart disease? 
7. How do you think other people perceive your condition (health professionals, 
friends, family, people in general) 
Experiences with medication use and adherence pattern 
8. What have you been told by the health care providers about high BP and its 
treatment?  
9. What would you say is the most important to you to control high BP?  
10. What would you say is the least important to you to control high BP? 
11. Are you satisfied with your current treatment? How much do you think your 
medication can help to control your high BP? Why? Why not? 
12. How do you self-administer these prescribed anti-hypertensive medicines/pills 
daily? 
13. What do you think about missing a single drug dose? What do you do so that 
you do not forget to take your medicines 
14. What information have you received about your medicine? Are you satisfied with 
this information (prompt: how it works, side effect, how long to use, drug interaction, what to do 
if forget)  
15. What is your opinion about your prolonged regimen? 
16. What makes it hard, if any, that you encounter to take antihypertensive 
medication as prescribed by your doctor? (Prompt: Not taking problem seriously? 
Forget fullness?  Feeling well?  Drug reaction or side effect?  Too many medicines?  
Medicine not working properly?  Family commitments? Priority? Lack of transport?) 
(Alternatively, next question for women with high medication adherences) 
What are the factors that motivate you to take your antihypertensive medication 
as prescribed by your doctor? (prompt: Belief in therapy? Experience with 
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medication? Supportive family members? Relationship with GP? Previous events? 
Prioritizing health?Time management?) 
Experience with health service 
17. Where do you prefer to go for your treatment?  
Public health facility? Private health practitioners? Please explain why? 
18. Have you received advice from your GP about lowering your risk for heart 
disease? If yes, what did your GP say you should do to lower your risk? 
19. In the past 5 years, has your GP assessed your risk of or tested you for heart 
disease?                    
20. Is there anything you would like to say about the care you have received whilst 
attending the service facility? 
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Appendix 11: Interviewer Guide- for Health care Providers 
                                                                                                                                                    
 
 
Perceptions of global coronary heart disease risk, and adherence to anti-
hypertensive treatment among low income urban women in Delhi, India 
 
Introduction Including Informed Consent 
 
I want to thank you for taking the time to meet with me today. 
We are undertaking a research project that aims to guide policy planners in the 
development of interventions to reduce heart attack risk among women with 
hypertension living in low income urban area in India.  
I am-------------------------, I would like to talk to you about your perception on perceived 
coronary heart disease risk of women with hypertension living in low income urban 
areas and their adherence pattern to antihypertensive treatment recommendations. You 
are being invited to participate in this study because your participation will help us to 
understand more about how to reduce the risk of heart attack among hypertensive 
women.  
 
The interview will take 30 to 60 minutes. I will be taping the session because I don’t 
want to miss any of your comments. Because we are on tape, please be sure to speak 
up so that we don’t miss your comments.  
 
I can assure that full confidentiality and anonymity will be maintained and you will not be 
identified in the resulting report. Remember, you don’t have to talk about anything you 
don’t want to and if you wish, you can withdraw during the interview at any time without 
prejudice. 
Are there any questions about what I have just explained? 
Are you willing to participate in this interview? 
_______________            __________________          __________ 
Interviewee                                  Witness                            Date 
 
 
  International Heath Program 
School of Nursing, Midwifery and Paramedics 
                     Faculty of Health Science 
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Questions: 
1. Think about your women patients, living in low income urban areas, who have a 
more difficult time keeping their blood pressure under control. Do you feel they 
are at risk of heart disease? Why/why not? 
2. Do you think they are aware of their heart disease risk as a consequence of 
uncontrolled hypertension?   
3. Do you use CHD risk prediction chart to assess and communicate CHD risk to 
your patient in your daily practice? 
4. Do you think they view the seriousness of heart disease risk differently than their 
actual risk? 
5. Can you influence how they perceive their risk? Why/why not? 
6. Do you think some of your patients feel that there is nothing they can do to 
prevent downstream effect of hypertension? (prompt: heart attack) 
7. What are the adherent characteristics to your treatment recommendations 
among them? Please explain your experiences. 
8. Do you think some patients hold certain beliefs about hypertension that may 
make affect how they adhere to your treatment recommendations 
9. What factors do you think associated with high level of medication adherence 
among them? 
10. What factors do you think associated with low level of medication adherence in 
women? 
11. What strategies would you recommend to help women better understand how to 
take their medications as recommended? 
12. Do you have sufficient opportunity during routine health service to counsel 
patient about prevention of coronary heart disease? Please explain your 
experiences. 
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Appendix 12: Hindi version of participants’ documents 
 
Participant Information Sheet /प्रतिभागी सूचना पत्र                                            
 
International Heath Program 
School of Nursing, Midwifery and Para medicine 
Faculty of Health Science  
प्रतिभागी सूचना पत्र 
पीएचडी शोध परियोजना शीर्षक 
Perceptions of global coronary heart disease risk, and adherence to anti-
hypertensive treatment among low income urban women in Delhi, India 
       , दिल्ली में, कम आय वाले शहिी मदहलाओ ंमें संपरू्ष कोिोनिी हृिय िोग के खििा की धािर्ाओ ंऔि उच्च 
िक्िचाप वविोधी उपचाि के पालन संबधंधि शोध 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
पषृ्ठभूमि- कोिोनिी हृिय िोग (हृिय िोग / दिल के िौिे) भािि में मौि के प्रमखु कािर्ों में से एक है। 
िस में से नौ ऐसे मामलों में कािकों को तनयतं्रत्रि या इलाज ककया जा सकिा है। इन कािकों में उच्च 
िक्िचाप, उच्च कोलेस्ट्रॉल, मधमेुह, िंबाकू के इस्ट्िेमाल, अस्ट्वास्ट््यकि आहाि, मोटापा, औि शािीरिक 
तनष्क्रियिा शाममल है। ष्क्जन मदहलाओं में इन जोखखम कािकों में से ककसी भी एक उपष्क्स्ट्िि है आमिौि 
पि उच्च िक्िचाप, उन मदहलाओं में हृिय िोग होने का खििा अधधक है। उच्च िक्िचाप का तनयतं्रर् 
भववरय में हृिय िोग के जोखखमको कम किने के मलए मिि कििा हैं। 
 
शोध अध्ययन की प्रकृति और उदे्दश्य: हम भािि में कम आय शहिी के्षत्र में उच्च िक्िचाप के साि जी िही 
मदहलाओ ंके बीच हृिय िोग के खििे को कम किने के उपायों को ववकमसि किने के मलए, नीति तनयोजकों का मागषिशषन  
अनुसंधानकिाा 
डॉ मलवप धि  
पीएचडी छात्र, कदटषन ववश्वववद्यालय 
कें ट स्ट्रीट, 6102 पष्क्श्चमी ऑस्ट्रेमलया 
Mobile no: +61426235090 
Email: lipi.dhar@postgrad.curtin.edu.au 
 
एसोमसएट पयावेक्षक 
     कौि 
पीएचडी (Nutrition) 
अखखल भाििीय आयुववषज्ञान संस्ट्िान 
टेलीफोन +91-9717387654 
Email:supreetaiims@gmail.com 
 
िुख्य पयावेक्षक 
एसोमसएट  प्रोफेसि जया अनेस्ट्ट 
त्रबष्क्ल्डगं 401, कदटषन ववश्वववद्यालय 
कें ट स्ट्रीट, 6102 पष्क्श्चमी ऑस्ट्रेमलया 
टेलीफोन +61 89266 4151                                                         
Email:J.Earnest@curtin.edu.au 
 
सह- पयावेक्षक 
डॉ मोहम्मि अली 
त्रबष्क्ल्डगं 401, कदटषन ववश्वववद्यालय 
कें ट स्ट्रीट, 6102 पष्क्श्चमी ऑस्ट्रेमलया 
 टेलीफोन +61 89266 3974                                                          
Email: M.Ali@curtin.edu.au  
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के उदे्दश्य से इस शोध अध्ययन के उपिम कि िहे हैं । 
 
शोध अध्ययन िें  क्या शामिल होगा: शोध अध्ययन के पहले भाग में, एक व्यष्क्क्िगि साक्षात्काि शाममल हैं। 
अनसुंधान िल के प्रमशक्षक्षि औि अनभुवी स्ट्वास्ट््य कायषकिाष आपको अपनी उम्र, धचककत्सा मशक्षा, िोजगाि, आय, 
िंबाकू के इस्ट्िेमाल, शिाब सेवन, फल औि सष्क्जजयों का सेवन, शािीरिक गतिववधध, उच्च िक्िचाप औि अन्य 
बीमािी का इतिहास के बािे में प्रश्न पछूेंगी। अगि आपको उच्च िक्िचाप है, वे वपछले िो हफ्िों में आपके स्ट्वास्ट््य 
औि उपचाि के बािे में कुछ अधधक ववमशरट प्रश्न पछूेंगी। इस साक्षात्काि में लगभग 30-45 ममनट का समय लगेगा 
। अध्ययन के िसूिे भाग में क्लीतनकल औि शािीरिक माप है; जहा ंअनसुंधान स्ट्टाफ, साक्षात्काि के पिूा होने के 
बाि, आपके िक्िचाप (बीपी) की जांच, औि ऊंचाई, वजन, कमि औि कूल्हे परिधध को नाप किेंगे. इन मापों में 
लगभग 15-20 ममनट लगेंगे । 
 
शोध अध्ययन िें भागीदारी का संभव लाभ:  
 हम आशा किि ेहैं कक इस अनसुधंान परियोजना में आपकी भागीिािी आपको अपने स्ट्वास्ट््य के बािे में 
औि अधधक जागरूक बनने के मलए मिि किेगा। यदि आपको उच्च िक्िचाप है, िो आप अपने िक्िचाप 
को नीचे लाकि एक दिल का िौिा होने के अपने जोखखम को कम कि सकि ेहैं। यदि आवश्यक हो, हम 
आपके  हृिय िोग के जोखखम को िोकने के मलए ििा तनवािर् किने के मलए तनकटिम सिकािी अस्ट्पिाल 
में भेज िेंगे (सफििजंग अस्ट्पिाल)  
 इस अध्ययन में भाग लेने वाले प्रतिभाधग, पहले से दिल की बीमािी होने के खििे में हैं, उन्हें भी मिि 
ममलेगी। यदि आवश्यक हो, हम उन्हें उनके हृिय िोग के जोखखम को कम किने के मलए तनकटिम 
सिकािी अस्ट्पिाल में भेज िेंगे (सफििजंग अस्ट्पिाल) 
 इस शोध अध्ययन में आपकी भागीिािी, भािि में कम आय वाले शहिी के्षत्रों में िहने वाले मदहलाओ ंमें 
हृिय िोग के खििे को कम किने के बािे में अधधक मात्रा में समझने के मलए, हमें मिि किेगा।  
 
शोध अध्ययन िें भागीदारी का संभव खिरा: इस अनसुंधान परियोजना में आपकी भागीिािी से आपको न कोई 
शािीरिक नकुसान या ववत्िीय बोझ होगा । 
 
शोध अध्ययन िें  स्वैच्छिक भागीदारी और वापसी: कृपया ध्यान िें कक आपकी भागीिािी स्ट्वषै्क्च्छक है । आप 
ककसी ववशेर् प्रश्न का  जवाब िेने के मलए या ककसी भी शािीरिक प्रकियाओं को मना किने के मलए स्ट्विंत्र हैं । ककसी 
भी लाभ या नकुसान के त्रबना अनसुंधान  प्रकिया के ककसी भी चिर् में  अपने आपको वापस लेने के का आप का 
अधधकाि है; यहां िक कक, शुरू में भाग लेने के मलए सहमि  होने के बाि भी आप अपने आप को वापस ले सकि ेहैं: 
गिै भागीिािी अन्य स्ट्वास्ट््य सेवाओ ंका उपयोग किने से  आपके अधधकािों को प्रभाववि नहीं किेगा । 
 
गोपनीयिा: आप से प्राप्ि की गई सूचना पिूी ििह से गोपनीय होगी औि िसूिों को नहीं बिाया जाएगा। औि 
ष्क्जसके परिर्ामस्ट्वरूप रिपोटष में आपको पहचान नहीं जा सकिा।  
 
प्रतिपूतिा: इस अध्ययन में भाग लेने के मलए आपको भुगिान नहीं ककया जाएगा। आपकी भागीिािी औि समय के 
मलए सिाहना की तनशानी के रूप में, आपको एक िसोई बिषन उपलजध किाया जाएगा। 
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प्रश्न या च िंायें: अगि आपको अनसुंधान परियोजना के बािे में कुछ औि प्रश्न हैं, कृपया आप 
अनसुंधानकिाषओं के साि संपकष  किें; डॉ मलवप धि(मोबाइल नबंि:+91-8586,893522) या      कौि 
(मोबाइल नबंि:+91-9717387654)  
अगि आपको अध्ययन के बािे में ककसी भी नतैिक धचिंा है, िो आप संपकष  कि सकिे हैं: डॉ य ूवी        , 
मसग्मा आईआिबी सिस्ट्य सधचव, मसग्मा रिसचष एंड कंसष्क्ल्टंग प्राइवेट मलममटेड (संपकष  नबंि: +91 11 4619 
5555) 
 
क्या आप समझ ेजो मैं बस समझाया है? या मुझे कफि से स्ट्परट किना चादहए? 
 
क्या आप इस सचूना पत्र की एक प्रतिमलवप चाहि ेहैं? 
 
 
शोध अध्ययन िें  भाग लेने के मलए बहुि बहुि धन्यवाद 
इस    स             (HR42/2015)         स   )                       स      स                             . 
स             ,         ,      ,        औ                                        .  इस                     
               .            ,          स     ,                         स     , स /    स    औ           
    स,                ,        स U1987,    , 6845    92662784 स                                             
स      hrec@curtin.edu.au 
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Participant Consent Form/ भागीिाि सहमति फॉमष                      
                                                                                                                         
          
International Heath Program 
                                                                                                              School of Nursing, Midwifery and Paramedicine 
Faculty of Health Science                                                                                                          
   स                स      
  ……………………………………………………………                                                
          
 
“Perceptions of global coronary heart disease risk, and adherence to anti-
hypertensive treatment among low income urban women in Delhi, India” 
                     आ                                                  
                                        संबधंधि शोध” 
 
                                    
1.                                                            चाहिी हूूँ    
                                           । 
2.                         ,        आ                                  
                                                सभी                
               । 
3.                                                               ।        
                                  । 
4.                                                    ।                  
                                                        आ            
  िी हूूँ । 
5.      िी                                       ।      िी              
                            आ                                             
                                                         की    गी । 
 
---------------------------                        ------------------------             ------------------------ 
प्रतिभागी का नाम                                                              
           तनरक्षर:  
                                  को                            को             
        ।                  कििा हंू,                                 । 
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Questionnaire 
 
International Heath Program 
School of Nursing, Midwifery & Paramedics 
Faculty of Health Science 
 
Perceptions of global coronary heart disease risk, and adherence to anti-
hypertensive treatment among low income urban women in Delhi, India                             
        दिल्ली में, कम आय वाले शहिी मदहलाओ ंमें संपरू्ष कोिोनिी हृिय िोग के खििा की धािर्ाओ ं
औि उच्च िक्िचाप वविोधी उपचाि के पालन संबधंधि शोध  
 
प्रश्नावली की संख्या  
 
  
    
घि की कोड  
 
  
    
प्रतिभागी का कोड  
 
  
    
 
प्रतिभागी का पिूा नाम 
 
 
--------------------------------------- 
 
 
घि का पिूा पिा 
 
 
-------------------------------------- 
  
 --------------------------------------- 
 
 
 
संपकष  नबंि: 
 
 
 
--------------------------------------- 
 
दिवस       
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भाग 1 * जनसांष्क्ख्यकीय जानकािी 
बॉक्स में दटक (√) िेकि अपने तनम्नमलखखि प्रश्नों के उत्िि प्रिान किें या  दिए गए स्ट्िान में  
मलखs 
 
प्रश्न                                                                    उत्िि             
Q1 आप ककिने साल के हैं? साल          
                    ---------------- 
 
Q2 आपका  मशक्षा का उच्चिम स्ट्िि क्या है? तनिक्षि 
मसफष  साक्षि 
प्रािममक स्ट्कूल (5 वर्ष िक) पिूा 
माध्यममक स्ट्कूल पिेू ककए (10 वर्ष) 
उच्च माध्यममक स्ट्कूल पिेू ककए            
(12 साल) 
कॉलेज / ववश्वववद्यालय पिूा 
पिा नहीं / याि नहीं कि सकिे  
अन्य (तनदिषरटकिे )-------------------- 
 
Q3 आपका धमष क्या है? दहिं ू
मुष्क्स्ट्लम 
ईसाई 
मसख 
अन्य (तनदिषरटकिे )-------------------------- 
 
Q4 अपनी ववैादहक ष्क्स्ट्िति क्या है? कभी नही ंशािी की  
विषमान में शािीशुिा हूूँ  
अलग  
िलाकशुिा  
Q5 तनम्नमलखखि जो वपछले 12 महीनों में अपने 
मुख्य कायष ष्क्स्ट्िति का सबसे अच्छे से वर्षन 
कििा है 
सिकाि कमषचािी   
गिै सिकािी कमषचािी  
स्ट्विोजगाि  
अकुशल / मैनअुल मजििू  
गदृहर्ी  
सेवातनवतृ्ि / पेंशनभोगी  
बेिोजगाि 
अन्य               ---------------- 
 
 
Q6 
 
वपछले 12 महीनों में (प्रति माह) अपने पिेू 
घि के औसि आय क्या िे? (INR में) 
 
रु:   
अतनष्क्श्चि / कोई जवाब नहीं पिा 
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Q7 परिवाि के प्रकाि: मसगंल/ एकल 
संयकु्ि 
अन्य: (तनदिषरट किे ) -------------------- 
 
Q8    घि के सिस्ट्यों की संख्या 
 
 
-------------------------------------------- 
 
 
Q9 
जब आपको डॉक्टि के पास जाने के मलए 
आवश्यकिा होिी है िो ज्यािािि कोई 
आपके साि जािा है? 
   हां                  नहीं                        
                                              
 
Q14 क्या आपने कभी त्रबयि, शिाब, या अन्य 
अल्कोहल पेय के रूप में सेवन ककया है? 
 
Q15 आपने वपछले 30 दिनों के अंिि शिाब का 
सेवन ककया है? 
 
भाग 2 व्यवहाि  माप   
अब मैं आपको ववमभन्न स्ट्वास्ट््य व्यवहाि के बािे में कुछ सवाल पछूने जा िहा हूूँ।  इस में िंबाकू 
के इस्ट्िेमाल, शिाब पीने की, खाने में फल औि सष्क्जजयों औि शािीरिक गतिववधध  की बािें  
शाममल है। 
प्रश्न                                                             हां        नहीं 
                                                                                                                                                                                                                                         
 
Q10 
 
आपने  वपछले एक महीने में धूम्रपान ककया िा ? 
 
                                                   
                     
Q11  आप विषमान में िैतनक धमू्रपान किि ेहैं?  
Q12 आपने वपछले एक महीने में गटुखा, पाउडि, खैनी, जिाष पान, के 
रूप में ककसी भी तनधूषम िंबाकू का उपभोग ककया िा? 
 
 
 
Q13 
 
आप विषमान में िैतनक तनधूषम िंबाकू का उपयोग किि ेहैं? 
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अगले सवाल आपके द्वािा आमिौि पि खाद्य वस्ट्िुओं, फलों औि सष्क्जजयों खाने के बािे में 
पूछिे हैं। 
 
Q.16 
वपछले एक महीने में, ककिनी बाि 
आप तनम्नमलखखि खाद्य वस्ट्िुओं 
खािे हैं? 
िैतनक 2 या 
अधधक बाि 
िैतनक 
एक बाि 
 
साप्िादहक 
 3-5 बाि 
 
साप्िादहक 
 1-2 बाि 
कभी 
कभी 
कभी 
नहीं? 
A 
अनाज ((चपािी, चावल, िमलया, 
सूजी, बाजिा, ज्वाि, िागी आदि)   
  
  
B 
िधू या िधू के उत्पाि (िही, चाच, 
लस्ट्सी, पनीि, खोआ, चाय, कॉफी 
आदि)   
  
  
C 
िाल या सेम ( सभी िालों  जसेै 
अिहि, मूंग, िाजमा, चना, उड़ि आदि) 
औि सोयाबीन   
  
  
D 
(हिी पत्िेिाि सष्क्जजयों) पालक, 
सिसों, cholaiy, सोया, मेिी आदि   
  
  
E 
जड़ें औि कंि (मीठे आल,ू आलू, 
colocasia, ििालू आदि )   
  
  
F 
अन्य सष्क्जजयों (सभी अन्य सष्क्जजयों 
उपयुषक्ि को छोड़कि)   
  
  
G 
फल (सेब, अंगिू, आम, अमरूि, 
केला, ििबजू, पपीिा, जामुन आदि   
  
  
H अंड े   
  
 
 
 
I 
मछली (मछली औि अन्य समुद्री 
भोजन)   
  
  
J धचकन या मांस    
  
 
 
 
K 
नट औि तिलहन (बािाम, काजू, 
ककशममश, खूबानी, मूंगफली आदि)   
  
  
L 
वसा औि िले  
(खाना पकाने में इस्ट्िमेाल कि िहे हैं क 
सभी वसा)   
  
  
M चीनी औि गडु़   
  
   
N 
िले हुए खाद्य पिािष ( (Poori, 
पकोिा, समोसा, कटलेट, दटक्की, पिांठे, 
वड़ा, kachori आदि)   
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शािीरिक गतिववधध 
आपके द्वािा वपछले 7 दिनों में की गई सभी जोििाि गतिववधधयों के बािे में सोचो। जोििाि शािीरिक 
गतिववधधयों का मिलब है कदठन शािीरिक प्रयास औि सामान्य से बहुि कदठन सांस लेन ेकी जरूिि। आप, 
एक बाि में कम से कम 10 ममनट के मलए की गई शािीरिक गतिववधधयों के बािे में सोचो। 
 
Q19a 
 
वपछले 7 दिनों के िौिान, ककिने दिन 
आपने जोििाि शािीरिक गतिववधधयों की 
? (उिाहिर् के मलए: बहुि भािी सामान 
उठाना, खुिाई के काम किना, या िेजी 
से साइककल चलना) 
 
       ककिने दिन -प्रति सप्िाह   ----------                               
               
       कोई नही ं                                                                                                                                             
 
Q19b 
 
आमिौि पि ककिना समय आपने उन दिनों में 
से एक  दिन जोििाि शािीरिक 
गतिववधधयों कि खचष ककया? 
 
घटें प्रति दिन   -------------------- 
 
ममनट प्रति दिन  -------------------                                              
 
बिाने से इनकाकि दिया 
/अतनष्क्श्चि 
आपके द्वािा वपछले 7 दिनों में ककया गया सभी मध्यम गतिववधधयों के बािे में सोचो। मध्यम 
गतिववधधयों का मिलब है मध्यम शािीरिक प्रयास औि सामान्य से कुछ हि िक कदठन सासं लेने 
की जरूिि। आप एक बाि में कम से कम 10 ममनट के मलए ककया गया शािीरिक गतिववधधयों के 
बािे में सोचो। 
O 
जंक फूड (बगषि, वपज्जा, पास्ट्िा, 
नडूल्स, फ्रें च फ्राइज़ आदि)   
  
  
P ममठाई (भाििीय औि अन्य ममठाई)    
  
  
Q 
वातिि पेय ( काबोनेटेड शीिल पेय-
कोक, पेप्सी, सोडा आदि)   
  
  
Q17 
 
ककिना नमक (ककलो में) एक महीने में अपने घि में सेवन ककया जािा है?                        
                                                      
                                                     -------------------ककलोग्राम 
Q18 
 
ककिना खाना पकाने के िेल, कुल में वपछले एक महीने के िौिान अपने घि में इस्ट्िेमाल 
ककया गया िा (रिफाइंड िेल (सभी प्रकाि के), सिसों का िले, नारियल िले, मछली के िेल, 
डालडा, िेसी घी)                                                  
                                                   --------------------- ककलोग्राम 
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Q20a 
 
वपछले 7 दिनों के िौिान, ककिने दिन आपने 
मध्यम शािीरिक गतिववधधयों की ? [उिाहिर् 
के मलए: धीमी साइककल से चलना, ववमभन्न 
खेल, कपड़े धोना, पानी की बाल्टी उठाना 
(पिैल चलना शाममल न किें] 
 
        ककिने दिन -प्रति सप्िाह--------- 
 
            कोई नही ं                                                                                                                                             
 
Q20b 
 
आमिौि पि ककिना समय आपने उन दिनों 
में से एक दिन मध्यम शािीरिक गतिववधधयों 
कि खचष ककया? 
 
      घटें प्रति दिन      ------------ 
            ममनट प्रति दिन -  --------      
अतनष्क्श्चि /  
बिाने इनकाि कि दिया 
वपछले 7 दिनों में चलने पि त्रबिाए गए समय के बािे में सोचो। यह चलना ककसी भी काम, यात्रा, 
औि मनोिंजन, खेल, व्यायाम, या  फुसषि में ककया     है। घि में भी चलना शाममल है। आप एक 
बाि में कम से कम 10 ममनट चलने के बािे में सोचो 
 
Q21a 
 
वपछले 7 दिनों के िौिान, आप एक बाि में 
कम से  
कम 10 ममनट के मलए ककिने दिन चले है?  
 
ककिने दिन -प्रति सप्िाह     ------------ 
 कोई नही ं                                                                                                                                                                                                               
 
 
Q21b 
 
 
ककिना समय आपने आमिौि पि 
उन दिनों में से चलने पि खचष 
ककया? 
  
       घटें प्रति दिन   -----------------                                           
ममनट प्रति दिन     ------------------------------- 
      अतनष्क्श्चि/ बिाने  
      से इनकाि कि दिया 
 
 
भाग 3 हृिय िोग के  खििा कािकों की ज्ञान का मूल्यांकन                             
दिए गए स्ट्िान में दटक (√) िेकि अपनी प्रतिकिया प्रिान किें 
Q.22 तनम्नमलखखि में से कौन सा दिल का िौिा 
होने की खििे को बढा सकिे है? 
 
हां नहीं यकीन नहीं 
a) िंबाकू के इस्ट्िमेाल    
b) वजन में कमी    
c) मोटापा    
d)          
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e) उच्च िक्िचाप    
f) िक्ि में कोलेस्ट्रॉल/ उच्च वसा स्ट्िि    
g) िैतनक व्यायाम    
h) िनाव    
i) बहुि ज्यािा नींि    
j) मधमेुह    
 
 
 
 
भाग 4  मदहला स्ट्वास्ट््य समस्ट्या के बािे में ज्ञान का मूल्यांकन, ििा 
परिवाि में  दिल का िौिा पड़ने का इतिहास 
दिए गए स्ट्िान में दटक (√) िेकि अपनी प्रतिकिया प्रिान किें 
 
 
Q.23 तनम्न में से कौन सा आप मानिे हैं भािि 
में मदहलाओ ंके मलए सबसे बड़ी स्ट्वास्ट््य समस्ट्या 
है? 
 
एड्स 
कैं सि 
मधमेुह/डायत्रबटीज 
दिल की बीमािी/दिल का िौिा 
मािक पिािोंकी लि/शिाबखोिी 
मोटापा  
उच्च िक्िचाप 
िंबाकू के इस्ट्िेमाल 
स्ट्रोक 
पिा नहीं 
अन्य:  
(तनदिषरट किे ) -------------------- 
 
Q.24 क्या आपके परिवाि में ककसी को दिल की 
बीमािी कभी डॉक्टि द्वािा बिाई गई है? (मािा 
वपिा, भाई या बहन, या िक्ि से संबधंधि बच्चे?) 
   
हां  
नहीं 
यकीन नहीं                 
कहने से इनकाि कि दिया                                                                                                                                                                 
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भाग 5  उच्च िक्िचाप औि उसके उपचाि का इतिहास 
 
Q25 
 
एक धचककत्सक या अन्य स्ट्वास्ट््य कायषकिाष द्वािा कभी भी बिाया गया है ककआपको 
उच्च िक्िचाप है? 
                                                 हा          नहीं  
अगि नही,ं Q37 के मलए जाना 
 
Q26 
 
 
 आपके उच्च िक्िचाप से ग्रस्ट्ि ष्क्स्ट्िति की अवधध क्या है?  सालों ----------महीने--------                                                                                               
 
Q27 
 
क्या आप उच्च िक्िचाप के मलए विषमान में िवा पि हैं? 
                                                                                                                                  
हा                  नही 
अगि नही ं  
Q38 के मलए जाना
 
Q28 
 
ककिना समय से आप उच्च िक्िचाप के मलए िवा पि हैं?   सालों ---------------- महीने-------- 
 
Q29 
 
आपके उच्च िक्िचाप की िवाएं आपको बेहिि महससू किने में मिि कििी है? 
                             हा         नहीं        कह नहीं सकि े                                                     
                                                                                                            
Q30 वपछली बाि मापा गया अपने िक्िचाप / बीपी क्या िा? 
Systolic ---------- mmofHg  Diastolic ----------mmofHg    कह नहीं सकि े                                                     
Q31 आप उच्च िक्िचाप के मलए अपने विषमान इलाज के फायिे से सिंुरट हैं? 
                       संिुरट          संिुरट नही ं       कह नही ंसकि े  
 
Q32 तनधाषरिि बीपी िवा का वर्षन:   
  िवाओं के नाम  हि दिन आपको ककिनी 
बाि खाने की जरूिि हैं? 
यदि आपको कोई साइड इफेक्ट लगिा है 
a.     
 
b.     
 
c.     
 
 
Q33a.   क्या आप वपछले साि दिनों में, उच्च िक्िचाप की ककसी भी खुिाक नहीं मलया ?     
                                                  हा               नहीं 
             यदि हां, यह क्या िवा िा? ------------------------------ 
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Q33b. ककिने  बाि आप वपछले साि दिनों में अपनी खुिाक नहीं मलया?   संख्या.---------------- 
 
 
Q34.  उच्च िक्िचाप के मलए आपकी  िवा आसानी से उपलजध है? 
                                             हा       नहीं       कह नही ंसकि े                                                                                           
 
Q35.  आपके उच्च िक्िचाप के मलए प्रति माह धचककत्सा मूल्य क्या है?      रुपये ------------ / महीने 
 
 
Q36a. आपको कभी भी अपने धचककत्सक द्वािा तनम्नमलखखि सलाह के बािे में कहा गया है?                       
                                                        हा         नहीं                                                                                                                                                                
a. नमक का सेवन कम किने 
b. वजन कम किने के मलए  
c. िंबाकू के इस्ट्िेमाल को िोकने के मलए 
d. शुरु किना या अधधक व्यायाम किना 
Q37  यदि हां,आप विषमान में ऊपि की सलाह का क्या अनसुिर् कि िहे हैं कृपया एक सकष ल कि 
िीष्क्जये 
                           a)           b)             c)             d) 
 
Q38.   विषमान में,  आपको कोई   बीमािी है?       हा               नहीं                                           
 (उिाहिर् के मलए: मधुमेह, उच्च कोलेस्ट्रॉल/      , गुिे की बीमािी गदठया, फेफड़ों के िोगों या ककसी भी अन्य पिुाने 
िोगो) यदि हा,ं िोग का नाम तनदिषरट किें      ------------------------------------------- 
 
  
Q39.    आप के द्वािा उल्लेख की गई बीमािी के मलए आप विषमान में िवा पि हैं?       
                                                                                                 हा            नहीं 
 
 
Q40.    क्या आपके धचककत्सक एक िोस्ट्िाना औि ववनम्र ििीके से आप का इलाज कििे हैं? 
                                      हा       नहीं          कह नहीं सकि े                                                                                           
                                                                               
 
Q41.    क्या आपके धचककत्सक अपने उच्च िक्िचाप इलाज के मलए िवा (अिाषि क्या, क्यों, कब, कैसे, 
कब िक), औि िवा के सभंव साइड इफेक्ट की व्याख्या की िी? 
                                                         हा         नहीं        
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Q42. यदि हां, आपके धचककत्सक द्वािा प्रिान की गई िवा की जानकािी के साि आप संिुरट हैं? 
                                                        हा         नहीं           
                                                                                             
 
Q43. क्या आपके अपने धचककत्सक ककसी भी धचककत्सा पिीक्षर् किने के मलए कािर्ों की व्याख्या की 
िी? 
                                                      हा          नहीं 
 
 
भाग 6  स्ट्वयं में दिल का िौिा होने का खििा की धािर्ा औि उच्च 
िक्िचाप से ग्रस्ट्ि होने की धािर्ा 
 
Q 44.   अगले 5 साल में, एक रुपया में ककिना पसैा आपको लगिा है कक आपको दिल की 
बीमािी होने का खििा है अपनी उम्र के बिाबि एक मदहला की िुलना में?  (अगि आप अपने 
विषमान जीवन शलैी में कोई बिलाव नहीं कििे हैं जसेै आहाि, िवा पालन, शािीरिक गतिववधध, 
िंबाकू के इस्ट्िमेाल के रूप में)? 
 
लाइन पि एक एक्स (x) बनाओ 
 
                                                                                                      
 
 
         
0  पसैा  10   20    30      40   50पसैा    60    70       80    9   एक रुपया                                                                                                                                                                                            
कोई खििा नही ं                                                        (खििा उच्च) 
                                                                                                              
 
 
Q 45.     
उच्च िक्िचाप से ग्रस्ट्ि होने की धािर्ा 
तनम्नमलखखि प्रश्नों के मलए, अपने ववचािों से सबसे अच्छा मेल खाने व।ले नबंि पि सकष ल 
किना 
 
I.  उछ  रक्ि ाप आपके जीवन को  ककिना प्रभाववि करिा है? 
   1---------2---------3-------4--------5-------6---------7-------8-------9----------------10  
प्रभाववि नहीं करिा है                                              बरुी िरह  
प्रभाववि करिा है                                             
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II.   आपकी सोच के अनसुाि उच्च िक्िचाप  ककिना समय िक िह सकिा है?                                                                                
 1---------2---------3---------4--------5----------6---------7---------8---------9---------10 
 बहुि ही कम समय                                            हमेशा के मलए                                            
III.  आपके अनसुाि, आपको अपने उच्च िक्िचाप पे ककिना काब ुहै?  
 1---------2---------3---------4--------5----------6---------7----------8--------9---------10 
त्रबल्कुल कोई काब ुनही ं                                          बेहि काब ुहै  
                                                                                                                                                             
IV.  आपके अनसुाि, आपका इलाज उच्च िक्िचाप को ककिना मिि कि सकिा हैं? 
 1-------- 2---------3--------4---------5----------6---------7----------8--------9---------10 
त्रबल्कुल नही ं                                               अत्यिं सहायक                                                      
V.  आप उच्च िक्िचाप के लक्षर्ों को ककस हि िक महससु कििे हैं?                                 
1----------2----------3--------4---------5----------6---------7----------8---------9--------10 
कोई लक्षर् नही ं                                            बहुि गभंीि लक्षर्                                                                                                                          
 
VI.  आप अपने उच्च िक्िचाप के बािे में ककिने धचतंिि हैं?  
1----------2----------3--------4---------5----------6---------7-----------8--------9--------10                                                                                                                                                                                                                                                                                                                                                                                              
धचतंिि नहीं                                                   अत्यिं धचतंिि 
 
VII.  आपको क्या लगिा है आप अपने उच्च िक्िचाप को ककिने समझि े हैं? 
 1--------2----------3---------4--------5----------6---------7------------8--------9--------10 
समझ में नही ंआिा                                           बहुि स्ट्परट रूप  
                                                                                                                                    से समझिा हूूँ                                                       
VIII.  आपका उच्च िक्िचाप आपको भावनात्मक रूप से ककिना प्रभाववि कििा है? (जैसे यह 
आपको, डि, गसु्ट्सा पिेशान किने या उिास कििा है?) 
 1--------2----------3---------4--------5----------6---------7-----------8--------9---------10 
नहीं प्रभाववि कििा हैं                                       बहुि ही भावनात्मक      
                                                     रूप से प्रभाववि कििा हैं                                                                                                                 
IX.  शे्ररटिा िम में अपने उच्च िक्िचाप के िीन महत्वपरू्ष कािर् सूची िें.  
मेिे मलए सबसे महत्वपरू्ष कािर्: - 
1. __________________________________ 
2. __________________________________ 
3. __________________________________ 
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साक्षात्कािकिाष गाइड- उच्च िक्िचाप मदहला प्रतिभाधगयों के साि साक्षात्काि 
Perceptions of global coronary heart disease risk, and adherence to anti-
hypertensive treatment among low income urban women in Delhi, India 
        , दिल्ली में,    आ                                                        
                                   संबधंधि शोध” 
परर य और सूच ि सहिति 
मैं आज मेिे साि ममलने के मलए समय तनकालने के मलए आपको धन्यवाि िेना चाहिी हूूँ । 
 
हम भािि में कम आय शहिी के्षत्र में उच्च िक्िचाप के साि जी िही मदहलाओ ंके बीच हृिय िोग के खििे को कम किने 
के उपायों को ववकमसि किने के मलए, नीति तनयोजकों का मागषिशषन के उदे्दश्य से एक अनसुधंान परियोजना के उपिम 
कि िहे हैं । 
 
मेिा नाम ____________________________ है औि मैं आपकी उच्च िक्िचाप, उसके उपचाि, िवा का उपयोग 
औि इलाज के मलए धचककत्सक से  आपकी उम्मीि के बािे में बाि किना चाहिी हूूँ।  आपको इस अनसुंधान 
परियोजना में भाग लेने के मलए आमंत्रत्रि कि िहे हैं क्योंकक आपकी भागीिािी उच्च िक्िचाप से ग्रस्ट्ि मदहलाओ ंमें 
हृिय िोग के खििे को कम किने के बािे में अधधक मात्रा में समझने मैं हमें मिि किेंगे ।  
 
    साक्षात्कािमें 30 से 60 ममनट लगेंगे । मैं आपकी बाि को रिकॉडष करूूँ गी क्योंकक मैं अपनी दटप्पर्ी के ककसी भी 
दहस्ट्से को छोड़ना नहीं चाहिी हूूँ । मैं ववश्वास दिलािा हूूँ आपके सभी प्रतिकियाओ ंको गोपनीय िखा जाएगा । 
आपकी गमुनामी बनाए िखा जाएगा औि आपको ष्क्जसके परिर्ामस्ट्वरूप रिपोटष में पहचान नहीं की जा सकेगी ।   
कृपया याि िखें, ष्क्जसके बािे में आप बाि नहीं किना चाहि ेहैं आपको उन मामलों की बाि किने की जरूिि नहीं है । 
औि आप चाहें िो ककसी भी लाभ या नकुसान के त्रबना ककसी भी समय पि साक्षात्काि के िौिान आप जा सकि ेहैं; 
गिै भागीिािी अन्य सेवाएं के मलए  आपके अधधकािोंको प्रभाववि नहीं किेगा ।  आपके औि कोई सवाल है ? 
 आप इस साक्षात्काि में भाग लेने के मलए िैयाि हैं ?  
_________________            __________________          __________ 
प्रतिभागी                              गवाह                            तिधि 
प्रश्न: 
 
International Heath Program 
School of Nursing, Midwifery and paramedics 
Faculty of Health Science 
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बीिारी  
1. कैसे पिा चला कक आपको उच्च िक्िचाप हैं? 
2. आप अपने उच्च िक्िचाप के मलए ककसी भी लक्षर् अनभुव किि ेहैं? अगि हाूँ, ककिना? 
3. क्या उच्च िक्िचाप आपके िैतनक जीवन को प्रभाववि ककया है? 
उछ  रक्ि ाप का खिरा, और हृदय रोग के मलए खुद के खिरे को सिझना 
4. उच्च िक्िचाप के साि जुडे़ खििे क्या हैं?  
5. क्या आपको लगिा है आप हृिय िोग/ दिल की बीमािी के खििे में हैं? क्यों / क्यों नहीं? 
6. आप स्ट्वस्ट्ि िहने के मलए औि हृिय िोग का खििा कम किने के मलए क्या किि ेहैं? 
7. आपको क्या लगिा है, अन्य लोग आपकी हालि को ककिना गभंीि समझि ेहैं? (स्ट्वास्ट््य सेवा लोगों, 
ममत्रों, परिवाि, सामान्य लोग) 
दवा का उपयोग और पालन पद्धति के साथ अनुभव 
8. उच्च िक्िचाप औि उसके उपचाि के बािे में स्ट्वास्ट््य सेवा कायषकिाषओ ंद्वािा आपको क्या बिाया गया है? 
आप क्या महसूस कििी हैं यह तनिेश का पालन किना आसान है या नहीं? 
9. आप क्या कहेंगे उच्च िक्िचाप को तनयतं्रत्रि किने के मलए आप के मलए सबसे महत्वपरू्ष क्या है? 
10. आप क्या कहेंगे उच्च िक्िचाप को तनयतं्रत्रि किने के मलए आप के मलए सबसे कम महत्वपूर्ष क्या है? 
11. क्या आप अपने मौजूिा इलाज से संिुरट हैं? आप क्या महससू कििी हैं आपकी िवा आपके उच्च िक्िचाप 
को तनयतं्रत्रि किने में ककिना मिि कििी  हैं? क्यों? क्यों नहीीँ? 
12. कैसे आप िैतनक कायषकलापों में अपने िैतनक िवा को व्यवष्क्स्ट्िि किि ेहैं?  
13. आप िवा की एक खुिाक भलू जाने के बािे में क्या सोचि ेहैं? आप अपनी िवाइयाूँ लेना ना भलूने के मलए 
क्या कििे हैं? 
14. आपको अपनी िवा के बािे में क्या जानकािी ममला है? ( यह कैसे काम कििा है, साइड इफेक्ट, ककिनी िेि िक उपयोग 
किने के मलए, भूल जाने पि क्या किना ) आप इस जानकािी के साि संिरुट हैं? 
15. आपके लंबे समय िक इलाज के बािे में आपकी िाय क्या है? 
16. क्या आपके धचककत्सक द्वािा तनधाषरिि रूप में िवा लेना आपके मलए कदठन बना िेिा है? 
Check list: गंभीििा से समस्ट्या नहीं ले िही है? भूलकि? अच्छा महसूस कििे हैं? ड्रग्स क्या प्रतिकिया है? बहुि सािे िवा? धचककत्सा 
ठीक से काम नहीं कि िहा? पारिवारिक प्रतिबद्धिाओं? प्रािममकिा? परिवहन की कमी? 
 (अगला सवाल उच्च िवा पालन के साि मदहलाओ ंके मलए) 
आपके धचककत्सक द्वािा तनधाषरिि रूप में अपने उच्चिक्ििाबिोधी िवा लेने के मलए  क्या कािर् आपको 
पे्ररिि किने हैं? Check list: धचककत्सा में ववश्वास? िवा के साि अनुभव? सहायक परिवाि के सिस्ट्यों? जीपी के साि रिश्िा? 
वपछली घटनाओं? स्ट्वास्ट््य को प्रािममकिा? समय प्रबंधन? 
स्वास््य सेवा के साथ अनुभव 
17. अपने इलाज के मलए आप कहां जाना पसंि किि ेहैं? लोक स्ट्वास्ट््य सुववधा? प्राइवेट स्ट्वास्ट््य 
धचककत्सकों? कृपया बिाए ंक्यों? 
18. क्या अपने आपकी दिल की बीमािी के खििे को कम किने के बािे में अपने धचककत्सक से सलाह प्राप्ि की 
है? यदि हाूँ, आपके धचककत्सक ने खििे को कम किने के मलए क्या बिाया? 
19. वपछले 5 वर्ों में, आप का धचककत्सक, आपके दिल की बीमािी का खििे का मूल्यांकन ककया है या दिल की 
बीमािी के खििा के मलए आपकी जांच की?  
20. क्या आप स्ट्वास्ट््य सेवाओ ंसे ममली आपकी िेखभाल के बािे में कुछ कहना चाहि ेहो? 
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Appendix 13: Statement of accuracy of Hindi translation 
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Appendix 14: Permission to use copy righted question ‘Brief 
Illness Perception Questionnaire’ 
 
Re: Regarding permission to use Brief Illness Perception Questionnaire (B-IPQ)  
Elizabeth Broadbent <lizbroadbent@me.com>  
Mon 9/02/2015 4:39 PM  
To: Lipi Dhar <lipi.dhar@postgrad.curtin.edu.au>;  
Yes you may use the questionnaire. We already have a Gujarati and a Hindi version. 
See the website www.uib.no/ipq/ 
 
On 9/02/2015, at 7:03 pm, Lipi Dhar <lipi.dhar@postgrad.curtin.edu.au> wrote: 
Dr. Elizabeth Broadbent, 
Department of Psychological Medicine,  
Faculty of Medical and Health Sciences,  
University of Auckland,  
Auckland, New Zealand. 
 
Dear Dr. E. Broadbent, 
I am a PhD student at the International Health Programme in the School of Nursing and 
Midwifery at Curtin University, Perth, Western Australia. My PhD research topic is, 
“Perceptions of global coronary heart disease risk, and adherence to anti-hypertensive 
treatment among low income urban women in Delhi, India”, with Associate Professor 
Jaya Earnest and Dr. Mohammed Ali being my supervisors. 
Part of our study involves carrying out a survey to understand the perceptions of these 
hypertensive women about their illness, and for this the Brief illness Perception 
Questionnaire (B-IPQ) you have developed and validated would be invaluable 
instruments. We would very much appreciate if you can give consent for us to use the 
B-IPQ in our study. This scale will be translated from English into Hindi (local language 
in Delhi) with back translation and resolution of any discrepancies. 
 
Thank you in anticipation. 
 
Kind regards, 
Lipi Dhar 
PhD student 
International Health Programme, 
School of Nursing and Midwifery,  
Faculty of Health Sciences, 
Kent Street, Curtin University, 
Western Australia 6102 
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Author and 
year 
 
Country 
 
Study aim 
 
Sample size (N),  
sampling method 
and  patient 
population
a
 
 
 
%  
women  
 
 
Design and 
data 
collection 
tool 
 
Prevalence 
of MNA (%) 
and % of 
female not 
adhering  
 
 
Factors associated with 
medication adherence/ MNA 
1. Khanam 
et al. 2014 
362
 
 
Bangladesh 
To describe 
hypertension and 
factors affecting 
adherence to 
treatment among 
hypertensive person 
N=29,960 
Stratified two stage 
sampling from the 
population of three 
rural sites 
52.6 Cross-
sectional/ 
Questionnaire 
26 / - Factors associated with MNA: 
male sex (AOR = 1.67; 95% 
CI: 1.42–1.97), hypertension 
diagnosed by unqualified 
providers (AOR = 1.52: 95% 
CI: 1.31–1.77), and patients 
with cardiovascular 
comorbidity (OR = 0.79; 95% 
CI: 0.64–0.97).  
2. Hussain 
et al.  2011 
367
  
 
Bangladesh 
To identify factors 
that influence non-
adherence to 
antihypertensive 
therapy 
N=120  
Simple random 
sampling from 
eligible hypertensive 
patients of inpatient 
departments of a 
medical college and 
a private clinic 
 
30.8 
 
 
 
 
Cross-
sectional / 
Questionnaire 
 85 / - 
 
 
 
 
Factors determining MNA: 
lower level of education (OR = 
6.34; 95% CI: 1.65–24.41), low 
family income (OR = 11.60; 
95% CI: 3.77–35.65), poor 
Knowledge levels regarding 
management and 
consequence of untreated 
hypertension (OR = 24.50; 
95% CI: 6.28–95.58), believes 
and understanding of  disease 
(OR = 12.90; 95% CI: 1.65–
100.63), lack of accompanying 
person to go to the physician 
/hospital (OR= 3.54; 95% CI: 
1.04–11.99), deficiencies in 
information from  service 
provider (OR = 5.16; 95% 
CI%:1.13–23.66) and 
government hospital (OR = 
35.29; 95% CI: 9.76–127.63). 
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3. Barreto et 
al. 2015
389
  
 
Brazil 
To investigate the 
association between 
dissatisfaction with 
the public health 
service and MNA to 
antihypertensive 
therapy. 
N=392 
Hypertensive 
patients were 
selected randomly 
and stratified way 
from eligible patients 
in outpatients of 
primary health care  
 
60 Cross-
sectional/ 
Medicines 
Team 
Questionnaire-
Qualiaids  
(QAM-Q) 
42.1/ - 
 
 
Factors associated with MNA: 
dissatisfaction with the health 
services:  reception service 
(OR=1.6; 95%CI:1.08–2.46; p 
= 0.01), scheduling 
appointment (OR= 2.1; 95% 
CI:1.31–3.29; p = .000), care 
received from the health team 
(OR = 3.8 ; 95 %CI: 2.24–6.45; 
p = .000), solvability of health 
problems (OR= 5.4; 95% CI: 
3.08–9.56; p =0.00), group 
activities (OR = 4.7; 95% CI: 
2.77–7.81; p = .00) and 
physician professional (OR = 
6.5; 95% CI: 3.47–12.3; p = 
.00) 
4. Dosse et 
al. 2009
391
   
 
Brazil 
To determine 
attendance of 
patients to medical 
appointments; the % 
of adherence to 
medication and non-
medication regimens, 
and also identify the 
main reasons of 
hypertensive patients 
report for MNA 
N=68 
Hypertensive 
patients 
registered in the 
outpatient clinic of a 
teaching hospital 
 
64.71 
 
 
Cross-
sectional/ 
Morisky-Green 
test  
86.76 / - 
 
 
Main reasons reported for 
MNA: emotional factor 
(69.1%), could not tell the 
reason (10.3%) and eating 
habits (8.8%). Statistically 
significant relation between 
men and women- reasons 
reported: could not tell the 
reason (p = .006), alcohol 
consumption (p = .013), and 
associated disease (p = .049) 
5. Hu et al.  
2013
386
    
 
China 
To explore how and 
why patients adopt   
home blood pressure 
monitoring (HBPM) 
and  examine the 
association between 
HBPM and 
medication 
adherence. 
 
 
 
N=318  
Eligible hypertensive 
patients from a 
community health 
centre. 
 
71.7 Cross-
sectional/ 
Questionnaire  
38.67/38.59 Risk factors of MNA: 
shorter duration of 
hypertension (AOR = 3.31; 
95% CI: 1.91–5.72; p <.001) 
and less frequency in 
performing BP measurements  
(AOR = 2.33; 95% CI: 1.42–
3.83; p <.001)  
290 
 
6. Nsitou et 
al. 2013
373
   
 
Congo 
To assess the level 
of compliance in 
hypertensive patients 
and identify patients-
related predictors of 
MNA 
N=212  
Eligible hypertensive 
patients of outpatient 
departments of three 
urban hospital 
 
 
 
57.5 
 
 
 
Prospective 
cross-sectional 
/Questionnaire 
32.5/ 27.86 Patient related predictors that 
could predict poor adherence 
by bivariate analysis: no 
Knowledge of the treatment 
(OR = 4.16; 95% CI; 2.25–
7.68; p = <10
-5)
 no knowledge 
of high BP related 
complications (OR = 2.9; 95% 
CI: 1.61–5.29; p = .000), other 
pays for the medicine (OR = 
2.17; 95% CI:1.20–3.92; p = . 
009), no Knowledge of the 
severity of hypertension (OR = 
3.25; 95% CI: 1.5–7.02; p = 
.001), costly medication (OR = 
0.42; 95% CI: 0.23–0.76; p = 
.004), no tensinometer for self-
monitoring (OR = 3.16; 95% 
CI: 1.44–6.92; p = .002) and 
not existence of family 
member to remind to take 
medication (OR = 0.52 ;  95% 
CI: 0.29–0.93) p = .03. After 
adjustment by logistic 
regression, statistically 
significant association with 
poor compliance: knowledge 
of the treatment (p = .0170) 
and perception of the severity 
of complication (p = .0373) 
7. Fina 
Lubaki et al. 
2009
378
   
 
Congo 
To explore reasons 
for MNA among 
patients with 
hypertension 
N=3 focus groups. 
Purposive sampling 
from hypertensive 
patients of a 
cardiovascular clinic 
- Qualitative 
study/ Focus 
group 
interviews 
 Major causes of MNA: 
side effects of the medications, 
lack of information and 
support, difficulty in obtaining 
the medication and fact that 
the disease is mainly silent. 
8.Hareri et 
al. 2014
369
    
 
Ethiopia 
To assess the 
prevalence of 
poor adherence and 
factors associated to 
N=365 
Systematic random 
sampling technique 
to select 
51.2  Cross-
sectional/ 
Semi 
structured 
40.5 
 
 
 
Factors hinder adherence: age 
group (46–55) (AOR=0.30; 
95% CI: 0.142–0.640), lack of 
medication information 
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anti-hypertensive 
treatment 
hypertensive patients 
from a specialized 
hospital 
 
questionnaire (AOR=0.12; 95% CI: 0.258–
0.583) and presence of co-
morbidities (AOR = 0.50; 95% 
CI: 0. 290–0.893). Muslim 
followers were 3 times more 
likely to be adherent to their 
treatment (AOR = 3.20; 95% 
CI:1.69–6.08) 
9. Ali et al. 
 2014
376
   
 
Ethiopia 
To investigate 
antihypertensive 
medication non-
adherence and its 
determinants among 
patients 
N=121 
 All eligible 
hypertensive patients 
from outpatients of 
two referral hospitals 
 
62   Prospective 
cross-sectional 
/ MMAS-8 and 
patients 
medications 
charts 
26.4 
 
 
 
Factors significantly 
associated with MNA: family 
support (AOR = 0.170; 95% 
CI: 0.030–0.905); spot blood 
pressure (AOR = 0.052, 95% 
CI: 0.003–0.242), place of 
patient residence (AOR = 
0.184; 95% CI: 0.024–0.597) 
and hypertension related 
complications (AOR = 21.73; 
95% CI: 1.568–418.42)  
10. Gelaw et 
al. 2013
368
   
 
Ethiopia 
To assess the 
adherence of the 
patients to anti-
hypertensive 
medication and main 
risk factors 
contributing to MNA 
N=91 
Purposive sampling 
was conducted 
among eligible 
hypertensive patients 
who attended a 
referral Hospital 
during the study 
period 
 
56.06 Cross-
sectional / 
Questionnaire 
68.13 
 
 
 
 
 
 
 
Factors contributed to MNA 
significantly: economic 
problems (p =.04), less 
awareness about hypertension 
and its treatment (p <.01), 
social drug use (p <.01). Other 
factors were distance, forget 
fullness, insufficient 
information about the effect of 
MNA and adverse effect 
understanding 
11. Hareri et 
al. 2013
375
   
 
Ethiopia 
To assess 
medication 
adherence and 
factors associated 
with it among 
hypertensive patients 
N=286 
Systematic random 
technique was used 
to selected eligible 
hypertensive patient 
from a specialised 
hospital 
57.7 Cross-
sectional/ 
Questionnaire 
30.8/ 59.1 Respondents less likely to 
adhere to medication who had: 
private business (AOR = 0.28, 
95% CI: 0.130–0.606; p = 
.001) and duration of diagnosis 
of five or more years (AOR = 
0.11; 95% CI: 0.01–0.95; p = 
0.045). Respondents more 
likely to adhere to anti-
hypertensive medication: who 
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were married (AOR = 2.00; 
95% CI: 1.33–6.74), attended 
most of the time private clinic 
to receive health care (AOR = 
6.34; 95% CI: 1.17–33.96), 
treatment duration two to four 
years (AOR = 3.81; 95% CI: 
1.26–11.51) and who were 
motivated (AOR = 2.84; 95% 
CI: 1.47–5.43) 
12. Ambaw 
et al. 2012 
370
   
 
Ethiopia 
To assess 
adherence to 
antihypertensive 
therapy and 
associated factors 
among hypertensive 
patients on follow up 
N=384 
Systematic random 
sampling technique 
to select patients 
from an university 
teaching hospital 
 
63 
 
Cross-
sectional 
study/ 
MMAS 4 
35.4/ 33.5 Variables, significantly 
associated with treatment 
adherence: female  sex (AOR 
= 0.48; 95% CI: 0.28– 
 0.82), knowledgeable about 
hypertension and its treatment 
(AOR =  6.21; 95% CI: 3.22– 
11.97), decreased distance 
from the hospital (AOR = 2.02; 
95% CI: 1.19–3.43), having no 
or one co morbidity (AOR = 
2.5; 95% CI: 1.01–6.21) and 
who have controlled 
hypertension (AOR = 2.93; 
95% CI: 1.73–4.96) 
13. Boima 
et al. 2015 
359
 
 
Ghana and 
Nigeria 
To determine factors 
associated with 
MNA among 
hypertensive patients 
N=357 
All eligible patients 
were recruited from 
four hospitals from 
Ghana and Nigeria 
 
57.5 
 
Cross 
sectional study 
/  
MMAS 8 
66.7/65.4 
 
Adherence showed 
association with concern about 
medications (𝑟 = −0.0347, p = 
.002) and knowledge of 
hypertension (𝑟 = 0.14, p = 
.006). MNA was related with: 
depression (𝑟 = −0.208, p < 
0.001), formal education (p = 
0.001), younger age (p=.000), 
use of herbal preparation (p = 
0.014), insured participants (p 
= 0.032) and poor BP control 
(p = 0.006). 
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14. 
Srivastava 
et al. 2015 
385
   
 
India 
Measuring the 
medication 
adherence using 
validated tools and 
investigating the 
patient, disease, 
medication and 
health care system 
related factors 
affecting adherence 
to antihypertensive 
therapy. 
N=440  
Multistage sampling 
method to select 
eligible hypertensive 
patient from the 
community 
54.7 Cross 
sectional/ 
Self-report and 
MMAS 4 
27/ 30.8 
 
Older people was found to be 
significantly and independently 
associated with better 
adherence. Patients on mono 
therapy were less adherent 
compared to those on two or 
three drugs. Patients who 
were aware of the association 
between certain risk factors for 
hypertension had better 
adherence. 
15. Srikanth 
et al. 2015 
383
   
 
India 
To provide screening 
for hypertension to 
all the elderly and 
assess their 
compliance to 
medication 
N=304 
All elderly individuals 
>60 years residing in 
an urban slum. 
 
66.7 
 
Cross-
sectional/ 
MMAS 8 
38.6/- Pearson’s Chi square test 
showed significant association 
(p<.005) between compliance 
to medication and number of 
drugs consumed. With 
increase in number of drugs to 
be consumed, the adherence 
to medication decreased (p = 
.039) 
16. 
Venkatachal
am et al. 
2015
519
   
 
India 
To study the factors 
determining 
adherence to 
antihypertensive 
medication 
N=473  
All eligible 
hypertensive 
individual willing to 
participate from a 
community. 
 
52.2 Cross-
sectional/ 
MMAS-4 
75.89/ 74.5 The participants exhibited poor 
adherence with lifestyle factors 
like unrestricted meal habits 
(OR = 4.8), alcohol 
consumption (OR = 3.1), 
smoking (OR = 12.9), and salt 
intake >5 gm (OR = 3.6). 
Adherence was significantly 
higher among respondents 
taking only one medication 
and once daily compared with 
individuals taking four types of 
medication and as frequent as 
three or more times a day. 
17. Kumar 
et al. 2014 
477
   
 
India 
To assess the level 
of adherence and the 
factors influencing 
adherence among 
hypertensive patients 
N=120 
All eligible 
consenting  
hypertensive patients 
attending medicine 
36.7 
 
 
Cross-
sectional / 
MMAS 8 
45.8/ 50 
 
Factors significantly 
associated with good 
adherence: absence of side-
effects (OR = 0.1; 95% CI: 
0.03–0.52; p = .003) 
294 
 
outpatient 
department and 
peripheral outreach 
clinic of a medical 
college 
availability of free medication 
(OR= 0.4; 95%CI: 0.2–0.9; p = 
.030) and regular checkup of 
BP (OR = 0.5; 95% CI: 0.2–
0.9; p = 0.034) 
18. Rao et 
al. 2014
520
    
 
India 
To assess 
adherence to 
antihypertensive 
therapy and to 
assess associated 
factors for adherence 
among hypertensive 
patients 
N=220 
Eligible hypertensive 
patient residing in an 
urban slum 
settlement 
 
59.1 
 
Cross-
sectional / 
MMAS 4 
39.4/ 35.8 Factors contributed to 
treatment adherence 
significantly(p<.05): patient 
>60 years of age (67.2%) 
(OR = 1.91; 95% CI: 3.40-
1.08), married people (84.7%) 
(OR = 3.45; 95% CI: 8.43–
1.37); nonsmokers (74.8%) 
(OR = 3.83; 95% CI: 7.01–
2.12), non-tobacco users 
(68.9%) (OR = 6.36; 95% 
CI:14.63–2.93) and people 
consuming 1 tablet a day 
(67.7%) (OR = 2.26; 95% CI: 
4.11–1.26) 
19. 
Nagarkar et 
al. 2013
357
   
 
India 
To translate 
and validate MMAS-
8 and to determine 
association between 
patient 
characteristics and 
medicine adherence 
in hypertension 
N=174  
Randomly selected 
hypertensive patients 
attending medicine 
outpatients of a 
district hospital 
 
44.87 
 
Cross-
sectional / 
MMAS 8 
76.5 / 70.7 MNA was significantly 
associated with patients 
(p<.05): age less than 57 year  
(OR = 3.348;  95% CI: 1.665–
6.732), living in nuclear family 
setup (OR = 2.670; 95% CI: 
1.378–5.175) and not  
experience of symptoms of 
hypertension (OR = 0.414; 
95% CI: 0.192–0.892)  
20. Ahmad, 
S. 2013
379
   
 
India 
 
To assess the level 
of adherence and 
associated factors to 
antihypertensive 
treatment 
N=334  
Purposive sampling 
of hypertensive 
patients reporting to 
a urban health and 
training centre 
 
41.6 
 
Cross-
sectional/ 
MMAS 8 
42.8 / 53.95 Good adherence to treatment 
was present more among 
males (OR = 1.25) and in 
those patients who were either 
receiving one medicine per 
day (OR = 4.27), or taking 
medicine once a day (OR = 
1.96). Poor adherence to anti-
hypertensive treatment was 
seen in patients with the habit 
295 
 
of alcohol consumption (OR = 
0.52), tobacco chewing (OR = 
0.73) and smoking (OR = 0.40) 
21. 
Bhandari,S. 
2011
10
   
 
India 
To determine the 
prevalence and 
predictors of 
adherence 
to modern 
antihypertensive 
pharmacotherapy 
N=348 
All the eligible  
hypertensive patients 
living in a selected 
urban slum 
 
 68 
 
Cross-
sectional/ 
Questionnaire 
27 / 28.7  
 
Factors significantly 
associated with adherence 
(p<.05): duration of 
hypertension for ≥5 years 
(AOR = 2.98; 95% CI:1.73-
5.14), hypertension was 
detected during checkups for 
conditions related to 
hypertension (AOR = 2.35; 
95% CI: 1.25–4.39), living with 
≤4 family members  (AOR = 
2.01; 95% CI: 1.52–3.50), 
family income of ≥3000 rupees 
(AOR = 2.56; 95% CI: 1.47 –
4.45), getting free drugs (AOR 
= 4.16: 95% CI:1.36–12.69), 
perceived BP under control 
(AOR = 2.23: 95% CI: 1.17–
4.26) and  satisfied with 
current treatment (AOR = 3.77; 
95%CI:1.32–10.76) 
22. Dennis 
et al. 2010
39
   
 
India 
To assess 
medication 
adherence in 
hypertensive patients 
and to identify the 
main barriers 
associated with 
medication 
adherence. 
N=608 
Randomly selected 
hypertensive patients 
from the outpatient of 
internal medicine  
department of a 
teaching hospital 
 
48.68 
 
 
Cross-
sectional / 
BMQ and by 
detailed 
patient 
interviews 
49.67/- 
 
 
 
Belief barrier was reported in 
39.14% patients. Access 
barrier and recall barrier were 
reported by 82.57% and 
62.17%, respectively. 78.62% 
of patients reported that it is 
difficult to pay for the 
medication and 54.93% 
indicated that it is difficult to 
get a refill timely. Logistic 
regression analysis showed 
that the education level was 
not contributing to non-
adherence (OR = 0.75, 95% 
CI: 0.64–0.87). However, 
duration of hypertension, (p = 
296 
 
.031) showed a significant 
contributory effect to MNA (p = 
.031). Chi square analysis 
showed no relation between 
the adherence pattern and the 
number of antihypertensive 
medications being prescribed. 
23. Praveen 
et al. 2010 
363
   
 
India 
To determine factors 
that are associated 
with non-adherence 
to antihypertensive 
treatment 
N=804 
All eligible 
hypertensive patient 
from the outpatients 
of General Medicine 
department of a 
tertiary care hospital 
 
70% 
 
Cross-
sectional/ 
Questionnaire 
29/ 34.5 
 
Factors independently 
associated with MNA (p<.05): 
female sex (OR = 2.95, 95% 
CI: 1.39–6.24), not understand 
drug regimen well (OR = 4.06, 
95% CI:1.01–16.32), 
affordability to only some/none 
of prescribed drugs (OR =3.70, 
95% CI: 1.8–7.59) and longer 
time since last visit to a health 
care facility (OR = 7.26; 95% 
CI: 2.65–19.86) 
24. 
Kusuma, 
Y.S. 2010
387
    
 
India 
To gain insights into 
the perceptions of 
socio-economically 
disadvantaged 
migrants in Delhi 
regarding treatment 
seeking behaviour 
for hypertension 
N=14 key informants 
and 3 focus groups. 
Purposive sampling 
from a community 
- Qualitative / 
In-depth 
interviews with 
key informants 
and focus 
group 
discussions 
- Treatment seeking for 
hypertension was not 
adequate. Several patient- and 
provider-related issues have 
emerged as barriers in 
treatment seeking and 
adherence. 
25. Kamran 
et al. 2014 
380
    
 
Iran 
To determine the 
factors of adherence 
to hypertension 
medication based on 
HBM 
N=671  
Two stage random 
sampling methods to 
select eligible 
hypertensive patients 
from rural health care 
centres   
74.81 Cross-
sectional/ 
MMAS 4 
76 / 75.3 MNA was significantly 
associated with: unrestricted 
meal habits (OR = 4.8; 95% 
CI: 37.5), smoking (OR = 1.9; 
95% CI: 1.3–2.9) and salt 
intake >5 g (OR = 19.7; 95% 
CI: 12.2–31.7). Respondents 
with regular physical activity 
and non-smokers were more 
adherent to medication when 
compared to respondents with 
sedentary lifestyle and 
smoking (p <.01). 
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26. Ismael 
et al. 2015 
364
   
 
Iraq 
To assess the level 
of compliance to 
treatment and 
identified factors 
contributing to poor 
compliance 
N=200 
Purposive sampling 
was used to select 
participants among 
all eligible 
hypertensive patients 
in a general teaching 
hospital 
 
34 
 
 
Cross-
sectional/ 
Questionnaire  
55 / 61.7 Major factor for MNA was 
forgetfulness. There was a 
significant association 
between high level of 
adherence and age group of 
>65 years (p = .000), male 
gender (p = .003), no formal 
education (p = .000), and 
duration of hypertension less 
than 10 years (p = .003). Also 
there was significant relation 
between adherence and 
benefit of treatment, barrier of 
treatment, severity of disease, 
susceptibility to complication 
and reminder by advice from 
nurses (strongest predictor) 
27. Shima et 
al. 2013
381
   
 
Malaysia 
To explore patients’ 
experiences with 
their illnesses and 
the reasons which 
influenced them in 
not following 
hypertensive care 
recommendations 
N=2 
Purposive sampling 
from patients 
attending follow-up at 
primary health clinics 
56 Qualitative 
study/ One to 
one  in-depth 
interviews 
 
- 
Most of the reasons given for 
not taking antihypertensive 
medication were side effects or 
fear of the side effects of 
antihypertensive medication, 
patients’ attitudes, lack of 
information from health care 
professionals and insufficient 
social support  
28. Ramli et 
al. 2012
384
   
 
Malaysia 
To assess 
adherence to 
medications by adult 
patients undergoing 
hypertensive 
treatment 
N=653 
Random sampling 
method to select 
hypertensive patients 
from 7 primary health 
care clinics 
62.8 
 
Cross-
sectional 
multicentre 
study / The 
Hill-Bone 
Adherence to 
Blood 
Pressure 
Therapy Scale 
and MMAS-8 
46.6 / 43.7  
 
Female patients were found to 
be more likely to be adherent 
than male patients (OR = 1.38; 
95% CI: 1.00–1.90; p = .05]). 
Patients from the Malay (OR = 
1.68; 95% CI: 1.03–2.73) and 
Chinese ethnic group (OR = 
2.64; 95% CI: 1.52–4.58) were 
also more likely to adhere, 
compared to patients from the 
Indian subgroups. The mean 
number of drugs that patients 
were taking was higher in non-
adherers (3.67) than in 
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adherers (3.17 [t = 3.81, df = 
651; p = .001]) 
29. Turki.et 
al. 2009
521
    
 
Malaysia 
To identify patients 
with poor adherence 
to antihypertensive 
therapy and compare 
the levels of 
adherence with daily 
dose frequency of 
antihypertensive 
therapy 
N=518 
Convenience 
sampling   to select 
hypertensive patients 
from a clinic of a 
general hospital 
 
42.6 
 
Cross-
sectional/ 
MMAS 4 
51.3 
 
 
Study found a significant 
relationship between daily 
dose frequency groups and 
adherence at level p< .001. It 
shows that that who have 
more daily dose frequency, will 
show higher level of 
adherence towards 
antihypertensive medications 
30. 
Bhandari et 
al 2015
366
    
 
 
Nepal 
To explore the extent 
of adherence 
towards prescribed 
antihypertensive 
treatment and to 
elucidate the factors 
of MNA 
N=154 
Participants were 
selected from all the 
diagnosed 
hypertensive patients 
of a selected 
community by simple 
random sampling 
method 
 
 Cross-
sectional/ 
MMAS 4 
43.5/ 54.2 Predictors of MNA by logistic 
regression analysis (p<.05): 
Illiteracy (OR = 5.34; 95% CI: 
1.23-23), price of medicine  
(OR = 5.14;  95% CI: 1.1–
23.9), missed medicine due to 
cost (OR = 0.143; 95% CI: 
0.02–0.78), no family history of 
hypertension (OR = 4.46, 95% 
CI: 1.21–16.4), irregular follow 
up (OR = 6.39: 95% CI:1.22–
33.3) and more than one pills 
per day (OR = 5.33; 95% CI: 
1.19–23.7). 
31.Olowook
ere et al. 
2015
377
   
 
Nigeria 
To assess perceived 
family support and 
other factors that 
determine 
medication 
adherence among 
hypertensive patients 
N=420 
Adult patients on 
antihypertensive 
medications 
attending a medical 
outpatient clinic 
51 Cross-
sectional/ 
Questionnaire 
39 Common reasons for MNA 
include belief of cure (43%), 
high cost of treatment (33%), 
and the experiencing of side 
effects (27%). Patients with 
good family support had better 
adherence compared to those 
with poor family support (p 
<.05). MNA was higher among 
newly diagnosed hypertensive 
patients, those with higher pill 
burden, and those without 
family support (p <.05). 
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32. 
Campbell et 
al. 2014
374
   
 
Nigeria 
To assess 
compliance and 
knowledge of 
antihypertensive 
therapy amongst 
outpatients attending 
a hypertensive clinic 
N=262  
Multistage sampling 
technique was used 
to select the eligible 
hypertensive patients 
from outpatients of a 
hypertension clinic 
 
 52.6 
 
Cross-
sectional/ 
Morisky Green 
74.81/ 78.83  The significant reasons for 
MNA (p<.05): forgetfulness 
(OR = 14.8; 95% CI: 3.9–
54.8); ran out of prescribed 
drugs (OR = 1.3; 95% CI: 0.1–
0.4); avoiding side effects (OR 
= 3.0; 95% CI: 1.4–6.7) and 
absence of symptoms (OR = 
3.3; 95% CI: 1.3–8.0). Factors  
significantly associated with 
adherence to antihypertensive 
treatment: religion (X2 = 
5.0068, df = 1, p = .025) and 
knowledge (X2 = 6.6848; df = 
1, p =.0097; F-exact test= 
0.0184)  
33. Odusola 
et al 2014
372
   
 
Nigeria 
To explore patients 
views on 
hypertension 
management. 
N=40 
Purposive sampling 
from a rural primary 
health care 
60 Qualitative 
design/ 
Individual 
interview 
- Facilitators of medication 
adherence included 
affordability of care (through 
health insurance), trust in 
orthodox ‘western’ medicines, 
trust in doctor, dreaded 
dangers of hypertension, and 
use of prayer to support 
efficacy of pills. Inhibitors of 
medication adherence 
included inconvenient clinic 
operating hours, long waiting 
times, under-dispensing of 
prescriptions, side-effects of 
pills, faith motivated changes 
of medication regimen, herbal 
supplementation/substitution 
of pills, and ignorance that 
regular use is needed. Local 
practices and norms were 
identified as important 
inhibitors to the uptake of 
healthier behaviors. 
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34. Osamor 
et al.2011 
356
   
 
Nigeria 
To investigate the 
factors associate 
with self-reported 
compliance among 
hypertensive 
subjects in a poor 
urban community 
N=440 and 
8 focus groups. 
Consecutive 
sampling method 
was used to recruit 
participants from a 
list of hypertensive 
patients of a poor 
urban community. A 
purposive sampling 
technique was used 
for FGD from 
hypertensive 
patients. 
 
65.2 
 
 
Survey and 
qualitative 
interviews / 
Questionnaire  
41.5 
 
 
 
 
Factors associated with 
adherence: regular clinic 
attendance (p<.0001); not 
using non-western prescription 
medication (p<.00l); support 
from family members (p = 
.038); friends who were 
concerned about the 
respondent's hypertension 
(p<.0001) and helpful in 
reminding the respondent 
about taking medication 
(p<.0001). Beliefs about cause 
of hypertension were not 
associated with compliance (p 
= -0.090). Reasons given for 
MNA in focus group 
discussion: feeling better, 
forget to take medication and 
cost. 
35. 
Atulomah et 
al. 2010
522
   
 
Nigeria 
To collect information 
about perceived 
severity and threat to 
life from poor 
treatment response 
and medication 
adherence in 
hypertensive people 
N=130    
Systematic random 
technique was used 
to select 
hypertensive patients 
from a teaching 
hospital 
 
45.6 
 
Cross-
sectional/ 
Questionnaire 
30.7 
 
Bivariate analysis revealed 
that perception of severity of 
hypertension complications 
from poor treatment and threat 
to life positively correlated with 
medication adherence (r= 
0.46; p<.0001). 
36. Bilal et 
al. 2015
361
   
 
Pakistan 
 
To determine the 
frequency and 
factors associated 
with non-compliance 
to anti-hypertensive 
medications 
N=113 
Purposive sampling 
was conducted 
among all the eligible 
hypertensive patients 
of inpatients 
department of a 
specialized Hospital 
 
64 Cross-
sectional / 
Questionnaire 
68.14/ 58.33 
 
MNA was found to be 
associated with: male gender  
p = .008; less monthly income 
p = .046; unemployed persons 
(p = .002); duration of 
hypertension <5 years (p = 
.03);  mono therapy and di-
therapy (p = .02) and who paid 
themselves for their drugs (p = 
.06) 
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37. Saleem 
et al. 2012 
371
   
 
Pakistan 
To explore the 
perceptions and 
experiences of 
hypertensive patients 
toward medication 
use 
and adherence. 
N=16 
Purposive sampling 
among hypertensive 
patients of a 
government hospital 
25 Qualitative 
study / One to 
one in-depth 
interviews 
- The majority of the patients 
carried specific unrealistic 
beliefs regarding the long-term 
use of medication; yet these 
beliefs were heavily accepted 
and practiced by the society. 
Physician’s attitude, patient’s 
past experiences, and 
knowledge related to 
hypertension were noted as 
major contributing factors thus 
resulting in non-adherence to 
prescribed therapy. 
38. Saleem 
et al. 2011 
523
   
 
Pakistan 
To evaluate the 
association between 
patient’s knowledge 
of hypertension 
management and 
medication 
adherence 
N=385 
Eligible hypertensive 
patients from two 
tertiary care hospitals 
31.2 
 
Cross-
sectional  
observational/ 
Drug Attitude 
Inventory    
(DAI-10) 
64.7 Study shows an inverse 
association between 
knowledge scores of 
hypertension and adherence 
level. Correlation coefficient 
between total score of 
knowledge of hypertension 
and total adherence was – 
0.170 (p<.001) 
39. Hashmi 
et al.2007 
388
   
 
Pakistan 
To measure 
adherence to 
antihypertensive 
therapy and to 
investigate the 
factors associated 
with adherence in the 
studied population 
N=460 
Randomly selected 
participants from 
eligible hypertensive 
patients of two 
tertiary care hospitals 
 
54.6 
 
Cross-
sectional/ 
MMAS4 and 
Self-report on 
Pill taken 
23 / 23.8 Factors significantly improved 
adherence (univariate 
analyses) were increasing 
age, better awareness, 
increasing number of pills 
prescribed (by multivariate 
analyses): number of drugs 
that a patient was taking (p = 
.02) and  
whether he/she was taking 
medication regularly or only for 
symptomatic relief (p = .00001) 
40. Al-
Ramahi et 
al. 2015 
358
   
 
Palestine 
To assess 
adherence  to 
antihypertensive 
therapy and to 
investigate the effect 
of a range of 
N=450  
Simple random 
sample from patients 
visiting outpatient 
clinics of 
governmental 
 56.2 
 
Cross-
sectional/ 
MMAS8 
54.2/ 54.2 Factors  significantly 
associated with MNA: younger 
age (<45 years) ( AOR = 1), 
living in a village ( AOR = 1), 
forgetfulness (AOR= 5.12; 
95% CI: 3.12–8.41), 
302 
 
demographic and 
psychosocial 
variables on 
medication 
adherence. 
primary healthcare 
centers in addition to 
a group of private 
clinics and 
pharmacies 
 
dissatisfaction with treatment  
(AOR = 2.93; 95 %CI: 1.22–
7.02), side effects (AOR = 
4.58; 95% CI: 1.87–11.25), 
fear of getting used to 
medication (AOR = 8.00; 95% 
CI: 2.44–26.19) and evaluating 
health status as very good, 
good or poor (AOR = 1). Other 
factors (by univariate analysis): 
having lower income (p = 
.035); receiving a higher 
number of antihypertensive 
tablets (p = .001); a higher 
dosing frequency (p = <.0001) 
and having no other chronic 
disease (p = .009).  
41. Zyoud et 
al. 2013
524
    
 
Palestine 
To investigate factors 
associated with 
adherence to 
antihypertensive 
therapy among 
hypertensive patients 
and assess the 
relationship between 
medication 
adherence and 
treatment satisfaction 
N=410 
Convenient sampling 
of hypertensive 
patients from 
outpatients of a clinic 
and a hospital 
52% 
 
MMAS-8 36.8 
 
After adjusting the covariates 
using 
multiple regression, global 
treatment satisfaction was 
statistically significantly (p = 
0.001) associated with 
medication adherence (R = 
0.373; adjusted R2 = 0.122; F 
= 8.107; df = 8; p <.001) 
42. Lalic et 
al. 2013
360
    
 
Serbia 
To evaluate the 
degree of adherence 
in hypertensive 
patients and to study 
risk factors affecting 
adherence 
and the effects of 
non-adherence on 
BP 
N=170 
All eligible 
hypertensive patients 
treated in a primary 
health care 
outpatients 
 
65.9 Cross-
sectional/ 
MMAS 8 
25.88 
 
 
 
 
 
MNA was associated with 
elderly patients, longer 
duration of therapy and side 
effects of drugs. (p<0.01). 
Patients <65 years were found 
to be more likely to adhere to 
their medication regimen, 
compared to elderly patients 
(χ2 = 21.3; p<0.01; OR = 6.0; 
95% CI: 2.76–13.04). BP 
values over 140/90 mmHg 
were reported in 59.1% of 
303 
 
MNA patients and in 21.4% of 
adherent patients (χ2 = 19.84; 
p<0.01; OR = 5.30; 95% CI: 
2.39–11.85) 
43. Edo, TA. 
2009
402
   
 
Seychelles 
To describe factors 
that affected 
compliance with 
hypertension 
medications and 
lifestyle modification 
strategies in 
hypertensive people 
N=102 
Systematic random 
sampling from all 
eligible hypertensive 
patients registered at 
two public health 
centres  
 
56.86 
 
Quantitative, 
descriptive-co 
relational 
study/ 
Validated 
questionnaire 
and clinic note 
29.41 
 
 
 
Significant determinants of 
compliance behaviour: 
individual perception of the 
benefits of hypertension 
treatment (p = .0004); 
individual perception of risks of 
hypertension treatment (p = 
.0120) and cues to action (p = 
.0025 ) 
44. Bovet et 
al. 2002
482
    
 
Seychelles 
To examine the 
compliance to 
medication among 
newly diagnosed 
hypertensive patients 
screened from the 
general population of 
the Seychelles 
N=50 
Eligible hypertensive 
patients form a 
subset of participants 
in a population-
based cross 
sectional survey 
 
34 
 
Population 
based survey 
and follow up / 
Medication 
Event 
Monitoring 
System 
(MEMS) 
Initially 26%- 
after 12 
months 32% 
 
 
12-month adherence was 
higher with : skilled workers (p 
= .034); who knew their BP 
before diagnosis (p = .028) 
and who thought current 
lifestyle was important for 
future health (p = .050) 
45. Elzubier 
et al.2000
382
   
 
Sudan 
To estimate 
adherence with drug 
use, associated 
factors, and the 
effect of adherence 
on BP control 
N=198 
Registered eligible 
hypertensive patient 
attended medicine 
department of a 
teaching hospital 
76.3 
 
Cross 
sectional/ Pill 
count  
40.4 
 
 
Using multiple logistic 
regression analysis only 
variable that is positively and 
significantly associated with 
MNA is being unable to buy 
drugs (p<0.001) 
46. Joho et 
al. 2012
365
   
 
Tanzania 
To investigate factors 
affecting treatment 
adherence with 
antihypertensive 
therapy among 
hypertensive patients 
with the guide of the 
HBM conceptual 
framework 
N=135 
Randomly selected 
patient from three 
hypertensive clinics 
56.3 Cross 
sectional/ 
Questionnaire 
44 / 35.44 
 
With the use of bivariate 
analysis treatment compliance 
showed significant positive 
association with perceived 
benefit (r = 0.27; p = .001) 
cues to action(r= 0. 19; p = 
.022). Treatment adhrence 
showed significant negative 
association with: perceived 
barrier to treatment (r = -0.53; 
P = .000) 
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KYE: MNA=medication non-adherence; BP=Blood pressure; OR=Odds Ratio; AOR=Adjusted Odd Ratio; MMAS=Morisky Medication Adherence Score; 
BMQ=Belief about Medication Questionnaire; r =Pearson’s correlation coefficient 
a
Patients population comprised of both male and female
47. Mukora-
Mutseyekw
a et al. 2013 
525
    
 
Zimbabwe 
Measurement of BP 
control achievement, 
estimating 
prevalence of drug 
adherence behaviour 
and establishing  the 
association between 
drug adherence 
behaviour  and 
achievement of BP 
control 
N=102 
Convenience 
sampling from 
outpatients of a 
tertiary hospital 
69.6 Cross-
sectional/ 
MMAS 4 
59.8/66.19 
 
Participants with normal BP 
measurements were more 
than three times as likely to 
report maximal adherence to 
prescribed drug schedule 
(AOR = 3.37: 95% CI: 1.38–
8.24) 
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